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ABSTRACT  
 
A phenotypically distinct subgroup of familial isolated pituitary adenoma (FIPA) families has 
mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene leading to young-
onset acromegaly in most patients. These patients typically develop invasive pituitary 
adenomas, but the mechanisms by which AIP inactivation promotes pituitary tumorigenesis and 
an aggressive behaviour remain unknown. To date, more than 70 different AIP variants have 
been reported and determining the pathogenicity of missense variants is a challenging problem. 
The Drosophila AIP orthologue (CG1847) is located on the X chromosome and encodes a protein 
of similar size and structure to human protein (hAIP). I have generated CG1847 deficient flies via 
two methods: in vivo RNAi knockdown and imprecise excision of a transposable P-element, 
which generated a putative null allele of CG1847. Our data show that knockdown and knockout 
of CG1847 results in lethality confirming that AIP is an essential gene. 
To reveal the potential underlying molecular mechanisms of loss of AIP, a whole transcriptome 
analysis was performed in mutant versus control male larvae. This allowed us to determine gene 
expression profiles and to identify key pathways that are significantly altered in the mutant, and 
that are related to embryonic development or survival. 
To functionally test the homology between hAIP and CG1847, I used the Gal4/UAS system to 
perform rescue experiments. I subsequently tested whether wild-type hAIP, a truncated hAIP 
and four missense mutations identified in FIPA families could rescue the lethality of 
CG1847exon1_3 mutants by expressing hAIP during fly development. 
In this thesis were identified novel AIP features. CG1847 is a Drosophila melanogaster AIP 
orthologue and is essential for normal development. RNA sequencing revealed possible new 
underlying CG1847 molecular mechanisms as the tumour suppressor function of AIP might 
involve the regulation of cytoskeletal organisation. Drosophila is a useful in vivo system to study 
human AIP missense variants to establish pathogenicity. 
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CHAPTER 1: INTRODUCTION 
1.1 Pituitary gland  
The pituitary gland, or hypophysis, is one of the most important glands of the human endocrine 
system as it is involved in controlling the normal function of other endocrine glands, such as the 
thyroid gland, adrenals, and gonads. Its role is very complex as the different hormones secreted 
at this level can directly or indirectly regulate numerous processes concerning normal growth 
and development, sexual development and reproduction, metabolism, thermoregulation, stress 
response, sleep, and adaptation to changes in the external environment.  
Anatomy of pituitary gland  
The hypophysis is a small endocrine gland, weighing around 600 mg. The size of a normal adult 
pituitary gland was found to vary between 2.7 and 6.7 mm in a series of 14 women without 
known sellar or parasellar lesions1, but even sizes of around 9.7 mm were reported as normal 
by a study of direct coronal scans in 50 normal female volunteers2. The pituitary gland has two 
main parts: adenohypophysis (the anterior pituitary) and neurohypophysis (the posterior 
pituitary). The hypophysis is connected to the hypothalamus by the pituitary stalk, which 
consists of blood vessels and axons of the hypothalamic neuronal cell bodies. The hypophysis 
and the hypothalamus, compose the “hypothalamo-pituitary axis”3.  
This gland is located at the base of the skull, above the sphenoid sinus, inside a bony cavity called 
the “sella turcica”. This area is adjacent to many vascular and neurologic structures, hence 
processes which cause enlargement of the gland, may lead to significant mass effects. On the 
lateral sides of pituitary gland are the cavernous sinuses, which contain important structures as 
the internal carotid artery, and the cranial nerves III, IV, 2 of the 3 branches of cranial nerve V 
and VI. A pituitary tumour that extends laterally and invades the cavernous sinus may cause 
oculomotor paralysis and can sometimes even result in cerebral ischemia if the internal carotid 
artery is compressed4. A major neurologic structure located immediately above the hypophysis 
is the optic chiasm5. The optic chiasm is separated from the pituitary only by the diaphragma 
sella, a recess of the dura mater. This neurologic structure can be easily compromised through 
a mass effect from a pituitary adenoma. The most frequent manifestation of chiasmal 
disfunction is bitemporal hemianopia. As the pituitary gland is localised very close to the optic 
nerve chiasma, a tumorous process might result in partial blindness in the outer half of both 
visual fields. Headache is another complaint frequently reported in cases of pituitary adenomas; 
however, the mechanism of its appearance is the same as in case of any other space-occupying 
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brain lesion6, as traction on the pain-sensitive structures7 and dural stretch8,9. For example large 
tumors with cavernous sinus invasion might lead to headache as the sinus does contain pain-
producing structures, as the internal carotid artery and trigeminal nerve and ganglion. However, 
other factors apart from tumor size, such as family history of headache or the type of hormonal 
secretion might be important factors for the etiology of pituitary adenoma related headache10. 
The anterior pituitary gland secretes six major hormones: growth hormone (GH), prolactin (PRL), 
adrenocorticotropin hormone (ACTH), luteinizing hormone (LH), follicle-stimulating hormone 
(FSH), and thyroid-stimulating hormone (TSH). Around 50% of anterior lobe cells are GH 
secreting cells11. The main role of GH is in controlling body growth. This hormone acts either 
directly on multiple tissues or indirectly, by stimulating the tissue production of insulin-like 
growth factors (IGFs, mainly IGF-I). In men and nulliparous women, PRL secreting cells or 
lactotrophs may account for approximately 10% of the anterior pituitary cells. PRL stimulates 
breast enlargement and milk production during and after pregnancy and, as a result, in 
multiparous women the number of lactotrophs can be increased. ACTH is secreted together with 
pro-opiomelanocortin (POMC) derivatives by corticotroph cells (approximately 10-20% of 
anterior lobe). ACTH has a crucial role in the secretion of glucocorticoid hormone (cortisol) from 
the adrenal gland cortex. FSH and LH secreting cells, or gonadotroph cells, account also for 
around 10% of the anterior pituitary cells and are involved in the sex steroid hormone 
production and regulation of germ cell maturation. Thyrotroph cells (only 5% of the 
adenohypophyseal cells) secrete TSH, which stimulates thyroid hormone (T3/T4) production in 
the thyroid follicles. Thyroid hormone mainly controls metabolism and thermogenesis12.  
The posterior lobe consists mainly of the axons of neurons that are localised in the hypothalamus 
- neurons that secrete the antidiuretic hormone (ADH), involved in regulation of water retention, 
and oxytocin, a hormone with a role in social interactions and uterine contractions during 
delivery. As the posterior pituitary lobe is not the subject of this thesis, it will not be presented 
in more detail. 
Pituitary development 
The embryonic pituitary development was subject of numerous studies, and the maturation 
process of anterior pituitary cells is very well understood. From a developmental perspective, 
the anterior pituitary cells are embryologically derived from Rathke’s pouch13, a process that 
involves the complex interplay of lineage-specific transcription factors and locally-produced 
growth factors14 (Figure 1). 
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Figure 1: Molecular regulation of anterior pituitary gland development. Multiple transcription factors 
contribute to the establishment of the first structure of the developing pituitary gland, Rathke's pouch, 
and the subsequent differentiation of the five specialized, hormone-secreting cell types characteristic of 
the mature anterior pituitary gland: corticotrophs (ACTH), gonadotrophs (FSH and LH), thyrotrophs (TSH), 
somatotrophs (GH) and lactotrophs (PRL). Homeodomain-containing transcription factors critical to this 
process are highlighted in red, but the diagram includes other relevant transcription factors to give a 
broad picture of the cascade. Arrows indicate upstream relationships in molecular signalling pathways but 
do not necessarily imply direct activation. Flat arrowheads denote repressive relationships. The 
placement of specific cell types in the diagram does not reflect their actual location within the anterior 
pituitary gland. Adapted from Prince, K. L. et al. (2011)15 
Rathke's pouch is an ectodermal invagination that is formed anterior to the roof of the oral cavity 
at a very early stage of development, between the fourth and fifth week of gestation. Later in 
development, the pouch becomes distinct from the oral cavity and nasopharynx but maintains 
the connections with the stalk and hypothalamic infundibulum16. In the initial stages, Rathke's 
pouch cells express several transcription factors as LHX3, LHX4, and ISL-1, which belong to the 
LIM homeodomain family. These factors have an essential role in the very early determination 
towards pituitary development17. Recent studies have shown that SOX2 and SOX3 play key roles 
in regulating early pituitary morphogenesis both in rodent and man18. PITX1 and PITX2 are other 
essential transcription factors which are initially expressed in the oral ectoderm, and 
subsequently these factors will have a major role in the normal development of all pituitary cell 
types19,20. 
In the anterior lobe, the development of different hormonal cell lineages is under the influence 
of other transcription factors. Maybe the most important transcription factor is PROP1 which 
directly or indirectly controls the development of all anterior pituitary cell lineages. 
Somatotrophs, lactotrophs and thyrotrophs originate from a common lineage, under the control 
of PROP1 and Pit-1 expression. Both factors are essential for GH, PRL, and TSH secretion21. 
PROP1 in conjunction with other transcription factors is important for corticotrophs, and 
gonadotrophs lineages. Gonadotroph cell development is influenced by the expression of two 
  
21 
 
nuclear receptors, SF-1 (steroidogenic factor) and DAX-1 (dosage-sensitive sex reversal, adrenal 
hypoplasia critical region, on chromosome X, gene 1)22. PROP1 also have an indirect influence 
on development of LF and FSH secreting cells. Among these numerous transcription factors 
involved in the terminal differentiation of pituitary cell types, the T-Pit transcription factor is 
important for the development of corticotrophs, which express the pro-opiomelanocortin23. 
Mutations in the genes encoding the transcription factors involved in the linear development of 
anterior pituitary gland, such as Pit-1, PROP1, SF-1, DAX-1, and T-Pit, result in different 
pathologies that involve selective or combined pituitary hormone deficits. Fortunately, these 
are rare abnormalities. 
Regulation 
All the pituitary hormones are secreted in a pulsatile manner, reflecting the fact that the 
pituitary gland is under the control of the nervous system through the hypothalamus. Various 
external stimuli, such as ambient temperature, level of physical exercise, physical or 
psychological stress, or supplied nutrients, lead to secretion of specific hypothalamic releasing 
or inhibitory factors. The hypothalamic factors act on the surface receptors of specific pituitary 
cells, and as a response, pituitary hormones will be synthesised, secreted or inhibited. The 
pituitary hormones elicit specific responses in peripheral target tissues12.  
The stimulated peripheral glands will be consequently followed by specific hormone production 
that, in turn, will act via a feedback loop to control anterior pituitary function. There are mainly 
two mechanisms by which the hormonal products of peripheral glands, in turn, control at the 
level of the hypothalamus and pituitary: positive and negative feedback (Figure 2). 
The hypothalamus controls expression and secretion of anterior pituitary hormones through 
positive or negative regulation by releasing or inhibiting hypothalamic factors that act on their 
corresponding receptors on the adenohypophyseal cells. Through this mechanism, GH secretion 
is stimulated by GH-releasing hormone (GHRH); GH acts in the liver and other target tissues by 
mediating IGF-I production. Corticotrophin-releasing hormone (CRH) is secreted by 
hypothalamic neurons and induces positive regulation of ACTH secretion; the final result is 
glucocorticoid secretion from the adrenal glands’ cortex. Pituitary TSH is stimulated by a 
hypothalamic hormone, thyrotropin-releasing hormone (TRH). TSH acts through the same 
positive regulation on thyroid cells to promote thyroid hormone secretion (T3/T4). Gonadotroph 
cells have specific receptors for gonadotropin-releasing hormone (GnRH) and, when stimulated, 
will produce variable amounts of LH and FSH, depending on the frequency and amplitude of 
GnRH pulses24. In turn, LH and FSH control the production of sex steroid hormones (oestradiol, 
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progesterone, and testosterone) secreted from the ovaries and testes. PRL is the only pituitary 
hormone that is not stimulated by hypothalamic releasing factors. 
 
Figure 2: Hormonal axis, positive and negatives feedback loops. Schematic representation of the 
mechanisms regulating the anterior pituitary hormone secretion at the pituitary and at the hypothalamic 
level. Positive regulation is indicated by arrows, whereas negative regulation is shown by flat arrowheads. 
The negative feedback mechanisms are exerted both by hypothalamic inhibitory factors and by 
hormones released from the target glands25,26. Pituitary GH secretion is inhibited both by 
hypothalamic somatostatin and by IGF-I. In the case of PRL, the negative influence is exerted by 
dopamine. The glucocorticoid hormones secreted by adrenal glands have an inhibitory effect on 
the secretion of both ACTH and CRH. TSH and TRH are under the negative control of thyroid 
hormones produced in the thyroid gland. FSH and LH (and the hypothalamic factor GnRH) are 
inhibited by a negative feedback of the sex steroid hormones24. 
1.2 Pituitary tumorigenesis  
Definition 
Pituitary adenomas can arise from each of the cell types of the anterior pituitary (except of 
folliculo stellate cells). These tumours are usually benign monoclonal tumours27, presenting 
either due to hypersecretion of pituitary hormones, and/or due to local space occupying effects 
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and hyposecretion of some or all pituitary hormones. The main pituitary tumour types are 
prolactinomas, clinically non-functioning pituitary adenomas (NFPAs), GH-secreting adenomas 
and ACTH-secreting adenomas. TSH-secreting adenomas and gonadotroph adenomas with 
clinically relevant LH/FSH secretion are less frequent. A recently identified subgroup of pituitary 
adenomas detected as incidental findings during brain imaging are often referred as pituitary 
incidentalomas. The vast majority of pituitary tumours are benign, with very slow growing rates 
of the intrasellar masses, although dural invasion is present in almost 45% of the cases28. In these 
cases, the pituitary tumours present obvious extrasellar extension and invasion. Pituitary 
carcinomas are extremely rare cases, representing less than 0.2% of pituitary tumours; they are 
defined as pituitary tumours with a distant metastasis29. Pituitary adenomas are classified as 
microadenomas when they are less than 1 cm in diameter. They are usually restricted to the 
sella turcica, and usually do not have significant compressive effects on the surrounding tissue. 
Macroadenomas account for around 40% of all pituitary adenomas, can put pressure on the 
optic chiasm and the pituitary stalk, and can invade areas around the pituitary gland such as the 
cavernous sinus, the suprasellar area or the sphenoid sinus.  
Epidemiology of pituitary adenomas 
While previously pituitary adenomas were considered rare, recent studies have shown that the 
prevalence of pituitary tumours is higher than expected, probably due to better imaging 
techniques and improved diagnostic modalities. Pituitary adenomas account for 15% of all 
intracranial neoplasms, being the third most frequent tumour type after meningiomas and 
gliomas30. 
Data from national cancer registries, autopsy studies, imaging data, referrals to specialized 
centers, or population-based studies are the usual source for pituitary adenoma epidemiological 
statistics. Unfortunately, some of these sources are not entirely reliable. Cancer registries are 
extremely useful databases to monitor new disease cases every year at a national level. 
However, due to lack of mandatory reporting, the data available is actually an underestimation 
of the real prevalence. One of the first studies on the prevalence of pituitary adenomas based 
on autopsy samples was published by Costello et al. 193631. In 22.5% of unselected autopsy cases 
a pituitary adenoma was identified. More recent studies have found similar detection 
frequencies depending on the thickness of sections made through the pituitary gland. Therefore, 
it is becoming increasingly clear that pituitary adenomas are frequently found during autopsy of 
individuals from the general population. Still, when assessing autopsy data it is necessary to take 
into account that these studies usually represent a relatively older population. 
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In 2004, Ezzat et al.32 performed a meta-analysis of the prevalence of pituitary adenomas based 
on the English-language articles available at the time and identified 33 articles based on autopsy 
and radiological data. The results of the final statistical analysis suggest a wide interval in the 
prevalence of pituitary adenomas. The imaging studies were ranging from 1% to almost 40% 
(with an estimated mean prevalence rate of 22.5%). With regards to the postmortem studies, 
the prevalence of pituitary adenomas had a similar interval: 1% to 35% with an estimated mean 
of 14.4%. The overall estimated prevalence of pituitary adenomas in the general population was 
calculated by Ezzat et al. as 16.7%32. Community-based cross-sectional studies usually report 
either pituitary adenoma prevalence33-35, or their incidence36, although a recent article from 
Malta evaluated both of these parameters37. 
The first study that aimed to evaluate the prevalence of pituitary adenomas in a well-defined 
population was published by Daly et al. in 200633. They evaluated only clinically relevant pituitary 
adenomas and demonstrated a prevalence of one case per 1,064. These results were replicated 
by Fernandez et al.35 in the UK showing a prevalence of one case per 1,289. The results from 
both studies show significantly higher prevalence compared to previous studies based on data 
from tertiary referral centres (between 1:5,263 and 1:3,57138). This significant difference is 
probably due to different patient identification methods, and better imaging and diagnostic 
practices. These data were subsequently confirmed by other population-based studies (Table 1). 
The most recent epidemiologic study regarding the prevalence and incidence of pituitary 
adenomas took place in Iceland. It was a retrospective observational study and included all 
pituitary adenomas diagnosed on this area over more than 40 years. An extensive clinical 
database was generated and used for calculating the rates of prevalence and incidence. The 
authors confirmed the increased overall prevalence and incidence rates. In this study it is 
claimed that these findings cannot be totally justified by a facilitated access to imaging 
investigations in recent years as most of patients were already symptomatic at diagnosis39. 
However, the use of performing imaging investigations in recent years has had a significant 
impact on the diagnosis of pituitary lesions with or, more often without, clinical relevance. As a 
result, a clinical guideline on the management of pituitary incidentalomas was necessary and 
has been recently published40. The Endocrine Society recommendations for patients with a 
pituitary incidentaloma is to have a complete evaluation which should include detailed personal 
and familial past medical history, physical examination, laboratory investigations for both 
hormone hypersecretion and hypopituitarism. The visual field examination should not be 
missed. The frequency of the investigations should be adjusted accordingly to the changes in 
size of adenomas40.
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Table 1: Population based studies. A review of the literature regarding the prevalence of different types of pituitary adenomas (updated from Aflorei et al 201441) 
 
  
Study/ 
reference 
Size of 
population  
Size Gender 
Mean age 
 at diagnosis 
Incidence Prevalence 
Types % 
(Female/Male ratio) 
% 
Micro 
% 
Macro 
% 
Males 
% 
Females 
PRL NFPA GH ACTH TSH 
Daly et al.33 71972 57.4 42.6 32.4 67.6 
40.3 
 (range 12–86yr) 
- 1/1064 
66.2 
(2.88) 
14.7 
(0.42) 
13.2 
(0.5) 
5.9 
(4) 
0 
Fontana et al.34 54607 N/A N/A 27 73 -  -  1/1241 56 30 9 5 0 
Fernandez et al.35 81498 58.7 41.3 33.3 66.7 
37  
(range 16–79yr) 
-  1/1289 
57.1 
(8) 
28 
(0.5) 
11.1 
(0.75) 
1.58 
(0.1) 
0 
Raapana et al.36 
722,000 to 
733,000 
54 46 19.04 80.99 
40 
 (range 27.3–55yr) 
4.00/100,000/  
year 
1/1470 
51 
(4.3) 
37 
(1.2) 
8.5 
(0.6) 
3 
(2.8) 
1.2 
(2) 
Grupetta et al.37 
394,640 to 
417,608 
56.6 43.4 30.4 69.6 
40.6 
 (SD ±15.0yr) 
 
4.27/100,000/  
year 
1/1321 
46.2 
(1.4) 
34.2 
(4.4) 
16.5 
(1.36) 
2.2 
(6) 
0.94 
(2) 
Agustsson et al.39 
210.912 to 
321.857 
41.2 54.8 40.3 (59.7 
44  
(range 4–94yr) 
0.6/100,000/ year 
1955–1972 
5.8/100,000/ year 
2003–2012 
1/865 
39.9 
(3.0) 
43.1 
(0.95) 
11.3 
(0.65) 
5.7 
(2.85) 
0 
  
26 
 
Etiopathogenesis of pituitary adenomas 
Tumorigenesis requires two overlapping steps: initiation and promotion42. Most of the data 
suggest that human pituitary adenomas are the result of an intrinsic pituitary defect due to 
inherited or acquired genetic or epigenetic changes that probably confer growth advantage43, 
which represents the initiation step. In the promotion step, additional genetic changes, growth 
factors and environmental factors are involved, for example circulating hormones such as 
oestrogens or the microenvironment, with additional permissive effect on the behaviour of the 
altered cells. These defects lead to monoclonal expansion of a single modified cell, although 
heterogeneity in recurrences after treatment has been described44. 
Hormonal factors involved in pituitary tumour pathogenesis 
Despite several animal models suggesting that hormonal effects, such as hypothalamic trophic 
or inhibitory hormones, or abnormal feedback regulation from peripheral hormones could lead 
to pituitary adenomas45,46, there is little evidence for this in humans. Ectopic GHRH or CRH 
secretion result in pituitary hyperplasia, but an association with adenoma development has not 
been shown47,48. The lack of cortisol feedback in untreated Addison disease or congenital adrenal 
hyperplasia has not been consistently associated with corticotrophinomas, although individual 
case reports have been described49. The preponderance of microprolactinomas in females 
maybe linked to estradiol influence on the pituitary gland; however, there is no data suggesting 
a link between the use of the contraceptive pill and pituitary adenomas50. Factors involved in 
the physiological regulation of the pituitary gland, such as somatostatin analogues and 
dopamine agonists, are utilised therapeutically as analogues of inhibitory hypothalamic factors 
and have been used successfully in the treatment of acromegaly and prolactinomas. 
Environmental factors involved in pituitary tumour pathogenesis 
Most of the available evidence regarding the role of environmental factors as potentially causal 
factors in pituitary adenomas tumorigenesis comes from animal experiments. In mice and cats, 
environmental causal factors for pituitary adenomas have been found to include chemical and 
radiation exposure. 
Some of the earliest experiments were performed by Gorbman51, and demonstrated that mice 
exposed to radioactive iodine (I131) developed tumours of the pituitary gland. More recent 
experiments52 confirmed that when mice are exposed to radiation they will develop pituitary 
adenomas. Regarding the role of environmental carcinogens on the development of pituitary 
adenomas, it has been shown that Fischer 344 rats receiving acrylamide in drinking water for 2 
years developed pituitary tumours53. Acrylamide is known as an industry-related carcinogenic 
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substance, but recent discoveries have found that acrylamide is also formed in significant 
concentrations during high-temperature cooking of many common foods54. Recently published 
data reported that naturally occurring hypersomatotropic cats have increased plasma 
concentrations of organohalogenated contaminants as polyclorobyphenils and other substances 
with oestrogen-like activity compared to diabetic cats and controls. The mechanism of tumour 
formation seems to involve a link between AIP-induced xenobiotic metabolism, toxicity and cell 
cycle regulation55. 
However, very little evidence is available regarding the role of environmental factors in the 
aetiology of pituitary adenomas in humans. In 2010, Canavo et al.56 investigated the 
epidemiological characteristics of patients with acromegaly in Sicily. The study focused on the 
relationship between the prevalence of acromegaly and environmental pollution. Area of Sicily 
were divided into 4 zones with different pollution levels. In the most polluted zone, there were 
high concentrations of toxic substances such as benzene, toluene, cyclohexene, and ethane. 
There was increased prevalence of the disease in the highly polluted area compared to less 
polluted areas. The risk ratio (RR), calculated for the most polluted area, assuming the least 
polluted area as a reference, showed that the population of the most polluted region had an 
8.3-fold increased risk of developing acromegaly (P<0.0014). 
Given the fact that AIP is a molecular chaperone to the receptor of the environmental toxin 
dioxin, the prevalence of pituitary adenomas was investigated in Seveso, Northern Italy, 
following an industrial accident where considerable dioxin pollution affected well circumscribed 
areas57. Although no significant increase was identified, this is an issue that warrants further 
study. 
Genetic factors involved in pituitary tumour pathogenesis 
Data on genetic predisposition and on acquired somatic changes (mutations or epigenetic 
alterations) associated with pituitary adenomas is steadily accumulating58. The differentiation 
of the pituitary gland is under the coordination of a series of very specific and temporally 
events59, which are highly regulated by a various transcription factors. The succession of 
sequential activation of these factors has been shown to be also involved in every step of the 
tumorigenesis process. Figure 3 depicts an overview of pituitary development and intracellular 
tumour cell signalling associated with cell proliferation and tumour development. 
 
  
28 
 
 
Figure 3: Cascade of factors involved in anterior pituitary development and tumorigenesis. Sequential 
activation of series of factors that are involved in tumorigenesis process, from progressive differentiation 
of mature pituitary gland cell types to pituitary adenomas and carcinomas. Oncogene activation, tumour 
suppression gene (TSG) inactivation and different factors probably contribute to transformation from 
normal pituitary to adenoma. The role of hypothalamic factors in humans has not been convincingly 
shown in the development of human pituitary adenomas (dashed line). Additional mutations may 
facilitate aggressive behaviour or malignant transformation (adapted from Aflorei et al 201441). 
Numerous genes have been suggested to be involved as oncogenes or tumour suppressor genes 
(TSG) in the pathogenesis of sporadic pituitary adenomas. Table 2 presents a brief summary of 
some of the most frequent genetic disruptions observed in pituitary adenomas). 
Gene Mechanism of normal function Result of altered function 
Oncogene
/TSG 
Somatotroph adenoma 
CCND1 
Involved in progression through the 
G1-S phase of the cell cycle 
Increased expression, can 
stimulate both cell proliferation 
and apoptosis in GH3 cells 
Oncogene 
CREB 
Phosphorylation-dependent 
transcriptional activator of cAMP 
response elements (CREs) 
Constitutive activation by 
phosphorylation 
Oncogene 
GHR 
Transmembrane receptor that 
mediates GH action 
Loss-of-function somatic 
mutation 
-  
GHRH Stimulates GH secretion Increased expression -  
GHRH-R 
Transmembrane receptor that 
mediates GHRH action 
Truncated alternatively spliced 
nonfunctioning receptor 
-  
GNAS1 
Alpha subunit of the stimulatory G 
protein that activates adenylate 
cyclase 
Predominant maternal origin of 
GNAS1 transcripts; 40% of GH-
secreting pituitary adenomas 
have somatic mutations 
Oncogene 
Tpit
Neuro
D1
H-ras
Prop-1
Rpx/HesX-1
Pax-6
Six-1,3
Isl-1
Prop-1
Ptx1,2
Lhx-3, 4
GATA-2
Oral 
ectoderm
Thyrotroph 
cells
Corticotroph 
cells
Gonadotroph 
cells
Adenomas
Hypothalamus 
influences
Carcinomas
Metastases
Aggressive
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GHRH-R
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GPR10160 G protein-coupled receptor 101 gene 
increased by a factor as high as 
1000 in the pituitary tumours 
Oncogene 
SSTR2 
Specific high-affinity G-coupled 
receptor for somatostatin 
Decreased expression -  
Lactotroph adenoma 
BMP4 
Involved in the control of the 
differentiation and proliferation of 
the different cell types in the 
anterior pituitary 
Overexpressed in prolactinomas TSG 
DRD2 
G protein-coupled receptor for 
dopamine 
Decreased expression -  
FGFR4 
Membrane-anchored receptor for 
fibroblast growth factor 
Increased expression of a N-
terminally truncated cytoplasmic 
isoform (ptd-FGFR4) by 
alternative transcription 
initiation 
Oncogene 
TGF-α61 
Competes with EGF for binding to 
the EGF receptor and stimulates its 
phosphorylation in order to produce 
a mitogenic response 
Overexpressed under the 
prolactin promoter influence 
Oncogene 
Corticotroph adenoma 
CCNE1 
Promotes progression through the 
G1-S phase of the cell cycle 
Increased expression Oncogene 
HDAC2 
Enzyme that deacetylates lysine 
residues on the N-terminal region of 
the core histones 
Decreased expression Oncogene 
NR3C1 Nuclear receptor for glucocorticoids 
Loss-of-function somatic 
mutation 
-  
SmarcA4 
Member of the SWI/SNF protein 
family with helicase and ATPase 
activities. Regulates gene 
transcription by altering chromatin 
structure 
Decreased expression, altered 
subcellular localization 
TSG 
USP862,63 
 Involved in regulation of the 
endosome morphology via protein 
ubiquitination 
Gain-of-function somatic 
mutations in corticotropinomas 
Oncogene 
Nonfunctioning adenoma 
DKC1 
Pseudouridine synthase that 
modifies rRNA and regulates 
telomerase activity 
Loss-of-function somatic 
mutation 
TSG 
MEG3 
Induces apoptosis and inhibits 
proliferation of tumour cells 
Decreased expression TSG 
PITX2 
Member of the bicoid-like homeobox 
transcription factor family, which is 
involved in the Wnt/Dvl/β-catenin 
pathway 
Increased expression -  
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PLAGL1 
Zinc finger transcription factor that 
plays a role in pituitary development, 
differentiation, maturation and 
tumorigenesis 
Decreased expression TSG 
PRKCA 
Kinase that participates in growth 
factor- and hormone-mediated 
transmembrane signalling and cell 
proliferation 
Increased expression, 
gain-of-function mutation 
Oncogene 
Most or all pituitary tumour types 
AKT1 
Regulates many processes including 
metabolism, proliferation, cell 
survival, growth and angiogenesis 
Increased expression, especially 
in NFPAs 
Oncogene  
AKT2 
Regulates many processes including 
metabolism, proliferation, cell 
survival, growth and angiogenesis 
Increased expression, especially 
in NFPAs 
Oncogene 
BAG1 
Inhibits the chaperone activity of 
HSP70/HSC70 and the pro-apoptotic 
function of PPP1R15A 
Increased expression -  
CCNA1, B1, 
B2 
Involved in the control of the G2/M 
phases of the cell cycle 
Increased expression Oncogene 
CDKN1A – 
p21 
Regulator of cell cycle progression at 
G1 
Decreased expression in NFPAs, 
Increased expression in hormone 
producing adenomas 
TSG 
CDKN2A 
Induces cell cycle arrest in G1 and G2 
phases 
Decreased expression TSG 
PIT164 
Member of the POU transcription 
factor family; plays a key role in the 
speciﬁcation, expansion and survival 
of somatotrophs, lactotrophs and 
thyrotrophs during development 
Overexpressed in GH, PRL and 
TSH pituitary adenomas 
Oncogene 
PTTG 
Cell cycle regulation and cell 
senescence 
Increased expression, especially 
in corticotrophinomas 
Oncogene 
Invasive adenoma 
DAPK1 
Positive mediator of programmed 
cell death induced by gamma-
interferon 
Decreased expression either by 
promoter methylation or by 
homozygous deletion of the 
promoter CpG island 
TSG 
EGFR 
Transmembrane glycoprotein 
required for normal cellular 
proliferation, adhesion, migration 
and differentiation 
Increased expression Oncogene 
Galectin-365 
Extracellular Gal-3 mediates cell 
migration, cell adhesion, and cell-to-
cell interactions; intracellular Gal-3 
inhibits apoptosis  
Up-regulated during neoplastic 
progression  
Oncogene 
MYO5A66 
Actin-dependent molecular motor, 
with roles in tumour cell migration, 
invasion, and metastasis 
Increased expression -  
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NM2367 
N-terminal kinase domain could 
phosphorylate and downregulate 
cyclin B and could prevent the 
progression of cell from G2 to M 
phase of the cell cycle 
Allelic loss results in reduced 
NM23 expression 
TSG 
RB1 
Key regulator of entry into cell 
division 
Decreased expression partly by 
promoter methylation 
TSG 
Pituitary carcinoma 
COPS5 
Probable protease subunit of the 
COP9 signalosome complex, which is 
involved in various cellular and 
developmental processes 
Increased expression -  
HRAS 
GDP/GTP binding protein that 
regulates cell division in response to 
growth factor stimulation 
Gain-of-function somatic 
mutations 
Oncogene 
Table 2: Selected genes that may be involved in molecular pathogenesis of pituitary adenomas.This list 
is not exhaustive and exemplifies some of the complex genetic disruptions observed in pituitary 
adenomas. Updated from Gadelha et al., for references see original review article68. 
The key mechanisms that seem to be involved in the pituitary tumorigenic process are oncogene 
activation and TSG inactivation. These can occur either independently or in combination. 
Gain-of-function mutations occur most often in genes affecting signal transduction pathways 
and lead to prolonged activation of the downstream pathway. These are most commonly 
dominant mutations so a single mutated allele is sufficient to induce a phenotype. The most 
frequently observed genetic change in pituitary adenomas is the somatic heterozygous 
activating mutation of the GNAS gene coding for the G protein α-subunit. This is called the gsp 
mutation, which can be present in up to 40% of GH-secreting pituitary adenomas69,70. The 
mutation abolishes the GTP-ase activity of the  subunit, which leads to a constitutively 
activated adenylate cyclase, increased cyclic adenosine monophosphate (cAMP) levels and 
protein kinase A (PKA) activation. In turn, the cAMP response element-binding protein (CREB) is 
phosphorylated and leads to sustained GH hypersecretion and cell proliferation. H-ras 
mutations have been described in a few cases of invasive prolactinomas or distant metastatic 
pituitary carcinomas71-73. As most of these mutations were found in rare carcinoma samples, it 
was suggested that they may be important in malignant transformation and metastasis rather 
than pituitary adenoma initiation. 
Loss of TSGs on both alleles may initiate tumour cell growth (Knudson’s two-hit theory74). In 
inherited conditions the first genetic alteration event can be an inherited germ-line mutation of 
one allele, followed by a second somatic alteration event affecting the TSG, leading to the gene 
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being completely turned off. The second event can either be a large deletion (which can usually 
be detected by testing for loss of heterozygosity (LOH) at the mutation locus or microsatellites 
around it), a somatic point mutation, a reduction in gene expression due to promoter 
methylation, or the presence of inhibitory microRNAs75. The retinoblastoma gene (Rb) was one 
of the first described TSGs in pituitary adenoma. Although Rb knockout mice develop 
intermediate lobe ACTH-secreting pituitary adenomas, and germline mutations cause 
retinoblastoma in humans, no Rb mutations were identified in human pituitary adenomas43. 
Methylation of the Rb promoter76 has been described in human pituitary tumorigenesis. Areas 
of the genome typically lost in pituitary adenomas include the p and q arms of chromosome 11, 
locus 11q13, 13q12-14, 10q, and 1p, 9p, 13, 3, and 12 and X77. Many of these include TSGs, but 
no particular chromosomal loci in pituitary adenomas are free of allelic deletions. 
Other tumour-initiating and promoting factors have been studied using animal models and 
human tissue samples. Molecules that have been characterized to be involved in the 
proliferative potential of pituitary cells and tumour growth include cell cycle regulators, 
disrupted growth factors, transcriptional regulators or pituitary miRNAs. 
Cell cycle disruption: Proteins regulating the cell cycle can also be considered as oncogenes and 
TSGs in a tumorigenic process. Several transgenic mouse models have demonstrated that both 
inactivated78,79 and overexpressed cell cycle regulators are sufficient to initiate pituitary 
tumorigenesis. Cyclins and stimulated cyclin-dependent kinases (CDKs) promote initiation of the 
cell cycle by phosphorylation and therefore inactivation of Rb. This confers to the cyclins the 
capacity to lead to tumorigenesis and several have been shown to be overexpressed in different 
types of pituitary adenomas80.  
Growth factors: Various growth factors and their cognate receptors are essential for regulating 
pituitary cell growth and for regulating normal hormone production81. Transforming growth 
factor (TGFα)61 is a mitogenic protein which in pituitary tissue is expressed mainly in lactotrophs, 
where might be overexpressed under the influence of the PRL promoter. TGFα does not induce 
tumours of other pituitary cell subtypes, indicating a specific role in tumorigenesis of 
prolactinomas. Fibroblast growth factors (FGFs) are a very complex family of ligands that are 
involved in pituitary development and growth. In an article published in 2001, Ezzat et al.82 
demonstrated that the N-terminally truncated isoform of FGF receptor-4 (ptd-FGFR4), an altered 
growth factor receptor isoform, can be implicated in the neoplastic process of pituitary 
adenomas. Disruption of other growth factors involved in pituitary tumorigenesis include 
epidermal growth factor83, nerve growth factor84 and bone morphogenetic protein 4 (BMP4)85. 
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BMP4 is required for early embryonic and pituitary development and has been shown to be 
highly expressed in pituitary adenomas in mouse models. 
Transcriptional regulators: Anterior pituitary cell differentiation is a very complex process during 
which a series of transcription factors play key roles in each stage. PITX1 and PITX2 are some of 
the first transcription factors expressed in the Rathke's pouch and subsequently will have a key 
role in the normal development of all pituitary cell types20,19. PITX1 has been demonstrated in 
all normal anterior pituitary cell types and in the majority of pituitary adenoma subtypes86. One 
recent study reported reduced PITX1 mRNA expression in corticotroph tumours compared with 
other pituitary tumours. PITX2 (pituitary homeobox 2) is another pan-pituitary transcriptional 
activator involved in very early stages of pituitary cell differentiation. Pellegrini-Bouiller et al87 
described absent PITX2 mRNA expression in corticotroph adenomas, with high PITX2 expression 
in gonadotroph tumours. Interestingly, although Ptx2 expression was observed in PRL secreting 
tumours, no expression was observed in somatotroph adenomas. This might suggest that PITX2 
has an involvement in the terminal differentiation of these types of pituitary cells. A third factor 
implicated in early pituitary development is the Prop-1, which is required for Pit1 gene 
expression. Inactivating Prop-1 mutations occur in subjects with combined pituitary hormone 
deficiency. Regarding this very important transcription factor, RT–PCR analyses have 
demonstrated appropriate Prop1 expression in normal pituitary tissue and in all pituitary 
adenomas examined et al88. On the other hand Pit1 mRNA was increased up to fivefold in 
somatotropinomas and prolactinomas compared to normal pituitary tissue64. 
Therefore, the available data regarding the role of transcription factors in pituitary tumour 
pathogenesis are limited and quite old, and there are necessary more investigations to 
understand their involvement. 
The overwhelming majority (~95%) of pituitary adenomas arise sporadically89,90. However, 
genetic factors may also play a role. It is well described that certain animal strains are more 
prone to pituitary adenoma development, primarily prolactinomas91,92. Racial differences have 
also been identified in humans, with black people having increased prevalence of pituitary 
adenomas. Racial differences in pituitary adenoma incidence were first reported in 197693 and 
showed the incidence in black women to be tripled when compared to white women, while 
incidence rates for black men were 4 times as high as for white men. A more recent article94 
published in 2011 also found that, in the USA, blacks had significantly higher incidence rates of 
pituitary tumours than Asian/Pacific islanders, American Indians/Alaska natives, and whites. 
There were no significant differences between the latter 3 groups. One of the few possible 
explanations for this high incidence is the fact that the racial differences in incident rates are 
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naturally occurring. Another possible reason is that black people may have a different clinical 
presentation of pituitary adenomas that draws attention to this condition. A third possibility is 
that the higher incidence rates are an incidental finding. However, the real cause for these higher 
incidence rates is still unclear. Despite the fact that in 1991 Goldstone et al95. raised the question 
that there might be a genetic basis for the differences in cancer incidence between Afro-
Americans and Euro-Americans, no further experiments, involving ether whole genome 
sequencing or next generation sequencing, were performed. This might be due to the fact that 
the costing involved in order to reveal the genes/ transcripts significantly changed in Afro-
Americans versus Euro-Americans or other populations can be significant. 
Pituitary adenomas due to germline mutations  
The detection of germline mutations in a patient has major implications for family members 
because the relatives are at risk of developing the disease. Familial genetic screening is an 
important step in these pathologies as the mutations often can be identified. 
The main genetic causes of pituitary adenomas are summarised in Figure 4: 
 
Figure 4: The pathogenesis of pituitary tumours due to germline mutations. A germline mutation in the 
MEN1 gene, or rarely in the CDKN1B (coding for cell cycle regulator protein p27) gene causes MEN1 or 
MEN4; in a small proportion of affected cases, no gene abnormality can be found. A mutation in the 
protein kinase A regulatory subunit gene (PRKAR1A) is found in the majority (60%) of patients with the 
Carney complex; in the remainder, data suggest a causative gene in the 2q16 area. Patients have been 
described with an SDH mutation-related familial paraganglioma/phaeochromocytoma and familial 
pituitary adenomas96-100. Rare case reports of patients with neurofibromatosis type 1 and pituitary 
adenoma have been described. A mutation in the DICER1 gene, a gene which regulates microRNAs, may 
cause an ACTH-secreting pituitary blastoma of childhood onset 101. A fifth of families with familial isolated 
pituitary adenoma cases show a mutation in the AIP gene; in the majority of FIPA families, the causative 
gene has not yet been identified. Adapted from Korbonits et al 102. 
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Classical familial pituitary tumour syndromes have been described in around 5% of pituitary 
patients. The classical familial syndromes that predispose to pituitary adenomas are multiple 
endocrine neoplasia type 1 (MEN1) and type 4 (MEN4), Carney complex, and familial isolated 
pituitary adenomas (FIPA). More recent data raised the possibility that pituitary tumours can be 
caused by mutations in the DICER1101 and succinate dehydrogenase (SDH) genes98-100,97 among 
others. Isolated case reports have described pituitary adenomas in patients with 
neurofibromatosis type 1103-108. A very new syndrome of pituitary gigantism is called X-linked 
acrogigantism (X-LAG) and was published for the first time in 2014 by Trivellin et al.60. This 
pathogenesis is caused by microduplications on chromosome Xq26.3, affecting a gene named 
GPR101. GPR101 expression was found highly upregulated (up to 1000 times) in pituitary 
tumours of patients with Xq26.3 microduplications, compared with normal pituitary and 
tumours from patients who tested negative for microduplications60. 
MEN1 is an autosomal dominant syndrome that is caused by an inactivating mutation in the 
MEN1 gene. The main manifestation involves pancreatic, pituitary, and parathyroid gland 
tumours, and there is typically a high penetrance, with over 95% of the patients manifesting the 
disease by the age of 50. The incidence of MEN1 is estimated to be around 0.25% from post-
mortem studies and the prevalence estimated to be 1 in 20,000 to 40,000 individuals109,110. 
MEN1 affects both sexes equally but the pituitary manifestation, most commonly 
prolactinomas, has a female preponderance and sometimes paediatric onset. Pituitary 
adenomas can be the first presentation of MEN1 syndrome in 14% of cases. 
MEN4 is a novel and rare familial syndrome seen in patients with MEN1-like features, but no 
MEN1 gene mutations. Germline mutation in the CDKN1B has been described in a few cases, 
and single patients have been described with mutations in the genes coding for the CDKIs p15, 
p18, and p21cip1 111,112. p27Kip1 is known to interact with the menin protein which may explain the 
similar phenotype to MEN1. 
Carney complex (CNC) is an autosomal dominant disorder with numerous manifestations 
including myxomas (benign tumours of the skin, breast, and other sites), testis and adrenal 
tumours as well as somatotroph hyperplasia or adenomas. The majority of the cases are caused 
by an inactivating mutation in the regulatory subunit of protein kinase A PRKAR1A113. 
X-LAG syndrome is a very recently described paediatric disorder characterised by a 
microduplication on chromosome Xq26.3, and increased growth hormone secretion. At this 
locus 4 genes were identified. Of these 4 genes, GPR101 was found upregulated in pituitary 
lesions from patients with X-LAG. A variant was identified at position 924 (substitution of a 
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guanine with a cytosine (c.924G→C; p.E308D); however, the role of this change is currently 
under investigation. GPR101 encodes a G-protein–coupled receptor, and pituitary-specific 
GPR101 overexpression may be due to a gene-dose effect. Genetic analyses revealed that the 
phenotype associated with the identified GPR101 mutation is associated with an extremely 
early-childhood onset form of gigantism. In contrast, the patients with gigantism of other cause 
develop the disease during adolescence60. 
FIPA: Case reports about families with pituitary adenomas but no other syndromic features have 
been described previously, but the first comprehensive report establishing this new diagnosis 
was only published in 2006114. In about 20% of these families, a mutation in the Aryl Hydrocarbon 
Receptor-Interacting Protein (AIP) gene was described115, while in others the disease causing 
gene or genes have not been identified. More details on the section 1.3. 
1.3 Familial isolated pituitary adenomas 
Despite numerous studies that aim to understand the aetiology and pathogenesis of pituitary 
adenomas, many questions remain unanswered. One new puzzle has been the finding that 
heterozygous germline mutations of the AIP gene may lead to FIPA116. 
FIPA (OMIM #102200) is defined as the occurrence of a pituitary adenoma in two or more 
members of the same family in the absence of other syndromic clinical features, such as those 
characteristic of MEN1 and MEN4, CNC. This pathology is inherited in an autosomal dominant 
manner. However, the penetrance of the disease in FIPA families is highly variable within a range 
of 15-33%. Up to 48.6% of the families with AIP mutations had three or more pituitary adenoma 
patients per family. The maximum number of affected individuals within the same family was 
eight (six of them prospectively diagnosed) in a family carrying the p.R304*117. Owing to this 
incomplete penetrance, some of the carriers fail to express the phenotype. As the trait may not 
be expressed in one or more generations, it poses a challenge in detecting the inheritance in 
subsequent generations of the same kindred118. 
AIP mutations have been described as the cause of pituitary adenomas in about 15-20% of FIPA 
families, with a higher prevalence, up to 36-50%, in cases of families with only 
somatotropinomas89,115,116,119,120. Despite the fact that AIP germline mutations were not 
identified in patients with sporadic pituitary adenomas in some of the initial studies121, recent 
publications have shown that about 4% of the cases of apparently sporadic pituitary adenomas 
have AIP mutations115,122,123. 
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To date, more than 70 different AIP variants have been reported120. Various changes have been 
described throughout the entire region of the gene: missense, nonsense, deletions and 
insertions (in-frame or causing frame-shift), splice-site and promoter mutations as well as large 
genomic deletions. All these are germline mutations, and no AIP somatic mutations have been 
identified. The observed loss of heterozygosity (LOH) of the wild-type AIP allele in the tumour 
tissue of affected individuals supports the role of AIP as a TSG124-126. 
FIPA history 
Until 2006 the literature on families with two or more members diagnosed with different types 
of pituitary adenomas, without any other manifestations of MEN1 or CNC was scarce. In modern 
literature, the first prolactinoma family was described in 1967127 and was followed by a 
description of two acromegaly families128,129. A few years later, this was followed by the 
description of a corticotroph adenoma family130. Another familial prolactinoma case was again 
reported by Berezin et al. in 1995131. In the same year, a family with 3 patients affected by 
gigantism or acromegaly was described. It was the first time that association with the MEN1 
gene locus had been ruled out132. The first article that reported loss of heterozygosity (LOH) on 
chromosome 11q13 in pituitary adenomas of 2 siblings with familial acromegaly was published 
in 1997133. The MEN1 gene is localized at this locus. Two hypotheses were suggested: the first 
one stated that familial acromegaly was an alternative form of the MEN1 syndrome; the second 
hypothesis was that an independent gene located in the immediate vicinity is the one involved 
the pathogenesis of familial acromegaly133. The second hypothesis was convincingly confirmed 
8 years later by Soares et al. in an article published in 2005 on 8 novel families126. 
With every article that was published it became more obvious to the scientific world that 
pituitary adenomas could occur in a familial setting. In order to characterize these families with 
isolated pituitary adenomas as a distinct clinical entity different than MEN1 and CNC, in 2005 
Daly et al. proposed a new syndrome: familial isolated pituitary adenomas (FIPA) (OMIM 
102200)134. Since then, international collaborative efforts resulted in a collection of hundreds of 
families that exhibited different patterns of pituitary adenomas. Families with up to five affected 
cases were reported; these kindreds were characterized either as “homogeneous” (same 
adenoma phenotype among affected cases) or “heterogeneous” (different adenoma 
phenotypes among affected members)135,136. When these cases were investigated in more 
detail, a first-degree relationship between affected members was observed in the majority of 
the FIPA kindreds and an autosomal dominant inheritance pattern with incomplete penetrance 
was suggested for FIPA, based on pedigree analysis90. 
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However, the exact genetic cause remained elusive until 2006 when Vierimaa et al116 performed 
a study on two families with pituitary adenomas from Northern Finland. The Finnish group used 
high-stringency criteria and performed a genome-wide single-nucleotide polymorphism study 
on 16 patients in order to identify the gene locus. A linkage was identified at chromosome 
11q12–11q13, but the MEN1 gene locus was included. As none of the patients included in this 
cohort carried MEN1 mutations, a further screen was performed in both families included in the 
study. Further investigations on the AIP status in FIPA families showed that this pathology is an 
autosomal dominant disease with variable penetrance. The fact that AIP might be a TSG was 
suggested by the discovery that the majority of known affected individuals have LOH at the AIP 
locus, losing this way the wild-type allele, in concordance with the Knudson’s two-hit 
hypothesis137. In one particular case described in 2007 by Iwata et al. a missense mutation 
(V49M) was identified in a patient with gigantism. However, the wt allele of the AIP gene was 
retained in the GH-secreting adenoma, but the LOH cannot be completely ruled out possibly due 
to contamination with normal pituitary tissue138. 
One important problem that remains to be solved is that mutations in the AIP gene were 
identified only in about 20% of the families. It remains unknown which genes are involved in the 
pituitary tumorigenesis of the remaining FIPA families. 
AIP gene  
AIP gene has 6 exons, 8,075 bp, and is localized on chromosome 11: 67,250,505-67,258,579 on 
the forward strand (UCSC Genome Browser on Human Feb. 2009 (GRCh37/hg19) Assembly). All 
6 exons are part of the coding region (total size for the coding region: 7,835). 
Cloning 
Kuzhandaivelu et al.139 were the first to clone the AHR-interacting protein (AIP) gene in 1996. At 
the time, they designated it as XAP2 due to the fact that they used a yeast 2-hybrid system to 
identify proteins that interact with the hepatitis B virus (HBV) X protein. One year later, Carver 
and Bradfield140 showed that AIP (named ARA9 in this paper) interacts with AHR in a ligand-
dependent manner, also by using a yeast 2-hybrid assay.  
Mapping 
The mapping of AIP gene was a long process which started in 1993 when Thakker et al.141 
published the cases of 4 non-MEN1 patients with acromegaly and LOH for chromosome 11q13. 
In 1999, Gadelha et al. narrowed the region of LOH to 11q13, as they found LOH in all pituitary 
adenoma tissues from affected members of 2 unrelated families with acromegaly. As none of 
the patients had germline mutations in the MEN1 gene, they concluded that the pituitary lesions 
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might be due to another mutated gene located in the 11q13 region124. One year later, the same 
group125 managed to further narrow the LOH region to 8.6 cM: 11q13.1-11q13.3. The 8.6 cM 
region was reduced in 2005 to an only 2.21 Mb region as Soares et al.126 used haplotyping and 
allelotyping techniques to evaluate 8 familial isolated somatotropinoma cases which were 
compared to 15 sporadic somatotropinomas. Only three genes from this region were considered 
potential candidates and were further submitted to sequencing, but no mutations were actually 
identified. Only in 2006 Vierimaa et al. found linkage to chromosome 11q12-q13 by genotyping 
of a large Finnish family with pituitary adenoma predisposition116. 
AIP protein 
AIP belongs to the group of proteins harbouring conserved C-terminal tetratricopeptide-repeat 
(TPR) domains of 34 amino acids residues forming two palindrome alpha helices. The AIP protein 
has 3 TPR domains and a final 7th helix142. The N-terminal of AIP has a peptidyl-prolyl cis-trans 
isomerases (PPIase)-like domain and due to this structure AIP protein has a high degree of 
homology with proteins that belong to immunophilin family, such as FKBP52 (52 kDa FK506-
binding protein). 
The human AIP gene has four alternative mRNA transcripts (Figure 5) reported by the Ensembl 
database. Three of the four transcripts encode for a protein as they have the PPIase-FKBP 
domain and some of the TPR domains. Two of the isoforms are predicted to encode for shorter 
proteins that are also reported in GenBank, but their biological relevance is still unknown143. 
However, only the longest isoform has all three TPR domains, encoding for a 330-amino acid 
protein with a molecular mass of approximately 37 kDa (UniProt: O00170)144. 
 
Figure 5: A schematic illustration of the alternative splicing of human AIP into four isoforms. 
(http://www.ensembl.org/Homo_sapiens/Gene/Splice?db=core;g=ENSG00000110711;r=11:67250512-
67258574) 
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The crystal structure of human AIP protein was solved by two groups. In 2012, Linnert et al. 
published the N-terminal part of the protein145 while the C-terminal part was crystalized in 2013 
by Morgan et al142 (Figure 6). The main motifs of the protein are, according to UniProt (accessed 
on 22.07.2015): PPIase domain: amino acids 31-121; TPR1 domain: amino acids 179-212; TPR2 
domain: amino acids 231-264; TPR3 domain: amino acids 265-298 and the C-terminal α-7 helix: 
amino acids 300-330144. 
 
Figure 6: The AIP crystal 
structure. The most highly 
conserved residues are in the 
TPR domains, three antiparallel 
double helices and in the final 
alpha helix. 
In 1998, Das et al.146 published the crystal structure of the TPR domains of protein phosphatase, 
PP5. They showed that pairs of antiparallel α-helices, consisting of 34 amino acids, are packed 
together in an arrangement so that the protein folds into a right-handed super-helical structure 
necessary for the recognition of target proteins. Based on this three dimensional protein 
structure, Russell et al.147 predicted that some of the amino acid residues in TPR regions are 
conserved (Figure 7), and are likely to mediate protein-protein interaction. Their focus was 
mainly on the residues that may be important for interactions with Hsp90. Only a few years 
later, different groups introduced point mutations in AIP (Bell & Poland 2000148, Meyer et al. 
2000149, Laenger et al. 2009150), confirming the importance of the specific conserved amino acids 
for AIP–AhR or AIP–Hsp90 interactions. These changes were also identified in patients with 
pituitary adenomas. The first patient with a mutation in one of these crucial amino acids was 
published by Daly et al. in 2007151. The detected change was in lysine (K) at position 11: p.K241E. 
Later, Leontiou et al. 200889 identified a change in the cysteine (C) at position 8 (p.C238Y)), while 
the isoleucine (I) at position 27 (p.I257V) was the last one reported and it was detected in a 
patient with a TSH-secreting pituitary adenoma (Montanana et al. 2009152). 
PPIase domain
(purple, amino acids 31-121)
C-terminal α-7 helix
(red, 300-330)
TPR1
(green, 179-212)
TPR2
(yellow, 231-264)
TPR3
(orange, 265-298)
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Figure 7: Representation of the TPR motifs of AIP. Top panel: A TPR motifs are composed of a pair of 
antiparallel helices, A and B. Consensus amino acids are located at positions 4, 7, 8 and 11 in helix A and 
at positions 20, 24, 27 and 32 in helix B). Residues 8 and 20 are located at the position of closest contact 
between the A and the B helices of a TPR, whereas residue 27 on helix B is located at the interface of three 
helices (A, B and the A helix of the next TPR motif) within a three-helix bundle. Patients with familial 
isolated pituitary adenoma have been identified with mutations affecting these crucial amino acids, such 
as the cysteine (C) at position 8 (p.C238Y), the lysine (K) at position 11 (p.K241E) and the isoleucine (I) at 
position 27 (p.I257V). Adapted from Trivellin et al. 2011153. 
AIP protein is ubiquitously expressed in both developmental and adult stages. AIP expression is 
substantial and has been confirmed in human and murine multiple tissues including heart, brain, 
skeletal, liver, muscle, kidney, testis, ovary and pituitary etc. At the cellular level AIP is 
predominantly cytoplasmic139,154 but nuclear expression was also reported149. High expression of 
AIP is apparent in two types of adult pituitary cells: growth hormone (somatotrophs) and 
prolactin (lactotrophs)89. 
AIP interacts with a very wide repertoire of molecular partners155 (Table 3). The TPR domains 
mediate AIP’s interactions with most of its known partners, such as AHR, Hsp-70/90, survivin, 
phosphodiesterase-2A&4A5, TOMM20 and Gα12/13153.  
AIP
TPR2
231-264
Helix A Helix B
C238Y K241E I257V
Y268C H275Q
V291M
AIP
TPR3
265-298
p.Y202C
AIP
TPR1
179-212
p.C254R
p.C254W
AIP
TPR2 AIP
TPR3
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Partner Full name AC-MS co-IP Y2H RC Other 
Confirmed 
interaction 
Function Organism and/or cell type(s) 
ACTB156 Actin, cytoplasmic 1  ✓     N Cytoskeletal component COS-7 cells 
AGO1157 
Argonaute RISC catalytic  
component 1 
✓ ✓    N RNA interference 
 HEK 293, HeLa, and A549 
cells  
AhR154,158-160 Aryl hydrocarbon receptor   ✓ ✓ ✓  Y 
Adaptive and toxic responses, 
development 
HeLa, Hepa1c1c7, COS-1, B-
cells 
ARNT140,161 
Aryl hydrocarbon receptor nuclear 
translocator 
 ✓ ✓ ✓  Y 
Transcription factor activity, 
sequence-specific DNA binding 
HeLa cells, HepG2, HeLa, 
COS7 cells  
BIRC5162 
Baculoviral IAP repeat containing 5 
(Survivin) 
✓ ✓   ✓ Y Suppression of apoptosis 
HeLa, MCF-7, 
Raji cells 
CDC37163 
Hsp90 co-chaperone cell division 
cycle 37  
✓    AC-L N cell division, regulation of cell cycle 
Stable polyclonal 293T cell 
lines 
CDK9164,165 Cyclin-dependent kinase 9  ✓     Y regulation of transcription HEK293T cells  
EGFR166 Epidermal growth factor receptor     PCA N 
Cellular proliferation, survival, 
adhesion, migration, differentiation 
Human fetal brain 
EIF2S3167 
Eukaryotic translation initiation 
factor 2 subunit 3 
    Co-F N GTPase activity, GTP binding 3 populations of cells 
Gα13 
Guanine nucleotide binding protein 
(G protein), alpha 13 
  ✓ ✓  N 
Mediates receptor-stimulated 
signalling pathways 
HEK293T, epa1c1c7, COS-7 
cells 
GNAQ168 
Guanine nucleotide binding protein 
(G protein), q polypeptide 
   ✓  N 
modulators or transducers in 
transmembrane signalling systems 
 HEK293T, COS-7 and 
Hepa1c1c7 cells 
HSP90AA1161,163,16
9,170 
Heat shock protein 90kDa alpha 
(cytosolic), class A member 1 
✓ ✓  ✓ AC-L Y protein folding; response to stress 
293T, HeLa, COS7 and SK-N-
MC, HEK-293 cells; Mouse 
embryonic fibroblasts,  
HSP90AB1163 
Heat shock protein 90kDa alpha 
(cytosolic), class B member 1 
 ✓   AC-L N 
DNA binding, double-stranded RNA 
binding,  
293T cell lines 
HSPA8171 Heat shock cognate 71 kDa protein   ✓    N 
Repressor of transcriptional 
activation 
COS-7 cells 
HeLa cells 
HSPA9167 
Heat shock 70kDa protein 9 
(mortalin) 
    Co-F N ATP binding; poly(A) RNA binding 3 populations of cells 
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HSC70 Heat shock cognate 70 ✓     N 
Protein folding,  
Mitochondrial protein import,  
HeLa cells 
IRF7157 Interferon regulatory factor 7 ✓   ✓  N 
transcription factor activity, 
sequence-specific DNA binding 
 HEK 293, HeLa, and A549 
cells  
NADSYN1163 
Glutamine-dependent NAD(+) 
synthetase  
✓    AC-L N 
glutaminase activity; 
NAD+ synthase activity 
293T cell lines 
NR3C2169 
Nuclear receptor subfamily 3, group 
C, member 2 
 ✓    N Mineralocorticoid receptor  
 Mouse embryonic 
fibroblasts,  
SK-N-MC, HEK-293  
PDE2A3172 
cGMP-dependent 3',5'-cyclic 
phosphodiesterase 2A  
 ✓ ✓  Co-loc Y cAMP and cGMP degradation 
Human brain, 
COS-1, HeLa cells 
PDE4A589,173 
cAMP-specific 3',5'-cyclic 
phosphodiesterase 4A  
 ✓ ✓   Y cAMP degradation 
Rat brain 
COS-7 cells 
PPARα174 
Peroxisome proliferator-activated 
receptor alpha 
 ✓  ✓  N Regulation of energy homeostasis Mouse liver 
PTGES3163,169 Prostaglandin E synthase 3  ✓ ✓   AC-L Y 
prostaglandin-E synthase activity; 
telomerase activity 
293T cell lines, Mouse 
embryonic fibroblasts, SK-N-
MC, HEK-293  
RET162 
Rearranged during transfection 
tyrosine-kinase receptor  
 ✓ ✓  PCA N Development, maturation, survival 
Human fetal brain, rat 
pituitary, neuroblastoma and 
HEK293 cells 
TNNI3K175 TNNI3 interacting kinase   ✓   N 
Promotes cardiomyogenesis, 
enhances cardiac performance 
Human heart 
TOMM20142,171 
Mitochondrial import receptor 
subunit TOM20 homolog  
   ✓  N Mitochondrial import receptor 
Human fetal liver, COS-7, 
HeLa cells 
USP19163 Ubiquitin specific peptidase 19  ✓   AC-L N ubiquitin-specific protease activity 293T cell lines, 
YES1165 
YES proto-oncogene 1, Src family 
tyrosine kinase 
✓     N 
non-membrane spanning protein 
tyrosine kinase activity 
HEK293T cells 
Table 3: Interacting partners of aryl hydrocarbon receptor-interacting protein (AIP). The techniques used to identify the various interactions, the functions of the different AIP 
partners, cell types where the interactions have been examined are reported. Adapted from Trivellin et al.153 and updated from UNIPROT database144 
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Previous data suggested that the ubiquitously expressed AIP protein acts as a co-chaperone to 
heat-shock protein-90 (Hsp90) and regulates nuclear-cytoplasmic shuttling of the nuclear 
receptor AhR, whose ligands include the environmental toxin dioxin140. 
AHR 
Over the last few years there was an increased interest in understanding the function of AIP in 
the AHR signalling pathway. However, the vast majority of studies have focused on toxicology 
rather than mechanistic aspects of AHR function149,176,177. As a consequence, little is known with 
regards to the role of AHR in the regulation of tumorigenesis. AHR is chronically activated in 
tumour cells and facilitates all the major stages of tumorigenesis, from initiation and progression 
to metastasis178. In vitro studies have shown that AIP stabilizes AHR in the cytoplasm by forming 
an AIP/AHR/Hsp90/p23 complex. AHR is mainly a ligand-activated transcription factor, which 
binds to the environmental toxin 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Upon TCDD 
binding, the AHR/AIP/Hsp90/p23 complex translocates into the nucleus, where AHR undergoes 
conformational changes that enable it to detach from the complex. AHR then binds to DNA at 
xenobiotic response element sequences, inducing the transcription of xenobiotic-metabolizing 
enzymes179. Although TCDD is a known carcinogen that induces toxicity in the liver, endocrine 
glands or skin, it is still unclear whether this is involved in pituitary tumorigenesis. Epidemiology 
studies on the relationship between TCDD exposure and pituitary tumorigenesis in humans have 
not been conclusive56,57. 
Although no significant increase was identified, this is an issue that warrants further study. A 
mouse model of AHR deficiency is available. However, AHR mutant mice do not develop pituitary 
adenomas180,181 and consequently the role of AHR on pituitary tumorigenesis remains elusive. 
Site-directed mutagenesis experiments were used for finding the putative phosphorylation sites 
involved in AIP-AhR interaction. These were determined by a two-dimensional phosphopeptide 
mapping analysis. The findings revealed that changes in any or all of serine residues 43, 53, 131, 
132, and 329, did not interfere with AIP ability to bind AHR. However, serine residue S53 could 
be essential for the nuclear translocation of AIP182. Mass spectrometry studies revealed possible 
other putative phosphorylation sites183. 
cAMP pathway 
While the vast majority of studies involving AIP partners have focused on the AhR pathway, 
other AIP partners have been identified that could mediate disease pathogenesis153. Recently, 
two studies have highlighted a potential role of G proteins (Gαs and Gαi) in this process. 
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According to these reports, AIP inactivation is associated with low cAMP-Gαi signalling184,185 
enabling the development of somatotropinomas in AIP positive patients185  
It was previously shown that cAMP/PKA signalling is involved on the synthesis and secretion of 
GH and PRL186,187. Moreover, as cAMP production is regulated by G proteins, the cAMP pathway 
plays a crucial role in multiple endocrine tissues, and many hormone receptors are 
transmembrane G protein coupled receptors (GPCRs). G proteins have three different subunits, 
α, β and γ. Up to 40% of sporadic GH-producing tumours are caused by mutations in the 
GNAS1188 gene, which encodes the Gsα subunit. Pathogenic changes in this gene are also 
responsible for somatotropinomas and prolactinomas in McCune-Albright syndrome189. 
Deregulated cAMP signalling may also arise due to mutations in the gene which encodes for the 
protein kinase A type 1A regulatory subunit (PRKAR1A). Mutations in PRKAR1A have been 
identified in patients with GH/ PRL-producing tumours in the context of Carney complex190-192. 
Therefore, a potential role of AIP in cAMP signalling remains an attractive hypothesis to explain 
the effect of AIP loss in pituitary tumours. However, it is still unclear whether G proteins directly 
interact with AIP or if there are other specific molecular interactions necessary for the described 
functional changes to occur. Nevertheless, the AIP-cAMP link is a promising candidate pathway 
in the development of AIP positive tumours.  
Cytoskeletal proteins 
In sharp contrast to AHR and cAMP signalling, some of the proposed AIP partners have not been 
confirmed by independent studies. These include the cytoskeletal proteins actin and dynein, the 
epidermal growth factor receptor (EGFR), and the cardiac-specific kinase TNNI3K166,175. 
The putative interactions of AIP with cytoskeletal proteins are still controversial. One study 
reported no or very weak binding of the AIP PPIase-like domain to cytoplasmic dynein193. A 
different group156 reported that AIP-mediated cytoplasmic retention of AHR149,194,195 requires 
anchoring of the complex to actin filaments and proposed the existence of a direct AIP-actin 
interaction. However, in subsequent studies by Petrulis et al.177, this direct interaction was not 
validated. This discrepancy may be due to the fact that different cell types were used in the two 
studies. These results highlight the need for further studies regarding the role of the actin 
cytoskeleton in the regulation of AIP function. 
Based on the function of the actin cytoskeleton, it remains an interesting candidate for both the 
pituitary tumorigenesis process and the aggressive behaviour of pituitary adenomas. Actin is 
ubiquitously and highly expressed and has key roles in cell motility. Cell migration is a central 
process essential for normal development196, as well as a major player in pathologic processes, 
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especially tumorigenesis and metastasis197,198. The core molecular mechanism of cell migration 
involves a combination of actin polymerisation, integrin receptor ligand binding and actomyosin 
contraction. The actin cytoskeleton dictates how adhesions are assembled at the leading edge 
of a cell, by serving as a dynamic scaffolding network. This is a two-way process, as actin 
polymerisation and organisation is mediated by migration-related signals via integrin 
receptors199. It was shown that actin polymerisation is more intense at the leading edge of cells, 
where integrin receptors bind to their extracellular ligands and promote cell motility and 
migration200. 
Bearing in mind that AIP is a co-chaperone protein, with a wide range of interacting partners 
and with ubiquitous expression, it is likely that the effect of AIP mutation is due to poorly 
understood molecular interactions or disturbed signalling pathways, and not due to AIP 
expression levels or pattern. 
The adenohypophysis is a tissue with epithelial structure and most of this gland is formed of 
sinuous strings of epithelial cells in close contact with abundant vascular tissue. Consequently, 
to better understand the involvement of AIP in tumorigenesis and invasion of pituitary 
adenomas, it is essential to investigate how loss of this protein affects its interacting partners, 
the structure of the epithelial tissue and the connection with surrounding tissues. The 
developing Drosophila wing is a very simple in vivo model to investigate the molecular 
mechanisms involved in cell shape changes associated with rearrangement of epithelial sheets 
during tumorigenesis. 
Clinical features 
There is considerable phenotypic difference between families that exhibit or not AIP mutations, 
with childhood- and young-onset somatotroph adenomas often leading to gigantism, 
predominating in the families with AIP mutations. Numerous studies have revealed that both 
AIPmut positive tumours and AIPmut negative sporadic somatotrophinomas with low AIP 
protein expression show an invasive phenotype89,119,201,202. It was also published that up to 70% 
of AIP mutations are associated with somatotroph or somatolactotroph adenomas102,120,153. 
A very recent study conducted by Hernandez-Ramirez et al. in 2015117 revealed a number of 
novel FIPA aspects. The majority (71.7%) of FIPA AIPmut positive patients are young at the onset 
of disease as they had the first signs of pituitary adenoma during the second and third decades 
of life. Contrary, only 39.2% the AIPmut negative FIPA patients, developed the pituitary 
adenomas around the same stage of life. Most commonly, in both AIPmut positive and negative 
families, the patients were diagnosed with GH excess; however, a significantly higher number of 
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cases were diagnosed in the AIPmut positive. Regarding the size and extension of pituitary 
adenomas between these two types of families AIPmut positive FIPA patients were found to 
have significantly larger tumours, as revealed by evaluating the maximum diameter. Although 
the group published that they found a higher prevalence of macroadenomas in AIPmut positive 
FIPA, overall, not all the AIPmut patients had tumours with an aggressive behaviour. 
Interestingly, a phenotype-genotype correlation was also found as patients with truncating AIP 
mutations usually have a younger age at the onset of the disease. Consequently, a higher 
percentage of gigantism was found among patients with truncating AIPmuts compared to those 
with nontruncating AIP variants117. 
Previous studies have published that there an increase ratio of males to females in AIPmut 
positive familial cases; however, this finding was not confirmed by this study. Even more, it was 
found an equal number of male and female among unaffected carriers. 
Animal models for pituitary tumorigenesis due to loss of AIP 
The AIP protein sequence is evolutionarily conserved among species. The percentage of 
homology between species varies from 100% of protein identity in primates (P. troglodytes), to 
around 94% in rodents (R. norvegicus: 93%, M. musculus: 94%). The homology levels are much 
lower in more inferior organisms such as D. rerio (66%), or D. melanogaster (40%); however, in 
all the species the protein has the same PPIase-like domain and TPR repeats153. The fact that AIP 
is highly conserved among the species might be related to the fact that this is a disease-
associated protein203. 
For many years, animals have been used as models for understanding the mechanisms behind a 
wide variety of neoplasms that occur in humans. The initial studies used rodents that 
spontaneously develop cancers, which are also prevalent in humans, such as lymphoma, bladder 
cancer, and melanoma. The increased performance in the field of genetic engineering 
technologies led to a boost in recent years in the use of genetically-modified rodents that 
manifest a wide variety of neoplastic conditions. These changes have served to radically change 
the landscape of the studies that are focused on the mechanisms of pituitary adenomas 
tumorigenesis.  
Mouse models 
A first Aip KO mouse model was generated by Lin et al. in 2007 and demonstrated an essential 
role for AIP during embryonic development as Aip-/- mice die at E10.5-14.5204. Most of the 
abnormalities were present in the cardiovascular system: double-outlet right ventricle, 
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ventricular septal defects and pericardial oedema. In the same time, the heterozygous Aip+/- 
mice were apparently normal, with no obvious phenotype. 
A second attempt to generate the mouse model came from the same group and resulted in a 
hypomorphic model of Aip deficiency. The penetrance of the phenotype (a patent ductus 
venosus), was variable depending on the genotype; up to 83% of the Ara9(fxneo/fxneo) mice181. The 
same phenotype was described in a model of Ahr KO mouse205, and the fact that the levels of 
ARA9 expression were perfectly correlated with the frequency of the phenocopy of the Ahr-null 
allele led the authors to the conclusion that ARA9 is an essential protein for AHR signalling during 
development. 
As there was still necessary a mouse model for pituitary tumorigenesis, in 2010 Raitila et al. 
published a heterozygous partial deletion of Aip. In contrast to previous models, the 
heterozygous mice developed normally. However, as expected, this model developed pituitary 
adenoma, in particular somatotropinomas, more frequently of the pars distalis of the anterior 
pituitary. Only a small percentage of these mice developed prolactinomas and 
corticotrophinomas. LOH was also detected in the tumour tissue. The adenomas were first 
detected at six months, and reached full penetrance by 15 months. Ki-67 analysis of the tumour 
suggested a more aggressive disease, as the Aip-deficient tumours have a higher proliferation 
index206. Additionally, IGF-1 concentrations were significantly elevated, similar to the clinical 
presentation in the human pathology, thereby providing increased evidence for AIP involvement 
in pituitary tumorigenesis. Although this mouse model strongly resembles the human disease, 
it has two important limitations. In human pathology, almost 25% of AIP mutation-positive 
somatotropinomas developed during childhood and adolescent stages207-209; however, the 
mouse model developed the tumour at adulthood with full penetrance at 15 months. Secondly, 
low penetrance is a characteristic of AIP-associated which is also different than the described 
model. 
Zebrafish models 
The interest of using zebrafish (Danio rerio) in genetic studies comes from its ease of use, relying 
on the rapid development cycle, transparent embryos, fully sequenced genome and availability 
of mutant strains210. The zebrafish (Zf) model offers high anatomical and functional similarities 
to human neuroendocrine system. Zebrafish is an excellent model for the study of the human 
endocrine system211, displaying high anatomical and functional similarities with humans: the 
hypothalamus regulates pituitary function, producing oxytocin and vasopressin that are 
released from the posterior pituitary, and also produces releasing factors (at least six), which in 
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turn control the synthesis and secretion of the anterior pituitary hormones. Our laboratory has 
pioneered the use of Danio rerio and we have developed research tools for studying the effect 
of loss of AIP212. We generated Aip knockdown Zf embryos with antisense morpholino 
oligonucleotides injected to randomly-selected embryos at one-cell stage, using injected 5-base 
mispaired oligonucleotide as control morpholino. Aip Morpholino KD Zf embryos demonstrate 
brain, pericardium, eye, and swim bladder anomalies along with general developmental delay, 
pointing to wide developmental role of the AIP gene. Aip morphant embryos exhibit stronger 
PRL immunostaining in the pituitary compared to controls suggesting a possible increase in 
proliferative activity (hyperplasia or tumour) at the pituitary level in the absence of AIP gene 
function213. This attractive model can be proposed as an intermediary stage between cell 
culture/Drosophila and mammalian experimentation ultimately refining analysis and reducing 
costs. Nevertheless, despite all the efforts in understanding the physiological function of AIP 
regarding cell proliferation, the actual mechanism and the identity of its interacting partners 
relevant to pituitary tumorigenesis are still unknown. 
1.4 Drosophila melanogaster: a model system 
Drosophila as a model for cancer studies 
One main question that is always asked is: how relevant is Drosophila melanogaster for the study 
of human cancer mechanisms? The signalling pathways involved in tissue and organ 
development, cell proliferation, cell survival, and cell migration are highly conserved in 
Drosophila214,215. Different studies in flies have been extremely informative: Drosophila tumours 
successfully model many of the features of mammalian cancers including an unlimited 
proliferative potential. Also, in malignant neoplasia, Drosophila tumours mimic the disruption of 
tissue architecture and the proprieties to invade and to metastasize causing host lethality. The 
results of fruit fly studies were shown to be transferable to humans: more than half of the known 
human disease genes, have homologues in Drosophila melanogaster216. 
As most of the signalling pathways214,217 and most of molecular mechanisms involved in the 
control of growth and the cell cycle are well-conserved218-220, in this project I propose to utilise 
the experimental advantages of the fruit fly to discover the conserved functions of AIP. 
The first studies using Drosophila as an animal model were conducted by William Castle at 
Harvard University in 1901. This research was considerably improved by Thomas Hunt Morgan 
who first isolated a naturally occurring Drosophila mutation – white. This mutation causes a 
change in the eye colour, from red to white. Morgan and three of his students (Sturtevant, 
Bridges and Muller) demonstrated that genes are carried on chromosomes221,222. Their work on 
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multiple mutations allowed them to discover the notions of “crossing over” and genetic linkage. 
Another major step was introduced by Muller, who used balancer chromosomes in order to be 
able to maintain homozygous lethal mutations. 
But the moment that established the fruit fly as a valuable model system in research was the 
Nobel Prize awarded to Lewis, Nüsslein-Volhard and Wieschaus in 1995 due to their work in 
genes controlling development. More recent studies focused on tumorigenesis in Drosophila 
and understanding of some of the essential characteristics of human neoplasia. 
Today, it is consider that around 50% of the proteins that are involved in human diseases, 
including cancer, have a conserved orthologue in fruit fly223,224 . In some cases, it was already 
shown that the degree of conservation is so high that the human genes can rescue the loss of 
corresponding Drosophila orthologues225. As a result, it should not be a surprise anymore that 
very important findings derived from fly research are extremely relevant to human medicine. 
There are Drosophila studies that led to the identification of a protein and its molecular function 
long before its implication in cancer of the corresponding human homologue was discovered. 
An important example is Notch, which was first identified in fruit fly, and later genetic and 
molecular fly studies have unveiled some of the Notch targets and partners. Many years later 
aberrant expression of human NOTCH1 was identified as being involved in T cell acute 
lymphoblastic leukaemia226. Another important cancer gene that was first identified in fruit fly 
is hedgehog (hh) – a segment polarity gene. The Hedgehog signalling pathways were first 
understood with the help of Drosophila studies and a few years later human mutations affecting 
hh signalling were identified as a causing factor in basal cell carcinoma and medulloblastoma227. 
There are numerous studies on D. melanogaster that helped to understand the molecular basis 
of human cancer, I will mention a few below. 
Drosophila as a model for BRCA2 mutations 
Heterozygous mutations in BRCA2 confer a high risk of breast cancers in humans, but the BRCA2 
gene is the first example on how studies involving Drosophila melanogaster led to the discovery 
of the cancer-relevant proteins in humans. Studies involving genetic analysis of BRCA2 in fruit 
flies have shown that this gene plays a major role in homologous recombination by having a 
protective role against large deletions228. This gene is also an important example on how a 
protein that is involved in a human cancer involving a tissue that has no equivalent in flies (the 
mammary gland in this case) may be better understood due to basic research carried out in 
Drosophila. 
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Drosophila as a model for glioblastoma  
Another example includes fruit fly models of glioblastoma, one of the most malignant human 
brain tumours. This type of cancer is due to mutations that activate the epidermal growth factor 
receptor (EGFR) and phosphatidylinositol-3 kinase (PI3K) signalling pathways. The authors 
showed that loss of Rbf1, one of the two retinoblastoma (RB) genes in flies, led to constitutive 
co-activation of EGFR-Ras and PI3K pathways in Drosophila glia and to the development of 
invasive glial cells that create transplantable tumour-like growths, mimicking human gliomas229. 
Drosophila as a model for Neurofibromatosis 1 
Neurofibromatosis 1 (NF1) is typically a childhood onset multisystem genetic disorder 
characterized by café-au-lait spots, skeletal dysplasias, and by the benign and malignant brain 
tumours of the peripheral nervous system. Although most cases do not develop metastasis, the 
health burden is still significant as the majority of affected children/adolescents suffer from 
debilitating skeletal defects and learning disabilities. The genetic cause is mutation of the NF1 
gene230. An important step forward in understanding this disease pathology was the use of 
Drosophila. The first significant results were published in 2001 by Williams et al. and they 
successful provided evidence that NF1 regulates Ras signalling231. The end point of these studies 
was the development of Ras pathway inhibitors used in the treatment of neurofibromatosis 
patients232. 
Overall, the record of Drosophila use as a model for tumorigenesis is impressive. The tools 
developed in this field offer the advantage of detailed in vivo exploration of interactions 
between cells, tissues, and genes. There is a constant increase in the number of laboratories 
that choose to take advantage of this valuable animal model to explore cancer mechanisms and 
even therapeutics233. 
Advantages of Drosophila melanogaster as a model system 
As an animal model, Drosophila has important advantages that make it extremely valuable in 
research. Males are easily distinguishable from females. These insects are very small and as such 
require a limited space in the lab, are cheap, clean, harmless (some people might present 
occasional allergies), and easy to maintain in stable stocks. They have very short generation 
time, about 10 days at 25°C, and this allows multiple and parallel independent experiments to 
be performed and repeated within a relatively short time period. Even more, as the length of 
the life cycle is temperature-dependent, this enables researchers to increase the fruit fly life 
span by raising them at 18°C, or to shorten it at 29°C, based on the experimental requirements  
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The life cycle includes different phases that are easily identiﬁed (Figure 8). 
 
Figure 8: Life cycle of Drosophila melanogaster. The larva hatches 1 day after the egg is fertilised. First, 
second, and third instar are larval stages, each ending with a molt. During pupation most of the larval 
tissues are destroyed and replaced by adult tissues derived from the imaginal discs that were growing in 
the larva. Times are given for the life cycle at 25°C234. Source: 
http://www.nap.edu/openbook.php?record_id=9871&page=162 
 
One of the most important steps in Drosophila research was the sequencing of the entire 
genome223, a crucially important source of information that allowed the development of new 
bioinformatics studies. The entire genome sequencing revealed that more than 90% of the fruit 
fly genes are similar to the human and mouse genes. However, the Drosophila annotated 
genome, with its very small number of chromosomes, 180 million bases and ~13,600 estimated 
genes, offers a much simpler system than mammalian models223. 
Drosophila has only four pairs of chromosomes designated as 2, 3, 4 and X/Y (Figure 9). The Y 
chromosome has only a few genes that are important for spermatogenesis, but this 
chromosome is not essential for fly viability. 
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Figure 9: Mitotic chromosomes of D. melanogaster. The euchromatic regions, heterochromatic regions, 
and centromeres are displayed. Arms of the autosomes are designated 2L, 2R, 3L, 3R, and 4. The 
euchromatic length in megabases was derived from the sequence analysis. The Y chromosome is nearly 
entirely heterochromatic. Adapted from Adams et al. 2000223 
 
Apart from the fast development, another advantage of Drosophila is the fact that for each 
chromosome there were created balancer chromosomes. The first records of balancer 
chromosome use in Drosophila studies date back to 1975235. These are special modified 
chromosomes, which were designed via multiple, nested chromosomal inversions. The balancer 
chromosomes are able to suppress crossing over between homologous chromosomes during 
meiosis. If, by chance, the crossing over involving a balancer chromosomes occurs, the resulting 
chromatids either lacking some genes or have duplicated genes. As a consequence, the progeny 
is not viable. 
Typically, a balancer chromosome contains one or more dominant mutations that are visible 
phenotypic markers that enable researchers to follow the balancer through crosses. 
Furthermore, the main advantage of using balancer chromosomes is the ability to maintain 
lethal mutations in heterozygous stable stocks. Without balancer chromosomes lethal 
mutations would otherwise impair the survival of homozygotes216. The names of the balancer 
chromosomes are standardized based on the chromosome they serve to stabilize. The first letter 
of the chromosome's name represents the number of the chromosome it stabilizes. F stands for 
the first chromosome, S stands for second, and T stands for third. The second letter is an M, 
which stands for "multiply inverted". The M is followed by a number to distinguish balancers of 
the same chromosome: FM6, FM7s, and TM3. They also carry the name of the phenotypic 
marker the balancer carries. Additionally, the genetic marker or markers of the balancer are 
listed after the name and separated by a comma236. Below are a few examples of some markers 
used in this study, at least one for each chromosome (Figure 10). 
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Figure 10: Common phenotypic markers used in this study. Due to phenotypic markers the genetic 
crosses are totally predictable and verifiable, as the markers aids on tracing the inheritance of alleles (are 
clearly very distinct from wild-type)237. 
In the fly research community there is a free exchange of reagents and information (via 
databases such as Flybase, Virtual fly, etc.). Also part of the advantages is the wide spectrum of 
methods that can be used. The adaptation of the Gal4/UAS system238 from yeast (detailed in 
section 3.2.1), together with immunostaining and in situ hybridisation, mutants and rescue 
experiments, made it possible to achieve an increasingly more detailed analysis of tumorigenesis 
mechanisms.  
In addition to the advantages mentioned above, Drosophila provides the ability to perform 
forward genetic screens to generate mutant stocks that allow investigation of fundamental 
questions regarding tumour development during embryogenesis and in the adults. 
Disadvantages of Drosophila as model system 
All animal models have limitations, and Drosophila is no exception. This animal model organism 
has as a main disadvantage the issue of care and intensive handling as fly stocks have to be 
maintained alive and cannot be frozen. Another negative aspect of is that its small size precludes 
detailed study of pathology and cause of death. Together with some lacking information 
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regarding detailed anatomy during development, this poses a problem for developmental 
studies. 
There are also a few limitations of the fruit fly as an animal model for tumorigenesis. Flies do 
not have an adaptive immune system. Although flies possess a rudimentary heart with internal 
organs, they also do not have a closed circulatory system of endothelial cell-derived blood 
vessels. Flies also lack telomerase and use a different mechanism in order to maintain the length 
of the telomere. As a result of these differences, Drosophila is not a perfect cancer model to 
model mammalian carcinogenesis, but the fruit fly might be extremely informative about the 
essential factors that initiate tumour formation. 
Drosophila’s AIP orthologue 
The Drosophila melanogaster gene CG1847 (NM_132530.4)239 is the fruit fly’s single orthologue 
of human AIP (40% amino-acid identity). The gene is located on chromosome X at position 10F2, 
from base pair 11,869,170 to base pair 11,871,168 on the positive strand. It has 3 exons. As it is 
located on X chromosome, males will have only one copy of this gene. 
 
Figure 11: A schematic illustration of the alternative splicing of CG1847 into two isoforms. 
(http://www.ensembl.org/Drosophila_melanogaster/Gene/Splice?db=core;g=FBgn0030345;r=X:117622
33-11766188;t=FBtr0073567) 
Structurally, CG1847 is a 320 aa protein and shares a significant degree of identity and homology 
with its human orthologue as it has one peptidyl-prolyl cistrans isomerases (PPIase)-like domain 
and three TPR repeats (Figure 11). However, currently there is no published data focusing on 
the function of this Drosophila gene.  
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AIMS OF THE STUDY 
Overview on the subject 
The main aim of this study was to understand the role of AIP orthologue during Drosophila 
development and to reveal the signalling pathways and the AIP orthologue partners that enable 
cells to proliferate, migrate, and invade into surrounding tissues when AIP protein structure is 
changed.  
The structure of this thesis 
The aims of the work presented in this thesis are to understand the results of loss of CG1847 in 
an in vivo model. More specifically;  
 First (Chapter 3):  
- To establish Drosophila melanogaster as a model to study AIP/CG1847 silencing. 
- To characterise CG1847 function during fly development by silencing CG1847 
(by knockdown and knockout). 
- To reveal the potential underlying molecular mechanisms of loss of AIP by 
performing a whole transcriptome analysis using Illumina Next Generation 
Sequencing. RNA-seq was performed in 48 h old mutant (CG1847exon1_3) versus 
control male larvae isolated using fluorescent markers. This allowed us to 
determine gene expression profiles using an established analysis pipeline and 
to identify key pathways that are significantly altered in the mutant and are 
related to embryonic development or survival. 
 Second (Chapter 4):  
- To reveal the molecular partners of Drosophila AIP involved in cell-cell adhesion 
and to gain further insights on how CG1847 silencing leads to cell detachment, 
with a possible impact on tumorigenesis. 
 Third (Chapter 5):  
- To test the functional conservation between human and fly protein by rescuing 
the lethality of CG1847exon1_3 mutants via expressing human AIP cDNA under the 
control of a ubiquitous promoter during fly development.  
- To discriminate between pathogenic and non-pathogenic AIP mutations as this 
is a challenging problem in the management of patients carrying a missense AIP 
variant.  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Drosophila stocks  
The Drosophila melanogaster strains used in this study and their purpose and references are 
listed below, in Table 4. 
Control stocks 
wiso Gift from Nic Tapon 
Df(1) yw Lindsley and Zimm (1992)240 
yw,CG18472.39A/FM6 Precise excision generated in this project 
yw,CG18472.39A/FM7c,Dfd-YFP Precise excision generated in this project 
Stocks containing balancer chromosomes 
yw ; Bl/CyO ; Lindsley and Zimm (1992)240 
yw ; ; Dr/TM3 Lindsley and Zimm (1992) 
TrxR-1 D2/FM6 Gift from Fanis Missirlis241 
w+ Baz/FM7c,Dfd-YFP 
Bloomington Drosophila Stock Center:  
Stock ID: 23229 
Stocks containing GAL4 driver transgenes 
yw; Act-Gal4/CyO  Luo et al. (1994)242 
elav-Gal4 Luo et al. (1994) 
Hs-hid;hh-Gal4, UAS-DIAB/TM6B  Gift from Nic Tapon 
nub-Gal4/CyO Gift from Nic Tapon 
Cg-Gal4 
Bloomington Drosophila Stock Center 
Stock ID 7011 
Crq-Gal4 Gift from P. Ribeiro 
Dilp-Gal4/CyO Ikeya et all 2002243 
Mef2-Gal4 
Bloomington Drosophila Stock Center 
Stock ID 25756 
repo-Gal4 Glial cells specific driver 
drm-GAL4 
Bloomington Drosophila Stock Center 
Stock ID 7098 
HE-GAL4 
Bloomington Drosophila Stock Center 
Stock ID 8699 
c42-GAL4 Gift from P. Ribeiro244 
tinC-GAL4 Gift from M. Frasch (2001)245 
Stocks containing UAS-RNAi transgenes 
UAS-CG1847R-1 
National Institute of Genetics - Fly Stock 
Center: Stock ID: 1847R-1 
UAS-CG1847R-2 
National Institute of Genetics - Fly Stock 
Center: Stock ID 1847R-2 
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UAS-CG1847-T1: w1118; P{GD9582}v43701 
Vienna Drosophila RNAi Center: Stock ID: 
v43701 
UAS-CG1847 T2: w1118; 
P{GD9582}v43702/TM3 
Vienna Drosophila RNAi Center: Stock ID: 
v43702 
UAS-Dcr-2; ; UAS-CG1847T1 RNAi  
UAS-Dcr-2; ; UAS-CG1847T2 RNAi  
y[1] sc[*] v[1]; P{y[+t7.7] 
v[+t1.8]=TRiP.GL00168}attP2/TM3, Sb[1] 
Bloomington Drosophila Stock Centre 
Stock ID: 35270 
y[1] sc[*] v[1]; P{y[+t7.7] 
v[+t1.8]=TRiP.HMS00277}attP2 
Bloomington Drosophila Stock Centre 
Stock ID: 33399 
Mutant Drosophila AIP stocks 
w* P{EP}CG1847G1839 
Bloomington Drosophila Stock Center:  
Stock ID: 32600 
yw,CG1847exon1_3/FM6  
yw,CG1847exon1_3/FM7c,Dfd-YFP  
Stocks used for generation of mitotic recombination clones (Flp-FRT lines) 
w,Dm,FRT19ANeoR Gift from Nick Brown 
P{w[+mC]=Ubi-mRFP.nls}1, w[*], 
P{ry[+t7.2]= hsFLP}122 
P{ry[+t7.2]=neoFRT}19A 
Bloomington Drosophila Stock Center 
Stock ID: 31418 
w*ovo[D1]v24 P{FRT(whs)}101/C(1)DX, y1 
f1/Y; P{hsFLP}38 
Bloomington Drosophila Stock Center 
Stock ID: 1813 
Stocks containing GFP-tagged proteins 
mys5.4(βPS-GFP) Gift from Nick Brown246 
Recombinant lines 
CG1847exon1_3 FRT19ANeoR / FM7c, Dfd::YFP  
CG1847exon1_3/FM6; Actin-Gal4/CyO Ubiquitously driver 
CG1847exon1_3/FM6; Cg-Gal4/CyO Fat body specific driver  
CG1847exon1_3/FM6; Crq-Gal4/CyO Haemocytes specific driver 
CG1847exon1_3/FM6; Dilp-Gal4-Gal4/CyO Insulin secreting cells - specific driver 
CG1847exon1_3/FM6; Mef2-Gal4/TM3 Muscle specific driver 
CG1847exon1_3/FM6; elav-Gal4/TM3 Neurons specific driver 
CG1847exon1_3/FM6; repo-Gal4/TM3 Glial cells specific driver 
CG1847exon1_3/FM6; drm-GAL4/TM3 Gut specific driver 
CG1847exon1_3/FM6; HE-GAL4/TM3 Haemolymph specific driver 
CG1847exon1_3/FM6; c42-GAL4/TM3 Malpighian tubules specific driver 
CG1847exon1_3/FM6; tinc-GAL4/TM3 Heart specific driver 
Other lines 
y w ; ; Ki, pp, Δ2-3  
Table 4: Drosophila melanogaster lines used in this study.  Lines in white boxes were obtained from the 
Vienna Drosophila RNAi Center and the National Institute of Genetics - Fly Stock Center (Japan, 
http://www.shigen.nig.ac.jp/fly/nigfly/), as indicated in the text. Those in light grey boxes were existing 
lab stocks or gifts from other labs. The lines in dark grey boxes were generated during this study.  
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Transgenic lines carrying either wt CG1847 under the expression of its own promoter or human 
AIP cDNA variants generated by BestGene and used in this study are listed in Table 5:  
Transgenic lines 
CG1847/CyO 1M BestGene Stock ID: 12135-1-1M-Ch2 
CG1847/CyO 3M BestGene Stock ID: 12135-1-3M-Ch2 
UAS_hAIPwt/CyO 1M BestGene Stock ID: 14089-1-1M-Ch2 
UAS_hAIPwt/CyO 2M BestGene Stock ID: 14089-1-2M-Ch2 
UAS_hAIPtrunc/CyO 1M BestGene Stock ID: 12855-1-1M-Ch2 
UAS_hAIPtrunc/CyO 2M BestGene Stock ID: 12855-1-2M-Ch2 
UAS_hAIP-R16H/CyO 1M BestGene Stock ID: 14335-1-1M-Ch2 
UAS_hAIP-R16H/CyO 2M BestGene Stock ID: 14335-1-2M-Ch2 
UAS_hAIP-C238Y/CyO 1M  BestGene Stock ID: 14335-2-1M-Ch2 
UAS_hAIP-C238Y/CyO 2M BestGene Stock ID: 14335-2-2M-Ch2 
UAS_hAIP-A299V/CyO 1M BestGene Stock ID: 14335-3-1M-Ch2 
UAS_hAIP-A299V/CyO 2M BestGene Stock ID: 14335-3-2M-Ch2 
UAS_hAIP-R304Q/CyO 1M BestGene Stock ID: 14335-4-1M-Ch2 
UAS_hAIP-R304Q/CyO 2M BestGene Stock ID: 14335-4-2M-Ch2 
Table 5: Drosophila melanogaster transgenic stocks generated and used in this study  
2.1.2 Drosophila husbandry 
Fly strains were kept and raised in vials containing standard food medium (recipe in Appendix 3) 
and dry yeast. Two copies of each stock were kept in plastic vials (82x25 mm, B.T.P DREWITT) 
containing fly food and stored at 18˚C 65% humidity under 12 h: 12 h light: dark cycles. The 
stocks were flipped into fresh food vials every 4 weeks. For the working stocks or crosses, the 
ambient conditions were set to a 12 h: 12 h light: dark cycle, constant 25˚C, and 65% humidity. 
If required, crosses were flipped every 8-10 days to prevent the mix of individual flies from 
different generations. 
2.1.3 Collection of Adult Flies 
Unless otherwise indicated, fly crosses were maintained at 25°C. Recently eclosed males and 
females of the desired strains were collected using CO2 anaesthetisation. Male and female flies 
were separated during the first 4 hours after eclosion in order to select virgin females. Each food 
vial contained a maximum of 25-30 flies (depending on the purpose) and was kept at 18°C until 
the flies were crossed with the desired genotype. 
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2.2 Standard fly techniques 
2.2.1 RNAi-mediated silencing of CG1847  
CG1847 was silenced in Drosophila melanogaster using RNA-interference (a detailed description 
of the UAS-GAL4 system is described in section 3.2.1). Four UAS-CG1847-RNAi lines were tested 
(Table 4). UAS-CG1847-RNAi R1 and R2 lines were purchased from NIG-Fly Stocks (the RNAi 
constructs were inserted on chromosome 2 and 3, respectively). To confirm that the results were 
not due to an RNAi off-target effect, two additional RNAi lines, UAS-CG1847-RNAi T1 and T2 
were purchased from the Vienna Stock Center. These lines carry a different RNAi construct 
inserted on the 3rd chromosome. (Table 4). For more details regarding how these stocks were 
generated, the sequence of the inverted repeats, and the cloning strategies (Appendix 4 and 
Supporting Table 1). Figure 12 (below) depicts a schematic representation of the inverted 
repeats (IR) alignment to CG1847 showing non-overlapping of the IR constructs used by the two 
providers. 
 
Figure 12: Shematic representation of UCSC Browser Blat alignment of IR mapping to CG1847. The 2 IR 
constructs (in black) are targeting different areas of the gene. 
The Vienna stocks were combined with flies carrying the UAS-Dicer-2 transgene (Dcr-2) on the 
first chromosome in order to enhance RNAi potency247. This system facilitates the cleaving of 
the double-stranded RNA and the formation of the RNA-induced silencing complex (RISC), 
leading to a greater silencing of CG1847 (Table 4). 
NIG - Fly Stock Center:
Stock  ID  1847R-2
Vienna Drosophila RNAi Center:
Stock  ID v 43702
11,764,055
11,764,020
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Using 3 different drivers, I ectopically expressed specific CG1847 RNAi in all Drosophila cells, or 
specific subsets. The drivers used were elav-Gal4 (inserted in the X chromosome), Act-Gal4, nub-
Gal4 and hh-Gal4, inserted in 2nd and 3rd chromosomes, respectively (Table 4). Six to eight 
females carrying the universal or tissue-specific Gal4 driver were crossed with 3-5 males of the 
UAS-CG1847 RNAi line and maintained at 25°C. 
As stronger phenotypes resulted with UAS-CG1847-RNAi-R1, UAS-CG1847-RNAi-R2 and UAS-
CG1847-RNAi-T2 compared with UAS-CG1847-RNAi-T1, I will further present and discuss only 
these data. 
For UAS-CG1847-RNAi R1, the expected genotypes were: 
 Act-Gal4 / UAS-CG1847RNAi-R1  
 elav-Gal4 /+; UAS-CG1847RNAi-R1 / +  
 UAS-CG1847 R1 / +; + / hh-Gal4 
For UAS-CG1847-RNAi R2, the expected genotypes were: 
 Act-Gal4 / CyO; UAS-CG1847 R2 / + 
 elav-Gal4 / +;; UAS-CG1847 R2 / + 
 UAS-CG1847 R2 / hh-Gal4. 
 nub-Gal4 / CyO; UAS-CG1847 R2 / + 
For the third RNAi line, the combinations had the following genotypes: 
 Dcr-2 / +; Act-Gal4 / CyO ; UAS-CG1847 T2 / + 
 Dcr-2 / elav-Gal4; UAS-CG1847 T2 / +  
 Dcr-2 / +;; UAS-CG1847 T2 / hh-Gal4. 
 Dcr-2 / +; nub-Gal4 / CyO ; UAS-CG1847 T2 / + 
The RNAi efficiency was further tested by measuring the specific mRNA levels through semi-
quantitative RT-PCR (details in Chapter 3.2). Primer sequences are listed in Supporting Table 2. 
2.2.2 Generation of mutant CG1847 flies - Imprecise Excision screen 
To investigate the possible roles of the CG1847 gene, located on the X chromosome, a CG1847 
mutant line was created. The CG1847 gene was mutated by P-element transposase-mediated 
deletion of genomic DNA. For this, a fly line was obtained, in which a P-element is inserted within 
the 5’UTR of CG1847: w*P{EP}CG1847G1839 (Bloomington Drosophila Stock Center). This is a 
transgenic insertion stock generated through mobilization of a P-element construct P{EP} which 
carries a w[+mC] mini-white visible marker and UAS binding sites for GAL4 transcriptional 
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regulation248. The P-element was mobilised by crossing females homozygous for the P element 
with transposase carrying males of the strain: yw;+;Ki,pp,Δ2-3 (Mating scheme 1). 
F0: ♀ w P[w+]  
w P[w+]    
 X    ♂  y w; ; Ki, pp, Δ2-3  
 Y      Ki, pp, Δ2-3 
Set up about 200 individual crosses with females that have a lethal mutation on the X 
chromosome (allows easier selection in the next generation) 
 
F1: ♀ w P[w+]  ; ; Ki, pp, Δ 2-3    
    Y                      +                    
 X    ♂  TrxR-1 D2 
   FM6 
In the 3rd generation, screen for virgins that have w eyes, i.e. those who lost the P-element 
F2: ♀ w [E{P}]  
   FM6   
 X    ♂  FM6 
   Y 
In the next generation, the stable stock is obtained. Putative excision alleles were identified 
based on the lethality of male flies 
F3: ♀ w [E{P}] 
       FM6 
♀ FM6 
    FM6 
Infertile 
♂ FM6 
       Y 
♂ w [E{P}] 
         Y 
    LETHAL 
Mating scheme 1: Crossing scheme for generating CG1847 mutant fly 
Individual F1 males (which carry both the P element and the transposase) were crossed with 3 
first chromosome balancer w, FM6 females. These females also carried a lethal mutation on the 
other X chromosome TrxR-1D2 (Thioredoxin reductase1)241 which allowed selection of the 
desired alleles in the next generation as both TrxR-1D2/Y males and TrxR-1D2/ w [E{P}] (possible 
mutated) were lethal. In F2 the recently eclosed adults were selected for the presence of the 
dominant Bar marker and possibly one copy of the mutated CG1847 identifiable by Bar+ eye. 
Using the eye shape phenotype as a marker, the offspring with the desired genotype was 
selected. Single white-eyed female progeny from the F2 generation were back-crossed to FM6 
males to create a stable stock. Putative excision alleles were identified based on lethality of male 
flies. Females homozygous for the CG1847 mutation are not viable, while the hemizygous males 
do not emerge as adult flies. 
Mapping: Genomic DNA was isolated from heterozygous mutant females. The resulting stable 
stocks were screened by PCR to identify the shorter amplicons using the primers described in 
Appendix 5. The putative mutants were then sequenced to confirm the imprecise excision. In 
stock Δ25A a deletion of exons 1 and 2, and 3rd exon of CG1847 was identified, generating the 
desired CG1847 mutant (henceforth designated as CG1847exon1_3). 
For collection of male larvae carrying the CG1847 mutation, the FM6 balancer chromosome was 
replaced with the FM7c balancer, which also carries a fluorescent marker Dfd-YFP249. 
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F0: ♀ CG1847exon1_3  
   FM6   
 X    ♂  FM7c, Dfd-YFP 
           Y 
F1: ♀ CG1847exon1_3  
FM7c, Dfd-YFP 
 X    ♂  FM7c, Dfd-YFP 
            Y 
Mating scheme 2: Replacement of balancer chromosome in the CG1847 mutant stock 
2.2.3 Generation of control stock for mutant CG1847 (revertant) - Precise Excision 
screen 
The type of mutagenesis screen described above (section 2.2.2) has the advantage that it could 
generate both the desired mutant stock via imprecise excision of the P element, and, at the 
same time, a control stock (revertant) through precise excision250. The revertant can therefore 
be used as a control as it has the same genetic background as the mutant line. The P-element 
was mobilised in the same screening experiment as in section 2.2.2 (see below). 
F0: ♀ w P[w+]  
w P[w+]    
 X    ♂  y w; ; Ki, pp, Δ2-3  
 Y      Ki, pp, Δ2-3 
Set up about 200 individual crosses 
F1: ♀ w P[w+]  ; ; Ki, pp, Δ 2-3    
    Y                      +                    
 X    ♂  w FM6 
   l(1) 
In the 3rd generation screen for virgins that have w eyes, i.e. those who lost the P-element 
F2: ♀ w [E{P}]  
   FM6   
 X    ♂  FM6 
   Y 
In the next generation I obtained the stable stock. Putative excision alleles were identified 
based upon male’s lethality 
F3: ♀ w [E{P}] 
       FM6 
♀ FM6 
    FM6 
Infertile 
♂ FM6 
       Y 
♂ w [E{P}] 
         Y 
    VIABLE 
Mating scheme 3: Crossing scheme for generating revertant stock 
The stocks with viable males were screened by PCR, and in stock 2.39A, I confirmed by 
sequencing that the excision deleted almost the entire P element, with the exception of a 12bp 
region (footprint of the P element) generating the CG1847 control line. For further reference, 
this stock will be named CG18472.39A.  
As above, the FM6 balancer chromosome was also replaced with the FM7c,Dfd-YFP. 
F0: ♀ CG18472.39A  
   FM6   
 X    ♂  FM7c, Dfd-YFP 
           Y 
F1: ♀ CG18472.39A   
FM7c, Dfd-YFP 
 X    ♂  FM7c, Dfd-YFP 
            Y 
Mating scheme 4: Replacement of balancer chromosome in the control stock 
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2.2.4 Recombination crosses 
Recombination of CG1847exon1_3 mutant allele with FRT19ANeoR site 
The gene CG1847 is located at position 10F2 on the X chromosome. To generate mitotic clones 
mutant for CG1847, we recombined our CG1847 mutant allele with a transgenic stock carrying 
FRT recombination sites in the X chromosome. The FRT site is inserted on the X chromosome at 
19A2. For recombination, flies harbouring CG1847exon1_2 were crossed with those carrying the 
FRT19ANeoR site [w, Dm, FRT19ANeoR / w, Dm, FRT19ANeoR], a gift from Nick Brown (Table 4). 
F0: ♀ CG1847exon1_3  
       FM6 
X ♂  w,Dm,FRT19ANeoR 
              Y 
F1: ♀   CG1847exon1_3     
w,Dm,FRT19ANeoR          
X ♂  FM6  
   Y 
Set up 30 individual crosses 
F2: 
♀ CG1847exon1_3 FRT19ANeoR                  
FM6 
X ♂  FM6 
   Y 
Mating scheme 5: Recombination of the CG1847exon1_3 mutant allele and the FRT19A site.  
From the F1 generation females with both CG1847exon1_3 and the FRT19ANeoR on different X 
chromosomes were selected among the progeny. These females were selected on neomycin 
food, and were mated with first chromosome balancer males (FM6). In the last generation, 
individual recombined females were crossed back to three FM6 males. 
The identified recombinants were screened by PCR for the CG1847exon1_3 allele and for the 
presence of the neomycin the resistance gene, in order to confirm these combination event (for 
primers sequences see Appendix 5). 
Recombination of CG1847exon1_3 with mys5.4 
The mys gene is located at 7D5. For recombination, flies harbouring CG1847exon1_3 were 
crossed with those carrying mys5.4 (a βPS-GFP). In the next generation, females with both 
CG1847exon1_3 and mys5.4 on different X chromosomes were selected from the progeny. These 
females were selected based on the lack of a FM6 chromosome (females without Bar+) and 
were mated with first chromosome balancer males (FM6). In the last generation individual 
recombined females were crossed back to three FM6 males (Mating scheme 6).  
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The identified recombinants were screened for the presence of GFP at the site of muscle 
attachment. 
F0: ♀ CG1847exon1_3  
      FM6 
X  ♂  mys5.4 
  Y 
F1: ♀ CG1847exon1_3  
     mys5.4       
X  ♂  FM6 
  Y 
Set up 30 individual crosses  
F2: ♀ CG1847exon1_3mys5.4         
FM6 
X  ♂  FM6 
Y 
Mating scheme 6: Recombination of the CG1847exon1_3 mutant and mys5.4 
2.2.5 Generation of homozygous mutant clones  
Mitotic recombination was induced using the FLP/FRT system251. Virgin females of the genotype: 
CG1847exon1_3, FRT19A / FM6 were mated with Ubi-mRFPnls, hsFLP, FRT19AneoR males. Eggs were 
collected for 4 hours and left at 25°C for 48 hours, at which stage they were subjected to a heat 
shock of one and a half hours at 37°C in a water bath on 2 subsequent days. The larvae were 
allowed to develop at 25°C until the 3rd instar stage and the desired genotype CG1847exon1_3, 
FRT19A / Ubi-mRFPnls, hsFLP, FRT19AneoR was selected based on fluorescence. The larval 
imaginal wing discs were prepared at late 3rd instar. CG1847exon1_3 homozygous mutant clones 
were identified based on the absence of RFP expression. 
To assess the role of the CG1847exon1_3 mutant in the wing homozygous clones of adult flies, 
larvae from a cross between CG1847exon1_3, FRT19A / FM6 females and Ubi-mRFPnls, hsFLP, 
FRT19AneoR males were subjected to heat shock as described above and then allowed to reach 
maturity. As control, I used the progeny from the cross between w, Dm, FRT19ANeoR females and 
Ubi-mRFPnls, hsFLP, FRT19AneoR males. Larvae from control crosses were subjected to the same 
heat-shock treatment described above. 
The generation of somatic clones was investigated in wing imaginal discs dissected from 3rd 
instar larvae and the size of the clones was compared between heterozygous mutant progeny 
with somatic wing clones (females CG1847exon1_3, FRT19AneoR / Ubi-mRFPnls, hsFLP, FRT19AneoR) 
and control progeny (females w, Dm, FRT19ANeoR / Ubi-mRFPnls, hsFLP, FRT19AneoR). 
Adult wing phenotype was compared between adult progeny. 
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2.2.6 Rescue of CG1847 function  
To determine whether deletion of CG1847 was responsible for male lethality, I tested whether 
it could be rescued by the introduction of a genomic rescue-construct containing wt CG1847. To 
this end, a wt CG1847 genomic rescue construct was prepared by subcloning a genomic DNA 
fragment that contained a 2227 bp region located upstream of the start codon of the CG1847 
DNA, along with a 412 bp fragment located downstream of the start codon, into the P-element 
transformation vector pWhiteRabbit containing an attB site252. This construct was sent to Best 
Gene Inc. (USA) where it was microinjected into 200 embryos which harbour an attP40 landing 
site (attP40-y1 w67c23; P{CaryP}attP40), following a standard protocol to create transgenics253. 
The advantage of the PhiC31 integrase system is the integration of the plasmid DNA at precise 
landing sites as opposed to random integration. The PhiC31 integrase (also known as ΦC31 
integrase) encodes a serine-type recombinase that mediates the sequence-specific 
recombination between two different attachment sites, attB and attP. However, these sites 
share a small 3 bp central region, where the crossover occurs254. 
Five lines were produced and balanced over CyO. Two of the five transgenic lines survived during 
transportation. Males from these two lines were individually crossed with heterozygous females 
carrying the mutant CG1847exon1_3 allele. In the F1 generation the ability to rescue developing 
mutant hemizygous males was evaluated. 
2.2.7 Rescue of mutant lethality by expressing wt human AIP (hAIPwt) under the 
control of a ubiquitous promoter (actin)  
In order to test in vivo the degree of functional conservation between fly and human AIP (hAIP), 
I generated an UAS::hAIPwt construct by inserting the hAIP coding sequence, downstream of 
the GAL4-dependent UAS promoter into the pUASK10attB vector derived from pUAST238. This 
construct was sent to BestGene Inc. where it was then microinjected into 200 embryos (section 
2.2.6). Five lines were produced and balanced over CyO. All five transgenic lines survived during 
transportation, but only 2 lines were used in rescue experiments. 
The Gal4-UAS system was used for rescue experiments at 25°C, as the UAS-hAIPwt was 
overexpressed ubiquitously in the respective genetic mutant background. 
To rescue CG1847 mutant lethality, heterozygous females carrying both the mutant 
CG1847exon1_3 allele and a ubiquitous driver (Act-Gal4, located on the 2nd chromosome) were 
required. These flies were generated as detailed below (Mating scheme 7).  
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F0: ♀ CG1847exon1_3 
          FM6 
X ♂  Bl 
 CyO 
In the next generation, I simultaneously performed 2 different crosses: 
F1a: ♀ CG1847exon1_3 
FM6                 
X ♂ FM6; +  
Y      CyO 
F1b: ♀    x    ;   +  .    
FM6     Bl 
X ♂ x ; Act-Gal4 
Y          CyO 
F2: ♀ CG1847exon1_3; +  
      FM6          CyO 
X ♂ FM6; Act-Gal4 
   Y   Bl 
F3: ♀ CG1847exon1_3; Act-Gal4 
       FM6    CyO  
X ♂ FM6; Act-Gal4 
   Y CyO 
Mating scheme 7: Combination of the CG1847exon1_3 mutant and actin-Gal4 driver 
To ubiquitously express the hAIP cDNA, males from two transgenic lines were individually 
crossed with females CG1847exon1_3 / FM6; Act-Gal4 / CyO. In F1 generation, I evaluated their 
ability to rescue developing mutant males (CG1847exon1_3 / Y; UAS::hAIPwt / Act-Gal4). 
2.2.8 Rescue of mutant lethality by expressing hAIP under the control of specific 
tissues promoters  
The UAS-hAIP construct allowed us to express the hAIP not only ubiquitously during fly 
development, but also in specific fly somatic cells or tissues, under the control of tissue-specific 
GAL4 drivers. To this end, I combined our heterozygous CG1847exon1_3 mutant females with 10 
different tissue-specific promoters: fat body, haemocytes, insulin-secreting cells, muscle, 
neurons, glial cells, gut, haemolymph, malpighian tubules, and heart (all the crosses below). 
For fat body targeted rescue of lethality, UAS-hAIPwt was overexpressed under Cg-GAL4 driver 
in our genetic mutant background. For this purpose I generated heterozygous females carrying 
both the mutant CG1847exon1_3 allele and a fat body driver (Cg-GAL4) (Mating scheme 8).  
F0: ♀  CG1847exon1_3  
      FM6 
X   ♂    X ; Bl 
  Y   CyO 
In the next generation, I simultaneously performed 2 different crosses: 
F1a: ♀   FM6 ;  + . 
  Y       CyO 
X   ♂  CG1847exon1_3 ;  + . 
    FM6                Bl 
F1b: ♀   X   ;  + . 
FM6  CyO 
X ♂   X ; Cg-GAL4 
  Y    Cg-GAL4 
F2:   ♀  CG1847exon1_3 ;  Bl . 
    FM6                CyO 
X   ♂  FM6 ;  Cg-GAL4 
  Y           CyO 
F3: ♀  CG1847exon1_3 ;  Cg-GAL4 
    FM6                    CyO 
X   ♂  FM6 ;  Cg-GAL4 
  Y            CyO 
Mating scheme 8: Combination of the CG1847exon1_3 mutant and fat body driver Cg-Gal4 
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For haemocyte-targeted rescue of lethality, UAS-hAIPwt was overexpressed under Crq-GAL4 
driver in our genetic mutant background. For this purpose I generated heterozygous females 
carrying both the mutant CG1847exon1_3 allele and a haemocyte driver (Crq-GAL4), which was 
introduced into the second chromosome of mutant stock (Mating scheme 9). 
F0: ♀  CG1847exon1_3  
      FM6 
X   ♂    X ; Bl 
  Y   CyO 
In the next generation, I simultaneously performed 2 different crosses: 
F1a: ♀   FM6 ;  + . 
  Y       CyO 
X   ♂  CG1847exon1_3 ;  + . 
    FM6                Bl 
F1b: ♀   X   ;  + . 
FM6  CyO 
X ♂   X ; Crq-GAL4 
  Y    Crq-GAL4 
F2:   ♀  CG1847exon1_3 ;  Bl . 
    FM6                CyO 
X   ♂  FM6 ;  Crq-GAL4 
  Y           CyO 
F3: ♀  CG1847exon1_3 ;  Crq-GAL4 
    FM6                    CyO 
X   ♂  FM6 ;  Crq-GAL4 
  Y            CyO 
Mating scheme 9: Combination of the CG1847exon1_3 mutant and haemocytes driver Crq-Gal4 
For the insulin-secreting cell targeted rescue of lethality, UAS-hAIPwt was overexpressed under 
dilp-GAL4 driver in our genetic mutant background. For this purpose I generated heterozygous 
females carrying both the mutant CG1847exon1_3 allele and an insulin secreting cells driver (dilp-
GAL4), which was introduced into the second chromosome of mutant stock (Mating scheme 10).  
F0: ♀  CG1847exon1_3  
      FM6 
X   ♂    X ; Bl 
  Y   CyO 
In the next generation I performed 2 different crosses at the same time: 
F1a: ♀   FM6 ;  + . 
  Y       CyO 
X   ♂  CG1847exon1_3 ;  + . 
    FM6                Bl 
F1b: ♀   X   ;  + . 
FM6  CyO 
X ♂   X ; dilp-GAL4 
  Y   dilp-GAL4 
F2:   ♀  CG1847exon1_3 ;  Bl . 
    FM6                CyO 
X   ♂  FM6 ;  dilp-GAL4 
  Y           CyO 
F3: ♀  CG1847exon1_3 ;  dilp-GAL4 
    FM6                    CyO 
X   ♂  FM6 ;  dilp-GAL4 
  Y            CyO 
Mating scheme 10: Combination of the CG1847exon1_3 mutant and insulin secreting cells driver dilp-Gal4  
For muscle cell targeted rescue of lethality, UAS-hAIPwt was overexpressed under MEF2-GAL4 
driver in our genetic mutant background. For this purpose I generated heterozygous females 
carrying both the mutant CG1847exon1_3 allele and a muscle cells driver (MEF2-GAL4), which was 
introduced into the third chromosome of mutant stock (Mating scheme 11). 
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F0: ♀  CG1847exon1_3  
      FM6 
X   ♂     X ; Dr 
  Y   TM3 
In the next generation, I simultaneously performed 2 different crosses: 
F1a: ♀   FM6 ;  + . 
  Y      TM3 
X   ♂  CG1847exon1_3 ;  + . 
    FM6                Dr 
F1b: ♀   X   ;  + . 
FM6   Dr 
X ♂    X ; Mef2-GAL4 
  Y     Mef2-GAL4 
F2:   ♀  CG1847exon1_3 ;  Dr . 
    FM6                TM3 
X   ♂  FM6 ;  Mef2-GAL4 
  Y             TM3 
F3: ♀  CG1847exon1_3 ;  Mef2-GAL4 
    FM6                TM3 
X   ♂  FM6 ;  Mef2-GAL4. 
  Y             TM3 
Mating scheme 11: Combination of the CG1847exon1_3 mutant and muscle cells driver Mef2-Gal4 
 
For nervous system targeted rescue of lethality, UAS-hAIPwt was overexpressed under elav-
GAL4 driver in our genetic mutant background. For this purpose I generated heterozygous 
females carrying both the mutant CG1847exon1_3 allele and a pan-neural driver (elav-GAL4), which 
was introduced into the third chromosome of mutant stock (Mating scheme 12). 
F0: ♀  CG1847exon1_3  
      FM6 
X   ♂     X ; Dr 
  Y   TM3 
In the next generation I performed 2 different crosses at the same time: 
F1a: ♀   FM6 ;  + . 
  Y      TM3 
X   ♂  CG1847exon1_3 ;  + . 
    FM6                Dr 
F1b: ♀   X   ;  + . 
FM6   Dr 
X ♂    X ; elav-GAL4 
  Y    elav-GAL4 
F2:   ♀  CG1847exon1_3 ;  Dr . 
    FM6                TM3 
X   ♂  FM6 ;  elav-GAL4 
  Y             TM3 
F3: ♀  CG1847exon1_3 ;  elav-GAL4 
    FM6                    TM3 
X   ♂  FM6 ;  elav-GAL4. 
  Y             TM3 
Mating scheme 12: Combination of the CG1847exon1_3 mutant and nervous system driver elav-Gal4 
For glial cell targeted rescue of lethality, UAS-hAIPwt was overexpressed under repo-GAL4 driver 
in our genetic mutant background. For this purpose I generated heterozygous females carrying 
both the mutant CG1847exon1_3 allele and a glial cell driver (repo-GAL4), which was introduced 
into the third chromosome of mutant stock (Mating scheme 13). 
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F0: ♀  CG1847exon1_3  
      FM6 
X   ♂     X ; Dr 
  Y   TM3 
In the next generation, I simultaneously performed 2 different crosses: 
F1a: ♀   FM6 ;  + . 
  Y      TM3 
X   ♂  CG1847exon1_3 ;  + . 
    FM6                Dr 
F1b: ♀   X   ;  + . 
FM6   Dr 
X ♂    X ; repo-GAL4 
  Y     repo-GAL4 
F2:   ♀  CG1847exon1_3 ;  Dr . 
    FM6                TM3 
X   ♂  FM6 ;  repo-GAL4 
  Y             TM3 
F3: ♀  CG1847exon1_3 ; repo-GAL4 
    FM6                TM3 
X   ♂  FM6 ; repo-GAL4 
  Y             TM3 
Mating scheme 13: Combination of the CG1847exon1_3 mutant and glial cells driver repo-Gal4 
For haemolymph targeted rescue of lethality, UAS-hAIPwt was overexpressed under HE-GAL4 
driver in our genetic mutant background. Heterozygous females carrying both the mutant 
CG1847exon1_3 allele and hemocytes driver (HE-GAL4), introduced into the third chromosome of 
mutant stock, were generated (Mating scheme 14).  
F0: ♀  CG1847exon1_3  
      FM6 
X   ♂     X ; Dr 
  Y   TM3 
In the next generation, I simultaneously performed 2 different crosses: 
F1a: ♀   FM6 ;  + . 
  Y      TM3 
X   ♂  CG1847exon1_3 ;  + . 
    FM6                Dr 
F1b: ♀   X   ;  + . 
FM6   Dr 
X ♂    X ; HE-GAL4 
  Y     HE-GAL4 
F2:   ♀  CG1847exon1_3 ;  Dr . 
    FM6                TM3 
X   ♂  FM6 ;  HE-GAL4 
  Y             TM3 
F3: ♀  CG1847exon1_3 ; HE-GAL4 
    FM6                TM3 
X   ♂  FM6 ; HE-GAL4 
  Y             TM3 
Mating scheme 14: Combination of the CG1847exon1_3 mutant and haemolymph driver HE-Gal4 
For gut targeted rescue of lethality, UAS-hAIPwt was overexpressed under drm-GAL4 driver in 
our genetic mutant background. Heterozygous females carrying both the mutant CG1847exon1_3 
allele the gut driver (drm-GAL4) were generated (Mating scheme 15).  
F0: ♀  CG1847exon1_3  
      FM6 
X   ♂     X ; Dr 
  Y   TM3 
In the next generation, I simultaneously performed 2 different crosses: 
F1a: ♀   FM6 ;  + . 
  Y      TM3 
X   ♂  CG1847exon1_3 ;  + . 
    FM6                Dr 
F1b: ♀   X   ;  + . 
FM6   Dr 
X ♂    X ; drm-GAL4 
  Y     drm-GAL4 
F2:   ♀  CG1847exon1_3 ;  Dr . 
    FM6                TM3 
X   ♂  FM6 ;  drm-GAL4 
  Y             TM3 
F3: ♀  CG1847exon1_3 ; drm-GAL4 
    FM6                TM3 
X   ♂  FM6 ; drm-GAL4 
  Y             TM3 
Mating scheme 15: Combination of the CG1847exon1_3 mutant and gut driver drm-Gal4 
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For Malpighian tubule targeted rescue of lethality, UAS-hAIPwt was overexpressed under c42-
GAL4 driver in our genetic mutant background. For this purpose I generated heterozygous 
females carrying both the mutant CG1847exon1_3 allele and a Malpighian tubule driver (c42-GAL4), 
which was introduced into the third chromosome of mutant stock (Mating scheme 16). 
F0: ♀  
CG1847exon1_3  
      FM6 
X   ♂  
   X ; Dr 
  Y   TM3 
In the next generation I performed 2 different crosses at the same time: 
F1a: ♀  
 CG1847exon1_3  
      FM6 
X   ♂  
FM6 ;  + . 
  Y        Dr 
F1b: ♀ 
  X   ;  + . 
FM6  TM3 
X ♂ 
   X ; c42-GAL4 
  Y     c42-GAL4 
F2:   ♀  
CG1847exon1_3 ;   + . 
    FM6                Dr 
X   ♂  
FM6 ;  c42-GAL4 
  Y            TM3 
F3: ♀  
CG1847exon1_3 ;   Dr  . 
    FM6               TM3 
X   ♂  
FM6 ; c42-GAL4 
  Y             TM3 
F4: ♀  
CG1847exon1_3 ; c42-GAL4. 
    FM6                    TM3 
X   ♂  
FM6 ; c42-GAL4 
  Y             TM3 
Mating scheme 16: Combination of the CG1847exon1_3 mutant and malpighian tubules driver c42-Gal4 
For heart targeted rescue of lethality, UAS-hAIPwt was overexpressed under tinC-GAL4 driver in 
our genetic mutant background. For this purpose I generated heterozygous females carrying 
both the mutant CG1847exon1_3 allele and a heart driver (tinC-GAL4), which was introduced into 
the third chromosome of mutant stock (Mating scheme 17) 
F0: ♀  CG1847exon1_3  
      FM6 
X   ♂    X ; Bl 
  Y   CyO 
In the next generation, I simultaneously performed 2 different crosses: 
F1a: ♀  CG1847exon1_3  
      FM6 
X   ♂  FM6 ;  + . 
  Y       CyO 
F1b: ♀   X   ;  + . 
FM6  Bl 
X ♂    X ; tinC-GAL4 
  Y     tinC-GAL4 
F2:   ♀  CG1847exon1_3;   +  
      FM6       CyO 
X   ♂  FM6 ;  tinC-GAL4 
  Y           Bl 
F3: ♀  CG1847exon1_3 ;  tinC-GAL4 
    FM6                    CyO 
X   ♂  FM6 ;  tinC-GAL4 
  Y            CyO 
Mating scheme 17: Combination of the CG1847exon1_3 mutant and fat heart driver tinC-Gal4 
Virgin females from each of these stocks were then mated with transgenic males carrying the 
hAIPwt and in the next generation their ability to rescue the hemizygous mutant males was 
evaluated. 
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2.2.9 Rescue of mutant lethality by expressing truncated or missense hAIP variants 
under the control of a ubiquitous promoter (actin) 
For rescuing the CG1847exon1_3 mutant with different hAIP variants I generated five UAS::hAIP 
constructs by inserting either a truncated version of hAIP or four different missense variants that 
were identified in FIPA families (sections 2.4.5 and 2.4.6). These constructs were sent to 
BestGene Inc. where they were microinjected into embryos harbouring attP40 landing sites, 
according to the standard protocol. Five lines were produced for each missense variant, and 
then each line was balanced over CyO. Not all the transgenic lines survived during 
transportation. However, for each of the rescue experiment I used 2 of the generated stocks 
(Table 5). 
I tested whether these UAS::hAIP transgenes (truncated or missense variants) were able to 
rescue CG1847exon1_3 mutants by expressing them with a ubiquitous driver (actin) during fly 
development. 
2.2.10 Larvae collection 
Egg laying plates 
To obtain developmentally staged egg/larvae collections precisely, I prepared embryo collection 
cages covering a 60 mm agar plate containing medium comprised of apple juice hardened with 
agar. Egg laying plates were produced according to the following protocol: For 1L of medium I 
used 750 ml of water, 21.5 gr agar, 250 ml of apple juice concentrate, 25 gr of sucrose, and 5 ml 
9:1 (propionic acid : phosphoric acid). The water and agar mix was autoclaved. Separately was 
prepared the second mix from sugar, apple juice and 5 ml of 9:1 propionic acid: phosphoric acid. 
When the water-agar mix cool down till around 60°C it was added the second mix, and carefully 
pour into 60 mm plates, without generating bubbles. 
Stocks  
In stocks CG1847exon1_3 / FM6 and CG18472.39A / FM6 stocks obtained during the P-element 
excision screen, the FM6 balancer chromosome was substituted with a FM7c, Dfd::YFP 
chromosome. As a result, I was able to differentiate mutant and control males (respectively, 
CG1847exon1_3 / Y and CG18472.39A / Y) based on lack of fluorescence. 
Staging to determine the lethality stage  
Stocks were grown at low density at 25°C. 50 mated females were allowed to lay eggs for 2 hours 
in food bottles, in order to minimize the variations associated with parental rearing conditions. 
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In the F1 generation, an additional 50 females from the mutant stock (CG1847exon1_3 / 
FM7::DfdYFP) and 50 females from the revertant stock (CG18472.39A / FM7::DfdYFP) were 
collected. They were allowed to mate with FM7::DfdYFP/Y males for 3 days. These parental flies 
were 4-10 days post-emergence before the start of the egg collections. Adults were set for 4 h 
of egg laying on apple juice plates. Mutant (CG1847exon1_3 / FM7::DfdYFP) and the revertant 
(CG18472.39A / FM7::DfdYFP) larvae were reared at 25°C. Embryos were allowed to age until the 
desired developmental stage as described in Figure 13. 
 
Figure 13: Design for larval staging. For determining the lethality stage for CG1847exon1_3 mutant males, 
larvae were selected for the presence or absence of the fluorescent marker 
Staging to collect larvae for RNA extraction  
For RNA extraction, mutant and control eggs were collected as described above and allowed to 
age for an additional 48 h, resulting in larvae from 46 to 50 h in age. The wandering non-
fluorescent larvae (CG1847exon1_3 / Y or CG18472.39A / Y) were collected using the fluorescent 
microscope. RNA was extracted using the technique described in section 2.3.2 B. The quality of 
the RNA was assessed using the 2100 Bioanalyzer (Barts Genome Centre). 
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2.2.11 Collection of pupae 
Food bottles 
To obtain large pupae collections, flies were raised in bottles containing 15 ml of standard 
culture medium (Appendix 3), in an incubator with constant temperature of 25°C. 
Stocks  
The homozygous stock UAS-Dcr2; + ; UAS-CG1847-T2 was used both as control and to 
knockdown (KD) CG1847 expression in wing tissues, using the nubbin-GAL4 driver (UAS-Dcr-2; 
UAS-CG1847-T2>nub-Gal4). In F0 generation, I collected 100 virgin females from the control 
stock (UAS-Dcr2; UAS-CG1847-T2). Fifty virgins were mated with UAS-Dcr2 / Y; UAS-CG1847-T2 
males for control stock, while the other 50 females were crossed with nub-Gal4 males for KD 
purposes. They were allowed to mate for 3 days at 25°C. These parental flies were 4-10 days old 
when I started the egg collections. Adults were set for 4 h egg collection which were further 
reared at 25°C until they reached the pupal stage.  
Staging for pupae dissection 
For staging purposes, pupae were picked with a wet brush at the white pupa stage. White pupae 
are very easy to recognize and consistency was crucial to pick white pupae at the same stage. 
They were transferred to an empty Petri dish containing double-sided tape. The genotype and 
the time of collection were carefully marked. Pupae were dissected at the desired stage: 24 h 
and 28 h after puparium formation (APF). 
2.2.12 Dissection of Drosophila tissues 
Imaginal wing disc dissection 
To obtain imaginal wing discs for subsequent immunostaining studies, the head section of the 
3rd instar larvae was inverted. After removing the gut and fat, imaginal discs were fixed in 4% 
PFA in PBS at room temperature for 30 minutes, followed by the steps detailed in Appendix 6. 
Pupal wing dissection 
24 or 28 h AFP pupae were dissected in double-sided tape at the bottom of a Petri dish. Using a 
pair of forceps, the operculum was removed and a small incision was made in the head of the 
pupa to release the pressure and prevent damage to the wings by excess fat. I used a syringe 
needle to gently make an incision in the cuticle along the back of the pupa and separate it in two 
halves, which were stuck on their side on the double-sided tape. Dissected pupae were 
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immediately placed in 0.5 ml 1X PBS in the wells of a 96 well plate, which was the kept at 4°C 
until all pupae were dissected. Pupae were fixed in 4% formaldehyde in PBT at 4°C overnight. 
After fixing, pupal wings were dissected. Pupae were transferred one by one to a watchmaker’s 
glass dish with PBS. The wing epithelium is visible inside a translucent cuticle sac. While the pupa 
was held in position with one of the forceps, the cuticle was removed, starting near the wing 
hinge region. Wings were removed, with some excess hinge tissue and placed into 60 Well HLA 
Terasaki Microplates. For complete immunostaining protocol, see Appendix 6. 
Dissection of adult wings 
For adult wing imaging, flies were collected in 70% ethanol and kept at 4°C for at least 24h. For 
wing dissection, flies were placed in isopropanol and the wings were removed with a pair of 
Dumostar #5 forceps. For mounting, see section 2.2.15. 
Dissection of adult fly heads 
Total RNA or protein were extracted from adult fly heads of flies stored at -80°C before use. To 
separate the fly heads (around 25-30 heads), flies were kept on dry ice, vortexed vigorously, and 
placed on a piece of glace kept on top of dry-ice. Using a pair of forceps, heads were removed 
and placed in cooled 1.5 ml Eppendorf tubes, which were stored at -80°C prior to RNA/protein 
extraction. 
2.2.13 Immunostaining  
Dissected fly tissues were fixed in 4% PFA solution (4 % (w/v) paraformaldehyde in PBS for 20 
min. Three washes in PBT 0.3%, each for 5 min, were perform. In the next step the tissues were 
permeabilised in PBT 0.3% for 1 h at RT on the rotor, blocked with PBT 0.3% +3%BSA 1h, and 
incubated overnight with primary antibodies at 4°C on the rotor. On the second day, the primary 
antibodies were removed and tissues were washed 3 times in 0.3% PBT. The samples were 
incubated with fluorescent secondary antibodies diluted in PBT 0.3% for 1h, washed again 3 
times, each wash for 20 min in 0.3% PBT. In the final step the tissues were counterstained with 
4',6-diamidino-2-phenylindole (DAPI) and mounted for confocal microscopy analysis. For 
detailed protocols for immunostaining see Appendix 6. 
2.2.14 Antibodies 
The complete list of the antibodies used during the course of this study, the dilutions, the use 
and the provider can be found in Appendix 7. 
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2.2.15 Mounting 
Imaginal wing discs or pupal wings were mounted in 24 µl Vectashield (Vector Laboratories) 
using 22X22mm cover slips. Adult Drosophila wings were mounted on the slide with a drop of 
isopropanol. After waiting a few seconds for the isopropanol to dry, Euparal mounting medium 
(DS31 - Anglian Lepidopterist Supplies (ALS)) was added in small drops between the wings. A 22 
X 40 mm coverslip was added and the slides were dried at 65C for 4 hours. 
2.2.16 Image Acquisition and Processing 
Confocal images of imaginal wing discs or pupal wings were taken using an LSM 510 laser 
scanning microscope (Zeiss; release version 5.0 SP1.1. using the License Basic Software ZEN 2008 
version 500267 configuration 4.02.00). Stacks of confocal images were collected at different 
focal plane spacing, depending on experimental needs. Images were then processed using Image 
J freeware255 (http://rsbweb.nih.gov/ij/). Images were readjusted for each colour independently 
but always on the whole picture.  
Adult wing imaging was performed with Panoramic 250 High Throughput Scanner (Barts Cancer 
Institute, QMUL). 
2.3 General molecular biology techniques 
2.3.1 Oligonucleotide design 
For primer design, the publicly available software Primer3 (http://bioinfo.ut.ee/primer3-
0.4.0/primer3/) was used. A list of primers used, their sequence, and their applications can be 
found in Appendix 6. Genomic sequences were retrieved from the University of California (UCSC) 
Genome Browser http://genome-euro.ucsc.edu/cgi-
bin/hgGateway?redirect=auto&source=genome.ucsc.edu, version February 2009 (GRCh37). 
Primers were ordered from Sigma-Aldrich (http://www.sigmaaldrich.com/united-
kingdom.html) and they were delivered as a lyophilised pellet. To generate a 100 μM stock 
solution, the primers were re-suspended in distilled H2O and then stored at -20˚C. Further 
dilution with distilled water was performed to obtain a 10 μM working solution. 
2.3.2 Deoxyribonucleic acid extraction 
Adult fly DNA isolation 
For extracting Drosophila melanogaster DNA, I used the following buffers: 
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Buffer A (for 10 samples): 100 µl of 1 M Tris-HCl (pH7.5), 200 µl of 0.5 M EDTA (pH8), 20 µl of 5 
M NaCl, 50 µl of 10% SDS, 630 µl of ddH2O. 
Buffer B (for 10 samples) was prepared from 1 ml of 5 M KAc, and 2.5 ml of 6 M LiCl (no water). 
One adult fly was placed in a 1.5 ml reaction tube, which was then frozen at -20 °C for ten 
minutes. Then, frozen flies were physically disrupted in 200 µl of buffer A with a plastic pestle 
and incubated at 65°C for 30 minutes. 100 µl of buffer B was added and mixed by inverting the 
tube, this was then incubated for ten minutes at room temperature and centrifuged at 14000 
rpm for 15 minutes at room temperature. In the next step, 250 µl of the supernatant was 
transferred into a new 1.5 ml reaction tube and 200 µl of ice-cold isopropanol was added. The 
solution was inverted for mixing and then centrifuged again at 14000 rpm for 15 minutes. The 
genomic DNA pellet was re-suspended in 200 µl ice-cold 75% ethanol, air dried and dissolved in 
30 µl ddH2O. The samples were stored at -20°C until further use. 
RNA isolation from adult flies 
mRNA from adult flies was extracted from 15 fly heads. Vials containing previously collected flies 
that were stored at -80°C were placed into liquid nitrogen and left to cool. The samples were 
then vortexed in order to isolate the heads (section 2.2.12). The heads were placed in new 1.5 
ml Eppendorf tubes and the RNA extraction was performed using 500 µl of TRI reagent. Tissues 
were homogenised with a pestle, followed by brief vortexing and incubation at room 
temperature for 10 minutes. The tubes were then centrifuged at 4˚C at 15000 x g for 15 minutes; 
the resulting aqueous phase was transferred to a new 1.5 ml Eppendorf. 250 µl of isopropanol 
was added and this mixture was vortexed to ensure mixing had occurred. This was then 
incubated at room temperature for a further 10 minutes. The mix was centrifuged at 12000 x g 
for 8 minutes at 4˚C. The resulting supernatant was discarded. 500 µl of 75% ethanol (prepared 
with nuclease free water) was added and a new centrifugation step was performed at 7500 x g 
for 6 min at 4˚C. The ethanol was removed by air drying the RNA pellet. RNA was eluted in 30 µl 
of nuclease free water and it was incubated at -20˚C for the same day analysis. The samples 
were stored at -80˚C. 
RNA isolation from Drosophila melanogaster larvae 
mRNA from Drosophila larvae was extracted using the RNeasy Micro kit from Qiagen, according 
to manufacturer’s specifications. The collected larvae (section 2.2.10) were homogenized in 350 
μl Buffer RLT using a pestle. The lysate was centrifuged 3 min at 12000 x g. The supernatant was 
carefully transferred to a new Eppendorf. In the next step, 1 volume of 70% ethanol was added 
to the lysate, and mixed well. The sample was transferred to an RNeasy MinElute spin column 
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in a 2 ml collection tube, which was centrifuged for 15 s at ≥8000 x g. The flow-through was 
discarded and 350 μl Buffer RW1 was added to the RNeasy MinElute spin column. A new 
centrifugation step took place for 15 s at ≥8000 x g. The flow-through was again discarded and 
a 10 μl DNase I stock solution mixed with 70 μl Buffer RDD was added to the column. The sample 
was incubated at room temperature for 15 min. Additional 350 μl Buffer RW1 were added to 
the RNeasy MinElute spin column and centrifuged for 15 s at ≥8000 x g. The RNeasy MinElute 
spin column was placed in a new 2 ml collection tube. The RNA sample was washed with 500 μl 
Buffer RPE followed by centrifugation for 15 s at ≥8000 x g. The flow-through was discarded and 
added 500 μl of 80% ethanol. The next centrifugation step was for 2 min at ≥8000 x g. The RNeasy 
MinElute spin column was placed in a new 2 ml collection tube and centrifuged at full speed for 
5 min to dry the membrane. RNA was eluted by adding 14 μl RNase-free water. The last 
centrifugation step was for 1 min at full speed to elute and recover the RNA. 
2.3.3 Nucleic acids quantification 
DNA and RNA sample purity and concentration was assessed using a ThermoScientific Nanodrop 
1000 Spectrophotometer. Purity was measured based on the ratio of OD260:OD280. Readings 
of >1.8 for DNA and >2.0 for RNA indicated acceptable levels of purity. 
2.3.4 First strand cDNA synthesis 
Complementary DNA (cDNA) was produced from RNA using a M-MLV Reverse Transcriptase Kit 
(Invitrogen). Before performing the reverse transcription, RNA samples were diluted in RNA free 
water and standardized to the same concentration (500ng RNA in 16.95 μl of H2O). In the next 
step the cDNA dilutions were incubated in the thermocycler (G-Storm GT-12061) for 10 min at 
65oC and added to each individual reaction. For each reaction the master mix consisted of 0.5 μl 
M-MLV (100U), 5 μl M-MLV RT 5x buffer M531A, 1.25 μl dNTPs (20mM), 0.25 μl Random 
Hexamers (250 ng/µl), 0.05 μl RnaseOUT 40 U/μl, 1μl DTT 100 mM, and 1 μg RNA. A volume of 
8.05 µl of the mix was added to each RNA sample (to make a final volume of 25 µl). The 
incubation was performed in the thermocycler under the following conditions: 10 min at 26oC, 
60 min at 37oC and 10 min at 92oC. 
The cDNA was then frozen at -20˚C if not used immediately. 
RT-PCR was performed according to the standard PCR protocol using the cDNA as the template 
and primers that spanned intron/exon boundaries to act as a control against contamination with 
genomic DNA. The integrity of the cDNA was usually verified by PCR of the housekeeping gene 
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Ribosomal protein L32 (RpL32). For PCR conditions refer to section 2.3.5. PCR products were 
analysed on 2% agarose gels. 
2.3.5 Polymerase Chain Reaction (PCR) 
PCRs were performed at optimized conditions, according to standard procedures. 
The basic protocol was modified depending on the DNA/RNA sample and the primer annealing 
temperatures. The annealing temperature was set to the calculated temperatures seen in 
Supporting Table 2. Temperature gradients were used to identify the optimal annealing 
temperature for the various primer pairs. 
To test the efficiency of RNAi-mediated gene silencing, the specific mRNA levels were measured 
via semi-quantitative RT-PCR (for the primer sequences and annealing temperatures are 
described in Appendix 6) using the following protocol: 
Component 12.5 µl Reaction Final concentration 
5X Green GoTaq reaction buffer 2.5 µl 1X 
MgCl2 0.75 µl 1 mM 
10 mM dNTPs 0.25 µl 0.2 mM 
10 µM Forward Primer 0.5 µl 5 µM 
10 µM Reverse Primer 0.5 µl 5 µM 
Template DNA variable <1.000 ng 
Go-Taq DNA Polymerase 0.06 µl 5 u/µl 
Nuclease-Free Water to 12.5 µl  
Table 6: The reaction mix used for semi-quantitative RT-PCR 
Cycling was performed in 0.2 ml thin wall PCR tubes using a G-Storm GT-12061 thermocycler. 
Cycling procedures were typically:  
 95˚C 5 min 
 94˚C 30 s 
 Primer specific ˚C 30sec 31 cycles  
 72˚C 30 sec 
 72˚C 10 min 
 Samples were then cooled to 4˚C 
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PCR techniques were used to identify Drosophila mutants generated during the imprecise 
excision screen. The GoTaq polymerase (Promega) was used to identify large genomic deletions, 
according to the supplier’s recommendations. 
Component 12.5 µl Reaction Final concentration 
5X Green GoTaq reaction buffer 2.5 µl 1X 
MgCl2 0.75 µl 1 mM 
10 mM dNTPs 0.25 µl 0.2 mM 
10 µM Forward Primer 0.5 µl 5 µM 
10 µM Reverse Primer 0.5 µl 5 µM 
Template DNA variable <1.000 ng 
Go-Taq DNA Polymerase 0.06 µl 5 u/µl 
Nuclease-Free Water to 12.5 µl  
Table 7: The reaction mix used to identify large genomic deletions 
Cycling was performed in thin wall 0.2 ml PCR tubes using a G-Storm GT-12061 thermocycler. 
Cycling procedures were typically:  
 95˚C 5 min 
 Touch-down 71-62˚C 10 cycles 
 94˚C 45 sec 
 60.9˚C 45 sec 28 cycles  
 72˚C 2 min and 30 sec 
 72˚C 10 min 
 Samples were then cooled to 4˚C 
The small genomic deletions from the screen were identified using Taq polymerase (NEB) 
according to the supplier’s recommendations.  
Component 25 µl Reaction Final concentration 
5XQ5 reaction buffer 5 µl 1X 
10mM dNTPs 0.5 µl 100 µM 
10µM Forward Primer 1.25 µl 0.5 µM 
10µM Reverse Primer 1.25 µl 0.5 µM 
Template DNA variable <1.000 ng 
Q5 DNA Polymerase 0.25 µl 2,000 u/ml 
Nuclease-Free Water to 25 µl  
Table 8: The reaction mix used to identify small genomic deletions 
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Cycling was performed in 0.2 ml thin wall PCR tubes using a G-Storm GT-12061 thermocycler. 
Cycling procedures were typically:  
 94˚C 5 min 
 94˚C 30 sec 
 54.2˚C 30 sec 30 cycles  
 72˚C 45 sec 
 72˚C 10 min 
 Samples were then cooled to 4˚C 
2.3.6 Agarose gel electrophoresis of DNA 
PCR reaction products were loaded on agarose gels to verify their size. The bands were 
separated by electrophoresis for 60 minutes at 120 V on 2% agarose gels. The 2% agarose gels 
were prepared by mixing 2.4g of agarose (Sigma-Aldrich, UK) with 120 ml of 1x TAE buffer 
(Tris/Acetat/ethylenediaminetetraacetic acid (EDTA)) (National Diagnostics, UK). Gels were 
stained with 12 μl of 1000X Red Nucleic dye (Life Technologies). A DNA marker (GeneRulerTM 
DNA Ladder Mix, 0.5 mg DNA/ml, Fermentas, UK) was run alongside the samples to determine 
PCR product sizes. 6x loading dye was added to DNA samples prior to gel loading. 
2.3.7 DNA gel extraction 
When necessary, DNA bands were visualised on UV lamp and excised from the agarose gel using 
a sterile scalpel. The extraction and purification of DNA from the agarose gel was performed 
using a QIAquick Gel Extraction Kit (Qiagen).The extracted DNA was finally eluted with 30 μl 
ddH20. Following this, the PCR buffer components were removed and the purified fragments 
were then used for sequencing or ligation reactions. 
2.3.8 Site-directed mutagenesis 
In vitro site-directed mutagenesis allows the introduction of site-specific mutations in double 
stranded plasmids. Mutagenic primers were designed using the Stratagene’s QuickChange 
primer design program at www.stratagene.com/qcprimerdesign. Two oligonucleotides flanking 
the nucleotide to be changed were designed. The primers utilised are listed in the Appendix 5. 
The QuickChange XL Site-Directed Mutagenesis kit is performed in three steps: synthesis of the 
mutant strand, digestion of the parental strand with DpnI and transformation of competent cells 
with plasmid DNA.  
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Mutant strand synthesis: a PCR was performed for denaturation of the DNA template, annealing 
of the mutagenic primers containing the desired mutation. The primer extension was performed 
with PfuUltra HF DNA polymerase (2.5 U/μl). Sample reactions were prepared as indicated: 
Component 50 µl Reaction 
10x reaction buffer 5 µl 
10mM dNTPs 1 µl 
125ng sense primer 1.25 µl 
125ng reverse primer 1.25 µl 
10ng/µl Template dsDNA 1 µl 
PfuUltra DNA Polymerase 1 µl 
Nuclease-Free Water 38.20 µl 
Table 9: The reaction mix for direct site mutagenesis 
The thermal cycling conditions were the following: 
 95°C 1 min 
 95°C 50 sec 18 cycles 
 60°C 50 sec 
 68°C 5 min (1 min/kb of plasmid length) 
 68°C 7 min 
Following PCR samples were placed on ice for 2 min followed by digestion with DpnI. 
DpnI digestion of template: methylated parental and hemimethylated DNA were digested with 
DpnI. To each PCR reaction, 1 μl of DpnI restriction enzyme (10 U/μl) was added and the reaction 
was gently mixed several times by pipetting up and down. The reaction was centrifuged for 1 
min and then incubated at 37°C for 1 h. 
Transformation: mutated plasmids were transformed into XL10-Gold Ultracompetent cells for 
nick repair following the protocol recommended by the producer. 
2.3.9 Automated DNA sequencing 
Sequencing was carried out at the Genome Centre (Barts and The London, Queen Mary, 
University of London). The Genome Centre uses BigDye 3.1 chemistry with visualization on the 
ABI 3730 capillary sequencer. This is an automated capillary gel electrophoresis that generates 
read lengths of up to 850 base pairs with a quality (Phred) score of over 20. Each PCR product 
was sequenced using both forward and reverse primers. Sequence chromatograms were 
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visualised and analysed using the BioEdit Sequence Alignment Editor software 
(http://www.mbio.ncsu.edu/bioedit/bioedit.html) (Ibis Biosciences, Carlsbad, CA).  
2.3.10 Protein extraction  
For western blot analysis, 25 fly heads were collected as described in section 2.2.12. Proteins 
were extracted in 35 µl of protein extraction buffer. For 1000 µl were used 857 µl protein 
extraction buffer, 1 µl DTT 1M, and 142 µl of protease inhibitor 7X. Fly heads were homogenised 
with a pestle. Following this, the tissues were subjected centrifugation at 4˚C at 15000 x g for 15 
minutes; the resulting aqueous phase was transferred to a new 1.5 ml Eppendorf prior to 
quantification. 
2.3.11 Protein quantification according to the Bradford method 
To prepare concentration standards, 12 µl of 10 mg/ml BSA (Bovine Serum Albumin Promega 
R3961) and 18 µl of ddH2O were mixed in a PCR tube to obtain the Standard 6 (4000 µg/ml). In 
the next step, 15 µl of Standard 5 were mixed with 15 µl of ddH2O to obtain the Standard 2 
solution (2000 µg/ml). Each dilution step resulted in a further 2-fold change in the concentration 
from the previous one until I obtain the Standard 1 solution (125 µg/ml). For the standard 0 was 
used ddH2O only. For triplicate readings, 4 µl of each standard or sample were mixed with 196 
µl of 1X Bradford reagent and added to three contiguous wells of a 96-well plate. The absorbance 
was read with the Wallac VICTOR plate reader at 595nm. The results were exported to an Excel 
file for further analysis.  
2.3.12 Western Blotting 
Buffers: 
6X SDS loading buffer: 0.3M Tris-Cl pH 6.8, 0.6M DTT, 12% SDS, 0.6% Bromophenol blue, 60% 
glycerol and ddH2O till 50 ml. 
Running buffer: NuPAGE MES SDS Running Buffer (20X), Invitrogen (Product code: NP0002). 
Adjust with 1X running buffer to a final volume of 1 l. 
Transfer buffer: 25mM Tris base, 190 mM Glycine, 20% (v/v) Methanol. Adjust with ddH2O to a 
final volume of 1 l. 
Phosphate buffered saline (PBS): Oxoid Products (Code BR0014). Dissolve 10 tablets in 1 l ddH2O 
and autoclave.  
Washing buffer (PBS-T): 0.1% Tween 20. Adjust with 1X sterile PBS to a volume of 1 l. 
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Blocking buffer: 5% (w/v) Semi-skimmed milk in PBT (2.5g of non-fat milk powder in 50 ml of 1 
X 0.1% PBS-Tween). 
Protocol: 
After quantification, protein samples were normalised to the same concentration, 20 µg/ml 
protein, and the dilutions were kept on ice in 0.6 ml tubes. Equal volumes of 6X SDS loading 
buffer were added to the samples. Samples were boiled for 5 min at 95°C on a thermal cycler to 
denature proteins’ quaternary and tertiary structure, allowing them to run through the gel. 
The protein separation was carried out using pre-cast 12 wells NuPAGE Novex 4-12% Tris-
Acetate Protein Gels (Life Technologies) at 120 V, for 1.5 hours in 1x Running Buffer or until the 
samples reached the bottom of the gel chamber. The separated proteins were transferred into 
a Protran BA85 nitrocellulose membrane (GE Healthcare) by a “semi-dry blotter" for 30 min at 
15 V/500 mA. The membranes were then blocked for 1.5 h at room temperature in 5% milk in 
PBS-T. The membranes were incubated with the primary antibodies (Appendix 7) diluted in 
blocking buffer, overnight at 4°C. On the second day, after removal of primary antibodies, the 
membranes were washed with PBT 3X for 10 minutes at RT and incubated with secondary 
antibodies, diluted in blocking buffer, for 1.5 h at room temperature. Odyssey Infrared Imaging 
System (LI-COR) was used for image acquisition. 
2.4 Cloning 
2.4.1 Plasmids 
Table 10 lists the plasmids used in the course of this study, and their purpose. 
Plasmids used  Purpose Reference 
pGEM-T easy  vector used for sub-cloning Promega 
pW@RpA Transformation vector Kind gift from Nick Brown256 
pW@RpA CG1847 Transformation vector  
pUAS-k10_attP Transformation vector Kind gift from Nick Brown 
pcDNA3-Myc-AIP   
pUAS-k10_attP_AIPwt Transformation vector  
pUAS-k10_attP_Myc-AIPtrunc Transformation vector  
pUAS-k10_attP_AIP-R16H Transformation vector  
pUAS-k10_attP_AIP-C238Y Transformation vector  
pUAS-k10_attP_AIP-A299V Transformation vector  
pUAS-k10_attP_AIPR-304Q Transformation vector  
Table 10: List of plasmids used in this study. Lines in the white boxes were obtained from specific supplier 
or were gifts from other labs. The lines in the light grey boxes were existing lab stocks generated during 
previous studies. The lines in the dark grey boxes are genomic rescue constructs cloned during this study 
for generating the transgenic fly stocks. 
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2.4.2 Subcloning 
PCR amplification  
PCR was used to generate the gene specific constructs, which were used to generate transgenic 
flies. Q5 (NEB) High-Fidelity DNA Polymerase is a high-fidelity, thermostable DNA polymerase 
with 3´→ 5´ exonuclease activity, fused to a processivity-enhancing Sso7d domain to support 
robust DNA amplification. This enzyme was used to ensure high fidelity DNA amplification. The 
reaction mix was set up as described in the manufacturer’s protocol as follows: 
Component 25 µl Reaction Final concentration 
5X Q5 reaction buffer 5 µl 1X 
10mM dNTPs 0.5 µl 100 µM 
10µM Forward Primer 1.25 µl 0.5 µM 
10µM Reverse Primer 1.25 µl 0.5 µM 
Template DNA variable <1.000 ng 
Q5 DNA Polymerase 0.25 µl 2,000 u/ml 
Nuclease-Free Water to 25 µl  
Table 11: The reaction mix used to generate gene specific constructs 
Cycling was performed in 0.2 ml thin wall PCR tubes using a G-Storm GT-12061 thermocycler. 
Cycling procedures were typically:  
92°C 30 sec 
92°C 30 sec 
50-72°C 30 sec 25-30 cycles  
72°C 30 sec/kb 
72°C 2 min 
Hold 4°C 
Samples were then cooled to 4˚C 
Each PCR reaction consisted of 35 cycles and the annealing temperatures were set using 
temperature gradients to identify the optimal annealing temperature for each primer pair. 
After the PCR reaction, the products were loaded on an agarose gel to verify the size of the 
products. Afterwards the PCR buffer components were removed from the fragments according 
to the protocol described in section 2.3.7). The purified fragments were then used for ligation 
reactions. 
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Addition of 3' A overhangs to PCR products 
Because the PCR amplification was performed using a proofreading DNA polymerase, such as 
Q5, the resulted products have blunt ends. As a consequence, to make the DNA amplicons 
purified and extracted from the gel suitable for TA cloning onto pGEM-T easy backbone (below) 
the Taq DNA polymerase (NEB) was used in the next step to add an adenine residue to the 3´-
end of both strands of the amplicons. 
For the next step is critical to remove all the Proofreading DNA Polymerase by purifying the PCR 
product carefully (with QIAquick Gel Extraction Kit from Qiagen –section 2.3.7). It might be 
possible that the proofreading activity of any DNA Polymerase remains will degrade the freshly 
added A’ overhangs. 
The typical Taq DNA polymerase reaction mix for a typical 25 μl reaction: 
 Final Concentration Volume(μl) 
Purified PCR product 0.15 to 1.5 pmol Variable* 
dATP (10 mM) 0.2 mM 0.5 
10X Taq Buffer with Mg 1x (1.5 mM MgCl2) 2.5 
Taq DNA Polymerase (5 U/μl) 1U 0.1 
ddH2O - up to 25 μl 
Table 12: The typical Taq DNA polymerase reaction mix for adding A' overhangs: 
The specific amount of purified PCR products was calculated based of the size of the amplicons. 
The recommended amount is 10–100 ng PCR product for each 100 bp length of the PCR product.  
The mix was incubated at 72 °C for 1 hour, immediately followed by the TA cloning protocol, as 
for increased efficiency, it is recommended to use fresh PCR products. 
pGEM-T Easy Vector 
Both the human gene (hAIP) and fly orthologue gene (CG1847) were amplified by PCR 
(previously described in section 2.4.2 in order to be subcloned into the pGEM-T easy vector. The 
pGEM-T easy vector system (Promega, UK) (Figure 14) is a useful system that was developed for 
the cloning of PCR products. The vector is linearized and has T overhangs at both ends (a 3’ 
terminal thymidine). These T overhangs at the ends of the insertion site improve the efficiency 
of the PCR product ligation into the plasmids, as well as prevent vector re-circularisation. 
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Figure 14: Schematic structure of the pGEM-T Easy Vector. The vector contains a multiple cloning site 
(MCS) flanked by T7 and SP6 RNA polymerase promoters. The ampicillin (Ampr) resistance gene is useful 
for selection of colonies positive for the presence of the desired insert (source Promega protocols) 
DNA restriction digest 
The PCR products inserted into the pGEM-T vector were retrieved with either NEB or Promega 
restriction endonucleases, according to the producer’s recommended protocol. The destination 
plasmids were also digested with the same enzymes to allow for the sub-cloning of the insert. 
The restriction digestion reactions were performed at 37°C in a water bath. 
For directional cloning of the insert into the plasmid, inserts were cloned using two different 
restriction sites at the 5’ and 3’ ends, where possible. If this was not possible, only one restriction 
site was used and plasmids obtained from different colonies were screened for the right 
orientation of the insert. Where double digests were performed, digests were performed in a 
single reaction using the appropriate buffer. To confirm the presence of the insert and vector 
backbone I used restriction digestions of mini-preps.  
Dephosphorylation of DNA fragments: 
In order to avoid self-ligation of the plasmid backbones in cloning strategies, I used Antarctic 
Phosphatase (NEB), which removes the 5´ phosphates from DNA and RNA required by ligases.  
1/10 volume of 10X Antarctic Phosphatase Reaction Buffer was added to 1 µg of DNA (plasmid 
was cut with restriction endonucleases and cleaned by gel extraction). I then added 1 µl of 
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Antarctic Phosphatase (5 units) and the mix was incubated for 60 minutes at 37°C. The Antarctic 
Phosphatase was heat inactivated for 15 minutes at 70°C. 
DNA ligation 
Ligations were performed using the DNA ligation kit (Promega). Before proceeding with the 
ligation of the PCR/digested fragments into the pGEM-T easy vector, the amount of the insert 
to be ligated was calculated. The amount of vector used was 100 ng. The following formula was 
applied: 
 
[ng of vector × size of insert (kb)] ÷ size of vector (kb) × molar amount of (insert ÷ vector) = ng of insert 
 
The ratio between the vector and the insert was calculated as followed: 
a) If the insert was smaller than vector, then a 3:1 ratio (insert:vector) was used; 
b) If the insert was almost equal to vector, then a 1:1 ratio (insert:vector) was used 
As a control for self-ligation of the plasmid backbone I used the same calculations, but nuclease-
free water was added to the reaction instead of the PCR product.  
Reactions were incubated overnight at 4°C and subsequently used for transformation of E.coli 
competent bacteria as described in 2.4.7. 
2.4.3 Cloning of genomic rescue construct pWhiteRabbitpolyA (pW@RpA)+CG1847 
To obtain the genomic rescue construct pW@RpA+CG1847 (Figure 15), 2672 bp CG1847 insert 
(CG1847 with upstream and downstream sequences) was retrieved from pGEM-T easy using the 
restriction enzyme Not1 (NEB) and subsequently cloned into the pWhiteRabbitpolyA 
transformation vector. After the independent digestion reactions were carried out for the 
CG1847 inserts and the pW@RpA backbone, the samples were separated on 2% agarose gels. 
The fragments corresponding to the desired products sizes were cut from the gel and purified 
according to the purification protocol in section 2.3.7. The purified backbone was treated with 
Antarctic Phosphatase (section 2.4.2). 
As described above, 100 ng of vector was used for DNA ligations, with an insert: vector ratio of 
3:1. The reaction was incubated overnight at 4°C.  
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Figure 15: Schematic structure of genomic rescue construct pW@RpA+CG184 
Afterwards I proceeded to transform the vector into competent E.coli as described in section 
2.4.7. 
2.4.4 Cloning of genomic rescue construct pUASK10attB+ full-length hAIPwt  
To obtain the genomic rescue construct pUASk10attB-AIPwt (Figure 16) hAIP insert (1001 bp) 
was amplified from a pcDNA3-Myc-AIPwt vector existing in our lab (primers sequence in the 
Appendix 5).  
 
Figure 16: Schematic structure of genomic rescue construct pUASk10attB-hAIPwt 
pW@RpA-CG1847
8914 bp
CAM[R]
CG1847
polyA
white, exons
white, exons
white, exons
white, exons
white, exons
white, exons
attB
Kpn I (1877)
Kpn I (8902) Not I (1)
Not I (2673)
pUASKattB+hAIPwt
10538 bp
Amp
hAIPcDNA
Gal4-UAS
lox-P
GAGA site attB site
K10 3' UTRMCS
exon white
Not I (1)Not I (9538)
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The PCR amplified product was subcloned into a pGEM-T easy vector. This construct was 
sequenced, and revealed that the last 7 bases of AIP together with the enzyme restriction site 
were not amplified. The QuickChange XL site-directed mutagenesis kit (Stratagene, La Jolla, CA) 
was used to introduce the missing 7bp to repair the pGEM-T easy+hAIPwt construct. The site-
directed mutagenesis protocol is detailed in section 2.3.8. 
The repaired hAIPwt insert was released from pGEM-T easy vector using the restriction enzyme 
Not1 (as one of the desired enzyme restriction sites was lost). The pUASK10attB backbone was 
also digested with Not1. The digestion products were separated on 2% agarose gels. The 
fragments corresponding to the desired products sizes were cut from the gel and purified 
according to the purification protocol in section 2.3.7. 
The purified backbone was treated with Antarctic Phosphatase (section 2.4.2). As described 
above, 100 ng of vector was used in DNA ligations, with an insert: vector ratio of 3:1. The reaction 
was incubated overnight at 4°C. Afterwards I proceeded to transform competent E.coli as 
described in section 2.4.7. In further experiments, I generated a set of 4 constructs carrying AIP 
missense variants downstream of the attB site (for detailed description of the phiC31 system 
see section 3.2.3).  
2.4.5 Cloning of genomic rescue constructs pUASK10attB+ truncated hAIP 
(hAIPtrunc) 
To obtain the genomic rescue construct pUASk10attB-AIPtrunc (Figure 17) 907 bp of hAIP 
together with the upstream Myc tag were amplified from a pcDNA3-Myc-AIPwt vector. The last 
86 bp of AIP, the ones encoding for the 7th alpha helix were deleted, generating a truncated hAIP 
variant (hAIPtrunc). This fragment was cloned into a pGEM-T easy vector after adding A’ 
overhangs (detailed protocol in section 2.4.2), from which was released using the restriction 
enzyme Not1 (NEB). The pUASk10attB backbone was also digested with Not1. 
After the independent digestion reactions were carried out at 37°C, the samples were separated 
on 2% agarose gels. The fragments corresponding to the desired products sizes were cut from 
the gel and purified according to the purification protocol in section 2.3.7. 
The purified backbone was treated with Antarctic Phosphatase (section 2.4.2) to avoid re-
circularization. As described above, 100 ng of vector was used for DNA ligations, with an insert: 
vector ratio of 3:1. The reaction was incubated overnight at 4°C.  
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Figure 17: Schematic structure of genomic rescue construct pUASk10attB-hAIPwt 
Afterwards I proceeded to transform competent E.coli as described in section 2.4.7. 
2.4.6 Cloning of genomic rescue constructs pUASK10attB+ hAIP missense variants 
The genomic rescue construct pUASK10attB+hAIP was used to introduce missense variants via 
site-directed mutagenesis (section 2.3.9). The primers for mutagenesis were designed using the 
QuikChange Primer Design tool:  
Variant Location  Pathogenic Primers (Sequence 5' to 3') 
c.47G>A (p.R16H) N-terminus No 
ggacgggatccaaaaacatgtgatacaggaaggcc 
ggccttcctgtatcacatgtttttggatcccgtcc 
c.713G>A (p.C238Y) TPR2 domain Yes 
tgctgctcaactactgaccagtgcaagctggt 
accagcttgcactggtcagtagttgagcagca 
c.896C>T (p.A299V) TPR3 domain Unlikely 
acccagccctggtgcctgtggtgag 
ctcaccacaggcaccagggctgggt 
c.911G>A (p.R304Q) TPR3 domain Yes 
ctgtggtgagccaagagctgcgggc 
ggcccgcagctctcagctcaccacaggc 
Table 13: Missense variants generated in the study 
Site-directed mutagenesis was carried out using the QuikChange II XL Site-Directed Mutagenesis 
Kit according to the protocol suggested by the manufacturer (detailed protocol 2.4.4). 
Afterwards I proceeded to transform competent E.coli as described in section 2.4.7. Isolated 
pUASK10attB+MycAIPtrunc
10531 bp
MycAIP
Amp
Gal4-UAS
lox-P
attB siteGAGA site
K10 3' UTR
MCS
exon white
Not I (1)
Not I (9538)
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colonies were selected and grown overnight at 225 rpm/37°C in 5 ml LB broth supplied with 100 
µg/ml ampicillin.  
2.4.7 Transformation of competent cells with plasmid DNA  
E. coli strains 
The bacterial hosts used in this study are seen in Table 14 
Strain  Genotype 
JM109 (Promega) 
endA1, recA1, gyrA96, thi, hsdR17 (rk–, mk+), relA1, supE44, Δ( lac-proAB), 
[F´ traD36, proAB, laqIqZΔM15] 
JM109 Home-made –protocol at Appendix 8 
XL10-Gold 
Ultracompetent cells 
TetrΔ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 relA1 
gyrA96 relA1 lac Hte [F´ proAB lacIqZDM15 Tn10 (Tetr) Amy Camr]. 
Table 14: E. coli strains used in this study 
To prepare competent cells for plasmid DNA transformation, I used the method detailed in 
Appendix 9. 
Antibiotic usage 
Selection for ampicillin resistance on L-Agar or in L-Broth was performed using 10 µg/ml 
ampicillin, from a 100 mg/ml stock solution (w/v) which was stored at – 20°C. 
Preparation of LB/ampicillin plates  
15g of LB (Luria Bertani) (Sigma-Aldrich, UK) media was mixed with 6g Agar (Sigma-Aldrich, UK) 
and 500 ml of ddH2O was added. The medium was the autoclaved. After sterilized, the medium 
was melted and allowed to cool before adding 100 μg/ml of ampicillin. Then, 25 ml of medium 
were poured into petri dishes. 
Transformation of competent cells with plasmid DNA  
Cells were thawed on ice, and aliquoted into pre-chilled 1.5 ml falcon tubes to a volume of 50 
μl. 25-50 ng of DNA of interest or up to 10 μl of ligation reaction were added under sterile 
conditions, and gently mixed. A control for ligation tube with 10 μl of control for ligation reaction 
was also prepared as well. The cells were incubated on ice for 30 min, and heat shocked for 45 
sec in a 42°C water bath. The tube was immediately transferred to ice, and following a 2 min 
recovery step, 900 μl of pre-warmed SOC broth (Invitrogen) was added. The tube was shaken at 
250 rpm at 37°C for one hour, and spread on a LB-agar plate containing the appropriate 
antibiotic. The plates were incubated overnight, inverted, at 37°C. 
  
93 
 
2.4.8 Plasmid DNA purification- Miniprep 
In order to purify plasmid DNA QIAprep Miniprep kit (Qiagen, UK) was used according to the 
producer’s specifications. A single isolated white colony from a plate was inoculated in 5 ml of 
LB medium containing 5 μl of 100mg/ml ampicillin and incubated overnight at 37°C at 250 rpm. 
After incubation, bacterial cells were harvested by centrifugation for 3 minutes at 8000 rpm at 
room temperature. The supernatant was then removed and the pellet re-suspended in 250 μl 
of buffer P1, followed by 250 μl of buffer P2 and mixed thoroughly by inverting the tube 4-6 
times. 350 μl of buffer N3 were also added and mixed immediately by inverting the tube 4-6 
times. The solution was centrifuged for 10 min at 13000 rpm. Supernatants were applied to a 
column and centrifuged for 30-60 seconds. The column was further washed with 0.75 ml of 
buffer PE and centrifuged for 30-60 seconds. To remove any residual buffer, the column was 
centrifuged for an additional 1 min. The plasmid DNA was eluted in 50 μl of H2O. The 
concentration of each sample was determined using the Nanodrop. To confirm the integrity of 
the isolated plasmids a digestion with appropriate restriction enzymes was performed, 
separated on an agarose gel and sequenced. 
2.4.9 Preparation Maxi prep for plasmidic DNA extraction  
In order to purify higher volumes of plasmid DNA GenElute™ HP Plasmid Maxiprep Kit was used 
according to the producer’s specifications. 
The plasmid DNA was isolated from a 150 ml culture by centrifugation at 5000 X g for 10 minutes 
to pellet the cells. The cells were resuspended by adding 12 ml of Resuspension/RNaseA Solution 
and completely mixed by pipetting up and down, or vortexing. In the next step, 12 ml of Lysis 
Solution was added and the tube was immediately gently inverted 6 to 8 times. The mixture was 
allowed to sit and clear for 3 to 5 minutes. 12 ml of chilled Neutralization Solution were added 
to the mixture and gently invert 4 to 6 times. The tubes were allowed to sit until a white 
aggregate (cell debris, proteins, lipids, SDS, and chromosomal DNA) separated. In the next step 
were added 9 ml of Binding Solution and invert 1 to 2 times. Samples were immediately poured 
into the barrel of a filter syringe. The cell lysate was allow to sit for 5 minutes until the white 
aggregate should float to the top. GenElute HP Maxiprep Binding Columns were placed into 50 
ml collection tube and prepared by adding 12 ml of the Column Preparation Solution. The 
columns were then spin at 3000 X g for 2 minutes. The eluate was discarded and the lysate was 
filtered in order for plasmid DNA to bind to the column. The columns were centrifuged at 3000 
X g for 2 minutes and the step was repeated until the rest of the cleared lysate was filtered. 12 
ml of Wash Solution 1 were added to the column, which was spun at 3000 X g for 2 minutes. 
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After discarding the eluate, 12 ml of Wash Solution 2 were added to the column and centrifuged 
at 3000 X g for 5 minutes. The plasmid DNA was eluted by adding 3 ml of ultrapure water and, 
for maximum recovery of plasmid, collection tubes were centrifuged at 3000 X g for 5 minutes. 
Sample concentration was determined using the Nanodrop. 
2.5 Illumina TruSeq stranded mRNA sample preparation - Low sample 
protocol  
Total RNA was isolated from eight larval collection (above, section 2.3.2) using Qiagen RNeasy 
MicroKits. RNA samples were purified using the DNase I as suggested in the Qiagen protocol and 
resuspended in 14 μl of RNAse free water. RNA samples were measured using Nanodrop and 
subjected to Agilent 2100 bioanalyzer for checking the integrity of the extracted RNA. The 
samples were normalized to 500 ng/μl. Equal volumes of RNA from four control and four mutant 
samples were used for generating the cDNA libraries according to the Illumina protocol (detailed 
protocol in Appendix 10). Samples were prepared using four replicates for controls and four 
replicates for mutants. 
All libraries were sequenced in one lane, 30 million reads per sample on an Illumina HiSeq 1500 
instrument. 
Acknowledgement: The library preparation and the RNA sequencing were performed at the 
Barts and the London School of Medicine genomics core facility (Genome Centre). 
 
2.6 Sequence alignment to reference transcriptome 
Analysis pipeline short workflow 
To identify the genes whose expression is affected in CG1847 mutants a high-throughput RNA 
sequencing method was employed, which was performed with the help of colleagues at our 
Genome Centre (Dr. Charles Mein, and Dr Anna Terry Systems Administrator Bioinformatician). 
The raw results from the Illumina Hi-Seq were cleaned for removing the adaptors, then the 
FASTQ files were exported for analysis in Bowtie257 and TopHat258 to generate the database of 
transcripts.  
For the next step, assemble of the possible transcripts and their annotation, was used Cufflinks. 
Cufflinks (version 2.2.0) was run for each sample separately and the final results were assembled 
into a single merged.gtf file. 
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1. Pre-alignment  
The results from the sequencer platform were submitted to a primary analysis. After a pre-
alignment quality control, the unaligned reads were cleaned by trimming the bases from both 
3’ and 5’ ends. The reads that were too short were removed after trimming. 
The sequence alignment is a key step on this type of experiment. As a consequence, the read 
alignment program should be carefully chosen. One of the most efficient programs developed 
in the last few years – Bowtie257 (http://bowtie-bio.sourceforge.net/index.shtml) – was the best 
option to align our data to the reference transcriptome for Drosophila melanogaster. Both the 
forward and reverse strands were considered for alignment. The unaligned reads were split and 
realigned by TopHat (http://ccb.jhu.edu/software/tophat/index.shtml), a junction aware 
pipeline258. 
2. Checking quality of data using FastQC 
FastQC is a key control step that offers a simple quality control checks which provides a quality 
control report which is necessary to reveal the possible problems. This analysis presents the 
results in Per Base Sequence Quality mode using a Box Whisker type of plot. The quality scores, 
are also known as Phred quality scores, as they were developed initially for the Phred program 
for automation of DNA sequencing during the Human Genome Project259,260. 
All the samples were submitted for quality control (Figure 18). 
 
Figure 18: FastQC quality control of cDNA libraries. The background of the graph is divided along the y 
axis into three fields: green, which represents very good quality calls; orange, denoting calls of acceptable 
quality; and red, indicating poor quality calls. Control and mutant samples are shown in the top and 
bottom row, respectively. The yellow boxes represent the 25-75% quartile range, while the upper and 
lower whiskers represent the 10% and 90% points. The y-axis on the graph shows the quality scores also 
called the Phred quality scores. 
 
Mut_7_R1_fastqcMut_6_R1_fastqcMut_5_R1_fastqcMut_4_R1_fastqc
Ctr_4_R1_fastqc Ctr_5_R1_fastqc Ctr_7_R1_fastqc Ctr_8_R1_fastqc
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All the samples passed the Phred quality control, reaching high scores as the maximum Phred 
quality for Illumina technology is 40. 
3. Transcriptome assembly using Cufflinks 
Cufflinks version 2.2.0 (http://cole-trapnell-lab.github.io/cufflinks/releases/v2.2.0/) was used 
for transcriptome assembly and differential expression analysis of RNA-Seq raw data. 
All the alignment files were merged together by Cuffmerge, and the merged files were compared 
with the reference annotation to find novel unannotated features. Raw sequencing data was 
aligned to the most recent genome release: dmel_r6.03_FB2014_06 
(ftp://ftp.flybase.net/genomes/Drosophila_melanogaster/dmel_r6.03_FB2014_06/). 
The new released version 2.2.0 includes two new programs, Cuffquant and Cuffnorm. Our 
samples were passed through Cuffquant, which quantifies the levels of expression for a single 
BAM file. The results were visualized using CummeRbund. 
A schematic overview of the workflow is described in  
Figure 19. Cufflinks version 2.2.0 (CummeRbund branch) was used in this analysis. 
4.  Read count normalisation and quantification  
The actual RNA-seq quantification process takes in account both the molar concentration and 
the transcript length. The Mortazavi’s261 formula for a unit of measure of read density reflects 
the molar concentration of a transcript in the starting sample by normalizing for RNA length and 
for the total read number in the measurement. The normalization method allows comparison 
of transcript levels not only between the samples, but also within the same sample (Mortazavi 
et al., 2008)261.  
As a specific measure of reads density we used RPKM, as this is the most commonly used 
formula. RPKM indicates the Reads Per Kilobase of exon model per Million mapped reads: 
RPKM = C/ N x L (C = number of mappable reads that belongs to exons, N = total resulted number 
of mappable reads, L = the sum of the exons (bp)) 
For example, a 1kb transcript with 2000 alignments in a sample of 10 million reads (out of which 
8 million reads can be mapped) will have a RPKM=2000/ (1 x 8) = 250. A pair of reads constitutes 
one fragment261.  
The final results were assembled into a single merged.gtf file. 
 
  
97 
 
 
 
 
Figure 19: Overview of the bioinformatic workflow. The most recent version and the previously published 
workflow, described in Trapnell et al262 are presented  
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2.7 STRING analysis 
STRING (Search Tool for the Retrieval of Interacting Genes)263 (http://string.embl.de/) was used 
to analyse the interactions and relationships among the significantly up- or down-regulated 
genes. STRING pipeline assembles the input data based on neighbourhood information, high-
throughput experiments, co-occurrence, co-expression and data mining. 
This database reveals the functions of proteins at the molecular level by generating the protein-
protein interactions (PPI) network. Confidence scores is calculated for each interaction pair and 
default cutoff scores of above 0.4 were selected. 
 
2.8 Validation by multiplex- qPCR of selected transcripts 
A custom designed GeXP multiplex qPCR for gene targets was performed using 100ng of total 
RNA. The GeXP multiplex assay consisted of 16 pairs of chimeric primers: CG1847 transcript, two 
different reference genes (alpha-Tubulin at 84B, and Ribosomal protein 39) and 13 transcripts 
of interest. Target-specific reverse transcription and PCR amplification was performed in 
accordance with manufacturer’s instructions (Beckman Coulter, Wycombe, UK). In brief, a 
master mix was prepared for reverse transcription reactions as detailed in the GeXP Start Kit 
(Beckman Coulter, Wycombe, UK) and performed using a G-Storm thermal cycler, using the 
program protocol: 48°C, 1 min, 42°C, 60 min, and 95°C, 5mins. From this, an aliquot of each 
reverse transcription reaction was added to PCR master mix containing GenomeLab kit PCR 
master mix, Thermo Scientific Thermo-Start Taq DNA polymerase.  
The qPCR reaction was performed using a G-Storm thermal cycler with a 95°C activation step 
10mins, followed by 35 cycles of 94°C, 30 secs, 55°C, 30 secs and 70°C, 60 secs. Products were 
separated by capillary gel electrophoresis using CEQTM 8000 Genetic Analysis system. Following 
fragment separation, peaks were analysed and matched to corresponding genes using 
GenomeLab Fragment Analysis software (Beckman Coulter). 
ANOVA (post hoc test Fishers LSD) was applied for comparisons revealing at least a twofold 
change in expression levels. P values of less than 0.05 were considered significant. 
Information on all primers can be found in Appendix 5. 
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2.9 Statistical analysis  
Experimental data sets were analysed in JMP® (SAS institute). The Shapiro-Wilk and the 
Kolmogorov-Smirnov tests were used to check the normal distribution of the quantitative 
variables. Two way ANOVA or Kruskal-Wallis non-parametric if the distribution was non-normal 
tests were used to evaluate the significant differences. Means and standard deviations were 
used to report parametric data. The chi-square (I) test was used to determine whether there is 
a significant difference between the expected genotypes frequencies and the observed 
frequencies in the rescue experiments. A P<0.05 was considered to be statistically significant. 
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CHAPTER 3: ESTABLISHING A DROSOPHILA MELANOGASTER 
MODEL TO STUDY AIP FUNCTION 
3.1 INTRODUCTION  
At the start of my project the majority of investigations of AIP roles had focused on the 
developmental aspects, particularly on its involvement in limiting the normal morphogenesis 
processes during the embryological period. 
Previous studies had examined mainly the AhR-mediated xenobiotic signalling possibly by 
influencing AhR nuclear translocation. However, in addition to xenobiotic metabolic processes 
the AIP protein is also a chaperone involved in a variety of essential molecular functions as: 
domain binding142,145,172,264, signal transducer activity140, transcription coactivator activity and 
transcription factor binding265. AIP function in adult organisms has been relatively less explored 
as the loss of AIP is associated with lethality during early embryological stages. It was previously 
reported that loss of the Aip gene in mice leads to lethality at e14.5 accompanied by cardiac 
malformations such as double outlet right ventricle, ventricular-septal defects, and pericardial 
edema204. 
Taken together, these data indicate an extended AIP involvement in normal mammalian biology, 
apart from its role as an AhR co-chaperone. Therefore, it was reasonable to hypothesise that AIP 
might play a role as a key regulator of developmental growth. The initial aim of my project was 
to formally examine the actual role of AIP in development and the mechanism behind the 
lethality associated with the loss of this protein. Furthermore, it is well known that AIP functions 
as a tumour suppressor gene in pituitary tumorigenesis and understanding what role this protein 
plays in abnormal growth could therefore be of significance to cancer initiation and progression. 
Over the years, Drosophila melanogaster has evolved from being a useful animal model for 
investigating genetics and the mechanisms of inheritance to being one of the most valuable tools 
for understanding gene function. This insect proved to be a powerful model for the study of 
normal development and the mechanisms underlying disease pathogenesis, as well as an aid for 
the development of new drugs. New advanced tools and techniques are constantly being 
developed keeping Drosophila at the forefront of research. 
Some of these approaches and methods were employed in the present study for a better 
understanding of AIP function. 
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3.2 BACKGROUND 
We used some of the valuable tools that were developed in Drosophila model to gain further 
knowledge on the impact of CG1847 loss of function. 
3.2.1 The Gal4/UAS system 
With its powerful genetic tools, Drosophila is an important animal model for functionally 
characterising genes involved in specific biological processes. A breakthrough for Drosophila 
genetics came with the ingenious combination of budding yeast (Saccharomyces cerevisiae) and 
Drosophila genetics which resulted in the GAL4-UAS system238. This technique allows selective 
induction of gene expression in a temporally and spatially controlled manner. This system 
involves the creation of two fly lines carrying either a Gal4 or a UAS transgene, which are then 
crossed to achieve a desired genotype. 
The Gal4-UAS system has two essential components. The first is the Gal4 gene, which encodes 
a transcription activator protein originally found in S. cerevisiae, where it controls the expression 
of galactose metabolism genes. Gal4 can directly bind to the second element of the system, a 
DNA consensus sequence called "Upstream Activating Sequence" or UAS, which acts as an 
enhancer sequence for neighbouring genes. The versatility of the system arises from the fact 
that the Gal4 and UAS elements can be combined with specific promoter sequences (a driver). 
In other words, one of the flies (the female or the male) is a transgenic for the Gal4CDS coupled 
with either a ubiquitous promoter (e.g. Act-Gal4) or a tissue-specific promoter (e.g. Elav-Gal4). 
The other fly is a transgenic for a P-element containing the UAS site fused with a sequence of 
interest, as the CDS of a specific gene or a particular RNAi (e.g., UAS-CG1847-RNAi Figure 20). 
 
Figure 20: UAS-Gal4 system in Drosophila. The system consists of two parts: flies expressing the yeast 
GAL4 transcription factor under the control of specific promoters/enhancer named driver (red oval) and 
flies carrying a CG1847-RNAi sequence downstream of an UAS promoter region (yellow ovals). GAL4 is 
only expressed in cells where the driver is active. Gal4 specifically binds to UAS (green triangles) to activate 
transcription. Adapted from www.hoxfulmonsters.com/wp-content/uploads/2008/05/uas-gal4.jpg 
GAL4 cDNA
Actin promoter
First line (UAS)
GAL4 protein
CG1847-RNAi
Second line (Gal4)
UAS sequence
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The offspring of the cross between these two lines will include individuals that carry both genetic 
elements and, therefore, will express the desired CDS/RNAi ubiquitously (e.g., UAS-CG1847-
RNAi expression in actin+ cells by Act-Gal4/UAS-CG1847RNAi) 266. 
The Gal4/UAS system presents a few very important advantages. Maybe the most important is 
the separation of the driver (Gal4) and the eﬀector (UAS) between in two parental lines. This 
prohibits the activation of the transcription in the parents, which means that it is possible to 
generate transgenic lines for proteins that are toxic, or lethal, which is the case for AIP. 
3.2.2 Transposable elements for mutagenesis use  
Another revolution in the Drosophila field was introduced by Rubin and Spradling in 1982253 with 
the use of the P-element for transgenesis267. A P-element is an 8-10 kb transposon that has the 
ability to insert and excise itself within the genome. In order for transposition to take place a 
transposase enzyme is necessary. Transposase recognises inverted repeat sequences that are 
localised at the ends of P-elements and promotes transposon excision and reinsertion at a 
different genomic locus. Naturally occurring P-elements encode an internal transposase gene, 
whereas P-element lines developed for laboratory use have been specifically designed to lack 
this transposase to avoid deleterious effects of having a mobile DNA element in the genome. 
This allows researchers to induce transposition in a controlled manner by crossing lines that 
carry a P-element with a line that carries the transposase (e.g. enzyme Δ2.3). 
One important molecular biological aim a Drosophila researcher needs to achieve is to silence a 
gene of interest and P-elements are valuable tools for this268,269. If the function of a gene cannot 
be disrupted by inserting a P-element, it is possible to use the P-element system to induce a 
deletion of the target gene. This is possible because P-elements preferably insert into the 5’ UTR 
of genes and their excision from a genomic locus may be imprecise. Indeed, when P-elements 
are mobilised they often carry flanking genomic sequences. If this occurs in the vicinity of a gene, 
it can generate a deletion mutant for that gene. When a P-element is excised from a 
chromosome a double-stranded break (DSB) is created, which can be repaired either by 
homology-directed repair or by non-homologous repair270. In some cases, the DSB ends may be 
degraded before the repair occurs and, as a result, a deletion of the genetic material may occur, 
an event known as imprecise excision271. This event may excise also the flanking genomic DNA, 
which is removed with the P-element and generates deletions around the original P-element 
insertion point. In so-called precise excisions the size of the deleted genomic DNA occurring 
during such an event may vary from a few base pairs to several kilobases. The size of the 
remaining fragments of the P-element inverted terminal repeats ranges between 5 and 18 bp, 
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and are called “footprints”272,273. The resultant stocks are called “revertant”, and might be used 
as a control, if the remaining insertion is not in a coding region or if it does not introduce a 
frameshift mutation. 
Public and commercial fly stock repositories contain transgenic fly lines with P-elements inserted 
in different areas of the genome. One advantage of this tool is the fact that P-elements were 
engineered to carry the white gene as a marker. Therefore, excision of the P-element and the 
surrounding DNA (“imprecise excision”) will also excise the white gene, therefore providing a 
means of screening those flies in which the excision has taken place. 
3.2.3 PhiC31 system 
In 1998 a genome integration system was developed that allows a very precise insertion of DNA 
elements into the genome274. This system is based on the site-specific phiC31 integrase. PhiC31 
is a bacteriophage that encodes a serine integrase enzyme, which has the ability to mediate 
sequence-directed recombination between a bacterial attachment site (attB) and a phage 
attachment site (attP)254 (Figure 21). 
 
Figure 21: Schematic diagram of the phiC31 integration system into the Drosophila genome. A plasmid 
carrying a gene of interest and an attB attachment will be integrated into the Drosophila genome at an 
attP landing site 
 
One of the main advantages of this system is the fact that the phiC31 integrase does not require 
any cofactors to mediate site-specific recombination. In 2004, this system was adapted for use 
attB
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in Drosophila275 and stable recombinants (transgenic flies) were generated to aid in vivo studies 
and the understanding of gene function and regulation. 
Since the system’s introduction, an entire library of well characterized, highly efficient landing 
sites that span the four chromosomes of the Drosophila genome have been generated. The 
landing sites were designed and selected to prevent them from interfering with other Drosophila 
transposon systems and to minimize: 1) effects of the insertions (e.g. interfering with the gene 
function at the insertion site); 2) effects on gene expression of genes on the P-element (e.g. 
enhancer-trap). 
3.2.4 High-throughput sequencing (RNA-seq) for identifying differentially expressed 
genes 
The transcriptome is the full range of total or messenger RNA (mRNA) and their level of 
expression during normal or pathologic conditions expressed by an organism. The main purpose 
of transcriptomic analysis is to evaluate all the transcripts in a specific sample, to quantify 
changes in expression levels of transcripts during development or under different physiological 
conditions. 
These approaches were first developed at the beginning of 1990s with Sanger sequencing cDNA 
libraries276. In recent years, deep sequencing technologies based on RNA (total or fractionated, 
such as poly (A+)) were highly improved. The recent development of high-throughput DNA 
sequencing methods has provided a new tool, termed RNA sequencing or RNA-seq, which allows 
both transcriptome mapping and quantification. Briefly, total RNA is fragmented and converted 
to a double-stranded cDNA library. Adaptors are attached to the ends of the cDNA strands and, 
after library validation, samples are normalized and mixed in a pool that is subjected to 
sequencing (Figure 22). Illumina Next-Generation Sequencing allows whole-transcriptome 
analysis via total RNA sequencing. The TruSeq Stranded Total RNA results in a complete 
transcriptome, including coding and noncoding RNA, and a very accurate gene expression 
quantification. 
The resulting raw sequencing data is used to generate de novo transcriptome assembly as RNA-
seq has an important advantage over previous techniques: previous knowledge of the genome 
sequence is not required277. RNA-seq allows genome sequencing to a single base resolution. The 
quantification of transcript expression levels is based on counting the number of reads 
corresponding to the RNA from each known exon261. 
  
105 
 
 
Figure 22: RNA-Seq workflow. Briefly, long RNAs are first converted into a library of cDNA fragments 
through either RNA fragmentation or DNA fragmentation (see main text). Sequencing adaptors (blue) are 
subsequently added to each cDNA fragment and a short sequence is obtained from each cDNA using high-
throughput sequencing technology. The resulting sequence reads are aligned with the reference genome 
or transcriptome, and classified as three types: exonic reads, junction reads and poly(A) end-reads. These 
three types are used to generate a base-resolution expression profile for each gene, as illustrated at the 
bottom; a yeast ORF with one intron is shown (adapted from Wang et al.277). 
 
In this chapter, I used RNA-seq technology to discover changes in transcript expression elicited 
by loss of expression of Drosophila AIP (CG1847). This approach allowed me to identify several 
transcripts whose expression was significantly altered in Drosophila AIP mutants. The results 
from the RNA-seq approach were subsequently confirmed via multiplex qPCR. 
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3.3 OBJECTIVES 
AIP is involved in organism development and survival, and its deregulation leads to lethality. 
Genes that are essential for development are more likely to contribute to disease than non-
essential genes278, so it is important to fully understand their function. To analyse the molecular 
mechanisms of loss of AIP in vivo, I used Drosophila as a model system to:  
a. Characterise the effect of Drosophila AIP (CG1847) knockdown, using RNAi-mediated 
gene expression silencing under the control of the GAL4/UAS-system.  
b. Generate a CG1847 knockout mutant by imprecise excision of a P-element (P-
CG1847G1839) located in the 5’UTR of CG1847. 
c. Rescue the AIP mutant via re-expression of wt CG1847 under the control of its 
endogenous promoter, to unambiguously verify that mutant phenotypes are a result of 
CG1847 disruption. 
d. Reveal the underlying molecular mechanisms of AIP loss by performing whole 
transcriptome analysis. 
e. Validate via multiplex-qPCR the significantly differentially expressed genes detected by 
RNA-seq in mutant larvae compared to controls. 
 
3.4 RESULTS  
3.4.1 CG1847 is a Drosophila melanogaster AIP orthologue 
Bioinformatic analysis identified CG1847 as a putative Drosophila orthologue of the human AIP 
gene (identified via GenBank BLAST search). Very little is known about the role of CG1847 as it 
has never been studied in the fruit fly. CG1847 is a protein coding gene with 2 annotated 
transcripts (CG1847-RA and CG1847-RC), encoding 2 polypeptides. The molecular function 
mentioned for CG1847 in FlyBase is as aryl hydrocarbon receptor binding protein, and it is 
described as being involved in protein folding. No phenotypic data ara available in public 
databases. 
Alignment of the amino acid sequences of CG1847 (FBtr0073567) and human AIP 
(ENST00000279146) using the Clustal Omega suite revealed that CG1847 has 37.74% overall 
identity with human AIP proteins (Figure 23). Clustal Omega is a multiple sequence alignment 
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program for proteins producing biologically meaningful multiple sequence alignments of 
divergent sequences (http://www.clustal.org/omega/)279. 
 
 
Figure 23: Sequence alignment of Drosophila CG1847 protein and human AIP. Stars indicates identity; 
high similarity amino acids are indicated by colons ( : ) while low similarity amino acids by dots ( . ). Source 
of protein sequences: Ensembl release 81 - July 2015 © WTSI / EBI http://www.ensembl.org 
 
According to the ClustalW algorithm the human and Drosophila proteins share 120 identical 
amino acids, 80 are strongly conserved, while 34 of the amino acids are weakly conserved. The 
other 96 amino acids are unique between the 2 species. 
Large-scale gene expression studies have been performed in Drosophila and they have proved 
to be extremely useful in providing data regarding transcription of specific genes during different 
developmental stages280,281. Overall, during the majority of development stages the CG1847 
levels of expression are very low, or just moderate. The highest expression of CG1847 was found 
in the first 2 hours, maybe due to maternal contribution (due to the mothers supplying the eggs 
with their own mRNA or proteins, to support the development during the very initial stages). 
Gene profiling from the earliest stages of embryonic development to adulthood revealed that 
CG1847 expression varies in different tissues. The available data from the FlyAtlas282 and 
modENCODE283 platforms provide an extensive overview of CG1847 expression during 
development in multiple larval and adult tissues (Figure 24). 
FBtr0073567          ---MQSRSKSDMKPIRKEILNPG-NAYIELTPGTRVKFHFQTRRAG-DSRIIDDSRKMEK   55
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FBtr0073567          KSTVSKELKSIEDQQQARNVQDRIHMQKLF-- 320
ENST00000279146      APVVSRELRALEARIRQKDEEDKARFRGIFSH                               330
.**:**:::* : : :: :*: ::: :*  
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Figure 24: Expression of CG1847 during development in different tissues and organs. Data was extracted 
from FlyAtlas, which reveals expression data during 30 stages of development (top panel) for 8 and 17 
distinct larval and adult tissues respectively (bootom panel). The dataset comprises Affymetrix Dros2 
expression arrays (representing 18770 transcripts282), with 4 replicates per tissue. 
(http://flybase.org/reports/FBgn0030345.html) 
 
CG1847 protein has the same features as human AIP: an N-terminal FKBP-type domain and C-
terminal tetratricopeptide repeats. Indeed, a three dimensional theoretical model of CG1847 
generated by my collaborator Chris Prodromou revealed a protein structure that closely 
resembles the published AIP protein structures (Figure 25). 
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Figure 25: Three dimensional theoretical model of CG1847. The Drosophila protein has a similar 
predicted structure to its human orthologue: it has all three pairs of conserved anti-parallel alpha-helices 
(tetratricopeptide domains, TPR) and the final extended alpha-helix, alpha-7. This model was based on 
the crystal structure of human AIP142,145,234 and was prepared by Chris Prodromou (Sussex University). 
 
3.4.2 CG1847 is essential for Drosophila development  
Essential genes are defined as those necessary for growth and survival under a given condition. 
To investigate the function of CG1847 in Drosophila, I examined the consequences of disrupting 
CG1847 gene expression in developing flies using RNA interference via the GAL4/UAS-system238. 
To achieve this, I used 4 fly stocks that carry different UAS-RNAi constructs targeting CG1847, 
which were expressed during fly development under the control of a ubiquitous (Act-Gal4) or 
neuron-specific (elav-Gal4) promoter. Here, I present and discuss the results obtained with 3 of 
these stocks as they were the ones that yielded more promising phenotypes. 
When UAS-CG1847-RNAi-R2 males were crossed with Act-GAL4 females, as actin is ubiquitously, 
and rather abundant, expressed, this cross resulted in strong knockdown of CG1847 expression 
in all tissues. No viable adult offspring were observed, suggesting that complete AIP-knockdown 
is not compatible with viability. In contrast, UAS-CG1847-RNAi-R1 produced a few viable 
offspring. However, RT-PCR analysis revealed that the knockdown of CG1847 expression with 
RNAi-R1 was only partial (Figure 26 A). As RNAi constructs can occasionally generate phenotypes 
due to off target effects, I used new RNAi stocks with a different non-overlapping sequence of 
PPIase domain
(purple, amino acids 31-151)
C-terminal α-7 helix
(red, 285-320)
TPR1
(green, 163-211)
TPR2
(yellow, 213-252)
TPR3
(orange, 254-283)
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CG1847 (section 2.2.1). Using the new RNAi stocks, I obtained similar results to those obtained 
with UAS-CG1847-RNAi-T2 line, that is, expression of CG1847 RNAi under the control of Act-Gal4 
resulted in 100% lethality. As previous ubiquitous knockdown resulted in lethality, I crossed UAS-
CG1847-RNAi-T2 males with females carrying a tissue speciﬁc driver. Elav-Gal4 was used to 
silence CG1847 expression only in nervous cells. We choose this driver for two different reasons. 
First, based on the microarray data CG1847 has a higher level of expression in the brain (Figure 
24). Second, most of the knockdowns in the fruit fly nervous tissue do not have a lethal 
outcome284. 
  
 
Figure 26: CG1847 RNAi knockdown. RT-PCR was performed using RNA extracted from adult fly heads. 
Upper panels CG1847 amplicons, 165 bp product; Ribosomal protein 32 (RpL32) expression was used as 
housekeeping gene control (lower panels). A) KD with UAS-CG1847-RNAi-R1. Lanes 1 and 2 – UAS-RNAi 
stocks R1 and R2 were used as a control and tested for leak expression of the IR constructs. Lane 3 CG1847-
R1>Act-Gal4 flies showing knockdown of CG1847 expression, see arrow. Stars indicate primer dimers B) 
KD with UAS-CG1847-RNAi-T2. Lane 1 CG1847-T2 flies were crossed with y w flies, in order to be used as 
a control and to prove that the RNAi construct is not expressed in absence of a Gal4 driver. In Lane 2 
CG1847-T2> elav-Gal4 flies show knockdown of CG1847 expression. 
RNAi-mediated depletion of CG1847 using UAS-CG1847-R1 did not cause lethality with either 
Act-Gal4 or elav-Gal4, with some flies reaching the adult stage. This enabled the quantification 
of the efficiency of CG1847 knockdown using RT-PCR (Figure 27). For UAS-CG1847-R1 and R2 the 
average amount of CG1847 transcript in the parental lines was compared to the average amount 
of CG1847 transcript in the Act-GAL4-driven UAS-RNAi lines, and an expression ratio was 
calculated. For UAS-CG1847-T2 the average amount of CG1847 transcript in the control crosses 
was compared to the average amount of CG1847 transcript in the elav-GAL4-driven UAS-RNAi 
lines. For quantification the above images were uploaded into the ImageJ software and the 
intensity of the bands was evaluated. The average of the target genes was normalized to the 
average of the control gene RpL32 and expressed in intensity units. 
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Figure 27: Quantification of CG1847 RNAi knockdown efficiency. Relative CG1847 expression was 
quantified by semiquantitative RT-PCR. RT-PCR was performed on total RNA isolated from adult fly heads. 
A) Quantification of CG1847 expression in parental lines and UAS-CG1847-R1 Act-Gal4-driven knockdown. 
B) Quantification of CG1847 expression in control flies and UAS-CG1847-T2 elav-Gal4 driven knockdown. 
Shown are the averages of the ratio of the expression of CG1847 and RpL32 from two independent 
experiments. Error bars represent SE. 
 
In summary, a very efficient RNAi-mediated depletion of CG1847 was obtained using all RNAi 
lines. The average levels of CG1847 was less than 13.3% of control for UAS-RNAi-R1 expressed 
with a strong driver as Act-Gal4. With elav-Gal4, even though the expression of UAS-RNAi-T2 is 
restricted to nervous tissue, resulted in reducing the CG1847 expression to less than 33.3% of 
controls. 
Next, taking advantage of the temperature sensitivity of the GAL4 system285, it was assessed 
whether increasing the potency of UAS-CG1847-RNAi-R1 might result in a lethal phenotype. 
Higher temperature increases Gal4 activity and when animals were grown continuously at 29°C 
no adult UAS-CG1847RNAi-R1>Act-Gal4 flies were recovered. 
3.4.3 CG1847exon 1_3, a null CG1847 allele, confirmed the essentiality of this gene 
To confirm the results obtained with RNAi-mediated depletion of CG1847, I performed an 
imprecise P-element excision screen267 to generate a “classical” mutation in CG1847. For this, I 
used an existing fly stock carrying a P-element insertion in the 5’ UTR of CG1847 (P-CG1847G1839). 
The P-element was mobilized using standard genetic techniques (detailed protocol in section 
2.2.2). In the second generation of the excision screen, 200 single crosses were set up, each with 
a single virgin female and 3 FM6 males. In the following generation, I screened for virgins with 
white eyes, that is, those who lost the P-element. I identified 49 virgin females with white eyes, 
which were used to generate independent putative mutant stocks, by backcrossing to FM6 
A) B)
  
112 
 
males. Out of these 49 lines, 18 stocks were lethal as no non-FM6 males were recovered in the 
offspring. Table 15 summarises the different steps of the excision screen. Based on the PCR 
screening described below, the majority of the stocks carrying putative mutant alleles were 
discarded as the deletions were too big, affecting either the upstream or the downstream genes 
in addition to CG1847. 
Stocks  Number 
Total crosses 200 
White eye virgin females identified 49 
Lethal alleles (putative mutants) 18 
Stocks discarded (very large deletions) 17 
 
Table 15: Summary of P-element excision screen. 
For a precise characterisation of these putative mutant alleles and to identify the extent of the 
deletion, genomic DNA from heterozygous females was analysed by PCR (primer sequences 
Appendix 5). Flanking primers (Dm_EP_EL_F and Dm_EP_EL_R) and PCR conditions were 
designed to amplify a fragment resulting from a deletion in the CG1847 locus, but not a P-
element-containing fragment (more than 8000bp in our case). These primers were also designed 
at the border with the upstream and downstream neighbouring genes in order to detect 
deletions that will be too large. Identification of the CG1847 control stock where the P-element 
has undergone precise excision (revertant) was based on the detection of a larger amplicon 
when using the second pair of primers (Dm_EP_F and Dm_EP_R). See Figure 28 for a schematic 
representation of primer annealing: 
 
Figure 28: Schematic representation for primer annealing. For detecting the genomic deletion were used 
2 pairs of primers. Pair P1 (Dm_EP_EL_F and Dm_EP_EL_R) was design to bind into the neighbouring genes 
and to amplify a 2487 bp amplicon. Pair P2 (Dm_EP_F and Dm_EP_R) amplifies a 298 bp fragment, inside 
CG1847 gene. 
 
As a control to verify that the PCR conditions were correct, I used y w flies and homozygous FM6 
females that eclosed in these stocks. After validating the efficiency of the PCR approach in the 
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controls, I screened the putative mutant stocks from the excision screen to identify a CG1847 
mutant stock (representative PCR images in Figure 29). 
 
 
 
Figure 29: Agarose gel for selected number of CG1847 mutant alleles. Identification of alleles containing 
a loss of genomic DNA. Each sample was amplified with 2 different pairs of primers. (a) and (c) The first 
pair (Dm_EP_EL_F and Dm_EP_EL_R) was designed to amplify a 2478 bp. Different alleles show different 
size amplicons from the control y w. (b) and (d). The second pair (Dm_EP_F and Dm_EP_R) was designed 
to amplify a 298 bp. 
 
The first pair of primers (Dm_EP_EL_F and Dm_EP_EL_R) was designed to amplify a 2478 bp 
amplicon in wt flies (y w) or flies carrying the FM6 balancer (Figure 29 a) and c)). In the revertant 
the PCR analysis also resulted in a 2478 bp amplicon, as the P-element footprint does not 
produce a significant amplicon size difference. In flies carrying deletions, the PCR analysis 
revealed a band smaller than 2478bp or no amplicon. Failure to detect an amplicon was likely 
due to a large deletion that prevented primer annealing and DNA amplification. In this case, the 
stock was discarded as the deletion may affect not only CG1847 but also surrounding genes 
(Figure 28). The second primer of pair Dm_EP_F and Dm_EP_R was design to amplify a 298 bp 
amplicon in y w flies or flies carrying the balancer chromosome FM6 (Figure 29 b and d). 
Therefore, I expected that “non mutant” alleles would produce a similar 298 bp DNA amplicon 
(or slightly larger in case -the footprint of the P-element was still present). 
One excision Δ125A (named CG1847exon1_3 thereafter) exhibited promising results that led to its 
selection as a loss-of-function allele. This allele carries a deletion of 1512bp in the CG1847 locus 
that encompasses exon 1, 2 and part of exon 3 (Figure 30). 
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Figure 30: Creation of CG1847 knockout fly line. 
CG1847exon1_3 is a loss-of-function allele, having deleted 
1512bp containing exon 1, 2 and part of exon 3. PCR from 
adult fruitfly DNA using primers designed for a 2478bp 
product. Lane 1: sample 125A extracted only from 
females (heterozygous) as there were no viable males. In 
this PCR the normal size CG1847 was less amplified 
probably due to the polymerase primarily amplifying the 
smaller mutant fragment (approx. 1000p) rather than the 
larger (2478bp) wild-type fragment. Lane 2: yellow white 
fly was used as controls; Lane 3: empty lane, Lane 4: water 
control, Lane 5: size marker. 
To confirm the deletion, we sequenced the DNA amplicon obtained in CG1847exon1_3 flies using 
the diagnostic primers (Figure 28). The Sanger sequencing identified the excision of 1512bp 
(exon 1, 2 and exon 3) creating the CG1847exon1_3 mutant. A schematic representation of the 
mutant is shown in Figure 31. 
 
Figure 31: Schematic diagram of the CG1847 locus in wt and CG1847exon1_3 mutants. Intron and exon 
boundaries are based on the sequencing results of CG1847exon1_3 mutants. 
 
This mutant allele is homozygous and hemizygous lethal, confirming the results obtained with 
CG1847 RNAi and reinforcing the notion that CG1847 is an essential gene. The CG1847exon1_3 
mutant was used in subsequent experiments to analyse CG1847 function. 
In the same mutagenesis experiment, I also generated a control stock via precise excision of the 
P-element. As this revertant originates from the same genetic background as the mutant, it can 
therefore be used as a control (see below for details). For initial characterisation of stocks from 
the P-element excision screen, genomic DNA from heterozygous flies was analysed by PCR 
technique (primer sequences Appendix 5). For detecting the control stock the flanking primers 
were designed in such a way that they will amplify a 298 bp amplicon around the area of P-
element insertion. Identification of CG1847 revertant stocks was based on detection of a higher 
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amplicon than the 2 controls (y w stock and FM6/FM6 females resulting from the same cross). 
Figure 32 is a representative agarose image gel for detecting the revertant stock. 
 
Figure 32: Agarose gel of PCR results - selected 
stocks resulted from the P-element excison 
screen. Identification of alleles which have lost 
the P-element via precise excision. The pair of 
primers (Dm_EP_F and Dm_EP_R) was designed 
to amplify a 298 bp. Some of the stocks show 
different size amplicons from the 2 different 
controls (y w and homozygous FM6 females). 
Samples 2.39A-2.39D shows an amplicon only 
slightly longer than the controls. 
 
The primer pair Dm_EP_F and Dm_EP_R was designed to amplify a 298 bp amplicon in wt flies 
(y w) or flies carrying the FM6 balancer chromosome. In the PCR screening, a “revertant control” 
was expected to display a slightly larger amplicon than the controls, due to the fact that a few 
bp of the P-element are usually not excised when the transposon is mobilised and is excised 
correctly (the transposon footprint). As the transposon footprint indicates that the P-element 
was correctly excised, it also indicated that these alleles did not contain a genomic deletion of 
the CG1847 gene. 
Based on the PCR screening, four excision stocks 2.39A-2.39D were selected as precise excision 
controls for RNA-seq. As all 4 stocks showed similar footprint sizes, I confirmed the sequence of 
one of them (stock 2.39A) by Sanger sequencing. DNA was extracted from males which are 
hemizygous for P-element excision (Figure 33). 
 
Figure 33. Comparation between the CG1847wt sequence and the chromatograms of CG18472.39A. The 
CG18472.39A stock presents a 15 bp expected insertion (footprint). 
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The females lacking FM6 balancer chromosome (homozygous for P-element precise excision) 
are also viable. Although the precise excision control lacks the transposon, it is possible that the 
P-element footprint sequence may disrupt CG1847 expression, if it is located in a conserved 
genomic area that has regulatory functions. To determine whether this was a likely possibility, I 
performed a BLAST alignment of the CG1847 region in the vicinity of the P-element footprint, 
using as a reference the Drosophila melanogaster UCSC Genome Browser (Figure 34). 
 
Figure 34: BLAST alignment. The DNA sequences of the region immediately surrounding the foot print of 
the P-element was blasted using UCSC Genome Browser to determine if the area has a high degree of 
conservation. 
Despite the fact that the original P-element was inserted in the 5’UTR of CG1847, the BLAST 
analysis revealed that the remaining P-element footprint is not in a conserved region and, 
therefore, it is unlikely that it affects CG1847 expression levels. However, for Drosophila 
melanogaster it was not possible to evaluate if in the proximity of this area are any consensus 
binding sites for transcription factors (the online databases are not as complete as human 
databases). Consequently I was not able to determine if the footprint of the P-element might 
disrupt such a binding site for a transcription factor, with further consequences on the 
expression of CG1847. 
3.4.4 CG1847exon1_3 mutant display total loss of CG1847 expression 
To confirm that CG1847exon1_3 is a CG1847 null allele, CG1847 gene expression was analysed by 
RT-PCR performed using RNA extracted from 48 h hemizygous mutant male larvae. As controls 
RNA samples extracted from either 48 h y w larvae or from y w male adults were used (Figure 
35). However, none of the controls were the appropriate ones as the RNA extracted from 48 h 
larvae started from a mix of males and females collection, while the adults are known to have 
different levels of CG1847 expression. 
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Figure 35: CG1847 expression in mutant male larvae. A) RT-PCR amplification products from CG1847 48h 
mutant male larvae and controls (48 h y w larvae and y w adult). Upper panel: CG1847 RT-PCR (165 bp 
product); Lower panel RpL32 RT-PCR (housekeeping gene, 120 bp product). B) CG1847 gene expression in 
mutant larvae was quantified by semiquantitative RT-PCR. RT-PCR was performed using specific primers 
on total RNA isolated from mutant male larvae and controls. Data shown as average of mean target gene 
normalized to the control gene RpL32 of three independent experiments. Error bars represent SE. 
Asterisks indicate statistical significance as determined by Student’s t-test (*P<0.05, **P<0.01).  
CG1847 expression was not detected in male larvae hemizygous mutants indicating that this is 
a null allele. This was associated with 100% lethality. Interestingly, the levels of expression of 
the housekeeping gene were increased in mutant larvae revealing possible increased 
proliferation in the mutant male larvae. For more details see Discussion section. 
3.4.5 Lethality occurs in late larval stage of development 
To determine at which developmental stage lethality occurs in CG1847 mutants, I balanced the 
CG1847 mutant allele over a balancer chromosome containing a fluorescent marker (FM7c, 
Dfd::YFP (Table 4)). 
Embryos were collected for 4 h (details in section 2.2.10). I counted the larvae produced at 
various time points during development. Two separate collections were performed for each 
stage of development. In this stock four different genotypes are possible in each generation, due 
to allele segregation and combinations of X and Y chromosomes. Consequently, each genotype 
should count for 25%. However, homozygous FM7c females are not viable, so each genotype 
should count for around 33.3% at any time point during development. However, the 
homozygous FM7c dfd::YFP females cannot be differentiated from the heterozygous FM7c 
dfd::YFP larvae and, consequently, the moment of their lethality was not able to be precisely 
established. 
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24 h 194 (66.9%) 96 (33.1%) 
48 h 65 (72.3%) 25 (27.7%) 
72 h 471 (89.1%) 58 (10.9%) 
96 h 218 (100%) 0 (0%) 
Table 16: Determination of lethality stage during development. Larvae were counted at 24, 48, 72 and 
96 h AEL, and selected based on the presence or absence of fluorescence (dfd-YFP). Numbers represent 
total number of larvae counted in 2 separate experiments. Red represents significantly reduced numbers 
than expected.  
From a total of 290 larvae counted at 24 h AEL, there were 194 controls (FM7c, Dfd::YFP) and 96 
hemizygous mutant males (CG1847exon1_3/Y). This was in accordance with Mendelian inheritance 
as the mutant genotype should count for around 33% out of the total number of larvae (Figure 
36). On the other hand, from a total of 529 larvae counted at 72 h AEL there were 471 controls 
and just 58 hemizygous mutant male larvae (just 10% of the total viable larvae –Table 16). A chi-
square analysis indicated that significant mortality of CG1847exon1_3/Y males was associated as 
the ratio of the genotypes obtained (8:1) was significantly different from the expected (2:1) ratio 
based on Mendelian segregation. The total number of larvae counted was 1127. The observation 
that our genotyping at 48 h AEL indicated a control /hemizygous mutant frequency of 2.6:1, 
indicates that the lethality of mutant Drosophila males occurs after this developmental point 
and before reaching 72 h AEL. 
Together, these data indicate that CG1847 is an essential gene in fruit flies, as total deletion of 
CG1847 leads to lethality during the 2nd instar stage of larval development. This stage begins 
immediately after the first larval molt and takes approximately 24 hours at 25°C. Larvae are very 
small, but they are active and very mobile in the food. The salivary glands extend to the first 
abdominal segment and the larvae are actively feeding with the food medium. Unfortunately 
the available information regarding the development of Drosophila during the second instar 
stage (L2) is very scarce. Detailed description of fruitfly normal development was presented by 
Hartenstein in 1993, but his investigations were focused mainly on embryonal, 3rd instar (L3) and 
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pupal stages286. Consequently it is very difficult to speculate which might be the tissues and 
organs affected by loss of CG1847. 
 
Figure 36: Survival rate between 24 and 96 h AEL. The numbers represent averages of percentages of 2 
separate countings for mutant (grey) versus control fluorescent (green) larvae. At 24 h AEL the percentage 
of mutant larvae reaches the expected value of 33%, but is dramatically decreased by 72 h AEL. No 
CG1847exon1_3/Y larvae could be found by 96 h AEL in 2 separate countings of a total of 218 larvae 
 
3.4.6 Abnormal larval development in CG1847exon1_3 mutants 
To further analyse the impact of CG1847 loss of function, we focused on the early larval stages, 
before lethality occurs. I compared the phenotype of mutant male larvae with the offspring that 
expressed the YFP fluorescent marker present in the same 4 h AEL eggs collections (Figure 37). 
Apart from the obvious stop in larval growth, I was unable to detect any obvious phenotype that 
could predict the cause of lethality, or might be indicative of the organs and tissues affected by 
loss of function of CG1847 (Figure 37A). 
I first investigated these larvae ability to eat. However, evaluation of food consumption in the 
fruit fly is quite challenging as, in contrast to mammals, food ingestion cannot be properly 
quantified. To overcome this problem, I evaluated the food intake of mutant larvae by feeding 
them on gelled media marked with a visible dye287,288. Surprisingly, I was able to notice the 
presence of food even in the gut of the 72 h mutant larvae.  
I also attempted larvae dissection and Trypan blue staining which did not reveal any necrotic 
tissues. 
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Figure 37: Delayed larval development in CG1847exon1_3 mutants. The mutant male larvae show retarded 
growth. (A) Third instar larvae (72 h AEL) orientated with the anterior end to the top. Hemizygous 72 h 
CG1847exon1_3 mutant larvae are shorter and slimmer than the control dfdYFP larvae. (B) Larval length 
analysis at different developmental stages. Error bars represent SE. Asterisks indicate statistical 
significance as determined by Student’s t-test (**P<0.01, ns=not significant). 
 
Apart from being shorter and slimmer than the control dfdYFP larvae, the 72 h CG1847exon1_3 
mutant larvae did not displayed any other significant phenotypic differences. However, the 72 
h mutant males appeared to be less mobile than the controls. The length difference between 
hemizygous CG1847exon1_3 mutant larvae and control dfd::YFP is detectable at the beginning of 
the second instar larva (L2), although without reaching a statistical significance. The halt in 
development is significantly more obvious by 72 h AEL.  
Further more detailed investigations are required to determine more specific phenotypes which 
could be indicative of the cause of death. 
3.4.7 The lethality of CG1847 mutants can be rescued by expression of CG1847wt under 
the control of its own promoter 
To confirm that the lethality of CG1847exon1_3 is due to the absence of CG1847 and not due to 
the P-element imprecise excision affecting additional genes, I tested whether the CG1847exon1_3 
mutant could be rescued by reintroducing the normal allele on the mutant background. A 
genomic rescue construct containing the entire CG1847 gene with its own promoter and 
regulatory elements was generated (section 2.4.3) and injected into Drosophila embryos to 
obtain transgenic lines. Transgenic flies were subsequently crossed to the CG1847exon1_3 mutant 
and examined for their capability to rescue the lethality. The degree of rescue was analysed by 
counting all the males and comparing the percentages of each viable male genotype in the 
second generation (Figure 38). 
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Figure 38: Results of rescue experiments. Images of male genotypes resulted from rescued cross with 
full-lenght wild-type CG847 gene. The segregation of the alleles and the possible combinations are shown 
in the lateral panels. a) Rescued males. They inherited only the mutant allele on the X chromosome (from 
their mothers), but are rescued by CG1847 normal allele on the second chromosome. Males c) are not 
viable because they inherited the other second chromosome from father (CyO), which can not 
compensate for the deletion inherited from mother. This genotype (C) also acts as an internal negative 
control. 
Males CG1847
exon1_3
/Y; GC1847/+ (Figure 38A) are the rescued genotype. On the X chromosome 
they have the mutant allele, inherited from the mother. They are rescued by the wt CG1847 
gene reintroduced on the second chromosome and inherited from the father. The genotype 
CG1847
exon1_3
/Y; +/CyO is not viable as the balancer chromosome (CyO) is inherited from the 
father. Consequently, they have no wt copy of CG1847. 
NOTE: the genotype CG1847exon1_3/Y; +/CyO (c) should not be viable and should act as an internal 
negative control. However, I did find a reduced number of males that were phenotypically 
similar. In reality these males were the result of a non-disjunction phenomenon and they carried 
a normal CG1847 allele on the X chromosome, inherited from paternal line. For more details on 
the non-disjunction phenomenon see Discussion in Chapter 5. As among the rescued genotype 
there were also a few males which were the result of non-disjunction, in all the crosses we 
checked if the differences between the rescued males and the internal negative control 
(CG1847exon1_3/Y; +/CyO) reached a significant statistical difference. 
The CG1847 rescue construct allowed rescue of the lethal phenotype. Mutant males expressing 
this construct developed normally and exhibited normal behaviour. To evaluate the rescue 
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capacity of the CG1847 construct we used males from 2 transgenic stocks (CG1847-1M and 
CG1847-3M) and for each of these stocks the rescue crosses were performed in triplicate. The 
percentages of each of the above genotypes are plotted below (Figure 39). 
 
Figure 39: Rescue experiment of the CG1847 lethal phenotype with a wt CG1847 construct. The 
associated letters (a-d) correspond to the phenotypes depicted in Figure 38. Analysis of the statistical data 
reveals that the CG1847 rescue construct is capable of rescuing significantly the lethality of the CG1847 
mutant, based upon the relative normal percentage of rescued males. CG1847-1M and CG1847-3M – 2 of 
the transgenic stocks carring the rescue construct. N=4 experiments. Error bars represent the standard 
error of the mean. Asterisks indicate statistical significance as determined by Student’s t-test (**P<0.01). 
Interestingly, the CG1847wt construct rescued the lethality of the mutant males very efficiently 
as, in both experiments, this genotype is the most represented genotype amongst all offspring. 
Based on the expected Mendelian distribution, the percentage of each male genotype should 
be around 33% of the total number of viable adult males (only 3 genotypes are viable). The 
percentage of rescued males varied between 33.5% and 65.9% in all 4 experiments (an average 
of 52.2%). When males from transgenic line CG1847-1M were used, I detected a small 
percentage of flies that appeared to have the phenotype of the lethal combination 
(CG1847exon1_3/Y; +/CyO). These were in fact the result of chromosomal non-disjunction and 
were found in a significantly lower percentage than the percentage of rescued genotype. 
To further validate these experiments, I also counted the eclosed females from each experiment. 
Four female genotypes were expected according to Mendelian inheritance (combination of 2 X 
(X and FM6) chromosomes and 2 second (wt CG1847 gene and CyO) chromosomes). The 
**
**
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percentage of each genotype was used to evaluate if the female genotypes are in normal 
distribution, as this would validate the results obtained with the males (Figure 40). 
 
Figure 40: Chi squared contingency test for the 
distribution of female’s genotypes. In the rescue 
experiment with the CG1847wt construct 4 
different female genotypes are possible (as result 
of combinations of X and second chromosomes). 
For plotting purposes each female genotype 
received a code (a - d) and a colour: a 
(CG1847exon1_3/X; CG1847/+) – red; b 
(FM6/X;CG1847/ +)– green; c (CG1847exon1_3/X; 
CyO/+) – blue; d (FM6/X; CyO/ +)– brown. There 
is no significant difference in the distribution of 
female genotypes between the F1 generation of 
CG1847wt rescued experiment with the 2 
transgenic stocks (P = 0.07).  
Figure 40 depicts a chi square analysis of the 4 possible female genotypes in the F1 generation 
of the rescue cross. For biological replicates were used males from two different transgenic 
stocks, carrying the same CG1847 construct (CG1847-1M and CG1847-3M) generated by 
BestGene. This analysis reveals that the 4 female genotypes do not differ significantly between 
the 2 experiments with the 2 transgenic stocks, as expected. These results validate the rescue 
and the previous data regarding the rescue of male lethality providing extra proof that this 
experiment was successful. 
3.4.8 Tissue specific hAIPwt expression cannot compensate for CG1847 deletion 
The Gal4-UAS system has evolved into a widely used and valuable tool for the temporal and 
spatial control of gene expression in Drosophila285. As mentioned above, I was unable to detect 
any overt phenotype that might account for the lethality of CG1847 mutants, or which might 
indicate the organs and tissues affected by CG1847 loss (section 3.3.5). Therefore, I decided to 
use the Gal4-UAS system to perform rescue experiments in a tissue-specific manner that is, 
expressing CG1847 under the control of tissue-specific promoters. 
Among the GAL4 drivers available in public databases, I chose 10 drivers that allowed me to 
overexpress human AIP cDNA in various tissues and organs. The panel of 10 GAL4 drivers 
selected for overexpression of hAIP in the CG1847 mutant background (Table 4 and Figure 41) 
has an expression pattern that ranges from ubiquitous to restricted to a specific tissue or cell 
type such as fat body, haemocytes, insulin secreting cells, muscle, nervous cells, glial cells, gut, 
malpighian tubules cells, and heart specific drivers. 
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The rescue experiments were performed using virgin heterozygous CG1847 mutant females 
expressing Gal4 under the control of tissue-specific drivers, which were crossed with males 
carrying a UAS-hAIPwt transgene on the second chromosome (hAIPwt/CyO; two different stocks 
were used: UAS-hAIPwt-1M and UAS-hAIPwt-2M). The tissue-specific promoters were introduced 
in the heterozygous mutant background either on the second chromosome (CG1847exon1_3/FM6; 
Gal4/CyO) or third chromosome (CG1847exon1_3/FM6; Gal4/TM3). All progeny (males and 
females) were counted and the numbers of rescued males, non-FM6 non-CyO/non-TM3, were 
determined. 
NOTE: more details regarding the validation of the rescue experiments with hAIPwt constructs 
can be found in Chapter 5. 
 
Figure 41: Rescue of the CG1847 lethal phenotype by ubiquitous or tissue-targeted overexpression of 
wt hAIP. Analysis of the statistical data reveals that the pUAS-hAIPwt construct rescues the lethality of 
the CG1847 mutant only when expressed under the actin promoter. None of the tissue-specific promoters 
was able to prevent lethality. Asterisks indicate statistical significance as determined by Student’s t-test 
(****P<0.0001). 
Expression of hAIP under the control of the ubiquitously expressed Act-Gal4 driver rescued the 
decreased viability of the CG1847exon1_3 hemizygous males. I obtained CG1847exon1_3/Y; 
hAIPwt/Act-Gal4) progeny at very high percentages (33% of total viable males). These results 
indicate that hAIP is able to compensate for loss of CG1847 during development, which strongly 
suggests that, indeed, CG1847 is the fruit fly orthologue of AIP. 
ns
****
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However, when tissue-specific drivers were used, the lethality associated with CG1847 deletion 
was not rescued. A very small number of flies with the apparent phenotype of the lethal 
genotype combination were recovered during these experiments but, as discussed above and in 
Chapter 5, these were in fact the result of the non-disjunction phenomenon).  
As seen in Figure 24 during larval stages the CG1847 is already expressed in some of these cells/ 
tissues (fat body, muscle, nervous cells gut, and malpighian tubules cells); however, the levels 
of expression are very low. While it seems that at this stage of development CG1847 is not 
expressed in heart cells, there are no available information regarding the expression levels on 
glial cells, haemocytes, and insulin secreting cells. 
3.4.9 Identification of differentially expressed genes by high-throughput RNA 
sequencing  
The main aim of the RNA-seq analysis was to identify the genes whose expression is affected in 
CG1847 mutants, as this might allow a deeper understanding of the AIP involvement during 
development and the pathogenic mechanism resulting from AIP mutations in humans. To 
investigate the changes in the Drosophila transcriptome elicited by loss of CG1847, I used the 
CG1847 null mutant stock and the control stock, both generated in the same imprecise/precise 
excision screen. Both stocks were balanced over a balancer chromosome carrying a fluorescent 
marker (FM7c, dfd:YFP) and male larvae were selected based on the lack of fluorescence (section 
2.2.10). 
Total RNA was extracted from pooled collections of male larvae (either mutant or control) at 48 
h AEL. The RNA quality of the RNA samples was assessed using an Agilent 2100 bioanalyzer, 
which performs a reliable RNA integrity test based on the RIN values (RNA Integrity Number) 
(Figure 42). 
The Agilent RNA bioanalyzer software relies on the human rRNA Ratio [28S / 18S] to generate 
RIN values. However, since Drosophila possesses different rRNA values, I was unable to calculate 
the RIN values for the RNA samples used in the RNA-seq approach. Consequently, I evaluated 
the quality of the RNA samples based on their gel migration pattern. Four biological replicates 
of control larvae and four biological replicates of CG1847 mutants with highest quality were 
submitted for comprehensive RNA-seq in order to achieve a better understanding of the 
mechanism(s) by which loss of AIP promotes organism lethality. 
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Figure 42: RNA Quality Control. A) Gel Image (from the Agilent 2100 Bioanalyzer) for Drosophila larvae 
total RNA. Lane 1: size ladder. Lanes 2-8 show very high quality RNA for 4 control and 3 mutant samples 
(high-quality sample appear as two distinct bands corresponding to the 18S and 28S ribosomal RNAs). B) 
and C) Electropherograms (from the Agilent 2100 Bioanalyzer) for Drosophila larvae total RNA for a control 
and a mutant sample (two well-defined peaks corresponding to the 18S and 28S ribosomal RNAs can be 
observed, similar to a denaturing agarose gel).  
 
The raw results from the Illumina Hi-Seq were cleaned for removing the adaptors, then the 
FASTQ files were exported for analysis in Bowtie257 and TopHat258 to generate the database of 
transcripts. FastQC, a key quality control step, was applied to reveal possible problems regarding 
the quality of RNA-seq raw data (FastQC results in Material and Methods section). For the next 
steps Cufflinks was run for each sample separately to obtain the fold-change of differentially 
expressed genes. The final results were assembled into a single merged.gtf file. 
An example of merged.gtf file for the top significantly changed transcripts is shown in Table 17. 
This file contains, for each transcript: test id (XLOC_...), gene name, genomic locus, sample 
values, logarithmic fold change, p value, q value, and the corresponding FlyBase number. This is 
only a small part from the original merge.gtf file, with some of the most significantly changed 
transcripts. The original file is too big to be included in the thesis, as in total 15011 transcripts 
where detected by the RNA-seq, of which 448 were significantly changed compared to controls 
(p value <0.05). The table with all these 448 transcripts can be found at Appendix 11. 
From the initial list, the top 400 transcripts (cut off fold change ±1; p value <0.05) were chosen 
for further analysis. As expected, CG1847 was one of the most significantly downregulated 
transcripts in CG1847 KO mutants (fold change –2.6, p value = 0.00005). 
 
A)
B) Mut 6
C) Ctr 8
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Table 17: Example of an excerpt from merged.gtf file The top down (<-2.0) and up-regulated (>2.0) 
transcripts are represented (separated by a thick line) 
 
The first step in RNAseq data analysis was to search for the significant changes of AIP known 
partners, such as AhR, a major AIP partner. The Drosophila orthologue for human AhR is called 
spineless (ss) and its levels of expression were surprisingly not significantly changed in the 
test_id gene locus Ctr Mut log2(fold_change) p_value q_value oID_genes
XLOC_009430 Hsp70Bbb 3R:8328231-8330822 6.44653 0.0622877 -6.69343 0.0001 0.00842937 FBgn0051354
XLOC_000064 Lsp1beta 2L:898643-901316 21.4665 0.259455 -6.37046 5.00E-05 0.00482773 FBgn0002563
XLOC_011176  αγ-element:CR32865 3R:8295701-8304065 170.163 7.67604 -4.47041 5.00E-05 0.00482773 FBgn0052865
XLOC_005304 IM23 2R:14270208-14270737 15.65 0.990021 -3.98256 5.00E-05 0.00482773 FBgn0034328
XLOC_011881 Hsp68 3R:19880139-19883029 186.155 14.6101 -3.67146 5.00E-05 0.00482773 FBgn0001230
XLOC_003924 CG10073 2R:15268047-15272470 81.7048 6.95278 -3.55476 5.00E-05 0.00482773 FBgn0034440
XLOC_002448 TepI 2L:15888638-15893811 0.736172 0.0691253 -3.41276 5.00E-05 0.00482773 FBgn0041183
XLOC_003925 CG10081 2R:15273427-15276823 50.3374 4.9139 -3.35669 5.00E-05 0.00482773 FBgn0034441
XLOC_005673 CG3264 2R:18096411-18098247 106.57 12.7437 -3.06395 5.00E-05 0.00482773 FBgn0034712
XLOC_014779 CG34330 X:18962305-18962925 153.186 20.898 -2.87385 5.00E-05 0.00482773 FBgn0085359
XLOC_013279 CG1847 X:11763220-11765201 7.15024 1.00986 -2.82384 5.00E-05 0.00482773 FBgn0030345
XLOC_008002 Hsp26 3L:9369517-9370475 506.525 77.7273 -2.70414 5.00E-05 0.00482773 FBgn0001225
XLOC_009431 Hsp70Bb 3R:8331514-8334105 51.4734 8.05832 -2.67528 5.00E-05 0.00482773 FBgn0013278
XLOC_009432 Hsp70Bc 3R:8334797-8337183 14.8785 2.36561 -2.65295 5.00E-05 0.00482773 FBgn0013279
XLOC_003992 CG13422 2R:16413831-16414331 8.78264 1.50562 -2.54429 0.00015 0.0112194 FBgn0034511
XLOC_001134 ninaD 2L:18081629-18083608 2.54273 0.43689 -2.54104 5.00E-05 0.00482773 FBgn0002939
XLOC_011175 Hsp70Ba 3R:8291025-8293500 9.46209 1.6779 -2.4955 5.00E-05 0.00482773 FBgn0013277
XLOC_004016 IM14 2R:16757896-16758183 28.9807 5.21566 -2.47417 0.0012 0.04902 FBgn0067905
XLOC_006565 Hsp23 3L:9374981-9375865 380.894 70.5371 -2.43294 5.00E-05 0.00482773 FBgn0001224
XLOC_006566 Hsp27 3L:9377162-9378382 191.486 35.5828 -2.42798 5.00E-05 0.00482773 FBgn0001226
XLOC_014469 mamo X:13744880-13884528 0.754739 0.140359 -2.42686 5.00E-05 0.00482773 FBgn0030532
XLOC_001238 CG16772 2L:19962678-19963844 3.01629 0.563837 -2.41943 0.0001 0.00842937 FBgn0032835
XLOC_001566 CG15353 2L:2006762-2007193 296.896 57.2366 -2.37495 5.00E-05 0.00482773 FBgn0040718
XLOC_003841 IM2 2R:14274101-14274535 41.7845 8.13862 -2.36011 0.0001 0.00842937 FBgn0025583
XLOC_013810 CG13360 X:678823-684312 123.1 24.1893 -2.34739 5.00E-05 0.00482773 FBgn0025620
XLOC_003839 IM1 2R:14271456-14271883 58.4099 12.4957 -2.22478 0.0001 0.00842937 FBgn0034329
XLOC_007314 CG32444 3L:21630046-21632160 59.4285 12.8388 -2.21065 5.00E-05 0.00482773 FBgn0043783
XLOC_005615 CG30289 2R:17406747-17409482 2.97581 0.667241 -2.157 0.00045 0.0246363 FBgn0050289
XLOC_006292 CG11350 3L:4482808-4484370 1205.94 271.73 -2.14991 5.00E-05 0.00482773 FBgn0035552
XLOC_006562 Hsp22 3L:9365821-9368064 184.278 42.7333 -2.10845 0.0005 0.0268207 FBgn0001223
XLOC_006562 Hsp67Bb 3L:9372722-9374964 184.278 42.7333 -2.10845 0.0005 0.0268207 FBgn0001228
XLOC_007387 CG13239 3L:22853886-22854590 2.45051 10.5349 2.10403 0.00025 0.0161905 FBgn0037197
XLOC_003096 PGRP-SC1b 2R:4600948-4601587 19.1541 82.845 2.11276 5.00E-05 0.00482773 FBgn0033327
XLOC_011912 CG17780 3R:20199175-20210770 5.05373 22.4148 2.14903 5.00E-05 0.00482773 FBgn0039197
XLOC_010154 CG13616 3R:20218631-20219502 5.15558 24.2132 2.23159 5.00E-05 0.00482773 FBgn0039200
XLOC_010088 CG31148 3R:19526359-19528324 7.66618 36.3397 2.24497 5.00E-05 0.00482773 FBgn0051148
XLOC_009691 CG31268 3R:12857538-12859237 11.4359 55.3391 2.27473 5.00E-05 0.00482773 FBgn0051268
XLOC_000087 CG42329 2L:1219317-1229802 0.947499 4.65085 2.2953 5.00E-05 0.00482773 FBgn0259229
XLOC_004842 Damm 2R:7751665-7753908 4.32486 21.288 2.29932 5.00E-05 0.00482773 FBgn0033659
XLOC_009915 TotC 3R:16698709-16699310 1.90684 9.76976 2.35714 5.00E-05 0.00482773 FBgn0044812
XLOC_000287 CG33003 2L:4400952-4403142 3.33855 17.4334 2.38456 5.00E-05 0.00482773 FBgn0053003
XLOC_005578 Cht4 2R:16952884-16954592 26.7254 146.95 2.45904 5.00E-05 0.00482773 FBgn0022700
XLOC_009223 CG8147 3R:5320033-5322675 0.801251 5.04261 2.65384 5.00E-05 0.00482773 FBgn0043791
XLOC_003686 CG15919 2R:12680161-12680585 5.52152 37.6471 2.7694 5.00E-05 0.00482773 FBgn0040743
XLOC_006653 CG12522 3L:11101334-11101832 69.8909 477.68 2.77287 5.00E-05 0.00482773 FBgn0036131
XLOC_008168 CG42397 3L:11966184-11966890 3.11117 22.0361 2.82434 5.00E-05 0.00482773 FBgn0259748
XLOC_001815 CG9021 2L:5903358-5904674 0.258776 1.97669 2.93331 0.0002 0.0137935 FBgn0031747
XLOC_009842 CG17751 3R:15432975-15435044 5.39754 42.5566 2.97901 5.00E-05 0.00482773 FBgn0038717
XLOC_008095 CG32071 3L:11096520-11096973 18.3088 161.103 3.13738 5.00E-05 0.00482773 FBgn0052071
XLOC_008037 CG6749 3L:9724337-9726907 0.629835 5.62862 3.15974 0.00025 0.0161905 FBgn0036040
XLOC_010837 snRNA:7SK 3R:3300274-3300718 1.6693 37.6917 4.49693 5.00E-05 0.00482773 FBgn0065099
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mutant larvae. On the other hand, among the top downregulated genes, members of the heat 
shock family of proteins emerged as candidates from the RNA-seq analysis. Interestingly, almost 
all affected heat shock gene transcripts were downregulated in the CG1847 mutant compared 
to the control samples (Figure 43). 
 
Figure 43: RNA levels for heat shock protein genes are downregulated in CG1847 mutants. With the 
exception of Hsp70-2 (detected significantly upregulated), all transcripts beloging to the heat shock 
protein family were detected in RNA-seq as significantly dowregulated (P<0.05). Data is shown as the 
logaritmic fold change of expression levels in the mutant samples. 
 
To find out the functional relationship among relevant genes, the top 400 differential expressed 
genes were mapped using STRING database, by selecting Drosophila melanogaster as a model 
organism. 393 transcripts were recognized by the database and displayed as a network of nodes 
(proteins) connected by coloured edges representing functional relationships of known and 
predicted protein interactions. The map was filtered for non-connected proteins. A medium 
combined score of protein pairs (confidence score) > 0.4 was considered as the cutoff value. The 
STRING confidence score is calculated based on the number and types of evidences that support 
each association (low confidence scores: <0.4; medium: 0.4 to 0.7; high: >0.7). 
As shown in the Figure 44, only one interaction was found for CG1847, with one of the heat 
shock proteins (Hsp83). In humans AIP–Hsp90 is one of the most investigated AIP interactions. 
A number of different groups (Bell & Poland 2000148, Meyer et al. 2000149, Laenger et al. 2009150) 
have shown that specific conserved amino acids of the AIP TPR domains are important for this 
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interaction. Consequently, in CG1847 deficient Drosophila model the members belonging to 
heat shock proteins might be downregulated due to losing these interactions. 
 
Figure 44: STRING analysis: the heat shock protein cluster. Nodes represent proteins whose transcripts 
were identified in the RNA-seq analysis as being differentially expressed in the absence of CG1847. Lines 
connecting individual nodes indicate predicted functional associations. Among these significant genes, 
different members of Hsp family were identified. 
 
The STRING analysis also highlighted a cluster of a very interesting group of proteins called Osiris 
proteins. The Osiris genes belong to a large conserved family which was for the first time 
described in 2003 by Dorer et al. in Drosophila melanogaster289. These proteins have a secretion 
signal peptide and four domains that identify them as Osiris family members; however, there 
are limited publications and their function is still unknown. 12 out of 24 members of this protein 
family were found significantly upregulated in the RNA-seq data. Strikingly, among this cluster 
(Figure 45), were found a few Twdl proteins (TwdlG, TwdlS, and TwdlF). Additionally, different 
members of cuticular proteins (Cpr100A, Cpr47Eg, Cpr49Af, Cpr65Eb, Cpr66Cb, Cpr66D, and 
Cpr97Eb) were also hub nodes in this network. So far no interactions between CG1847 and these 
proteins have been suggested. Twdl and cuticular proteins were previously shown to be involved 
in body size regulation and normal development, as the exoskeleton of insects (cuticle) is mainly 
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formed of chitin and cuticle proteins. The Tweedle proteins are secreted by the ectodermal 
tissues and members of these proteins were shown to also contribute to formation of the 
cuticle290. 
 
Figure 45: STRING analysis: the Osiris, Tweedl and cuticule proteins cluster 
Surprisingly, all transcripts belonging to the Osiris and Tweedl group were upregulated in 
CG1847 mutants (Figure 46). 
 
Figure 46: RNA levels for Osiris and Tweedl transcripts are significantly changed in CG1847 mutants. 
With the exception of some of the cuticular proteins, all transcripts beloging to one of these 3 clusters 
were detected in the RNA-seq as significantly upregulated (P<0.05). Data is shown as the log fold change 
in the CG1847 deficient larvae. 
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To identify the human orthologues for Osiris protein candidates found in the RNA-seq approach, 
I used the BioMart free software (http://www.ensembl.org/) (Table 18).  
Ensembl 
Transcript ID 
Associated 
Gene Name 
Homology Type Transcript ID 
Human Ensembl 
Gene ID 
FBtr0085710 Cpr100A ortholog_none    
FBtr0088183 Cpr47Eg ortholog_none    
FBtr0087921 Cpr49Af ortholog_none    
FBtr0070815 Cpr5C ortholog_none    
FBtr0333582 Cpr65Ax2  ortholog_none    
FBtr0077022 Cpr65Ax2  ortholog_none    
FBtr0076928 Cpr65Eb ortholog_none    
FBtr0076601 Cpr66Cb ortholog_none    
FBtr0076567 Cpr66D ortholog_none    
FBtr0074933 Cpr76Bb ortholog_none    
FBtr0085135 Cpr97Eb ortholog_none    
FBtr0082707 Hsc70-2 ortholog_none    
FBtr0100558 Hsp22 ortholog_many2many FBpp0100010 ENSG00000109846 
FBtr0309504 Hsp23 ortholog_many2many FBpp0301282 ENSG00000109846 
FBtr0076496 Hsp26 ortholog_many2many FBpp0076224 ENSG00000109846 
FBtr0076454 Hsp27 ortholog_many2many FBpp0076182 ENSG00000109846 
FBtr0076495 Hsp67Ba ortholog_many2many FBpp0076223 ENSG00000109846 
FBtr0303473 Hsp67Bb ortholog_one2many FBpp0292525 ENSG00000215845 
FBtr0084589 Hsp68 ortholog_none    
FBtr0082679 Hsp70Ba ortholog_none    
FBtr0082636 Hsp70Bbb ortholog_none    
FBtr0082638 Hsp70Bc ortholog_none    
FBtr0332873 Hsp83 ortholog_none    
FBtr0073040 Hsp83 ortholog_none    
FBtr0078600 Osi10 ortholog_none    
FBtr0078601 Osi10 ortholog_none    
FBtr0078602 Osi12 ortholog_none    
FBtr0078607 Osi15 ortholog_none    
FBtr0078608 Osi16 ortholog_none    
FBtr0078610 Osi17 ortholog_none    
FBtr0078611 Osi18 ortholog_none    
FBtr0081707 Osi19 ortholog_none    
FBtr0301493 Osi19 ortholog_none    
FBtr0081708 Osi20 ortholog_none    
FBtr0078591 Osi24 ortholog_none    
FBtr0078596 Osi6 ortholog_none    
FBtr0078597 Osi7 ortholog_none    
FBtr0078599 Osi9 ortholog_none    
FBtr0078975 TwdlF ortholog_none    
FBtr0078982 TwdlG  ortholog_none    
FBtr0085054 TwdlO  ortholog_none    
FBtr0085049 TwdlQ  ortholog_none    
FBtr0085034 TwdlS ortholog_none    
FBtr0113190 TwdlU  ortholog_none    
Table 18: Human orthologues for Drosophila transcripts 
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No human orthologues were found in the human genome for any of members of the Osiris 
family. This is in agreement with the fact that the Osiris gene cluster is a family of genes that is 
present in all insects, but not present in mammals289. Conversely, for a few Drosophila heat shock 
proteins there are more than one single human orthologue. However, some of these proteins 
are Drosophila specific. Interestingly, no orthologue could be found for Hsp83, which is the only 
interacting protein with CG1847 revealed by STRING analysis. 
 
3.4.10 Multiplex qPCR validation of RNA-seq results 
RNA-seq is an extremely useful tool for whole transcriptome quantification, but the results need 
further validation via an alternative molecular technique. Toward this purpose, I employed a 
multiplex qPCR method, performed with the help of collaborators from Royal Veterinary College 
(Dr. Rob Fowkes and Dr Samantha M. Mirczuk). The GenomeLab™ GeXP Genetic Analysis system 
provides accurate simultaneous quantifications for hundreds of samples using very small 
amounts of total RNA. The system uses chimeric primers which are a combination of gene-
specific and universal tags. 
The main goal was to validate the changes in the expression levels of the transcripts possibly 
involved in lethality of CG1847 deficient fruit flies. For this purpose the same larval collections 
as for RNA-seq were used and the RNA was extracted from a pool of male larvae. As the STRING 
analysis of RNA-seq data revealed clusters of interacting proteins of several families (section 
3.3.7), I chose a few transcripts of each cluster/protein family for validation (Figure 49). 
A key feature is the fact that the gene ratio between mutant and control in RNA samples is 
maintained during the PCR process. In the initial stage the reverse transcription of RNA was 
performed with the reverse chimeric primers (containing the gene-specific sequences and 
universal primer sequence). At the end of this step the cDNA library had universal tag sequences 
incorporated into the amplicons. The chimeric primers were designed for 2 housekeeping genes, 
CG1847 and 8 various transcripts with a possible involvement in the lethality mechanism 
(Appendix 5 for primer sequences). In a second step transcripts amplification with a forward pair 
of chimeric primers was performed. In the last step fluorescent dye-labelled forward and 
unlabelled reverse universal primers resulted in a relative and equivalent amplification of all the 
gene targets (Figure 47). 
  
133 
 
 
Figure 47: Schematic representation of the 3 main stepts of GeXP Genetic amplification. In the first step 
(top panel) chimeric primers were used containing the gene-specific sequences (blue, green and brown 
arrows) tagged with a universal primer sequence (red). In the second step (middle panel), the generated 
cDNA library, having incorporated the universal tag are further amplified via PCR using the forward 
chimeric primers, with a different universal tag (beige). In the third step a fluorescent (purple star) dye-
labelled forward primer and a unlabelled reverse universal primer are used for amplification of all the 
gene targets 
The amplicon mixture was then analysed with fluorescence capillary electrophoresis to identify 
the peak area and then converted to gene-expression values (Figure 48). 
 
Figure 48: Representative electropherograms corresponding to gene expression profiles.  
Representative data generated from mutant (A) and control (B) mRNA samples are shown. The intensity 
versus the size is depicted within a window of 100 to 350 bp. The red peaks are the size ladder, which 
ranges from 140nt to 425nt. The blue peaks are the amplicons corresponding to the genes of interest, 
which were detected by the multiplex qPCR system 
A B
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The gene-expression values were normalized to the RpL32 housekeeping gene, included in the 
multiplex. The final normalized values were used to compare levels of gene expression between 
control and mutant samples (Figure 49). 
 
Figure 49: Multiplex qPCR results. The mRNA levels of 9 specific transcripts that were significantly 
changed detected by the RNA-seq and that were represented in different STRING clusters. Relative 
expression levels are shown as a bar graph. Expression values were normalized to control in order to 
present expression ratios. RpL32 was used as housekeeping gene for normalization of genes of interest. 
Data is shown as mean ± SE. ANOVA was used to assess for statistical differences (*P<0.05).  
In this study I sought to determine if data obtained from the RNA-seq is accurate by testing if 
different techniques reproduce the same results. Data analysis confirmed that the expression 
levels of some of the specific genes were substantially different in mutant larvae, similar to the 
previous RNA-seq data. 
Figure 49 shows the gene expression profile obtained from comparing the level of expression 
between control and CG1847 deficient Drosophila larvae. The results show a marked 
downregulation of CG1847, validating the statistically significant changes detected by RNA-seq 
in the mRNA expression levels. There was also a significant increase in the mutant larvae of the 
expression of both Osiris transcripts selected for validation. This recapitulates the increase in 
Osiris gene expression previously observed in the RNA-seq analysis. TwdlG and both cuticular 
mRNA transcripts found to be involved in the same biological processes as shown by STRING 
analysis, were also validated. Mhc was also tested; this is a protein found to be involved in the 
same biological process as the Osiris, Twedl and cuticular proteins. This transcript was 
significantly downregulated in the mutant samples; however, without reaching a fold change of 
at least -1 and this change in the expression level was not confirmed by the multiplex qPCR.  
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Some of the most drastically differentially expressed genes detected by the RNA-seq were 
clustered with CG1847 and belong to the heat shock family of proteins. The available data 
confirmed that AIP acts as co-chaperone to form a complex with HSP90 and AhR, in order to 
allow nuclear translocation. The majority of heat shock proteins were strongly downregulated 
in the RNA-seq results and this was confirmed by the multiplex qPCR. Of the 2 chosen transcripts 
I was only able to validate the downregulation of Hsp83 in CG1847 mutants. Hsp83 was the only 
direct CG1847 interacting partner found in the STRING analysis (Figure 44). However, despite 
the fact that it was one of the genes with the highest fold change in expression levels in the RNA-
seq analysis (-5.7 Table 17), Hsp70bb transcript surprisingly was not confirmed in the multiplex 
qPCR analysis.  
This technique is simple, very efficient, and cost effective, providing an excellent solution for 
overcoming challenges, such as validation of a high number of transcripts, limited amount of 
sample and costly analysis. Further experiments are required for validation of other transcripts 
detected as significantly changed by the RNA-seq data in order to investigate other possible 
affected pathways by the loss of CG1847. 
 
3.5 DISCUSSION 
In an effort to elucidate the involvement of AIP during development and the pathogenicity of 
human pituitary adenomas associated with loss of function of AIP, I used an in vivo approach to 
assess the function of the fruit fly orthologue of AIP, CG1847. In this chapter, I focused on the 
generation of an in vivo genetic mutant of CG1847 and the initial characterisation of its function. 
Firstly, I used a bioinformatic approach to identify CG1847 as the fruit fly orthologue for human 
AIP. CG1847 is located on the X chromosome. The structure and function of AIP is conserved in 
Drosophila melanogaster. Amino acid alignment of Drosophila CG1847 and human AIP showed 
a high degree of sequence similarity between the 2 proteins, with one third of the amino acids 
being highly conserved. According to the ClustalW algorithm there is a 37.74% overall identity 
between human and Drosophila proteins. The amino acid sequence of CG1847 is highly 
conserved and shares all the proteins domains, both in the N-terminal and C-terminal parts, with 
members of other species. This suggests that the protein retains the same molecular functions 
as the other orthologues. The high degree of conservation of AIP is also an indication that its 
physiological function would also be conserved. To determine whether CG1847 plays a role in 
development, I used in this study three UAS-CG1847-RNAi stocks, carrying 2 different constructs 
targeting different parts of the CG1847 gene. As previously AIP was described as an essential 
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gene in mammals, studies were performed to determine the effect of CG1847 knockdown on fly 
survival. Lethality was classified if no GAL4-driven UAS-RNAi progeny emerged from a cross. 
When crossed to the Act-GAL4 driver, 2 out of 3 UAS-RNAi stocks (UAS-CG1847-R2 and UAS-
CG1847-T2) showed no surviving adult flies. The third stock (UAS-CG1847-R1) resulted in greatly 
reduced numbers of the expected genotype (at 25°) and no RNAi-driven progeny being observed 
(at 29°C). Complete AIP-knockdown lethality is suggestive for CG1847 being an essential gene 
and all these results correlate with the lethality of AIP deficient mice204,291. The result that flies 
with only around 30% residual expression of CG1847 are viable is also a confirmation of previous 
studies which reported that hypomorphic AIP mice have almost normal development181. The 
available human data support the theory that homozygous AIP mutations are not compatible 
with life, while one normal copy is enough for normal development. 
The Gal4/UAS system presents a few very important advantages. Maybe the most important is 
the separation of the driver (Gal4) and the eﬀector (UAS) between two parental lines, which in 
our project allowed us to avoid the parental lethality. Temperature dependence285 of GAL4 is 
another important feature of this system. By simply exposing the flies to lower (around 16°C) or 
higher (29°C) temperatures during development the potency of the system can be decreased 
and increased, respectively. By increasing the ambient temperature, a higher level of expression 
can be achieved266, and this temperature sensitivity feature was used to enhance the expression 
of a weaker RNAi construct, and confirmed the lethality noticed with the other UAS-RNAi stocks 
at lower temperature. 
However, the Gal4/UAS system also has some disadvantages that I had to be aware of. In gene 
expression knockdown experiments based on RNA interference (RNAi) technology, some results 
might be due to off-target effects. These are the result of the cross-hybridization phenomenon 
between the siRNAs molecules and non-target areas in endogenous RNA sequences and outside 
the gene of interest292-294. The occurrence of off-targets effects in RNAi experiments can be 
extensive and significant295. Randomly selected siRNAs can induce toxic changes by reducing cell 
viability in a target-independent fashion292. As a consequence, the resulting phenotypes might 
mislead the functional interpretation of gene silencing294. Whenever possible, good 
interpretation of results should be based on using more than one siRNA, or should be validated 
through an alternative method. The fact that using different RNAi constructs targeting different 
regions of CG1847 RNA resulted in partial or full lethality indicates that it is unlikely that this 
result was caused by an off target silencing. 
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Furthermore, I applied an alternative method. To investigate the mechanisms of CG1847 driven 
lethality and to help understand its role during Drosophila development, a proper loss of 
function mutant was generated via P-element mobilization. Following the imprecise excision 
resulted a CG1847exon1_3 allele that carries a deletion of the entire CG1847 ORF. The total loss of 
expression (Figure 35) together with the fact that homozygous CG1847exon1_3 females and 
hemizygous males are not viable indicates that CG1847exon1_3 is a null allele and that CG1847 is 
an essential gene.  
Unfortunately, this technique also has some potential problems and pitfalls. First, the frequency 
of such imprecise excisions may vary between loci (from 1 in 5 to 1 in 100 events)296,297 and the 
frequency of imprecise excision cannot be predicted from the outset of the experiment. In some 
cases hundreds of crosses need to be generate to achieve an imprecise excision. However, the 
P-element inserted into the 5’ of CG1847 was quite mobile (9%). Another problem that can occur 
is that the mobilized P-element can reinsert. The precise site in the genome where this event 
occurs is unpredictable. If it still carries the white gene, than these re-insertions are easy to 
detect. If the white gene is lost, the second hits are difficult to detect and might lead to mis-
interpretation of the observed phenotypes. The transposase activity can be controlled by adding 
or removing the transposase source. To prevent further mobilisations of the P-element, the 
source of transposase is separated in the subsequent generation by appropriate crossing.  
The third problem regards the issue that the size of the P-excisions are random268, therefore 
there is no guarantee that the desired mutation would not extend to other genes. The size of 
the deletion from the imprecise excision needs to be confirmed by molecular methods, including 
PCR on genomic DNA from heterozygous flies. Care should be taken with designing the necessary 
primers, as it could be extremely challenging to properly map the deletion. As the Drosophila 
genome is very small, upstream and downstream genes might be very close to the gene of 
interest and the design of the primers should be done in such a way to detect those excisions 
that are too large and affect the surrounding genes. One of the generated mutant alleles in my 
screen, CG1847 exon1_3, was confirmed via PCR not to affect the neighbouring genes.  
Consequently, the next obvious step was to validate the fact that the lethality is solely due to 
deletion of CG1847, and that no other genes were affected during P-element excision. 
Transgenic lines carrying wt CG1847 on the second chromosome were able to produce rescued 
males in the second generation (Figure 39). Surprisingly, the percentage of the rescue males 
from the total number of counted viable males was much higher than expected. The percentage 
of the rescued males (from the total number of viable F1 males) suggest that these are very fit 
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for survival during larval stages and they are strong competitors for nutrients. Another possible 
reason might be also the influence of the genetic background. The rescued males 
(CG1847exon1_3/Y; CG1847/+) have no balancer chromosomes. All the other male genotypes in 
the cross have one or even 2 balancer chromosomes (FM6 or/and CyO) and this might reduce 
their fitness. Balancer chromosome carry multiple inverted repeats which can weaken the fly. 
The last but not the least important issue regarding this technique is that some of these P-
element excisions events may only be partially successful – as they may leave some very small 
sequences behind (“footprints”). Around 75% of the footprints are usually very short, 4 or 7 
nucleotides, while the remaining 25% of the footprints might vary between 14–18 nucleotides 
of both inverted terminal repeats298. However, this issue was turned into an advantage as it 
helped generate the control stock, with the same genetic background. 
RT-PCR was used to assess CG1847 RNA expression in mutant male larvae in comparison to the 
same stage control larvae and control y w adult flies (Figure 35). Quantification after 
normalisation to the housekeeping gene RpL32 showed that knocking-out the CG1847 gene 
resulted in total loss of expression. This kind of data normalisation is a standard step in the 
quantification RT-PCR analysis299,300.  
The reliability of any quantitative RT-PCR data is based on including a stable endogenous control 
(reference gene) which allows for proper correction of sample variations. However, the levels of 
expression of any gene, including that of 'typical' housekeeping genes, might vary between 
tissues or between stages of development301. It is very important to choose the appropriate one. 
RpL32 was traditionally considered a very good internal control gene as it has equal transcript 
levels in all cells and in all stages of development302. This is due to the fact that ribosomal 
proteins are involved in protein biosynthetic pathways 303 and play critical roles in the 
development and growth of organisms303. Its levels are also stable in different experimental 
conditions.  
Surprisingly, the levels of expression of the chosen housekeeping gene for our mutant (RpL32) 
were increased in mutant larvae. I was surprised by this observation since, usually, reduced 
growth rates and survival rates are associated with reducing or even abrogating the efficiency 
of protein synthesis304,305. Generally, an increase in ribosome biogenesis is a characteristic of an 
increased cellular proliferation during tissue and organ growth306 and this might be related to 
the increase in proliferation associated with loss of AIP in human pituitary tumorigenesis. 
However, another factor to consider for quantification of gene expression levels is the genetic 
background. As the 2 controls (48 h y w larvae and y w adults) have similar levels of expression 
  
139 
 
for RpL32 suggests that the difference I noticed in mutant male larvae might be due to the fact 
that it has a different genetic background. As a consequence, in RNA-seq experiments I took 
great care in finding the perfect control to compensate for any possible differences in the genetic 
background, by generating both the mutant and the control Drosophila stock during the same 
experiment of P-element excision. 
The lethality of the CG1847 mutants was further investigated and I established that the flies are 
dying in the larval stage, suggesting that CG1847 is critical for survival beyond this point in 
development. These hemizygous mutant male larvae were much smaller in size after 48 h of 
development. No other obvious phenotype was noticed, therefore this did not help in 
understanding of the actual cause of lethality. Regarding the reduced size of the mutant larvae, 
it is necessary to take into consideration a few factors that might influence the larval 
development, in addition to the impact of the loss of CG1847.  
In Drosophila the body size is under the influence of the genetic background, the available food 
(the amount and the quality of food), and/or the environmental temperature during 
development307. It is well-established that temperature influences body size as fruit flies 
exposed to lower temperatures during development are larger than those exposed to higher 
temperature308. It was also found that male larvae have a significantly smaller size (35.6% 
reduction) than females (P = 0.008)309. As a consequence, we have to be cautious before claiming 
that the smaller body size of the mutant male larvae is due solely to the CG1847 deletion. As the 
length of male larvae was compared to the length of all the other fluorescent larvae in that 
collection (including females) this might introduce a bias in the analysis. On the other hand, if 
the loss of CG1847 has an influence in these mutant larvae fitness, then they had a more 
restricted access to nutrients comparing to the other genotypes, and as a result, their size is 
smaller due to undernutrition (which might be the case as they are not only shorter, but also 
thinner – Figure 37). 
Another important advantage of the UAS-Gal4 system is the possibility to target the expression 
of any gene or RNAi construct in a variety of spatial and temporal ways by using distinct Gal4 
drivers238, which can be ordered from public Drosophila libraries. For example, a high number of 
GAL4 drivers are publicly available at the Bloomington Drosophila Stock Centre: 
http://flystocks.bio.indiana.edu/gal4.htm. 
Overexpression of hAIPwt cDNA using the UAS/GAL4 system was employed to investigate if 
CG1847 is the functional orthologue of human AIP and to understand the role of this product in 
different cells/tissues. Numerous previous studies have reported a ubiquitous expression of AIP 
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in human and murine tissues, both at the mRNA and at a protein level139,149,154,159,171. As a 
consequence, it is difficult to determine solely on the literature data in which tissues AIP is more 
important for a normal function in a developing organism.  
As the UAS-GAL4 system can be spatially defined by choosing GAL4-drivers with tissue specific 
promoters, I utilised it to gain a better understanding of where CG1847 expression is more 
important. Surprisingly, overexpression of CG1847 throughout the fly during development using 
the actin-GAL4 driver was capable of rescuing lethal effect of loss of CG1847. However, none of 
the tissue specific Gal4 drivers was able to rescue this phenotype, suggesting that this gene is 
involved in many different processes and it has important function overall in the body. Thus, in 
analogy with other species, CG1847 deficiency is developmentally lethal. To confirm and to 
understand these results I investigated the public available data from modENCODE (Table 19). 
modENCODE (the model organism ENCyclopedia Of DNA Elements) is a key research project of 
the National Human Genome Research Institute (NHGRI)283. 
My data were confirmed by the results of the RNAi screen available on modENCODE, as none of 
the tissue targeted knock down of CG1847 expression resulted in lethality. 
Screen  Gene Phenotype Score PubMed ID 
Heat nociception (1) CG1847 
Increase heat 
avoidance 2.46 21074052 
Lipid storage CG1847 none -0.71 19067489 
Notch pathway regulation (4) CG1847 none 0 19363474 
Adiposity regulation (1) CG1847 none 0.48 20074523 
Heart development and function (1) CG1847 none 0.8 20371351 
Dendrite pattern formation CG1847 none np 16547170 
Muscle morphogenesis and function (1) CG1847 none np 20220848 
Cell size and cell-cycle regulation (1) CG1847 none sp 16496002 
Glycosylation regulation (1) CG1847 none sp 21203496 
 
Table 19: modENCODE RNAi screen for CG1847 (http://intermine.modencode.org/release-
33/results.do?noSelect=true&table=coll854&trail=%7Cresults.coll854) 
Studies involving mouse models revealed that AIP is essential for development, as lack of this 
product led to lethality during embryonic development. Further investigations described AIP 
involvement in cardiac development as the embryos displayed a range of heart deformations, 
including double outlet right ventricle, ventricular-septal defects, and pericardial oedema204. 
Unfortunately the exact molecular mechanisms and the exact partner via which AIP total 
deficiency leads to loss of viability is still not fully understood, and further work is required to 
identify the key proteins and pathways involved. 
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In summary, ubiquitous CG1847 expression is essential for survival to adulthood and the 
generated null mutant can be used for further investigations necessary for understanding its 
involvement. 
RNA-seq is a revolutionary tool developed for deep sequencing and quantification of transcripts 
and their isoforms261. RNA-seq provides accurate identification of novel transcripts, of 
alternative splicing events, and allele-specific expression277,310. Consequently I decided to use 
this technology for investigating the CG1847 knockout model’s transcriptome. Comparing to 
previous hybridization-based approaches, RNA-seq has an extremely important advantage as it 
is not limited to detecting transcripts that correspond to existing genomic sequence and brings 
the advantage of de novo assembly of the genome and of the transcriptome311,312. It was already 
undoubtedly proven that RNA-seq can detect the exon-exon borders which enable this 
technique to accurately detect novel isoforms, and even to discover completely new genes310,313. 
This might lead to the identification of novel transcripts in GC1847 deficient model. Regarding 
the quantification of expression levels, RNA-seq has a very wide dynamic range with very limited 
background level and it is capable of detecting and quantifying even the transcripts with 
extremely low levels of expression314,315 which might happen is this case as the RNA is extracted 
from fruitfly larvae. It also allows the exploration of different cellular pathways at the same 
time316. RNA-seq requires less starting material (total RNA), a valuable practical aspect as this 
brings a significant advantage in cases of limited sample availability. 
However, this technology does have a number of limitations which we have to be aware of277. 
As this method is based on fragmentation and amplification of RNA samples to produce the 
cDNA libraries, this step carries the risk of introducing bias and artefacts into the system. 
Another downside of the library preparation method itself is that it requires careful removal of 
polyA or ribosome RNA in order to avoid producing different transcriptome profiles. An 
additional disadvantage is brought by the levels of deep sequencing and lack of complete 
coverage which, for more complex organisms might result in under representation of some of 
the genes/transcripts/isoforms. Some genes/transcripts may not be detected as they might have 
a restrictived pattern of expression (tissue specific or in specific stages of development). This 
implies careful design of the RNA-seq study317,318. RNA-sequencing, is an extremely powerful 
method which has the potential to rapidly reveal the changes in normal development or in 
pathological processes, but the costs involved by the whole transcriptome sequencing are 
prohibitive, and limit the use of this method in routine research. 
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In parallel with the fast developing of RNA-seq technologies, many mapping tools have also been 
developed. The actual mapping methodologies could have a negative influence on the RNA-seq 
results as they could fail in detection of splice junctions319. In 2011 Roberts et al. reanalysed 
previous data using a different mapping methodology and identified many more novel 
transcripts320. Other authors also confirmed that the choice of appropriate methodology is 
important321. 
TopHat is maybe the most popular splice junction mapper for RNA-Seq reads. It aligns the raw 
RNA-Seq reads to genomes using the ultra-high-throughput short read aligner Bowtie to actually 
identify the exon splice junctions and to reveal novel gene or novel alternative splicing. For 
reconstructing the whole transcriptome, the most commonly tool used program is Cufflinks322 
which, similar to TopHat, is a freely available public domain software. 
TopHat, Bowtie and Cufflinks pipeline is the only available pipeline so far that includes all the 
required software for full analysis for RNA-seq data. However, a downside is that it requires a 
good annotation of the genome. The software were designed to be used with the Illumina data 
format, and, requires significant data storage. The large amount of data produced might be up 
to 1000 times bigger than the amount of data produced by microarrays, as a FASTQ files alone 
might be estimated to be between 20 and 40 Gb. 
As RNA-seq allows quantification of the entire transcriptome. I decided to use this technique to 
reveal the changes in expression levels between wt CG1847 and knockout Drosophila larvae. I 
also wanted to have a better understanding of AIP orthologue role during normal development 
by revealing the interacting proteins affected by CG1847 loss of function. As expected, CG1847 
was one of the most significantly downregulated transcripts in mutant samples. The normal level 
of expression of CG1847 at this stage of development (48h AEL) was very low. To confirm, 
understand and compare the RNA-seq results with data regarding normal fruit fly development, 
publicly available data from modENCODE was used. modENCODE’s main purpose was to identify 
previously unannotated transcripts in Drosophila melanogaster in 27 distinct stages of 
development. It identified 1,938 new transcribed regions not linked to any previously annotated 
gene323. Given the fact that this project was studied on normal development, it can serve as a 
useful comparison of my data. On examining the CG1847 expression patterns during Drosophila 
developmental stages in KO larvae I found significant differences with our control larvae. Within 
each stage of development (from embryo to adult fly), CG1847 had very low expression. The 
highest intensity was in the first 2 hours possibly due to maternal contribution - Figure 24. The 
level of expression are slightly increased in the later embryonic stages, and then they are 
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reduced again during all larval stages. The same reduced gene expression levels are maintained 
during pupal stage and adulthood in males and is slightly increased in females, but not more 
than during the larval stage. Furthermore, in third instar larvae, when we collected our mutant 
and control males, the normal level of expression of CG1847 are some of the lowest of all stages. 
The fact that at this stage the fruit flies’ requirement of CG1847 is minimal might be a possible 
explanation for the fact that even though our mutant is a KO and has no CG1847 expression 
(Table 17) it is not the transcript with the highest fold change as we would have expected. 
One of the most investigated AIP functions is the involvement in the xenobiotic processes. 
Numerous articles published that AIP is part of the AIP-AhR-Hsp90 complex which facilitates AhR 
translocation into the nucleus where it binds to ARNT148,154,324. In the next step the AhR:ARNT 
complex is able to bind a dioxin-responsive element (also known as xenobiotic responsive 
element). As AhR is an important AIP partner, I investigated this in the RNA-seq results. The 
Drosophila orthologue for human AhR is called spineless (ss) and its levels of expression were 
surprisingly not significantly changed in the mutant larvae. I then noticed that the levels of 
expression even in the normal control larvae at this stage of development were extremely low 
(0.35). Further, I investigated the modENCODE database and I had the confirmation that at the 
stage when I performed the larvae collection the levels of expression for AhR are actually zero. 
These results are in accordance with previous published data which suggest that AIP has a very 
early developmental expression, before the appearance of AhR transcript. This idea is supported 
by AIP whole mount in situ hybridisation of mice embryos. It was revealed that at embryonic day 
9.5 (e9.5) AIP expression can be detected while AhR is first expressed only around e13.5159,325. 
Taken together the available data from humans, mice and fruit fly suggest that during normal 
development AIP is expressed previous to AhR, and, at least in the very early embryonic stages, 
AIP function is independent of its interaction to AhR and of xenobiotic processes. 
AIP plays important roles in mammalian development, apart from xenobiotic receptor signalling. 
This was confirmed on the other members of the immunophilin family which appeared to have 
physiological importance outside of xenobiotic signalling326. The available data from human and 
mammalian systems point out that AIP protein is localised in the cytoplasm as part of 
multiprotein complexes with well-known partners such as HSP90 p23 and AhR. Many other 
cytoplasmic partners were also described, and these partners involve AIP in a number of 
different pathways. Known interacting proteins, as presented in detail in Table 3 are cyclic 
adenosine monophosphate (cAMP), chaperone proteins (HSP90 and HSP70), G proteins (Gα13 
and Gαq) and phosphodiesterases (PDE4A5, PDE2A3). Other interactions, not confirmed, have 
been described with a cytoskeletal protein (actin), a growth factor receptor (EGFR) and a cardiac-
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specific kinase (TNNI3K). Human data identified AIP as a tumour suppressor gene. Mutations of 
this gene lead to pituitary adenoma formation, which are, as discussed above, benign neoplasm 
of the anterior pituitary. 
Regarding the CG1847 interacting partners, the available information is very limited. There are 
only 3 described partners: Nurf-38 (Nucleosome remodeling factor - 38kD), CPB (capping protein 
beta) and CG9986. They were discovered in 2003 in a large project which generated a two-
hybrid-based protein-interaction map of the fly proteome327. However, none of these 3 
transcripts were found significantly changed in the RNA-seq data. Even more, their human 
orthologues PPA2 (pyrophosphatase 2), CAPZB (capping protein actin filament muscle Z-line 
beta) and C12orf4 (chromosome 12 open reading frame 4) respectively are not known 
interactors of hAIP.  
The performed RNA-seq experiments revealed a general up-regulation of genes closely 
associated with Osiris genes in mutant CG1847 deficient larvae. The Osiris genes are a large 
group of 24 orthologue genes that were first described in Drosophila melanogaster289. Out of 
the 24 Osiris genes, 20 are located on the third chromosome in the cytological region 83D4-5 to 
E1-2. This cluster is within a 168-kb region first described in 1972328 as being both triplo-lethal 
and haplo-lethal (Triplo-lethal (Tpl) locus). Previous studies have shown that flies with either one 
or three copies of Tpl die as late embryos or early first instar larvae. This group of proteins is a 
highly conserved insect-specific class. The structure of the proteins belonging to this family is 
characterized by five domains: (1) a hydrophobic region at the N-terminus that is likely a 
secretion signal peptide; (2) a two-Cys region; (3) a domain of unknown function, duf1676 (Pfam 
family: PF07898)329; (4) a hydrophobic putative transmembrane domain, and (5) a region 
including an AQXLAY motif. 
As lack of CG1847 resulted in significant overexpression of most of Osiris genes, it is possible 
that this might be the mechanism that leads to lethality, by mimicking the existence of 3 copies 
of Osiris genes. 
I further tested the hypothesis that the lethality of Drosophila model might be due to the 
upregulation of Osiris genes in mutant males. First I compared the phenotype of mutant CG1847 
deficient larvae with the one described in Triplo-lethal locus. The lethality induced by the 
presence of 3 copies of this cluster usually develops either in later stages of embryogenesis or 
in the early first instar larvae330, which is actually earlier than in our model. In these dying 
embryos/larvae at first the midgut turns brown due to intense apoptosis and cell death, a 
phenomenon that later extends to other tissues as the tracheae appear, which start to break 
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up330. None of these changes were present in CG1847 mutant. As I described in the Results 
section, CG1847 deficient larvae display a normal morphological phenotype, except the fact that 
their development is halted after the second instar larval stage. I could not detect any signs of 
cell death even after staining the larvae with Trypan Blue (a stain that is excluded by living 
cells331. 
A few studies have published that the lethality induced by the presence of three doses of Tpl 
might be prevented by inactivation, knockdown or mutations, of a locus called Suppression of 
Tpl (Su(Tpl))332,333. The mechanism behind suppressing the lethality of Tpl by the Su(Tpl) locus is 
not well understood. It is only known that this locus encodes for the transcriptional elongation 
factor dEll334. Drosophila ELL homologue (dELL) promotes RNA polymerase II (Pol II) elongation 
as it was shown that it has the ability to increase its the catalytic rate335,336. Eissenberg et al. 
showed that reduced dELL levels could further reduce the expression of each of the three-dose 
Tpl in larvae, resulting in Tpl gene product levels closer to wild-type levels (two Tpl doses). 
However, there are no proofs that dEll might act directly on Su(Tpl). The same group of authors 
proposed 3 possible models of dELL function: a) dELL may act on a specific subset of genes; b) 
dELL may act at a distinct kinetic phase of Pol II elongation; c) dELL may act additively or 
cooperatively with other elongation factors to achieve optimal Pol II elongation rates in vivo. 
Strong Su(Tpl) mutations are able to prevent all the described abnormalities associated with cell 
death, resulting in viable, fertile adults. Weak Su(Tpl) mutations induce only a delay in the 
development of the phenotypes, as the larvae are dying during the third instar stage, but still 
displaying the tracheal and midgut phenotypes described above. I did knockdown the Su(Tpl) 
expression in our mutant larvae, via adding an actin-Gal4 promoter in the CG1847exon1_3 
background, but this was not enough to prevent lethality. Still, this does not totally exclude a 
contribution of the Osiris genes in the lethality, as the levels of upregulation in our mutant were 
much higher than the presence of 3 copies. Some of the Osiris transcripts were up to 6 times 
more abundant in the mutant compared to control larvae. According to FlyBase 
(http://www.flybase.org) the Osiris genes are expressed during developmental stages in a wide 
variety of tissues, including epidermis, hindgut, foregut, and trachea.  
Altered dosage of Tpl also alters the response to hypoxia330. The triple-lethality is suppressed by 
hyperoxia and this might suggest that there is a slight degree of hypoxia in larvae with one or 3 
copies of Tpl. Interestingly, in CG1847 mutant most of the heat shock proteins are 
downregulated and these might have a further impact and enhance the lethality. It was already 
been published in 1993 that in response to stress factors, as a protective mechanism, all 
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organisms express heat-shock proteins (Hsps). By functioning as molecular chaperones the heat 
shock proteins confer stress tolerance and survival337.  
Six different members of Tweedle family genes (TwdlF, TwdlG, TwdlO, TwdlQ, TwdlS, TwdlU) 
were also significantly changed in CG1847 mutants. Apart from TwdlO which was 
downregulated, all the other members of this family were upregulated. Interestingly, based on 
the STRING analysis, TwdlO is actually the only member of this protein family that does not 
cluster with members of the Osiris family. The Tweedle family is another novel insect-specific 
protein family. The Twdl family consists of 26 genes that encode for homologous proteins. 12 of 
these 26 genes are located within the same 74kb region, confirming the initial observation of 
sequence similarity among protein products of candidate genes. All together these 26 proteins 
form a new protein family, named the Tweedle (Twdl) family290. The Twdl proteins are produced 
by ectodermal tissues as epidermis, foregut and trachea. Each Tweedle gene has a specific 
temporal and spatial expression and localization pattern and they might be crucial in 
determining body shape, as suggested by Guan et al. in 2006290. The expression of secreted Twdl 
family proteins in these locations, therefore, strongly suggests that these proteins might 
contribute to the chitin-based matrix system. Previous findings already established a connection 
between body shape regulation and matrix proteins that contribute to the cuticle formation. 
Recent studies have revealed a remarkable diversity of cuticular proteins. By far the largest, and 
taxonomically most widespread, cuticular protein family is the CPR family, which is characterized 
by a conserved domain first identified by Rebers and Riddiford in 1988338. Zygotic disruption of 
any one of cuticular genes was shown to result in embryonic lethality339. As a result is not 
surprising that members of fruit fly cuticular proteins as Cpr65Eb, Cpr66Cb, Cpr66D, Cpr97A and 
Cpr100A were found strongly affected in CG1847 mutant larvae and Cpr proteins 
downregulation might be the cause of lethality of CG1847 mutants. 
The animal model generated during this project will be further used in the next 2 chapters in 
order to evaluate the potential tumorigenic mechanisms initiated by loss of the AIP orthologue 
and to investigate the pathogenesis of human AIP missense variants. However, the RNA-seq data 
should be also further exploited to identify other possible candidates and validate new putative 
mechanisms involved in lethality. A special focus should be on those candidates that have 
human orthologues in order to find data relevant for humans. 
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3.6 CONCLUSION 
In order to analyse the role of AIP during development I generated a Drosophila melanogaster 
model of CG1847 deficiency. The bioinformatics data, protein structure and rescue experiments 
results prove without doubt that AIP and CG1847 are orthologue genes. 
The RNA-seq sets provided a useful insight into the types of gene which are highly changed in 
the CG1847 deficient larvae. In this study, I pooled RNA from mutant and control Drosophila 
larvae and performed RNA deep sequencing using the Illumina platform. A very interesting 
cluster of genes emerged from the analysis of the RNA-seq data: Osiris, Twedl and cuticular 
proteins were all significantly changed Drosophila mutants. To date, there are no information in 
the literature regarding possible interactions between CG1847 and proteins involved in body 
development, cuticle formation or body size. Clearly this cluster is in need of further 
investigation for the roles of these proteins during development as this association remains 
poorly understood for the moment. 
Based on my observations, I propose a model for the roles of CG1847 in Drosophila 
development. CG1847 is involved in body size and cuticular formation by interacting with 
different group of proteins as Osiris, Twedl and cuticular proteins, interaction that were never 
described before. Even more loss of CG1847 expression result in downregulation of heat shock 
proteins which might further enhance the mechanism of lethality.  
The data obtain in this discovery study support promising research directions that could lead to 
better understanding of these genes complex roles in development.  
The role of AIP in human development remains an open question as all presented results are 
limited to insect specific mechanisms.  
However, the availability of these new data will facilitate the isolation and characterization of 
other functional genes involved in the role of the AIP orthologue during development and 
different pathways, as well as to disclose possible new mechanisms involved in the development 
of tumorigenesis. 
Data resulted from this model will be further used in the next chapter, for a possible deeper 
understanding of involved pathways.  
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CHAPTER 4: THE DROSOPHILA AIP ORTHOLOG IS ESSENTIAL FOR 
ACTIN CYTOSKELETON STABILISATION AND CELL ADHESION  
4.1 INTRODUCTION 
The actual mechanism by which AIP silencing disrupts normal function in the pituitary is still 
unknown, despite the fact that causality between AIP mutations and pituitary adenomas has 
been established. Clinical, genetic and experimental data suggest that AIP functions as a tumour 
suppressor gene (TSG) in the pituitary gland89,115,116,153. Review of the published clinical data 
suggests that patients with AIP mutations have some special characteristics such as age of onset 
around 10-20 years, the pituitary adenomas are mostly sparsely granulated, and have a higher 
disease penetrance. FIPA families with AIP mutations have more affected individuals than 
families where no AIP mutations are found136. 
Tumours with AIP mutations are in the majority of cases macroadenomas, often invasive and 
disease onset occurs during adolescence or young adulthood119,340, suggesting a more aggressive 
behaviour when there is AIP loss of function. Some authors found that AIP expression is lower 
in more invasive somatotroph adenomas, even in case of patients in which no AIP germline 
mutations have been identified201,341. 80% of the cases of AIP positive pituitary adenomas have 
a certain degree of extrasellar extension, 56% of them invading local structures. These pituitary 
adenomas typically do not respond well to somatostatin analogue treatment, AIP mutation-
positive patients developing partial or total resistance to this therapy reflected in a significant 
reduction of GH and IGF-I levels and smaller, or no tumour shrinkage. Even the long-term disease 
control, with similarly cumulative numbers of therapies, is lower in these patients119. 
The fact that AIP is a tumour suppressor gene is also supported by the fact that loss-of-
heterozygosity was detected in pituitary adenomas from FIPA patients342,343. In accordance with 
the Knudson’s “two-hit” hypothesis137 this resulted in the loss of the wild type AIP allele in almost 
all cases116. No FIPA patients homozygous for AIP mutations have been identified so far. In 
addition, the AIP tumour suppressor role was firmly established by functional in vitro studies: it 
was previously shown that siRNA AIP knockdown results in increased cell proliferation of GH3 
cells344. 
Still, more functional investigations are required to elucidate the role of AIP mutations in 
pituitary tumorigenesis. To achieve this goal we need to know more about the identity and 
functions of AIP interacting partners. Molecules that can induce remodelling changes in the 
epithelial tissue of the normal pituitary gland are of a particular interest. 
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4.2 BACKGROUND 
4.2.1 The Drosophila wing development 
The developing Drosophila wing is a widely used model system for examining how cells respond 
to changes in cell shape associated with rearrangement of epithelial sheets during 
organogenesis345. 
Wing development is a relatively simple process described in detail by Fristrom et al. in 1993346. 
This involves the transition from a single layered columnar epithelium to a flattened bilayer. In 
the larval stages the wing imaginal disc is an epithelial sac. During pupal stages, this tissue 
undergoes a series of folding, unfolding and flattening processes345. 
The first step towards the final pattern of the wing takes place in the early phases of the prepupal 
period, when the monolayered epithelium is folded into two columnar layers346. This is 
Apposition 1 and it is immediately followed by Expansion 1, a stage where the two-layered 
epithelium suffers a series of alterations leading to an increase in wing surface area. The 
expansion process proceeds gradually from the wing margins towards the middle347. The 
epithelium flattens and the wing final pattern becomes more obvious. During the Adhesion 1 
stage, cuticulin is secreted and no major wing shape changes occur. Cuticulin is the first layer of 
the insect cuticle to be deposited and it is laid down as a sheet over the apical surface of cuticle-
secreting cells348. Between 16 and 18 hours after puparium formation, the reapposition of dorsal 
and ventral epithelia takes place (Apposition 2 stage). At the same time, the pattern of wing 
veins becomes obvious. The wing veins are not properly formed and remain as open spaces filled 
with hemocytes (circulating immune surveillance cells). As the reapposition is still not complete 
at this stage, the wing has a “spongy” texture, but with a general shape and vein pattern of the 
adult wing346. The Adhesion 2 stage follows this phase and lasts approximately 10h. The dorsal 
and ventral cell layers are completely adhered, as the cells of the 2 layers connect via basal 
junctions, but only in the areas between the wing veins. After approximately 45 hours of 
pupariation, the wings starts undergoing a final lateral expansion (Expansion 2). In order to fit 
into the pupa, the wings are folded in a characteristic manner349. 
The final step in wing formation takes place after eclosion from pupae. The wings unfold and 
expand. The intervein cells suffer an apoptotic process, as any viable intervein cell degenerate, 
while only the cells surrounding the wing veins persist forming the wing veins350. A summary of 
these processes is depicted in Figure 50. 
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Figure 50: Early wing development. Timeline depicts morphological landmarks of wing development, the associated Waddington’s stages, and the times at which they occur at 25°C 
temperatures. Development within the pupal case is divided into PP (pre-pupae) and P (pupae) stages that are separated by a molt. During evagination, in the first PP stage (PP1), 
the dorsal and ventral halves of the wing pouch begin to adhere along their basal surfaces and the wing epithelium folds along the future wing margin to assume an approximately 
semicircular shape. In PP2, the tissue elongates and narrows until it resembles a thick cylinder three times as long as it is wide (at about 5 h APF at 25°C). During PP3 (6–9 h APF at 
25°C), the wing cells flatten and the wing dramatically increases its surface area. Cuticle deposition begins at this time, and forms a chitinous sheath during PP4, when the wing 
becomes inflated and the dorsal and ventral surfaces move apart. This leaves the wing looking like a balloon. During inflation, a wave of cell divisions runs through the wing. Ecdysis 
of the cuticle—the shedding of the chitinous cuticle from the apical side of the wing epithelium—starts late in the first P stage (P1). Waddington351 subdivides the second P stage 
into substages A–D. In P2A, dorsal and ventral wing surfaces begin to reappose beginning at the wing margin, and the adhesion of the two basal surfaces spreads from the distal, 
anterior, and posterior ends of the wing during P2B and early P2C. P2D starts with the initiation of prehairs. Eventually hairs will cover the whole wing. Proliferation and migration 
of glial cells along vein 3 initiates in the beginning of P1 (by 15 h APF at 25°C). Migration, accompanied by proliferation of glial cells along vein 1 begins at approximately late P1 (by 
17 h APF at 25°C). Glial cells cover the sensory nerves in vein 1 and 3 by mid P2D (32 h APF at 25°C). Abbreviations: APF, after puparium formation;hrs APF 25°C, hours APF at 25°C. 
(Adapted from Classen et al.2008)352 
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In the adhesion process the basal surfaces of the dorsal and ventral epithelia come to close 
contact and form basal junctions (BJs), which are mediated by the integrin family of cell surface 
receptors353,354. The extracellular domain of integrins recognises and binds to ECM proteins, 
whereas the intracellular domain associates with cytoskeletal elements345 (Figure 51). 
 
Figure 51: A schematic summary of adhesion mechanism. The localization of βPS integrin, laminin A and 
F-actin is depicted during the four key stages in the differentiation of pupal wings. White areas represent 
nuclei. Black bars (black arrows) connecting cells in B, C and D represent basal junctions. Wing veins 
(green) are shown only in A and B but persist unchanged for the remainder of development. Extracellular 
spaces containing matrix (ECM) of unknown composition in (A), disappear (B) and reappear (C, D). 
Adapted from Fristrom et al. 1993346 
 
In the process of wing development integrins are essential for the cells to adhere to ECM 
components. Even more, these receptors are involved in the transmission of signals from the 
ECM to the actin cytoskeleton, hence influencing numerous cellular activities during wing 
development. One of the first molecular steps in the formation of the integrin–cytoskeleton link 
is the binding of Talin to integrins355. Talin is essential for further recruitment of other proteins 
such as ILK, PINCH and Paxillin. 
4.2.2 The FRT/FLP system 
As described in Chapter 3, I generated a heterozygous CG1847 deficient Drosophila 
melanogaster animal model. One of my aims was to investigate and identify proteins that are 
deregulated in the absence of CG1847 in vivo. 
A. Basal Apposition C. Expansion
B. Basal Adhesion D. Connections
PS β integrin
Laminin A
F-actin
ECM (secreted in the prepupal period) 
ECM (secreted in the pupal period) 
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A major restriction of the imprecise excision technique is the fact that, in the case of essential 
genes, animals can be maintained only as heterozygous stocks, which makes the study of 
homozygous gene deletions in adult tissue difficult. To overcome this problem, diﬀerent 
techniques have been developed, one of which is the elegant FLP-out system which is based on 
site-speciﬁc DNA recombination356. The FLP recombinase is an enzyme native to a plasmid of 
Saccharomyces cerevisiae and rearranges DNA sequences in a very speciﬁc manner. The FLP 
recombinase acts on a particular 34 base pair DNA sequence, termed the FRT (FLP recombinase 
target) sequence. When two of these FRT sites are present on homologous strands, FLP creates 
double-stranded breaks in the DNA, exchanges the ends of the ﬁrst FRT with those of the second 
target sequence, and then reattaches the exchanged strands. If this site-specific recombination 
occurs between the two chromosomes of the pair, in the G2 phase of the cell cycle in a 
proliferating mother cell, subsequent divisions will generate two clones of daughter cells that 
are homozygous for one or the other chromosomal arm (Figure 52). In my experiments, FLP 
recombinase was expressed under the control of a heat shock protein promoter357. 
Furthermore, the FLP/FRT system can also be used to produce genetic mosaics of marked loss 
of function, or gain of function clones in an otherwise heterozygous background358. 
 
Figure 52: Schematic representation of the FLP/FRT system used to generate mosaic clones. The FLP 
enzyme catalyzes mitotic recombination at the FRT sites between homologous chromosomes; in this 
example one X chromosome carries a mutant allele (*) distal to the FRT site (triangle), the other 
chromosome carries a visible marker, RFP. After recombination and cell division, one daughter cell is 
homozygous mutant and lacking red fluorescence, the other cell is homozygous wild-type and carries both 
copies of the fluorescent marker (bottom right). 
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Pairs of daughter cells generated following a mitotic recombination event are adjacent to each 
other and throughout development are exposed to the same cellular environment. Thus, in the 
same tissue, clones of cells that represent a mutant experimental and a wild-type control are 
generated, whose subsequent proliferation and growth can be compared. I used the FLP/FRT 
system to generate mitotic clones of cells that are totally lacking CG1847 expression in 
heterozygous females. 
 
4.3 OBJECTIVES 
To identify putative molecular partners of AIP with a role in tumorigenesis I investigated the 
molecular mechanisms of loss of AIP in vivo via:  
a) Generation of RNAi-mediated CG1847 knockdown under the control of the wing 
specific GAL4 drivers. 
b) Validation of RNAi-induced phenotypes using FRT/FLP clonal analysis. 
c) Live observation of βPS-GFP integrin in AIP mutants during development. 
d) Characterisation of the impact of the CG1847 deficiency by immunostaining (where 
the necessary antibodies are available), in 2 stages of development: 
1) In third instar larval imaginal wing discs with homozygous CG1847 deficient clones 
generated via FRT/FLP system. 
2) During pupal stages, by immunostaining CG1847 deficient wings generated by 
RNAi-mediated gene silencing. 
e) Validation of transcripts with possible involvement in blister formation identified in the 
RNA-seq screening. 
 
4.4 RESULTS 
4.4.1 CG1847 depletion in the developing wing results in a loss-of-adhesion 
phenotype 
To avoid the lethality associated with the use of ubiquitous drivers, I used tissue speciﬁc drivers 
to express RNAi constructs targeting CG1847. The Drosophila wing provides an excellent system 
for morphogenetic studies. The major advantage is the fact that the wing is not an essential 
organ and this allows important genetic manipulations without affecting viability. An additional 
benefit is the fact that almost any resulting phenotype is easily identifiable. I screened for 
possible pathways affected by CG1847 by eliminating CG1847 function in large areas of the wing 
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during development and examining adult wing phenotypes. I used two different Gal4 drivers to 
express the hairpin RNAi constructs in the wing imaginal disc: nubbin–Gal4 (nub-Gal4) and 
hedgehog–Gal4 (hh-Gal4)359. While nub-Gal4 leads to expression in the whole wing pouch, hh-
Gal4 promotes expression only in the posterior compartment of the wing. 
Remarkably, in both cases I observed a very specific phenotype with CG1847 RNAi flies displaying 
wing blisters (Figure 53). 
 
Figure 53: The CG1847 silencing in wing discs produces wing blisters. Expression of the UAS-CG1847-
RNAi-R2, under the hh-Gal4 driver (A) or nubbin-Gal4 (B) drivers produces wings with blisters. C) UAS-
CG1847-RNAi-R2 crossed with y w (control) do not develop wing blisters. Live images and mounted wings. 
Wing blistering induced by hh-Gal4 driver is much stronger. Scale bar 500μm. 
 
Although the knockdown wings look smaller, their real size cannot be properly evaluated. The 
blister itself may put traction on the surrounding wing tissue and this mechanism may leads the 
appearance of wing shrinkage (Figure 54). 
Interestingly, nub-Gal4 led to a more moderate phenotype, as the blisters affected only the wing 
hinge area, but with a very high percentage, as approximately 95% of the adults presented this 
phenotype. In contrast, hh-Gal4 resulted in a stronger phenotype, with blisters affecting the 
whole wing, but only in 77.5% of the cases (compare blister size, shape and localisation in Figure 
53 A and B and Figure 54). 
A A’ A’’
B B’ B’’
C C’ C’’
500 µm
500 µm
500 µm
500 µm
500 µm
500 µm
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Figure 54: Quantification of blister formation. Expression of CG1847-RNAi-R2 under the hh-Gal4 resulted 
in 77.5% of blisters in Drosophila wings. Expression of CG1847-RNAi-T2 with nub-Gal4 driver resulted in 
95% of blisters. CG1847-RNAi-T2 crossed with y w was used as control. Error bars represent SE 
 
To confirm that these results were not due to an off-target effect of the RNAi constructs, I 
repeated the experiment using a different RNAi line (UAS-CG1947-RNAi T2)247. Comparable 
results were obtained as flies expressing CG1847 T2 RNAi also displayed wing blisters with both 
hh-Gal4 and nub-Gal4 (Figure 55). Similar, hh-Gal4 resulted in a stronger phenotype and while 
nub-Gal4 led to a higher penetrance of blister formation (Figure 56). 
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Figure 55: The CG1847 silencing with UAS-CG1847-RNAi-T2 produces wing blisters. Expression of the 
UAS-CG1847-RNAi-T2, under the hh-Gal4 driver (A) or nubbin-Gal4 (B) drivers produces wings with 
blisters. C) UAS-CG1847-RNAi-R2 crossed with y w (control) do not develop wing blisters. Live images and 
mounted wings. Scale bar 500μm. 
 
 
 
Figure 56: Quantification of blister formation. Expression of CG1847-RNAi-T2 under the hh-Gal4 resulted 
in 81% of blisters in Drosophila wings. Expression of CG1847-RNAi-T2 with nub-Gal4 driver resulted in 91% 
of blisters. CG1847-RNAi-T2 crossed with y w was used as control. Error bars represent SE 
A A’ A’’
B B’ B’’
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These results suggest that the wing blister phenotype is due to CG1847 depletion and not to an 
RNAi off target effect. 
This phenotype was unexpected and it can be the result of a few possible causes. This phenotype 
strongly resembles that of loss of integrin function345, suggesting that depleting CG1847 in the 
wing may have a negative effect on the integrin-actin cytoskeleton network. Wing blistering may 
also result from a gain of integrin function360, which raises the possibility that CG1847 may in 
fact promote integrin function. However, the wing blistering phenotype is not unique to 
defective integrin-actin-cytoskeleton signalling and, thus, detecting the pathway that is affected 
by loss of CG1847 function may be challenging. 
4.4.2 CG1847 mutant clones cause wing blister formation  
As the RNAi constructs carry the possibility of an off target effect, to validate the defective 
adhesion phenotype seen in CG1847 RNAi flies were undertaken mitotic recombination 
experiments. This technique brings the significant advantage of being possible to compare 
mutant and control cells in the same tissue of a heterozygous animal.  
To generate CG1847 mutant clones, a recombination site was introduced in the CG1847 mutant 
background (FRT19AneoR (section 2.2.5 in Materials and methods)). Heterozygous CG1847exon1_3, 
FRT19A / FM7c,dfd::YFP recombinant females were mated with Ubi-mRFPnls, hsFLP, 
FRT19AneoR/Y males to generate CG1847exon1_3FRT19AneoR/ Ubi-mRFPnls, hsFLP, FRT19AneoR 
females (the short version of this genotype will be CG1847exon1_3, FRT19A /FRT19A). Four hour 
egg collections were performed and submitted to heat shock treatment during early larval 
stages as described in section 2.2.3.  
Mitotic recombination events were induced randomly, all over the body, via heat shock 
exposure in the very early larval stages. The resulting homozygous deficient mutant clones and 
twin wild type clones were examined in the wing imaginal discs of third instar larvae. 
Mutant clones in wing imaginal discs are shown in Figure 57. The CG1847exon1_3 mutant regions 
lack the RFP marker, which readily differentiates them from the wild-type twin clones expressing 
two copies of RFP (and 2 normal copies of CG1847) or the heterozygous areas expressing one 
copy of RFP (and one copy of CG1847). 
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Figure 57: Homozygous CG1847 mutant cell clones induced by the FLP/FRT system. Shown are wing 
imaginal discs from third instar larvae. A-A’’ Low magnification (10X) view of the entire wing imaginal disc. 
B-B’’: High magnification (63X) views of boxed area in A. Nuclei are stained with DAPI (blue). The tester 
stock expresses RFP (red fluorescence protein), which labels wild-type cells that have undergone mitotic 
recombination (bright red) and heterozygous cells (pale red). Homozygous mutant cells lack RFP 
expression and are therefore seen as a black area on A’ and B’.B and B’’: white area – the homozygous 
mutant clone, red area – wt clone. Scale bar 50μm 
 
As shown in Figure 57 A’, the mitotic clones are distributed throughout the wing disc, although 
their relative size is quite variable. As the objective was to validate the RNAi results (blister 
formation in adult wings), larvae were allowed to develop until adulthood. The wings of 
heterozygous CG1847exon1_3, FRT19A /FRT19A females were evaluated for blister formation. 
These females with homozygous mutant clones recapitulated the blister phenotype obtained in 
the RNAi experiments (Figure 58). 
As a control, I used flies carrying the FRT construct but lacking any genetic mutation. These flies 
where similarly exposed to the heat shock treatment to generate neutral clones. In sharp 
contrast to flies displaying CG1847 mutant clones, control flies did not exhibit wing blisters. 
(Figure 58 and Table 21). 
A A’ A’’
B B’ B’’
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Figure 58: Blister formation in adult females with mitotic clones. Blister (arrows) formation in adult 
heterozygous CG1847exon1_3, FRT19A /FRT19A females Top panel: heterozygous mutant females A) live 
image of animal with wing blisters; A’ and A’’- mounted wing with blister. Bottom panel: control in 
w,Dm,FRT19A /FRT19A B) live image; B’ and B’’- mounted wing. Scale bar 500μm. 
The heat shocked heterozygous CG1847exon1_3, FRT19A /FRT19A females survived to adulthood 
some of them developed wing blisters, exactly the same phenotype identified in the UAS-
CG1847-RNAi knockdown animals. I analysed all eclosed adults from 3 independent experiments 
and calculated the percentage of heterozygous CG1847exon1_3, FRT19A /FRT19A females with 
blisters (Table 20). 
 Males Females 
Offspring 
genotype 
CG1847exon1_3FRT19A 
Y 
FM7c dfd YFP 
Y 
CG1847exon1_3FRT19A 
FRT19A 
FRT19A 
FM7c dfd YFP 
Expected 
phenotype NOT VIABLE 
No 
Blisters 
Blister 
No 
Blisters 
Blister 
No 
Blisters 
Blisters 
TOTAL 0 162 0 358 34 (9.5%) 352 0 
 
Table 20: Quantification of blister formation in CG1847exon1_3, FRT19A /FRT19A females. The numbers 
represent the total members of counted offspring in 3 different experiments. In parantheses the 
percentages of heterozygous mutant females with blisters are shown.  
Only approximately 10% of the heterozygous females with mitotic clones developed blisters, 
while this phenotype was not identified in any of the other genotypes acting as internal negative 
controls. One noteworthy finding was the wide variability in the size, number and shape of the 
blisters in adult females. This is likely due to the fact that the clones were induced with heat 
shock and are therefore randomly localised within the whole animal. No blisters were detected 
in flies where neutral clones were induced (Table 21). 
A A’ A’’
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 Males Females 
Offspring 
genotypes 
w+,Dm,FRT19AneoR 
y 
w+,Dm,FRT19A 
RFPnls HsFLP FRT19A 
Expected 
phenotype 
No Blisters Blister No Blisters Blister 
TOTAL 121 0 152 0 
 
Table 21: Quantification of blister formation in control w,Dm,FRT19A /FRT19A females 
The small percentage (10%) of heterozygous females with mitotic clones developing blisters may 
be due to the size variability of the clones induced by the FLP/FRT system as seen in Figure 57. 
The majority of clones may be too small to induce the detachment of the wing layers. Clone size 
in an adult wing is determined by the developmental stage at which the larva is heat-shocked. 
For example, clones induced earlier in imaginal disc development are larger, whereas those 
induced later are smaller and more numerous. The reason is that later in development a larger 
number of cells may undergo recombination; however, the number of mitotic divisions that 
occur after the heat shock is reduced356. I attempted to optimise the timing and duration of the 
heat shock treatment, but heat shock treatment before 48 h of development or for longer 
periods of times resulted in lethality of the larvae. 
As AIP is described as a tumour suppressor gene, I also analysed the effect of CG1847 loss on 
cell growth. This was evaluated by examining and comparing the size of clonally related groups 
of cells resulting from mitotic recombination (Figure 57). 
CG1847 mutant tissue was not overtly different from the neighbouring wild-type cells. Following 
a more detailed analysis using ImageJ to carefully assess the area of 25 mutant clones and their 
twin associated wt clones, the CG1847 deficient clones were on average larger. As shown in 
Figure 57A’ and Figure 59 this size difference was statistically significant. It is necessary to 
mention that there was a large variability in the size of clones, both wt and CG1847 depleted. 
 
Figure 59: Quantification of the area size 
of of mitotic recombined clones.The area 
of mutant cells is signficantly increased 
comparing to the their neighbouring twin 
wild-type cells (P=0.0293) Statistical 
analysis was carried out using 
Wilcoxon/Kruskal-Wallis test. The bars 
represent the mean of are of the clones. 
N=25 clones from 10 imaginal wing discs. 
Error bars represent SE (* = P<0.05). 
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The area of CG1847 mutant clones of was found to be significantly larger than the wild-type 
controls. This is in agreement with the fact that AIP has been described as a tumour suppressor 
gene. However, the underlying mechanism is still unknown, as AIP could be involved in cellular 
growth, cell survival and/or cellular proliferation. 
To investigate in more detail the role of CG1847 in cell growth, I evaluated the cell density in 
CG1847exon1_3 mutant clones (Figure 60). Discs containing CG1847exon1_3 mutant clones were 
stained with the DNA binding dye DAPI for nuclei visualisation, and phalloidin staining to mark 
the cell boundaries.  
 
Figure 60: Wing disc clones stained with DAPI and phalloidin. 120 h AEL wing imaginal discs containing 
CG1847exon1_3 mutant and wild-type clones stained with DAPI (blue – B) to mark nuclei and phalloidin 
(green – C) to mark the cell bounderies. RFP expression (A) was used to identify the different clones (40X 
magnification). D: Merged chanells phalloidin and RFP. Scale bar=50 µm. 
 
A B
C D
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The size of cells within CG1847exon1_3 mutant clones (Figure 60) was examined, and compared 
with the size of the twin wt clones (for more details regarding the protocol and the antibodies 
see Appendix 6). I evaluated the number of cells in CG1847 mutant clones and compared it with 
the number of cells in their wt twin spot counterparts by counting the number of nuclei per 
clone. I also determined the clone area using the RFP signal (or lack of it in case of homozygous 
mutant clones). Cell density was calculated by dividing the number of cells to the respective 
area. Homozygous mutant cells were slightly bigger than their wt neighbours, but without 
reaching a statistical significance (Figure 61). 
The statistical analysis revealed that mutant cells are not visibly different in size from their twin 
spot wild-type neighbours (Figure 61) and counts of nuclei present within mutant and wild-type 
clones showed no difference in cell density (CG1847exon1_3 clones = 4.41x10-2 cells/μm2; wild-type 
clones = 4.46x10-2 cells/μm2). 
Together, these results support the hypothesis that CG1847 exerts a tumour suppressor role, as 
CG1847 mutant clones are larger than controls. However, CG1847 does not seem to be involved 
in individual cell growth, and thus it may instead affect cell proliferation or cell survival. 
 
Figure 61: Quantification of cell density. 
Imaginal wing discs were stained with DAPI 
and phalloidin, and the area (µm2) and the 
number of cells within each homozygous 
CG1847exon1_3 mutant and twin wt clone 
were counted. The cell density was found 
decreased in mutant clones, however, 
without reaching a statistical significance. 
The bars represent the mean of ratio: 
number of cells/area). N=25. Error bars 
represent SE 
 
In summary, our results from RNAi and mitotic recombination support the involvement of 
CG1847 in adhesion, proliferation and cell survival processes. As a role in adhesion has never 
been described for human AIP, there is virtually no information regarding the possible 
mechanism of action. Based on the available literature regarding blister formation in Drosophila, 
the candidate AIP-interacting partners identified belong to various classes, such as: cell 
adhesion genes Mys (FBgn0004657), Mew (FBgn0004456), If (FBgn0001250)361 blistery 
(FBgn0000244)362; receptors and members of signal transduction pathways: Gsα363; 
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transmembrane transport: blot (FBgn0027660)361; cell migration: ADAM metallopeptidase with 
thrombospondin type 1 motif A (FBgn0038341)361; DNA and RNA binding proteins: held out 
wings (FBgn0264491)361; Additional sex combs (FBgn0261823)364; protein deubiquitination and 
regulation of proteasome assembly: Ubiquitin specific protease USP5 (FBgn0035402), POMP 
(FBgn0032884)361; metabolic processes: sugarless (FBgn0261445)364; chitin based attachment: 
piopio (FBgn0020521)364, and transcription factors: mastermind (FBgn0002643)364, blistered 
(FBgn0004101)365. These genes were identified in three different screening studies. The first one 
was conducted by Prout et al.364 and was trying to identify autosomal mutations which might 
result in blisters formation fruitfly wing. 76 independent mutations were identified in this study 
and the genetic interactions with mutations in the integrin gene myospheroid were investigated. 
Mutations in three new genes (piopio, rhea and steamer duck) that affect myo-epidermal 
junctions or muscle function in embryos were isolated. One year later, in 1998, Brown et al.361 
published the results of the second screening. The aim of their project was to use FLP-FRT system 
to generate clones of randomly induced mutations and to screen for those mutations that cause 
wing blisters.  
A third study was recently published in 2014 and the authors also looked on Drosophila 
apposition of the dorsal and ventral wing sheets during metamorphosis. Using RNAi-silencing 
technique and the blister phenotype as readout, there were identify numerous novel proteins 
potentially involved in wing sheet adhesion: components of other cellular processes, e.g. cell 
cycle, RNA splicing, and vesicular trafficking366. 
Identifying the mechanisms via which loss of CG1847 leads to loss of adhesion may provide hints 
on the pathology of human pituitary adenomas due AIP mutations. 
4.4.3 CG1847 is not required for βPS integrin distribution at muscle attachment sites 
The most studied mechanism of blister formation in Drosophila involves the integrin–actin 
cytoskeleton network. Proteins belonging to this network, such as the integrins receptors, are 
not only localised in the wings, but they are involved in cell adhesion in many other tissues, 
including the connection between muscles and between muscle and tendon cells367,368. 
To study the possible interaction between integrin-associated proteins and CG1847, the 
expression of different proteins involved in the integrin adhesion pathway was evaluated during 
development by 2 methods: live imaging in embryos and larvae, and immunostaining during 
larval and pupal stages. 
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Previously published studies have shown that Drosophila mutants affecting cytoskeleton 
components are homozygous lethal due to the detachment of somatic muscles at late 
embryonic stages369. As the Drosophila AIP mutant is also lethal and it may be involved in 
adhesion processes, I assessed whether the lethality was associated with defects in integrin 
distribution at muscle attachment sites (Figure 62). 
 
Figure 62: CG1847 deficient mutants display normal muscle attachment sites pattern. Live imaging of 
GFP-βPS integrin (white arrow) in females CG1847exon1_3/FM7c,dfd::YFP (A and C) and males CG1847exon1_3 
(B and D) with confocal microscopy. A) and B): 24 hours old embryos. C) and D): around 50 (± 2) hours old 
larvae AEL. Scale bar=100 µm. 
For this, I used fly stocks where the CG1847 deletion was recombined with Mys-GFP 
(myospheroid (Mys) encodes for the βPS integrin subunit) and balanced over the same FM7c, 
Dfd::YFP chromosome (section 2.2.4). This allowed me to determine whether lack of CG1847 
impacts on the expression or localisation of GFP- βPS integrin246 in CG1847exon1_3/Y males 
embryos. Females CG1847exon1_3/ FM7c, Dfd::YFP were used as control for the normal Mys 
distribution. 
Live imaging of embryos lacking CG1847 failed to reveal any defects in adhesion or displacement 
of βPS integrin from muscle attachment sites. 
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4.4.4 CG1847 deficient mutants display normal expression of integrins and integrin-
associated proteins in the wing imaginal discs during larval stage 
As the CG1847 depleted adults display blister formation I examined the distribution of integrins 
and integrin associated-proteins in wing imaginal discs of CG1847exon1_3, FRT19A /FRT19 females 
(Figure 63). For this purpose I performed immunostaining with the relevant available antibodies 
(Appendix 6). 
 
A A’ A’’
B B’ B’’’
A’’’
B’’
C C’ C’’’C’’
D D’ D’’’D’’
E E’ E’’’E’’
β
Talin
PINCH
actin
50 µm 50 µm
  
166 
 
Figure 63: Normal distribution of PS integrin, integrin-associated proteins and actin at the basal 
surface. (A-E) Low magnification (10X) view of mitotic recombination clones in CG1847exon1_3, FRT19A 
/FRT19A female wing discs. A' A'' and A''' show disc in A at 63X magnifications. Similarly for the other 
panels. Note in A-E the wide variability in size, shape and location of the mitotic clones. A' - E''': wing discs 
stained for DAPI (blue; A' and E'), expressing mRFP (red; A'' and E''), and stained for integrin associated 
proteins (A''' and E'''). respectively. Note that DAPI and mRFP are images of the same slice in the Z-stack 
at the nucleai level, while A''' and E''' are images at the basal surface, where these proteins are normally 
expressed and invoved in cell adhesion. Scale bar 50 μm. 
 
In clones of cells lacking CG1847, βPS integrin, Talin, Parvin, PINCH and actin expression was 
compared with their expression in clones of homozygous wild-type cells. No obvious alterations 
were observed in the expression pattern of these proteins. 
4.4.5 CG1847 knockdown induces disruption in actin cytoskeleton networks 
During larval stages, the Drosophila wing imaginal discs are formed by a single layer of cells, and 
as the basal junctions (BJs) are not formed in this stage, it is not surprising that no changes were 
observed. As the folding and adhesion processes occur exclusively during the pupal stages, I 
performed subsequent experiments in pupal wings to investigate the mechanism behind the 
loss of adhesion in CG1847 mutants. 
To address whether the members of integrin-actin cytoskeleton network are deregulated later 
in development in the pupal stage, I silenced CG1847 expression in the developing wing using 
nub-Gal4. This driver was used as it generated blister formation in more than 90% of the 
offspring and with a more precise localisation, as all the blisters were in the hinge area of the 
wings (Figure 54 and Figure 56). Pupal wings were stained with the DNA binding dye DAPI for 
nuclei visualisation, and phalloidin to mark the actin cytoskeleton. I evaluated the pattern of 
actin distribution at two different developmental stages (Figure 64). To choose the time points 
for this evaluation, I took into consideration the normal wing development and morphogenesis. 
At 16 h APF, the wing already has two layers, but the dorsal and ventral layers are completely 
separated, and no wing veins can be distinguished. The actual apposition starts at approximately 
18h APF, when wing veins become more obvious. Between 20 h APF and 32 h APF (by the 
definitive stage), the adhesion process progresses from the tip of the wings towards the hinge 
and the wing veins are clearly formed and distinct from the surrounding tissue. Therefore, I 
chose to evaluate the effect of CG1847 silencing in pupal wing morphogenesis and adhesion at 
24 h and 28 h APF. These particular stages were chosen because at 24 h the adhesion process 
has already started and differences in the attachment of the cell layers can be evaluated in 
CG1847-depleted and control. At 28 h APF, the adhesion process should be reaching completion, 
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thereby allowing me to detect if there is a developmental delay resulting from CG1847 
knockdown. When considering the timing of the stages of development, different laboratories 
have reported significant variations: for example, Urbano et al. in 2009370 reported apposition 
and refinement at later time points (32-40h). Such differences may be influenced by genetic 
background, and differing laboratory conditions (e.g. if animals were raised at room 
temperature, rather than 25°C as in this work). 
For tissue specific knockdown I used the nubbin-Gal4 stock as this resulted in wing blister in 
more than 90% of the offspring (section 4.3.1). As a control pupal wings from UAS-CG1847-RNAi-
T2 stock were used, in order to have the same genetic background. Both knockdown and control 
stocks were submitted to the same food and temperature environment, and pupae collection 
and staging were performed as described in section 2.2.11. 
 
Figure 64: CG1847 silencing resulted in actin disorganisation  A-A’’ CG1847-RNAi-T2 overexpressed under 
nub-Gal4 driver induces blister formation (black arrow) in the hinge area of adult wings ; A) nub-Gal4 
CG1847 RNAi adult fly; A’-A’’ adult wings from nub-Gal4 CG1847 RNAi flies . B-E: low magnification (20X) 
visualisation of the entire wing blade in pupal stages. The genotype and developmental timing (h APF) are 
shown on the top. B and C: actin pattern in normal and CG1847 knockdown pupal wings at 24 h APF. D 
and E: actin pattern in normal and CG1847 knockdown pupal wings at 28 h APF.B’-E’ shows higher 
magnification of the hinge area. By 24 h APF the adhesion process is not completed (B’) as wing vein 
formation stops at the area marked by the yellow line At 24 h APF the adhesion process in knockdown 
wings (C’) is severely disrupted (white arrow) compared with normal development. At 28 h APF the 
adhesion of dorsal and ventral wing layers is completed in control wings (D’), while in CG1847 knockdown 
wings it is slightly halted (small gaps marked by white arrow). 
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Interestingly, loss of CG1847 resulted in a marked disorganisation of the actin cytoskeleton. Of 
note, the severity of the cytoskeleton disorganisation phenotype was variable. At 24 h APF the 
majority of pupal wings displayed very strong phenotypes as the ones depicted in Figure 64, 
while others had a more mild loss of adhesion. Surprisingly, this phenotype seems to be partially 
recovered by 28 h APF, as the actin cytoskeleton organisation is only mildly affected in CG1847 
knockdown wings. 
It has previously been demonstrated that AIP interacts directly with cellular cytoskeleton 
structures156, but these results have not been convincingly validated. The results represent the 
first time that AIP loss has been associated with a strong cytoskeleton-related phenotype in vivo. 
However, as aforementioned, not all wings exhibited the phenotype to the same extent, even 
at the earlier time point of 24 h APF. As the loss of adhesion phenotype seemed to be partially 
recovered by 28 h APF, I performed a more detailed analysis and specifically focused on the actin 
cytoskeleton at the basal surface of cell layers, where the apposition and adhesion take place. 
For this analysis, I assessed the hinge area of 24 h and 28 h APF pupal wings. I evaluated the 
pattern and intensity of actin staining visualized at higher magnification (63X). The samples were 
optically cross-sectioned by generating orthogonal sections from the Z stacks (Figure 65). 
 
Figure 65: Schematic representation of the orthogonal sections. The orthogonal sections from the Z 
stacks (A) were generated via 3D reconstruction. XY view is at the level of the red line/section (B). YZ view 
is at the level of the green line/section (C) The colours of the borders in the B and C panels correspond to 
the colours of the optical sections in the A) panel. 
 
A
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C
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At high magnification (Figure 66), I observed that CG1847 depletion caused not only a failure of 
wing layer adhesion, but also a strong deregulation and lower intensity of actin staining. 
 
Figure 66: CG1847 silencing specifically in the wing resulted in loss of adhesion. Gaps between the basal 
surfaces of wing cell layers in the hinge area are revealed in the Z sections of 24 h APF pupal wings. The 
nub-Gal4>UAS-CG1847-RNAi-T2 were raised at 25°C, collected at WPP, staged and imaged at 24 h APF. A 
and B: high magnification (63X) single sections from Z-stacks of KD and control pupal wings.A’-A’’’ and B’-
B’’’ are orthogonal views generated with ImageJ, at the level of the yellow lines. A’ and B’ are merged 
DAPI (blue) and phalloidin (red) channels. A’’-A’’’ and B’’-B’’’ are individual XZ sections of DAPI and 
phalloidin staining. Arrow in A’’’ points toward the actin continous layer involved in the adhesion (control 
wing), while arrows in B’ shows the gaps resulting from loss of adhesion. The low intensity of phalloidin 
staining it is also obvious in KD wings, suggesting that reduced actin levels are involved in adhesion in KD 
wings at 24 h APF (arrow in B’’’). Scale bar 10 μm. 
 
As the loss-of-adhesion phenotype seems to be repaired overtime, at least macroscopically, by 
28 h APF, I used the same approach to investigate the phenotype in more detail. However, when 
analysed at a higher magnification, CG1847-silenced wings still displayed gaps between the cell 
layers at 28 h APF. Moreover, CG1847 RNAi wings exhibited a much lower intensity of phalloidin 
staining, indicative of problems in the actin cytoskeleton, and a dysregulation of the normal wing 
pattern, with nuclei not linearly arranged and at different levels (Figure 67). 
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Figure 67: Overexpression of CG1847-RNAi in the wing causes persistence of gaps in the actin layer at 
28h APF. Gaps between the basal surfaces of wing cell layers in the hinge area are revealed in the Z 
sections of pupal wings. The nub-Gal4>UAS-CG1847-RNAi-T2 flies were raised at 25°C, collected at WPP, 
staged and imaged at 28 h APF. A and B: high magnification (63X) single sections from Z-stacks of KD and 
control pupal wings. A’-A’’’ and B’-B’’’ represent orthogonal views of A and B, respectively, at the level of 
the yellow lines. A’ and B’ are merged DAPI (blue) and phalloidin (red) channels. A’’-A’’’ and B’’-B’’’ are 
individual XZ sections of DAPI and phalloidin staining, respectively. In A’ the arrow indicates the 
continuous actin layer involved in adhesion (control wing). In B’’ the arrows indicate the nuclei which are 
not linearly arranged. In B’’’, arrows depict gaps in the actin cytoskeleton structure resulting from loss of 
adhesion. Scale bar 10 μm. 
 
The loss-of-adhesion phenotype was partially rescued in the 28h APF wings as the gaps in the 
actin basal layer were more subtle than at 24 h APF. Still, at 28 h APF CG1847 RNAi pupal wings 
showed a very weak phalloidin staining compared to control pupal wings. The disorganisation 
of the normal wing pattern, with nuclei at the different levels, not linearly arranged in KD wings 
at 28 h APF (arrow in B’’) can also be noticed. This suggests two possible mechanisms. First, loss 
of CG1847 directly affects the actin cytoskeleton, which will result in the loss-of-adhesion 
phenotype. Second, CG1847 controls the adhesion itself, which would indirectly be responsible 
for the actin cytoskeleton phenotype. Further experiments looking at adhesion molecules and 
at more members of integrin actin cytoskeleton network are required to determine which one 
of these two hypothesis is true.  
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4.4.6 CG1847 silencing induces wing vein widening in early pupal development  
When analysing closely the CG1847 RNAi pupal wings at 28 h APF, I noticed a slight increase in 
the size of the wing veins in the nub-Gal4>UAS-CG1847-RNAi-T2 wings (Figure 67 A and B). To 
determine whether this was a significant phenotype, I measured the diameter of the wing veins 
in 10 pupal wings of control and 10 pupal wings of CG1847 RNAi animals. For each wing, the 
diameter of the L2, L3 and L4 longitudinal wing veins was measured at 3 different points (yellow 
marks in Figure 68). 
 
 
Figure 68: Overexpression of CG1847-RNAi in the wings resulted in wider veins. A-A’’ Wing vein sizes in 
control samples (UAS-CG1847-RNAi-T2). B-B’’Vein sizes are markly increased in animals of the genotype 
UAS-CG1847-RNAi-T2 nub-Gal4 (KD) raised at 25°C until the WPP stage, dissected at 28 h APF and imaged 
with confocal microscopy. The phalloidin staining was done following the protocol described in Appendix 
6. C: There was a significant statistical difference in wing vein diameter as there is a delay in the adhesion 
of the intervein spaces which usualy closes the wing veins channels. Asterisks indicate statistical 
significance as determined by Student’s t-test (n=20 wings analysed). Error bars represent SE, 
****P<0.0001). 
Quantification of wing vein size revealed that depleting CG1847 in the developing wing causes 
vein widening at 28 h APF. At this stage of development, the actin cytoskeleton disorganisation 
is not as obvious as at 24 h APF, but is reflected in the significantly larger wing veins. However, 
no “blister-like” phenotype can be observed at this developmental stage. 
4.4.7 CG1847 is required for normal expression levels of integrin associated protein 
PINCH 
To distinguish whether the blister phenotype in wings lacking CG1847 expression is due to the 
cytoskeletal defect itself or if it is the result of deregulation of integrin receptors or integrin 
associated proteins, I evaluated the expression levels of βPS integrin, Talin, Parvin and PINCH in 
pupal wings. 
A A’’
B B’’
A’
B’
50 µm
50 µm
****
C
  
172 
 
UAS-CG1847-RNAi-T2 was overexpressed to repress CG1847 in whole wing during development. 
Pupae were collected, staged and dissected at 28 h APF. The immunostaining was performed 
according to the protocol in Appendix 6. Half of the pupal wings were immunostained for Talin 
and PINCH, while for the others we used anti-βPS and anti-Parvin antibodies. All samples were 
also stained with phalloidin to visualise the actin cytoskeleton and DAPI to stain the nuclei. Post 
immunostaining all the samples were scanned using identical laser confocal microscope 
parameters. The imaging of KD (nub-Gal4> CG1847-RNAi-T2) sample and corresponding control 
were taken on the same day to avoid any possible confounding factors as technical issues 
regarding the confocal microscope itself. As expected, I observed a dysregulation of the actin 
cytoskeleton in CG1847 RNAi wings (Figure 64). Talin levels and localisation in 28 h APF pupal 
wings were not noticeably affected by CG1847 depletion. However, PINCH expression levels 
were dramatically reduced compared to control samples. In addition, the pattern of PINCH 
expression was also altered. While in control samples PINCH is strongly increased at the apical 
border, in CG1847 RNAi wings this pattern is not obvious (Figure 69). 
 
Figure 69: CG1847 controls actin and PINCH stability in pupal wings. The nub-Gal4>UAS-CG1847-RNAi-
T2 were raised at 25°C, collected at WPP, staged and imaged at 28 h APF. A and B: high magnification 
(63X) single sections from Z-stacks of control and KD pupal wings. Orthogonal XZ views of individual 
channels, (DAPI – blue; phalloidin – red; Talin – green; PINCH – magenta) were generated with ImageJ at 
the level marked with a yellow line in A and B, respectively.  
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Next, I assessed whether CG1847 depletion induces changes in expression or localisation of βPS 
integrin or parvin. βPS integrin strongly co-localised with actin, especially at the basal level of 
the wing layers, as both proteins are involved in the establishment of adhesion. Parvin was 
localised preferentially at the apical level. My analysis of 28 h APF pupal wings revealed that 
neither PS integrin nor Parvin were significantly affected by depletion of CG1847 (Figure 70). 
 
Figure 70: βPS and Parvin are normal in pupal wings lacking CG1847. A and B: high magnification (63X) 
single sections from Z-stacks of control and KD pupal wings. Orthogonal XZ views of individual chanels, 
(DAPI – blue; phalloidin – red; βPS – green; Parvin – magenta) and merged (phalloidin – red; βPS – green) 
were generated with ImageJ at the level of the yellow line in A and B, respectively. Actin, as identified by 
phalloidin staining, is severely disregulated in CG1847 KD tissue. The expression of βPS follows the same 
pattern as actin as these proteins strongly co-localise at the basal surface of cell layers. The expression of 
Parvin is unchanged in the KD wings. 
NOTE: As previously was described that Talin, PINCH and Parvin are localized at the site of 
integrin adhesion, further immunostainings are required to confirm that these results are not 
due to nonspecific background staining. 
To confirm these results, I quantified the staining intensity of the proteins of the integrin 
complex in the XZ projections. For each protein, expression levels were quantified in 5 control 
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or RNAi samples. Phalloidin intensity was quantified in all 10 control or RNAi samples. For the 
quantification of βPS integrin staining, I defined a standardised area that was used to quantify 
the intensity of the signal exclusively in the basal level of the wing layers. This approach was 
used to avoid a potential effect of the βPS integrin fluorescent signal in the areas involved in 
lateral cell-cell adhesion. Importantly, the quantification of signal intensities (Figure 71) reflects 
the results shown in Figure 69 and Figure 70. Actin and PINCH were strongly downregulated in 
CG1847-depleted pupal wings, while there was no significant difference in βPS integrin, Talin or 
Parvin. 
 
Figure 71: Significant difference in actin and PINCH staining intensity between CG1847 knockdown 
samples and control. Post immunostaining, samples were scanned using identical laser confocal 
microscope parameters. The corresponding fluorescence measurements of different proteins were 
evaluated using ImageJ. The staining intensity unit was in pixels. Assuming that fluorescent intensity levels 
accurately reflect the quantity of protein present, 28 h APF KD wings have approximately 50% less PINCH 
protein expressed and significanltly lower levels of actin. No statistical significant changes were detected 
for Talin, βPS and Parvin. Error bars represent SE. Asterisks indicate statistical significance as determined 
by Student’s t-test (*P<0.05, **P<0.01) 
My results reveal that CG1847 signalling is strongly required for the maintenance of a normal 
tissue actin cytoskeleton. Silencing CG1847 leads to marked loss of wing cell layer adhesion and 
widening of wing veins in pupal stages, which are further translated into blister formation in 
adult flies. Even more, in Drosophila pupal wings, lack of CG1847 leads to marked 
downregulation of integrin-associated protein PINCH. 
*
**
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4.4.8 Overexpressed hAIP has a cytoplasmic localisation in Drosophila tissues  
A lack of availability of antibodies that recognise Drosophila CG1847 means that there is 
currently no experimental evidence regarding exactly where in the wing is CG1847 expressed 
during pupal development. Human and mouse studies revealed that AIP protein is ubiquitously 
expressed in both developmental and adult stages. AIP expression is abundant and has been 
confirmed in multiple tissues including the human heart, brain, skeletal muscle, kidney, testis, 
ovary and pituitary, among others. At the cellular level, AIP expression is predominantly 
cytoplasmic139,154; however, nuclear expression was also reported149. As CG1847 remains a non-
characterised gene in flies, precise information regarding its levels or expression pattern in 
Drosophila is lacking. 
To overcome this, I used a different approach. As described in Chapter 3, human AIP protein is 
able to compensate for CG1847 deficiency and to rescue the lethality of mutant hemizygous 
males. Consequently, it is formally possible that hAIP is also expressed in the same cellular 
compartments in order to be able to substitute for CG1847 in fulfilling its normal functions. 
Several antibodies that recognise human AIP are available (both commercial and homemade) 
and their specificity has been tested by western blot analysis to determine if some of the 
antibodies could detect the exogenous hAIP expressed in rescued CG1847 mutant males 
(Chapter 5). To determine the in vivo subcellular localisation of hAIP (and, by proxy, the 
localisation of CG1847), I used the UAS-Gal4 system to overexpress hAIP ubiquitously. Act-Gal4, 
was introduced (as previously described) in the heterozygous mutant background on the second 
chromosome (CG1847exon1_3/FM6;Actin-Gal4/CyO). Heterozygous mutant females were mated 
with homozygous transgenic males carrying hAIPwt cDNA on the second chromosome under the 
UAS promoter (UAS-hAIPwt/ UAS-hAIPwt). 
In the next generation half of the males were CG1847exon1_3/Y;Actin-Gal4/UAS-hAIPwt and 
expressed hAIP protein in all tissues (Figure 72 A’’). The other half of the males were 
CG1847exon1_3/Y;CyO/UAS-hAIPwt and acted as an internal negative control for specificity of 
antibody raised against hAIP protein (Figure 72 H’’)). 
I performed 4 h egg collections and the larvae were allowed to develop at 25°C until they 
reached the third instar stage. In this larval stage it was possible to visually select under the 
microscope the male larvae with the genotype of interest, which were then allowed to further 
develop. WPP were collected, staged and dissected at approximately 26 h APF. The images were 
taken with the confocal microscope; for each wing we took images with low (10X) and high (63X) 
magnification. 
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Figure 72: Overexpressed human AIP is localised in the cytoplasm of Drosophila wing cells. A-A’’ - low 
magnification (10X) visualisation of the entire wing blade at 26 h APF of wings overexpressing human AIP 
protein. B-D: high magnification (63X) single sections from Z-stacks of pupal wings: DAPI – blue; phalloidin 
– red; hAIP – green. C’-D’: Orthogonal XZ views of individual chanels. E-G: merged images 2 of the 
individual channels. E’-G’: orthogonal XZ views of merged chanels. H - H’’: low magnification (10X) 
visualisation of the entire wing blade from males CG1847exon1_3/Y;CyO/UAS-hAIPwt used as internal 
negative control for specificity of antibody. All the optical sections were generated with ImageJ at the 
same level in all images (see yellow lines in E, F and G). 
 
A A’ A’’
B
B’ C’ D’
C D
E
E’
F
F’
G
G’
H H’ H’’
100 µm
10 µm
10 µm
10 µm
10 µm
100 µm
  
177 
 
Human AIP protein overexpressed under actin-Gal4 is ubiquitously localised in the cytoplasm 
compartment of the cell. There is no co-localisation of hAIP with actin or DAPI. The results shown 
in Figure 72 confirm previous data, which showed that AIP is expressed throughout the 
cytoplasm without a particular pattern or a precise localisation. 
Note: as based on the Western Blot results presented in Section 5.4.6 we are now aware that 
this antibody against human AIP protein cannot detect the endogenous CG1847, a further 
control could be performed in the future: staining of a wt wing, to check for specificity of the 
staining and to exclude any possible leaky effects of the pUAS-hAIP construct. 
4.4.9 cAMP/PKA pathway is not significantly changed in Drosophila AIP mutants 
As described in Chapter 3, I performed an RNA-seq study for whole transcriptome quantification 
of the CG1847 mutant. The main purpose of using RNA-seq analysis was to identify the affected 
transcripts in Drosophila CG1847 deficient males, as this could allow a deeper understanding of 
the affected pathogenic processes. As the in vivo data supported an involvement of CG1847 in 
the adhesion process, I examined the RNA-seq data for possible candidates. 
The available literature regarding blister formation in Drosophila involves a wide range of 
possible candidates, apart from integrins and integrin associated proteins. Some of the 
alternative candidates are: Gsα, via cAMP/PKA pathway, proteins involved in the chitin based 
attachment and other classes as presented above. A very interesting candidate is Gsα, via 
cAMP/PKA pathway as the most frequently observed genetic change in pituitary adenomas is 
the somatic heterozygous activating mutation of the GNAS, the gene coding for the G protein α-
subunit. This can be present in up to 40% of GH-secreting pituitary adenomas69,70. Even more 
interesting, in Drosophila, expression by multiple Gal4 drivers of a constitutively active form of 
Gsα resulted in wing blistering363. The mechanism behind this phenotype is that expression of 
the constitutively activated form of Gsα in Drosophila wing induces premature cell death which 
interferes with the normal adhesion process during wing development371. Consequently the 
Gsα/cAMP/PKA pathway appeared to be a strong candidate to be examined for possible 
understanding of the mechanism of blister formation due to loss of CG1847, and I investigated 
the RNAseq data to see if these candidates were significantly changed in this mutant. 
I analysed the RNA-seq data and searched for changes in expression of transcripts known to be 
involved in cell-cell adhesion. Surprisingly, the majority of the genes previously described as 
being involved in blister formation were not significantly changed at the RNA level. The only 
putative candidate that was detected as significantly changed by the RNA-seq study was Act57B. 
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Gene Full name Log fold change p_value significant oID_genes 
Act42A Actin 42A 0.406432 0.2532 no FBgn0000043 
Act57B Actin 57B -0.633148 0.0001 yes FBgn0000044 
Act5C Actin 5C 0.276335 0.1869 no FBgn0000042 
Act79B Actin 79B -0.460301 0.3667 no FBgn0000045 
Act87E Actin 87E -0.493142 0.0848 no FBgn0000046 
Act88F Actin 88F -0.916564 1 no FBgn0000047 
Actbeta Actin beta 0.515229 0.0679 no FBgn0024913 
Actn3 α actinin 3 -1.54302 1 no FBgn0015008 
Asx Additional sex combs -0.0169036 0.9874 no FBgn0261823 
Bj1 Highwire -0.539097 0.2875 no FBgn0002638 
blot bloated tubules  -0.0593775 0.8388 no FBgn0027660 
CG1136 CG1136 (insect-specific) -0.151218 0.5831 no FBgn0035490 
Pka-C2 
Protein kinase, cAMP-
dependent, catalytic subunit 2 
-0.138539 1 no FBgn0000274 
CG14967 CG14967 0.0663947 0.8943 no FBgn0035420 
Clc Chloride channel-c  0.153304 0.6614 no FBgn0024814 
dl Delta -0.0269314 0.9375 no FBgn0260632 
Gs alpha Gs alpha -0.195469 0.4815 no FBgn0001123 
how held out wings  -0.045544 0.881 no FBgn0264491 
if 
inflated (αPS2 - ventral region 
of the wing) 
-0.391494 0.2154 no FBgn0001250 
mam mastermind  0.174134 0.5295 no FBgn0002643 
mew 
multiple edematous wings 
(αPS1) 
-0.0201201 0.9415 no FBgn0004456 
mys myospheroid βPS -0.0154065 0.9626 no FBgn0004657 
Pax Paxillin -0.453091 0.1577 no FBgn0041789 
pio piopio -0.350258 0.2197 no FBgn0020521 
Pomp pomp -0.155682 0.7813 no FBgn0032884 
rhea talin 0.0650331 0.8494 no FBgn0260442 
Sac1 Sac1 -0.167354 0.5496 no FBgn0035195 
sfl sulfateless -0.029291 0.9199 no FBgn0020251 
sgl sugarless 0.0745148 0.8112 no FBgn0261445 
shot short stop  -0.398396 0.1734 no FBgn0013733 
stck 
(PINCH) 
steamer duck -0.286582 0.3821 no FBgn0020249 
Tsf2 gigas -0.00332658 0.9898 no FBgn0036299 
Vinc Vinculin 0.024666 0.9356 no FBgn0004397 
Table 22: List of genes with a putative involvement in blister formation 
RNA-seq is a very powerful tool, but the results need further validation via an alternative 
molecular technique. For this, I used a multiplex qPCR method. Apart from Act57B, I chose to 
validate other putative candidates, which were selected on the basis of literature searches (both 
from human and Drosophila studies). Gsα and PKA (all 3 subunits: PKA-C1, -C2 and -C3 present 
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in fruit fly) were similarly expressed in the mutant and control samples via RNA-seq (Figure 73). 
However, I chose to include these genes for further quantification as they have been shown to 
be highly involved in the pathogenesis of pituitary adenomas, and also in blister formation. 
 
 
Figure 73: Quantitative PCR analysis of 
transcripts with a possible 
involvement in blister formation in 
Drosophila adult wings. None of the 
quantified transcripts were significantly 
downregulated in mutant larvae when 
compared to controls Target gene 
expression was normalised to the 
reference gene Ribosomal protein 
Rpl32 (Chapter 3). N=4 biological 
replicates with 2 technical replicates 
for each. Error bars represent SE. 
 
The comparison of the expression profiles for the other possible candidates during Drosophila 
development revealed that these specific transcripts were not substantially perturbed in mutant 
larvae. The multiplex qPCR analysis failed to detect significant changes in the mRNA expression 
levels of Act57B, Gsα or Pka-C1. 
Members of other protein families, such as the heat shock proteins, or proteins involved in 
cuticle formation and secretion, or chitin attachment were also validated via this method 
(Chapter 3). These also might have an influence on wing blistering. 
A very recently published article366 used the Drosophila wing tissue to investigate the 
components regulating the adhesion process. By using a library of Drosophila RNAi lines 
targeting 1573 protein coding genes and screening for the blister phenotype the authors 
identified 190 novel genes involved in apposition and adhesion of the two wing epithelial layers. 
Remarkably, Bilousov et al. revealed components of cellular processes as cell cycle, RNA splicing, 
and vesicular trafficking. With bioinformatics tools, they assembled the resulted data into a 
blisterome network. 
However, not even the huge data resulted from this study did not identify CG1847 as being 
involved in blister formation. Further validation of RNA-seq data and more specific experiments 
are required to investigate in more detail the mechanism behind loss of adhesion in the CG1847 
deficient mutant. 
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4.5 DISCUSSION 
The human adenohypophysis is a glandular epithelial tissue of ectodermal origin, derived from 
Rathke's pouch. The majority of this gland is composed of sinuous cords of epithelial cells 
surrounded by vascular tissue. Epithelial cells form many different tissues, but their 
characteristics are the same regardless the type of tissue or the organism they belong to. 
Epithelia are layers of simple or stratified interconnected cells. They have an apical and a basal 
surface, the latter being in contact with a basement membrane372,373. Based on their shape, 
epithelial cells are further classified as squamous (flat, thin cells), cuboidal or columnar epithelia 
(mainly composed of tall, thin cells). Another important characteristic of epithelial tissues is the 
abundance of cell junctions, which are formed of protein complexes involved in either 
connecting neighbouring cells, or connecting the cells to the extracellular matrix (ECM) via 
different types of adhesion. Connections between neighbouring cells is established by apical 
adherent junctions (AJs). The main component of AJs is E-Cadherin (E-Cad). E-Cad is a 
transmembrane protein, which can homodimerise with E-Cad molecules from surrounding cells 
via its extracellular domain. The cytoplasmic domain of E-Cad interacts with the actin 
cytoskeleton via a complex network of proteins374. Thus, the AJs are a link between the lateral 
surfaces of the cells, and they are essential structures for apical-basal polarity, a main feature of 
epithelial cells375. Another type of cell junctions is involved in connecting the epithelial cells to 
the ECM: the basal junctions (BJs)375. The ECM is a very complex mix of tissue-specific proteins, 
involved in tissue integrity and binding of extracellular signalling molecules376,377. The ECM 
initiates crucial biochemical cues required for tissue morphogenesis and differentiation during 
development378. The BJs involved in cell-ECM connections are mediated by integrin receptors, 
which are adhesion receptors for extracellular matrix ligands, that can also serve as 
transmembrane mechanical links to the cytoskeleton inside cells379. These bidirectional linkages 
integrate cells with their microenvironment. All integrins are heterodimeric molecules 
containing an α and a β subunit. The extracellular domains of the α subunit bind to specific ECM 
components such as laminin and collagen. The intracellular domains of the β subunit mediate 
intracellular connections to the actin cytoskeleton380,381. Thus, while AJs have an important role 
in connecting neighbouring cells, BJs connect the cell cytoskeleton to the ECM. The ECM is a key 
player in cancer development382-384. In tumorigenesis processes, the ECM is commonly 
deregulated and becomes disorganised. Abnormal ECM has a strong influence in cancer 
progression by directly promoting cellular transformation and motility385. An abnormal ECM can 
have increased collagen deposition, which in turn up-regulates integrin signalling, thereby 
promoting cell survival and increasing proliferation386,383. 
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To understand the role of AIP in the pathogenic mechanisms of pituitary adenomas, it is essential 
to investigate which are the interacting partners affected by the loss of this protein and what is 
their influence on the structure of the epithelial tissue, or connections with the ECM. The 
developing Drosophila wing is a very simple system which enables scientists to investigate the 
molecular mechanisms involved in cell shape changes associated with rearrangement of 
epithelial sheets during normal development or tumorigenesis. As previously presented in the 
Introduction section, Drosophila wing development is a relatively simple process, which involves 
the transition from a single layered columnar epithelium to a flattened bilayer tissue. The basal 
surfaces of the dorsal and ventral epithelia are in close contact to the basal membrane as during 
pupal stages they adhere by forming the BJs mediated by integrin receptors353,354. 
I used the Drosophila wing to show via two independent methods that silencing or deletion of 
CG1847 during development causes wing blister formation in adults. This phenotype strongly 
resembles that of a decrease in integrin function; homozygous mutant clones for integrins 
induced in the wing disc result in blisters. This is due to the fact that the dorsal and ventral wing 
epithelia fail to adhere in and around the integrin mutant clone387-389. The adhesion process is 
mainly regulated by the different proteins belonging to the integrin-actin-cytoskeleton network, 
and eliminating almost any of the components of this complex network results in failure of 
adhesion between wing surfaces390. Previous studies have found that the same phenotype, a 
fluid-filled blister, might be the result of silencing βPS integrin signalling in the wings381,389,391,392, 
or of a loss of PINCH393. Mutations of blistery, the gene which encodes for tensin, also result in 
loss-of-adhesion in the adult wing362, as well as integrin-linked kinase (ILK) mutations394. As a 
result, it is likely that a failure in any of the members of this integrin-actin cytoskeleton complex 
may lead to a loss-of-adhesion phenotype. However, there are no descriptions of an actin 
subunit mutation resulting in blister phenotype. As actin is essential for cell viability395, null 
mutations of this gene will result in lethality396. 
Besides the blister phenotype which strongly suggests defects in wing cell adhesion, our results 
reveal that CG1847 signalling is required for the maintenance of a normal actin cytoskeleton as 
actin is significantly downregulated. In addition, we show that apart from actin, in Drosophila 
pupal wings, loss of CG1847 leads to marked downregulation of the integrin-associated protein 
PINCH. Finally, another surprising result was the observation that CG1847 mutants display 
widened wing veins during the pupal stages. As a consequence, my results strongly suggest that 
CG1847 may be an important factor of cell-to-ECM adhesion via an intricate relationship of 
mechanisms involving the integrin-actin-cytoskeleton and the wing vein formation. 
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Integrins are a family of heterodimer receptors formed by the association of an α- and a β-
integrin subunit. The Drosophila genome encodes 5 α (αPS1-5) - and 2 β-subunits (βPS and βν). 
While βPS forms tissue specific heterodimers with all 5 α subunits, for the second β-subunit, βν, 
only one α partner has been identified so far223,224,397. Integrins have an extracellular, a 
transmembrane and a cytoplasmic domain. These receptors are classified based on the ECM 
molecules they bind to via their extracellular domain: some recognise fibronectin, while others 
bind specifically to laminins398. An important part of the adhesive function of integrins is their 
ability to connect to the actin cytoskeleton, therefore integrating cells with their 
microenvironment379,399,400. The integrins do not possess intrinsic enzymatic activity; however, 
numerous proteins and kinases (such as FAK, Ras, Raf, Mek, PI3K and PKA) have been involved 
in mediating the integrin involvement in signalling pathways that control cell migration, 
proliferation, differentiation and survival398,401. After binding to ECM ligands, integrins undergo 
an activating conformational change. This leads to focal adhesion kinase (FAK) and tyrosine auto-
phosphorylation of their cytoplasmic associated proteins. Integrin-ECM interaction is followed 
by the recruitment of integrin-interacting proteins that form complexes known as focal 
adhesions402. Some of the most studied integrins functions regards their involvement with the 
ECM, especially the role in mediating the dynamics of cellular migration. Integrin null mutations 
are lethal at early stages of development, and the mechanism is most often due to failure of 
integrin-mediated adhesion369,390.  
Actin is an abundant, essential protein found in all eukaryotic cells. It exists in two major 
conformations: G-actin (globular) or F-actin (filamentous). Numerous direct or indirect 
interacting partners have been described for actin, which are involved in a tight regulation of 
actin dynamics. Different ECM stimuli activate integrins, which bind to their ligands, become 
activated and send signals to the actin cytoskeleton403,404. In response, additional cytoskeleton 
proteins are recruited and these will influence ATP-bound actin monomers to assemble into 
filaments. The final result is that the newly assembled actin filaments will determine, also via 
integrins, the necessary changes in cell motility. It is well known that actin is involved in 
pathogenic states, and it plays a particularly important role in tumour invasion and 
metastasis405,406. Malignant cells migrate by invading adjacent tissues and the vasculature. These 
are multi-step processes, usually initiated by polymerization of actin filaments which leads to 
formation of membrane protrusions. Actin cytoskeleton signals were shown to be upregulated 
in invasive cancer cells407. 
Talin is a major integrin-binding protein as it has an atypical FERM (band 4.1, ezrin, radixin, and 
moesin) domain. The four subdomains (F0-F3) do not adopt the classic clover conformation of 
  
183 
 
FERM domains; however, it was shown that talin directly interacts with the cytoplasmic domain 
of β-integrin subunits246. The integrin-talin FERM domain complex plays a critical role in actin 
polymerization408. In Drosophila, mutations in rhea, which encodes talin, are also lethal during 
early embryonic development, while loss of this protein specifically in the wings causes failure 
in adhesion and blister formation381. As shown in Table 22, the rhea levels of expression are not 
significantly changed in CG1847 mutants. 
The ILK-PINCH-Parvin (IPP) complex has been shown to be downstream of talin and to connect 
talin to the actin cytoskeleton. As such, the IPP complex has a central role in the integrin 
adhesome network409,410. ILK is the first protein of this complex that is activated upon integrin 
signalling and is recruited to focal adhesion sites411. ILK has two different domains involved in 
binding to the other members of the complex. While the ILK ANKRs (five tandem ankyrin) 
repeats connect to PINCH, the kinase-like domain binds to parvin. Upon binding, both PINCH 
and parvin connect to actin412. Disruption of any member of the IPP complex significantly impairs 
the other two, and leads to changes in cell shape and motility413. In Drosophila, the IPP complex 
has been thoroughly investigated in two well-established models of integrin-mediated adhesion: 
muscle attachment sites and the wing epithelium. Surprisingly, at muscle attachment sites, ILK 
and PINCH do not require parvin, suggesting that parvin functions to strengthen the integrin–
actin link in the muscles414. On the other hand, studies in the wing epithelium revealed that the 
stability and localization of ILK/PINCH/parvin are interdependent in wing epithelium. Staining in 
wing imaginal discs revealed that knockdown of either PINCH, ILK or parvin resulted in reduced 
expression of the other two, whereas talin levels remained unchanged414. 
In summary, there is interdependence of all three IPP-complex components for their stability 
and subcellular localization at the basal side of wing epithelia, unlike the central role of ILK in 
IPP-complex assembly at the embryonic muscle attachment sites (MASs), as depicted in Figure 
74. 
Interesting, these results were confirmed by the findings of another group who proposed that 
mutations PINCH function is required for the stable adhesion between epithelial layers in the 
wing as mutations which inactivate PINCH in Drosophila wings leads to wing blisters. However, 
investigating the distribution of this network in the muscles of Drosophila embryos, PINCH 
inactivation do not result in ILK mislocalization, as ILK appears normal in PINCH mutant 
embryos393. 
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Figure 74: Genetic hierarchy of integrin–actin linker complex assembly at muscle attachment sites and 
in wing epithelium.  (A) At muscle attacment sites, assembly of the integrin–actin linker complex follows 
a linear pathway of genetic interactions. IPP complex assembly depends on ILK and there is no 
interdependency between parvin and PINCH. (B) In the wing epithelium, the genetic hierarchy can be 
classified at two levels: Integrins and talin are mutually dependent and both are required for PIP-complex 
stability. All proteins of the IPP complex are mutually dependent. This network is highly conserved in 
humans, mice but also in organisms such as fruit fly (Drosophila melanogaster), nematode (Caenorhabditis 
elegans), slime mold (Dictyostelium discoideum), and yeast (Saccharomyces cerevisiae)415. 
Given the blister phenotype upon CG1847 loss of function, and the identical phenotype of βPS, 
mutants, I assessed whether CG1847 is required for the subcellular localization of integrin β-
subunit at muscle attachment sites. We performed this investigation in male mutants, when 
they were just a little older than 48 hours of development (the moment when they start dying). 
We found identical distribution of βPS integrin in CG1847 male mutants and control larvae. 
However, βPS distribution was found normal also in pupal wings lacking CG1847. Hence, my 
results suggest that CG1847 loss of function does not affect βPS distribution in muscle 
attachment sites or in the wing epithelium. It remains to be determined whether loss of CG1847 
affects the signalling activity of integrins. 
Whereas actin and PINCH were significantly downregulated in pupal wings, talin expression 
levels were unchanged, this being in accordance with previously published results414. Likewise, 
the intensity of parvin staining was similar between knockdown and control samples which 
although is in disagreement with the results of Vakaloglou et al.414, it confirms the data published 
by Clarks et al. in 2003393. 
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In summary, my results show a novel connection between CG1847 and the integrin-actin 
cytoskeleton in the Drosophila wing epithelium. As I could not detect a significant change of 
actin at the RNA level, neither in the RNA-seq data nor by Multiplex qPCR, I propose that the 
loss of CG1847 leads to lower actin levels via post-transcription mechanisms. However, the 
actual mechanism of this interaction remains unclear and the direct interaction between AIP 
and actin remains controversial. The ECM–integrin–actin is an intricate complex which signals 
bidirectional and, therefore, it is not entirely clear which factors initiate a process involving this 
network. 
Some early studies involving Drosophila and C. elegans suggested that integrins are the origin of 
the stimulus for the linkage between ECM and the cell cytoskeleton as integrin mutants are not 
viable416,417. However, subsequent studies focused in understanding ECM structure have 
proposed that changes in the ECM components dictate the intracellular assembly of actin 
filaments. This is achieved via integrins and integrin-associated proteins; however, integrins are 
obviously not essential to generate the ECM, as ECM components still accumulate in integrin 
null mutants418,419. To further complicate matters, other groups have shown that polarisation of 
the cytoskeleton precedes changes in either the ECM components or integrin activity. Their 
hypothesis suggests that actin polymerisation leads to accumulation of ECM ligands, which in 
turn determine integrin activation420. Other groups supported a very similar hypothesis, 
proposing that integrin activation comes from inside the cell, without involving ECM 
components. It was shown that, at the muscle attachment sites, the cytoskeleton would first 
undergo polarisation which will lead to integrin activation and connection to the ECM. This 
mechanism has been supported by the phenotypic analysis of Drosophila PS integrins368,421,422. 
In summary, increasing evidence supports the sequential model of an initial cytoskeleton 
polarisation, resulting in the tissue-specific accumulation of different ligands in the ECM. Only 
then the integrins are able to attach to their ligands. Following integrin attachment to the ECM 
components, these receptors are able to recruit additional proteins to focal adhesions, such as 
talin, parvin, vinculin, which further strengthen the interaction. Nevertheless, this model raises 
a critical question: what controls intracellular actin polarisation? Interestingly, in our in vivo 
Drosophila model of CG1847 deficiency actin is severely downregulated and disorganised and 
this might be the causative factor for the various CG1847 phenotypes. Furthermore, PINCH 
downregulation brings additional support to the hypothesis that the loss-of-adhesion 
phenotype generated by lack of the Drosophila AIP orthologue involves the actin-integrin 
network. 
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In addition to the blister phenotype, inhibiting CG1847 signalling resulted in wing vein widening 
in pupal stage. When induced ubiquitously, CG1847 RNAi led to a strong defect in wing vein 
formation. Broader wing veins have been commonly associated with wing blistering365,423-425. The 
cascade of morphogenetic events during normal wing development is crucial to understand the 
mechanism of this phenotype. Following eversion, dorsal and ventral surfaces of the wing reach 
complete apposition at their basal surfaces, forming a bilayer epithelial tissue. At approximately 
18 h APF, longitudinal bands of cells send extensions of basal processes to connect with their 
partners on the opposite layer346. At this stage, the presumptive veins are not visible. The 
‘intervein bands’ first appear around the periphery of the wing and increase progressively from 
anterior to posterior. At 20 h APF, the veins emerge as areas which do not form basal connective 
processes, do not adhere to the opposite layer and appear as a network of vein lumens, with a 
pattern similar to the adult wing. Between 21 and 30 h AFP, all the cells in the intervein areas 
form BJs with the cells from the other layer, progressively ‘zipping’ the intervein epithelia. As a 
consequence, vein development is based on the persistence of dorsal-ventral separation. While 
all intervein cells become apposed basally via BJs mediated by integrin receptors, the vein 
channels remain unopposed and the vein network is fully formed. The vein cells remain relatively 
unspecialized, do not express integrins, do not form BJs and do not connect with the cells on the 
opposite layer. At approximately 30 h APF, the veins lumens become lined with laminin346. 
In Drosophila integrin mutants (e.g. inflated, myospheroid) the mechanism of cell adhesion in 
intervein areas is defective and vein channels are wider resulting in wing blisters387,391,392. 
However, in integrin mutants no evidence of blisters in pupal wings could be found; the intervein 
regions were basally apposed and were not laminin-lined. Even mutations that in adults led to a 
completely ballooned wing had an appearance of normal apposition between the cell layers 
during pupal stage. Consequently, it seems that blisters form later in development, during the 
expansion stage, 50-60 h AFP or during eclosion414. 
Interestingly, the wing vein widening phenotype has also been described in Drosophila when 
there are alterations in cadherins426. Cadherins are adhesion molecules involved in mediating 
the cell-cell adhesion via AJs, and in the control of the cell shape and the cell polarity427. The 
Drosophila E-cadherin (DE-cad) is encoded by the shotgun (shg) gene. Vein cells lacking shg, and 
consequently the AJs, failed to form a lumen. The vein cell fate specification in the developing 
Drosophila wing is mediated by Egfr, as there is evidence that Egfr controls shg both at 
transcriptional and posttranslational levels428. In summary, Egfr signalling is essential for normal 
DE-cad localization426 and alterations in DE-cad-mediated adhesion result in vein broadening. 
This mechanism might be relevant for this study, as E-Cad associates with the actin cytoskeleton 
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and negatively regulates cell migration in Drosophila by actin cytoskeleton remodelling429. 
Furthermore, E-Cad involvement in tumorigenesis is well known and it is strongly involved in 
epithelial-mesenchymal transition. Beside this, EGFR was reported to interact with AIP166, and 
EGFR inhibition has a repressive effect on rat pituitary tumour growth430. However, a report 
published by D’Souza-Schorey et al. in 2005427 did not describe the blister phenotype in wings 
of adult fruit flies with E-cad mutations. Moreover, there are no data supporting the hypothesis 
that mutations in E-Cad result in wing blistering in Drosophila. 
Briefly, my data supports the hypothesis that the Drosophila AIP orthologue is required for cell 
adhesion. The mechanism of CG1847 involvement in cell adhesion is via actin deregulation and 
integrin signalling, supported also by the wing vein widening. This novel possible interaction with 
cytoskeletal proteins and a role in cell adhesion indicate a putative involvement of AIP in cell 
motility and tumour behaviour. Cytoskeletal disorganisation is an important feature of 
epithelial-mesenchymal transition (EMT), the process by which cells develop increased 
migratory capacity, invasiveness, and resistance to apoptosis, resulting in the development of a 
more malignant cellular phenotype431,432. During epithelial-mesenchymal transition, epithelial 
cells lose their polarity and their ability to adhere to surrounding cells and become mesenchymal 
cells. 
Unpublished mass spectrometry and affimetrix data from other members of the laboratory also 
suggest the possibility of a functional interaction between AIP and the actin cytoskeleton as well 
as an involvement of this AIP-actin partnership in the pathogenesis of pituitary adenomas. 
In mammals, the combination of 18 α- and 8 β-integrin-subunits regulate cellular migration, 
invasion, proliferation and survival. Some oncogenes may require integrin signalling in order to 
initiate tumour growth and invasion385. In several tumour types the expression of specific 
integrins correlates with increased disease progression and decreased survival433. For other 
tumours, drugs have been already designed to target this pathway as for examples the integrin 
αv inhibitor cilengitide, which is now in Phase-III clinical trials as combined therapy for newly 
diagnosed glioblastoma patients434. Regarding pituitary adenomas, the specific pattern of 
integrin expression is altered compared to the normal pituitary435. While normal pituitary cells 
express α3β1 and α6β4 and stromal cells express α1β1, adenomas express αvβ3 and lose α3β1 and 
α6β4. These alterations are similar to those that occur in malignant tumours but, since pituitary 
tumours very rarely metastasise, these changes are probably important for their invasive 
behaviour. 
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Recent studies have suggested that the AIP-partner AHR activates FAK, thereby promoting 
integrin activation and increased cell migration22. On the other hand, another AIP-partner, 
Hsp90, is known to interact with ILK in tumorigenic processes436. 
With regards to the possible involvement of AIP in tumour growth, our data support the 
hypothesis that CG1847 exerts a tumour suppressor role, as the area of CG1847 homozygous 
mutant clones was significantly larger than controls. Still, CG1847 doesn’t seem to be involved 
in cell growth, as we failed to identify any differences in cell density. Hence, CG1847 deficiency 
may have an important role in promoting cell proliferation or cell survival. Further investigation 
is needed to distinguish between the two alternatives as previous data exists to support both 
mechanisms. 
Cell proliferation is tightly controlled by cyclins and their respective cyclin dependent 
kinases437,438. Although there are numerous studies regarding the control mechanisms of the cell 
cycle, the actual link between cellular proliferation and AIP-driven adenoma development 
remains incompletely understood. Cyclin-dependent kinase 9 (cdk9) is a cdc2-related 
serine/threonine kinase that has been shown to interact with AIP164. The mechanisms required 
for regulation of CDK9 and its involvement in processes regulating cellular growth and 
proliferation are poorly understood. It has been shown that Cdk9, together with cyclin T1, forms 
a heterodimer called P-TEFb, which is involved in cell cycle progression by stimulating 
transcriptional elongation via RNA polymerase II phosphorylation439,440. The P-TEFb complex is 
recruited to chromosomes at mid- to late anaphase. Inhibition of this process was shown to 
reduce the binding of P-TEFb and expression of key G1 and growth-associated genes, leading to 
G1 cell cycle arrest and apoptosis441. Consequently, CDK9 is a promising target for an 
antiproliferative drug in oncologic pathologies442, CDK9 inhibitors being currently under clinical 
investigation443. 
AIP was also shown to suppress apoptosis as Kang et al. published in 2006444 that AIP directly 
interacts with survivin and is required for its stability. Survivin is a member of the Inhibitor of 
Apoptosis family, which include evolutionary conserved members with key properties in 
regulation of mitosis and apoptosis445. Survivin protects cells against apoptosis and can reduce 
the sensitivity of tumour cells to apoptosis stimulation by increasing the survival capability of 
tumour cells. It was also shown that survivin changes can affect individual susceptibility to 
tumour formation446,447. All these characteristics make this protein a novel target for cancer 
therapeutics448. 
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By using the fly model I also fulfil the strategic priority of replacement in research using animals. 
So far, most studies used rodent models in the fields of pituitary tumour, therefore this project 
is entirely novel. In UK alone there are around 10 different labs using mouse models for pituitary 
tumorigenesis. We are aware of at least 5 more labs worldwide using mouse models for studying 
the mechanisms of pituitary tumorigenesis. It is difficult to estimate the total number of animals 
used in pituitary tumorigenesis studies in these labs, because for a single ongoing project in our 
lab a large number of mice are sacrificed which do not have the desired genotypes. From an 
average of 8-9 pups born in every litter only 2-3 pups are kept. For financial constraints all the 
unused pups are killed before weaning (day 21 postnatal). For a single project a relatively stable 
colony size is 120 mice in a year. Colony size control, dictated by practical and financial reasons 
leads to some of the adult mice being sacrificed, with an estimate of around 10 adult mice killed 
per month. Obtaining embryos (average of 7-8 per pregnancy) for the developmental part of 
this study unfortunately also requires sacrificing the mother. For most studies at least 15 
pregnancies are being examined, meaning that on average an additional 15 adult females and 
around 100 embryos will be sacrificed. In summary, each year around 120-150 mice and 100 
embryos are being used for a single study, with around 200 adult and 300 young (before 
weaning) more mice being sacrificed in a single project on pituitary tumorigenesis. Regarding 
costs, the basic housing costs for this study are approximately 1100 GBP/month (around 1300 
GBP/ month). The colonies need to be maintained for long periods of time, as pituitary tumour 
penetrance is age-dependent (Raitila et al. demonstrated in 2010 that full penetrance of 
pituitary tumours in AIP-KO mice was reached at the age of 15 months). 
This Drosophila model will be further developed to study the pituitary tumorigenesis, with 
estimated savings of hundreds of mice/year. This number may increase even further with the 
adoption of this model by other laboratories and future projects in our laboratory.  
 
4.5 CONCLUSIONS 
In conclusion, the study of CG1847, the Drosophila orthologue of human AIP revealed an exciting 
novel role for this protein in cell adhesion. I have shown that CG1847 is required for actin 
cytoskeleton stabilisation, with a possible involvement in the regulation of integrins. The 
possible interactions with actin indicate a possible strong influence of AIP in cell motility and 
migration, cellular functions which are essential for tumour growth, invasion and metastasis. 
In addition, I have shown for the first time a possible unique contribution of CG1847/AIP to 
integrin–actin cytoskeleton signalling. 
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Finally, my data supports the role of AIP as a tumour suppressor gene. However, further studies 
are required to uncover the exact molecular mechanisms involved. 
Although my results still need thorough investigation for translation to human data, this study 
provides an important insight into how the loss of AIP may promote adenoma formation and 
local invasion. Furthermore, the in vivo model developed in this study supports the use of 
Drosophila melanogaster as a system to elucidate the molecular mechanisms of human 
tumorigenesis.  
Replacing mammalian animal models with Drosophila ones enables research projects that would 
otherwise not be practically feasible, except for considerably large animal and financial expense. 
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CHAPTER 5: AN IN VIVO SYSTEM TO TEST THE PATHOGENICITY OF 
AIP MISSENSE MUTATIONS  
 
5.1 INTRODUCTION  
Despite significant progress on the understanding of AIP-associated pituitary adenomas, the 
etiology and pathogenesis have remained elusive. Many questions remain unanswered, some 
of them involving the pathogenicity of AIP variants. AIP-related pituitary adenomas are 
autosomal dominant with incomplete penetrance116. While different groups have reported a low 
prevalence of AIP mutations in unselected patients with pituitary adenomas (<4%)122,138 this is 
significantly increased in patients with young onset GH-excess (24%) and FIPA (17.1%)117. In the 
subgroup of the patients diagnosed with gigantism, the prevalence of AIP mutations is close to 
50%208,209,449. 
A few hotspot mutations in AIP, as well as a few cases of founder mutations have been 
described, and these have been shown to mostly affect CpG islands. CpG sites are regions of 
DNA where a cytosine lies next to guanine. “CpG” stands for a cytosine that is separated by a 
phosphate from a guanine (—C—phosphate—G—) on the same allele. In CpG sites, cytosines 
can be methylated by DNA methyltransferases, which attach a methyl group to carbon 5 of 
cytosine, thereby altering the DNA structure. In normal conditions, a spontaneous deamination 
of cytosine forms uracil, which is subsequently recognised and removed by DNA repair systems. 
A methylated cytosine which deaminated will form thymine instead of uracil, and this might not 
be recognised by the repair enzymes. This conversion will ultimately result in a transition 
mutation450. 
Examples of AIP founder mutations were found in Finland, Italy451 and Ireland, which helped the 
identification of the AIP gene. In Ireland, a DNA sample from an 18th century patient matched 
the haplotype of numerous current families carrying the p.R304* nonsense mutation452. Using 
coalescent theory, it was estimated that the common ancestor lived about 57 to 66 generations 
earlier. Interestingly, the 304 residue is at a CpG site, which is a mutational hotspot. Numerous 
cases, in at least 20 kindreds, of truncating (c.910 C>T, p.R304*) and missense (c.911 G>A, 
p.R304Q) mutations have been identified across the globe117,120. 
While pathogenicity is beyond doubt for some mutations, such as truncated or stop variants that 
alter important AIP domains, for other mutations this is not immediately obvious. An interesting 
synonymous variant, c.249G>T, was shown to be pathogenic as it results in changes in AIP 
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splicing136. Conversely, some non-synonymous changes have been shown not to affect AIP 
function (e.g. p.Q228K)344. In the case of missense mutations, the change in amino acid sequence 
can affect protein 3D structure, with consequences for its folding and stability. A missense 
mutation can also alter the binding to interacting proteins. While some of these genetic variants 
have been classified as benign, with no functional consequence on protein function, for others 
there it is still a debate on their effect.  
One of the challenges in the management of patients carrying a missense AIP variant is to 
determine whether the variant is a disease-causing mutation or not102. Several groups have 
exploited in silico predictions to test the pathogenicity of mutations. Even though in silico 
prediction pipelines could correctly predict the pathogenicity of some splice-site mutations453, 
in cases where clear deleterious effects were not present, caution should be used before 
labelling them as deleterious mutations. Different in silico prediction platforms have been used 
(reviewed in Thusberg et al.453), but no single method can evaluate all parameters involved. 
Therefore, other methods should be employed for evaluating whether missense variants are 
indeed pathogenic or not. 
To date, more than 70 different AIP variants have been identified, the majority (75%) resulting 
in a truncated AIP protein120, missing the C-terminal tetratricopeptide-repeat (TPR) domains. As 
the frequently used term "a pathogenic variant" might be confusing a 5 categories classification 
was proposed: a) pathogenic, b) likely to be pathogenic, c) unlikely to be pathogenic, d) not 
pathogenic and e) variants of unknown significance. In an article published in 2012, Korbonits et 
al.454 analysed the available data and grouped AIP variants into these five categories. Out of the 
fifty-two AIP variants identified at the time, 12 were previously reported as SNP or rare variants 
with apparently no pathological significance. Some of the AIP changes were classified as “not 
available” because the data regarding their pathogenicity was missing. Since then, progress in 
this area has been limited due to the lack of a reliable assay capable of differentiating between 
disease causing mutations and benign ones. 
New AIP variants identified in FIPA patients keep on being identified. The most recent article 
was published by a Turkish group which detected 2 homozygous missense single-nucleotide 
polymorphisms (rs641081 [Q228K] and rs4930195 [Q307R]) and their frequencies were 
significantly higher in FIPA patients compared to controls455. rs641081 was previously 
published344,456,457 and it is not considered to be a disease causing mutation. However, for other 
AIP variants the available data is more contradictory and there is an increased need for an in 
vivo test. 
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5.2 BACKGROUND 
Up to 60% of fly genes are evolutionarily conserved in human. Numerous technologies have 
been developed in the last decades to manipulate the fly genome allowing significant insight 
into the role of genes, especially for those ones whose mutated human orthologues were shown 
to cause genetic disorders. Many genes that are essential and conserved during evolution were 
associated with human diseases. Multiple studies have attempted to bring a better 
understanding into the mechanism by which these specific mutations cause genetic diseases. In 
2014 Yamamoto et al.458 conducted a genetic screen of lethal mutations. They identified 165 
genes on the Drosophila X chromosome, with a possible involvement in the development and 
function of the nervous system. An investigation of rare variant alleles in 1,929 human exomes 
from families with unsolved Mendelian disease allowed this group to identify disease-associated 
mutations in six families and to provide insights into microcephaly associated with brain 
dysgenesis. 
The recent progress in sequencing technology and bioinformatics allows not only a direct 
identification of mutations, but also the impact of different types of mutations on the levels of 
expression of the genes. However, these technologies bring the real challenge in the 
interpretation of such genomic data and functional experiments are required. These data can 
be obtained using human cell cultures, however Drosophila is an extremely useful model 
organism to obtain in vivo data. This degree of identity between fly and human genomics helped 
the functional annotation of evolutionarily conserved genes. 
Once a putative Drosophila orthologue is identified, a null allele or a strong hypomorph mutation 
should be generated as this will generate a specific phenotype and will provide a reference. In 
the next step, the human cDNA orthologue of a fly gene can be tested for rescuing ability. 
A description of the strategy that was used in this thesis is shown in Figure 75. 
Imprecise excision of a P-element from a gene of interest generated a null allele. Upon 
identification of the phenotype in the fly (lethality), rescue experiments by the UAS-hAIP cDNA 
transgene ubiquitously overexpressed under the actin-Gal4 driver allowed the testing of the 
functional conservation of AIP gene function between fly and human. 
Using this principle, the function of variants found in human patients can be further assessed. In 
the next step, comparing the rescue efficiency of wt hAIP cDNAs versus mutant versions is a 
rapid method of assessing whether a particular variant found in a human patient might be 
affecting the normal function of this gene. 
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Figure 75: Schematic representation of the rescue experiments. First, the potential fly orthologue of 
human AIP was identified. A mutant fruit fly was generated via imprecise excision of a P-element. Only 
heterozygous females are viable, as hemizygous males are lethal. The Act-Gal4 driver was introduced in 
the mutant background and the stock was balanced over CyO. The hAIP cDNA was cloned into a transgenic 
UAS vector. This allows generation of transgenic stocks for hAIP, which were then balanced over CyO. By 
crossing males that carry the transgene of the hAIP cDNA under the control of UAS with heterozygous 
mutant females (with Act-Gal4) it can be determined if hAIP is able to rescue the fly lethality. 
Orthologue 
prediction
P-element 
excision
Isolated hAIP cDNA
attB
attP
phiC31
integrase
Docking site
Drosophila genome
Transgenic flies with hAIP cDNA 
(wt or mutant versions)
UAS hAIP
UAS hAIP
Transgenic vector
Balanced over CyO
Combined with
act-Gal4/CyO
CG1847exon1_3
CG1847exon1_3
FM6
CG1847exon1_3 Act-Gal4
FM6              CyO
X UAS-hAIP
Y       CyO
Rescued males
CG1847exon1_3 UAS-hAIP
Y               Act-Gal4
CG1847 wt
Null allele
MUTANT MALES
CG1847exon1_3 LETHAL
Y
  
195 
 
 
5.3 OBJECTIVES 
The fruit fly model could be utilised to identify which missense variants affect human AIP 
function and are likely to be a disease-causing mutation (or not) via: 
1. Testing the functional conservation between human and fly protein  
2. Determining the functional importance of the C-terminal domain  
3. Testing which hAIP variants do or do not have a significant impact on protein function 
4. Evaluating the expression of human wild-type and missense mutations in Drosophila 
melanogaster via immunoblotting  
This structure-function analysis will determine which variant impairs the conserved function of 
AIP required for viability. This approach will ultimately help to determine the pathogenicity of 
human AIP missense mutations, with a significant impact on the genetic counselling of FIPA 
patients. 
 
5.4 RESULTS 
As seen in Chapter 3, I have shown that CG1847exon1_3 is a null mutation for CG1847, the 
Drosophila orthologue of mammalian AIP. Since CG1847 is located in the X chromosome, males 
lacking CG1847 function are lethal, while heterozygous females are fully viable. Therefore, 
CG1847 mutant flies are a very useful model to test the functional conservation between human 
and Drosophila proteins. Expression of mammalian AIP can functionally complement CG1847 
and rescue the lethality of CG1847 mutant males (Figure 38). This functional complementation 
can be extended to AIP mutant variants, in order to determine whether they are likely to be 
pathogenic or not, in an in vivo setting. Therefore, if a specific AIP variant rescues the lethality 
phenotype of CG1847 mutant flies, it would strongly suggest that the variant does not cause a 
major functional disruption of AIP function. Conversely, a failure to rescue the lethality 
phenotype would indicate that the variant is likely to be non-functional and can possibly account 
for the disease. In summary, this in vivo approach has the potential to identify the functional 
relevance of the hAIP protein domains and the pathogenicity of human AIP missense variants.  
The AIP protein contains several identifiable domains, which are similar between human and 
Drosophila, (Chapter 1, Figure 6 and Figure 11). Structurally, in its N-terminal region AIP shares 
a significant degree of homology with immunophilins, as it has a peptidyl-prolyl cistrans 
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isomerases (PPIase)-like domain. However, this protein does not function as an immunophilin. 
The PPI-like domain has been described as a protein-protein binding domain264. It was observed 
that it is required for the stabilisation and nuclear translocation of the dioxin receptor-hsp90-
XAP2 complex194,459. The C-terminal part of AIP contains three antiparallel helices that constitute 
TRP domains and a final α-helix. The α-7 helix is essential for AIP function, and its role as a 
protein-protein interaction domain has been well established142. To investigate the functional 
conservation between the human and the fly protein, the importance of the α-7 helix and to test 
the pathogenicity of 4 human missense variants in our in vivo model, 6 different UAS-hAIP 
constructs were generated and injected into Drosophila embryos to obtain transgenic lines. 
 
5.4.1 Selection of AIP variants  
For this study constructs with wild-type AIP, truncated and missense AIP variants were 
generated. The 4 missense mutations were selected as detailed below. 
 
AIP p.R16H (rs145047094, c.47G>A, chr11:67483205)  
p.R16H is a very controversial missense AIP variant, which to date has not been conclusively 
classified as a true mutation or as a rare benign polymorphism. However, a considerable amount 
of data supports the idea that this is a benign variant. Based on the work of Guaraldi et al.460, 
the AIP p.R16H variant does not segregate with the disease. Moreover, the R16H mutation does 
not affect the AIP-RET interaction162. Consequently, this variant was selected as a positive 
control. 
 
AIP p.C238Y (rs267606569, c.713G>A, chr11:67490383) 
In contrast to p.R16H, the AIP p.C238Y missense variant was shown to affect both cell 
proliferation89 and the PDE4A5 binding assays136. Based on the crystal structure of AIP, this 
amino acid is predicted to be involved in protein folding. In 2012 Morgan et al. described that 
their attempts to purify C238Y resulted in protein aggregating suggesting that the protein was 
at least partly unfolded. The C238Y mutation causes destabilisation of the packaging of α and β 
helices of the second TPR motif142. All the available data indicate that C238Y is a true disease-
associated mutation, with a strong pathogenic role and, therefore, it is not expected to 
compensate for CG1847 loss of function. 
  
197 
 
 
AIP p.A299V (rs148986773, c.896C>T, chr11:67258367) 
Functional studies for the A299V AIP mutant variant have shown that the mutation does not 
affect the AIP-RET interaction162. In addition, this mutation causes only a slight reduction in 
PDE4A5 binding in vitro136. However, similar to C238Y, the attempts to purify A299V resulted in 
protein aggregation142. The A299V mutant variant was first described in a sporadic acromegaly 
patient461. This mutation was identified in 5 subjects of a family where the p.R304* mutation 
was also detected. Two unaffected patients carried both changes, one unaffected patient 
carried only A299V, while one young female carried only A299V and was diagnosed with a 
microprolactinoma at the age of 30 years. As the 2 subjects with the compound heterozygote 
genotype (double mutants for p.A299V and for the certainly pathogenic p.R304*) were 
unaffected, A299V variant is unlikely to have a functional impact as this will lead to possibly 
totally silencing of the second AIP alleles. Based on the available clinical data, the AIP A299V 
mutant variant is not considered pathogenic, but there further functional studies are required 
to support this conclusion. 
 
AIP p.R304Q (rs104894190, c.911G>A, chr11:67258382) 
One of the most frequently reported changes is p.R304Q. R304Q is categorised as pathogenic 
mainly based on clinical data. Multiple groups have identified this change in patients with 
pituitary adenomas89,122,136,162,208,209,456,461-463. However, none of the functional data support the 
pathogenic role of the R304Q mutation. Taking into account the increased discrepancy between 
the numerous clinical cases and functional studies, I decided to test the p.R304Q variant in the 
in vivo model. 
 
Assembly of hAIP protein constructs 
The pUAS-k10-hAIPwt plasmid was used for the assembly of hAIP truncation or missense 
constructs. Deletion of the last α helix and the missense mutations were performed via PCR-
mediated mutagenesis as described in section 2.3.8. in Material and methods and Figure 76 
below, with primer combinations corresponding to the specific change (Appendix 5). 
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Figure 76: Schematic diagram of the UAS-hAIP constructs. The full-length construct UAS-hAIPwt is shown 
at the top. The deletion of the 7th α helix is represented in the second image. The position of amino acid 
changes introduced to match the missense mutations into hAIPwt domains are indicated with a star. 
Protein domains are indicated by the colour code shown below the deletion construct assembly.  
 
The positive clones for the mutations were identified via sequencing, as shown in Figure 77. 
Constructs were microinjected into fruit fly embryos harbouring attP40 landing sites, which 
enabled the generation of transgenic stocks with human AIP constructs on the second 
chromosome. Given that all transgenes are inserted in the same genomic locus, they are 
predicted to be expressed at similar levels and to not have differences due to positional effects. 
These transgenic fruit flies stocks were balanced over the balancer chromosome CyO. Once 
available, transgenic males were crossed into the CG1847 deficient mutant background and 
their ability to rescue the lethality of CG1847 mutants was examined. The ubiquitous actin-Gal4 
driver was used to drive the expression of the UAS-hAIP constructs during fly development. The 
degree of rescue was analysed based on the percentage of non-FM6, non-CyO males within the 
total number of viable adult males in the next generation. 
*
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199 
 
 
 
Figure 77: hAIP chromatograms. Partial nucleotide sequences of pUASK10 hAIPwt compared to the 
sequences of UAS-hAIP missense mutant constructs. 
 
5.4.2 Human AIP in Drosophila is able to functionally compensate for CG1847 loss of 
function  
All rescue crosses were performed at 25°C using females heterozygous for the loss-of-function 
mutation CG1847exon1_3 and carrying the actin-Gal4 ubiquitous driver on the second 
chromosome (section 2.2.13). Heterozygous CG1847exon1_3 /FM6; actin-Gal4/CyO females were 
then crossed to transgenic males carrying different human AIP variants (X/Y; UAS-hAIP/ CyO). To 
analyse the data from two independent biological replicates, males from two transgenic lines of 
each hAIP genotype were individually crossed with CG1847 heterozygous mutant females and 
each cross was performed in triplicate. Overall, six different crosses were performed for each 
hAIP variant. Successful rescue of lethality was scored as the presence of non-FM6 F1 males 
(with the genotype CG1847exon1_3 /Y; actin-Gal4/UAS-hAIP), which lack endogenous CG1847 as 
they inherited the deleted allele from their mothers. Figure 78 depicts the result of the rescue 
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experiment for the stock carrying hAIPwt on the second chromosome. Only the male genotypes 
are shown, as only mutant CG1847exon1_3 hemizygous males will suffer lethality in the absence of 
Actin-Gal4 driven transgene expression. 
 
Figure 78: Results of rescue experiment with wild-type AIP. Images of F1 viable males showing: a) 
Rescued males with full-length wild-type human AIP gene. These males inherited from their mothers the 
mutant CG1847 allele on the X chromosome, but are rescued by expression of the human AIP transgene 
on the second chromosome; c) and e) Males inheriting the mutant CG1847 allele on maternal 
chromosome X are not viable in the absence of hAIP expression due to either lack of driver – c) or rescue 
transgene – e) of the UAS-Gal4 system. These two genotypes also serve as internal negative controls; b) 
and d) Males expressing a wild-type CG1847 allele on the FM6 chromosome X balancer are viable. The 
parents genotypes and allele segregation are shown above and to the left of images 
 
Expression of wild-type hAIP resulted in a high percentage of rescued males, as this genotype 
accounted for almost 33% of the total number of viable F1 males. Therefore, ubiquitous 
expression of UAS-hAIPwt was able to rescue the lethality of Drosophila CG1847exon1_3 mutants, 
confirming that AIP gene is functionally conserved between flies and humans. 
Based on these results, I demonstrated that CG1847 is the functional Drosophila orthologue for 
human AIP. 
5.4.3. The AIP C terminal α-7 helix is essential for the conserved function of AIP 
To evaluate if the C-terminal portion of AIP, or more precisely, the last α helix is required for AIP 
function in vivo, I generated a rescue construct lacking this helix (section 2.4.5 and Figure 76). 
To obtain the genomic rescue construct pUASk10attB-AIPtrunc (Figure 79), 907 bp of hAIP 
together with the upstream Myc tag were amplified from a pcDNA3-Myc-AIPwt vector. The last 
86 bp of AIP, which encode for the 7th alpha helix, were deleted to generate a truncated hAIP 
variant (hAIPtrunc). 
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Figure 79: pUAS-hAIPtrunc DNA to protein sequence translation. Schematic representation of the 
protein encoded by the construct containing a truncated AIP version. Myc-Tag (blue) the Start (green) / 
Premature Stop (pink) positions are coloured in the protein sequences. Translator, online free software 
(http://www.fr33.net/translator.php) 
Transgenic males for hAIPtrunc were crossed with females heterozygous for CG1847 deficiency. 
A small number of non-FM6 non-CyO males were found in F1 generation. Between zero and 5 
adult males were recovered in most of the vials. DNA was extracted from individual males to 
determine whether these males inherited the normal or mutated CG1847exon1-2 allele via a 
diagnostic PCR approach (below Figure 85). No rescue males were found, and altogether, the 
rescue experiments with the hAIP truncation construct confirmed previous published data 
indicating that the last α helix is necessary and essential for AIP function. 
As a proof of principle, this construct was used as a negative control for subsequent in vivo 
rescue experiments. The ubiquitous expression of the truncated hAIP transgene is not sufficient 
to compensate for the mutant CG1847exon1_3 on the X chromosome and this validates our model. 
5.4.4. Human AIP missense variants differ in their ability to rescue CG1847 loss of 
function mutants 
Having demonstrated that human AIP expression in CG1847 mutant flies is able to rescue the 
male lethality phenotype, while a truncated construct does not, I next tested the rescue 
proprieties of hAIP variants found in FIPA families. 
To explore the pathogenicity of several hAIP missense mutations, four additional constructs 
were tested. Using a similar approach to the one described above, I used the UAS-GAL4 system 
to express human AIP transgenes of the c.47G>A (p.R16H), c.713G>A (p.C238Y), c.896C>T 
(p.A299V), and c.911G>A (p.R304Q) missense variants and assessed their capacity to rescue 
male lethality. 
To investigate if the p.R16H, p.C238Y, p.A299V and p.R304Q hAIP variants indeed compensate 
for loss of CG1847, I performed new crosses, similar to the one described above. Successful 
rescue was scored by the presence of non-FM6 F1 males (of the genotype CG1847exon1_3 /Y; actin-
 Foward frame 1 
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Gal4/UAS-hAIP variant). For statistical analysis, for each missense variant, the percentages of 
the rescued male genotype (from the total of viable males) were compared in with the 
percentages of non-FM6, non-CyO males resulting from the rescue crosses with wt and 
truncated hAIP constructs. 
When the percentages of rescued males within each of the hAIP constructs rescue crosses were 
evaluated and compared to the results obtained with the wt and truncated constructs, hAIP 
variants separated into 2 classes (Figure 80). 
 
Figure 80: Quantitative analysis of in vivo rescue experiments using hAIP missense variants. The rescue 
of the lethality phenotype by expression of UAS-hAIPwt, UAS-hAIPtrunc and the various missense mutant 
constructs is represented as the percentage of F1 males of the desired genotype relative to the entire F1 
male population. Bar graph shows the quantification of the rescue results, with 2 different stocks (s1 and 
s2) for each construct (each stock in triplicates). Error bars represent SE. Significant differences between 
samples are indicated by asterisks (****P<0.0001; Oneway Anova with post-hoc Tukey-Kramer analysis 
test). 
hAIP variants are separated into 2 classes by the proportion of rescued males. Ubiquitous 
expression of p.R16H, p.A299V and p.R304Q variants (at 25°C) rescued very efficiently the lethal 
CG1847exon1_3 mutation, at a similar rate to the ubiquitous expression of wild-type hAIP. There 
was no significant difference between these constructs regarding the percentage of rescued 
****
****
****
****
****
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males. In contrast, like the truncated version of hAIP, ubiquitous expression of the pathogenic 
variant p.C238Y was unable to rescue the male lethality of CG1847 mutants (p=0.0001). 
In fact, it should be noted that all the males scored as rescued males in the progeny of crosses 
with the truncated hAIP or p.C238Y mutant were actually flies with aberrant genotypes, as 
shown via PCR genotyping (Figure 84 and Figure 85). 
 
The p.R16H, p.A299V and p.R304Q missense variants have similar rescue capacities as the wt 
hAIP 
A statistical analysis comparing the distribution of all the male genotypes resulting from the 
rescue experiments show that there is no statistical difference between the capacities of the 3 
hAIP missense variants (p.R16H, p.A299V, and p.304Q) vs wt hAIP in rescuing the male’s 
lethality.  
 
Figure 81: Similar distribution of the males phenotypes To test the distribution of phenotypes in the male 
progeny of crosses with the four hAIP variants that rescued the lethality of CG1847exon1_3 mutants, a Chi 
square contingency test was performed. Each viable male phenotype received a colour code: a) rescued 
males (genotype CG1847exon1_3 /Y; actin-Gal4/UAS-hAIP variant) are indicated in red; b (FM6/Y; actin-
Gal4/UAS-hAIP) - green, d) (FM6/Y; UAS-hAIP/CyO) - blue, and f) (FM6/Y; actin-Gal4/CyO) - brown. There 
was no significant difference in the distribution of male genotypes between the F1 generation of 
ubiquitously expressed p.R16H, p.299V and p.304Q hAIP variant and the F1 generation of the wt hAIP 
(positive control) (p=0.9790). 
 
As seen in Figure 81, Chi square contingency test for the three hAIP missense variants and wt 
hAIP shows that there is no significant difference in the distribution of male genotypes between 
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the F1 generation of ubiquitously expressed p.R16H, p.299V and p.304Q hAIP variants and the 
F1 generation of the wt hAIP (positive control) (p=0.9790). 
I found that wt hAIP, p.R16H, p.299V and p.304Q hAIP constructs had the same rescue capacity 
as there was no significant difference in the distribution of the four possible male phenotypes 
(p=0.97, Chi-square statistical analysis). 
 
5.4.5 Validation of rescue experiments by PCR genotyping  
To confirm the genotypes of the F1 offspring, genomic DNA was extracted from a proportion of 
the rescued males from each of the rescue crosses. For each male, three different PCR reactions 
were performed to determine the genotype of the males: one for the detection of the mutant 
CG1847exon1_3 allele, a second for detection of the hAIP transgene, and a third one for the 
amplification of PPr-Y. PPr-Y is a gene located in the Y chromosome, which was used to detect 
the presence of the Y chromosome in the animals that were phenotypically males. This is 
necessary because a wild type male phenotype can also be produced by offspring with a X0 
genotype, which can occur by non-disjunction of the X chromosome pair in the mother (details 
in the Discussion section). 
Figure 82 shows the PCR products of genomic DNA separated by agarose gel electrophoresis for 
12 males from the rescue cross with hAIP wt. The expected PCR products in the rescued males 
are of a 1000bp for CG1847exon1_3 (instead of 2500bp the amplicon corresponding to the normal 
copy).  
Eight out of the 12 males carried the deleted CG1847 allele and were rescued by hAIP present 
on the second chromosome. Three males (m5, m6, and m12) were viable due to the presence 
of the wild-type copy of CG1847 (Figure 82 top panel) inherited from the male parents 
(Discussion section). The m6 and m12 males do not carry the Y chromosome as they result from 
a nondisjunction event in females. Occurrence of chromosome nondisjunction in females leads 
to the production of eggs containing either both maternal X chromosomes (XX) or none (0). The 
eggs with both X maternal chromosomes (XX) can combine with the Y chromosome from males 
resulting in individuals that are XXY and are phenotypically female. Eggs without maternal 
contribution (0) will inherit the X chromosome from males and the resulting X0 combination will 
have a normal CG1847 allele and will appear phenotypically male. 
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Figure 82: Genotyping of rescued males with hAIPwt. The resulting rescued males (Figure 78A) were 
genotyped by PCR. The CG1847 gene was amplified using a pair of primers that produce a 2500 bp 
amplicon for the wt allele and a 1000 bp for the mutant allele (top panel). The hAIP transgene was 
detected using primers against human AIP cDNA (middle panel). In addition, the presence of Y 
chromosome (bottom panel) was detected using a set of primers for the Ppr-Y gene. Abbreviation on the 
figure: hAIPwt s1 – the males used in the rescued cross were from first of the 5 individual lines generated 
by BestGene; m1-m12 – individual labelling of each of the 12 males collected for genotyping. Eight out of 
12 males had the expected rescue genotype as they carried the CG1847exon1_3 allele and hAIP cDNA on the 
second chromosome. Males m5, m6, and m12 do not carry the mutant CG1847 allele, and therefore are 
the result of maternal chromosome X non-disjunction. Although phenotypically male, males m6 and m12 
do not carry the Y chromosome. For sample m9 I could not amplify the CG1847 amplicon possibly due to 
a technical issue. 
 
Additionally, I observed 2 types of adult males in the F1 progeny that were phenotypically similar 
to genotypes CG1847exon1_3 /Y; UAS-hAIP/CyO (Figure 78C) and CG1847exon1_3 /Y; actin-Gal4/CyO 
(Figure 78E). These males are not expected to be viable, since they do not have the proper 
combination of both GAL4 driver and UAS-hAIP transgene on the second chromosome (Figure 
83). However, although these males are missing either the GAL4 driver or the UAS-hAIP they are 
viable as they are the result of the same nondisjunction phenomenon mentioned above. 
Consequently they have aberrant genotypes. 
CG1847
2500 bp
1000 bp
500 bp
1000 bp
500 bp
500 bp
100 bp
Ppr-Y
238bp
hAIP
1000bp
CG1847exon1_2
1000bp
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Figure 83: Two types of F1 males due to nondisjunction. These males are phenotypically similar to 
genotypes CG1847exon1_3 /Y; UAS-hAIP/CyO (genotype “c” in Figure 78) and CG1847exon1_3 /Y; actin-
Gal4/CyO (genotype “e” in Figure 78). These males are non-FM6 balancer chromosome (see the normal 
round shape of the eyes). As they have the CyO balancer chromosome inherited on the second 
chromosome; consequently they are missing one component of the UAS-GAL4 system: either UAS-hAIP 
(c) or the actin-GAL4 (e), therefore could not express hAIP. 
These phenotypes were found in extremely low numbers (in average 4% of viable male 
offspring). I genotyped the majority of the males with these 2 phenotypes in at least one cross 
for all the 6 constructs. Figure 84 depicts the result of the diagnostic PCRs for individuals with 
the aforementioned aberrant phenotypes from the progeny of crosses with hAIP wt. The same 
genotyping system described above was used for these experiments. 
 
Figure 84: Genotyping for the two aberrant 
male types. The two types of males 
described above were genotyped using PCR. 
All 5 males have the wt CG1847 copy (top 
panel, amplicons at 2500 bp). In the first two 
males (expected genotype CG1847exon1_3 /Y; 
UAS-hAIP/CyO) a copy of hAIP cDNA was 
detected (inherited from the father). As 
expected, the hAIP copy was not detected in 
the other three males for which the expected 
genotype, based on their phenotype, is 
CG1847exon1_3 /Y; actin-Gal4/CyO. In addition, 
in some of these phenotypical males the Y 
chromosome was not detected. 
 
All 5 males have the normal CG1847 allele, which is the reason for their viability in the absence 
of the FM7 balancer chromosome or without the proper combination of UAS-GAL4 system 
components. The hAIPwts1c) m1 and m2 males have the hAIP construct on the second 
chromosome, which demonstrates that they inherited this chromosome from transgenic male 
c) CG1847exon1_3 /Y; UAS-hAIP/CyO e) CG1847exon1_3 /Y; actin-Gal4/CyO
CG1847exon1_2
2500 bp
1000 bp
1000 bp
500 bp
500 bp
100 bp
Ppr-Y
hAIP
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parents (carrying the pUASk10-hAIPwt construct). On the other hand, in the 3 CG1847exon1_3 /Y; 
actin-Gal4/CyO males the hAIP cDNA could not be detected as they contain the actin-GAL4 
construct inherited from female parents. Some of these flies were also negative for the Y 
chromosome, which brings extra proof that they are result of nondisjunction. 
Together, these results suggest that the non-FM6 males are due to chromosome nondisjunction 
in F0 females (more details in the Discussion section). These particular phenotypes, observed in 
low numbers in subsequent experiments, were considered aberrant genotypes and, therefore, 
were excluded from statistical analysis. 
Regarding the individuals that are phenotypically identical to the rescued males found in the F1 
generation of the rescue crosses for hAIPtrunc construct: these males were also the result of the 
nondisjunction phenomenon. To confirm the genotypes of the F1 offspring, DNA was extracted 
from all the viable males from one of these crosses and diagnostic PCRs were performed to 
detect either the wt or the mutant CG1847exon1_3 allele. 
 
Figure 85: Genotyping of non-Fm6 non-CyO males resulting from crosses with the hAIPtrunc construct. 
The males were genotyped by using primers for CG1847. This gene was amplified using the same set of 
primers that produce a 2500 bp amplicon for the wt allele or a 1000 bp amplicon for the mutant allele. All 
8 males have the normal copy of CG1847. 
Figure 85 shows the results of the PCR genotyping. All non-Fm6 non-CyO males have the normal 
copy of CG1847 (2500 bp instead of expected 1000bp size of the amplicon in the CG1847exon1_3). 
All eight males actually inherited the normal CG1847 allele, and this is the explanation for their 
viability. These particular male phenotypes were found in very low numbers in subsequent 
experiments. The same result was seen in case of hAIP C238Y construct. 
The aberrant males in the rescue experiments with hAIPtrunc and hAIPC238Y constructs were 
used in the statistical analysis as “non-rescue” to evaluate the “rescued or not rescued result” 
based on a significant difference. 
CG1847
2500 bp
1000 bp
  
208 
 
5.4.6. hAIP rescue constructs have equivalent expression levels  
To determine the in vivo expression levels of AIP in the fruit flies, I used the UAS-GAL4 system 
to transgenically express human AIPwt, AIPtrunc and AIP with missense mutations (R16H, 
C238Y, A299V, and R304Q). In the Results section of this chapter it has been shown that 
ubiquitous expression of AIPwt, R16H, A299V and R304Q during development resulted in rescue 
of lethality. Total proteins were extracted from the rescued males and Western blots were 
performed using an antibody against the hAIP. The human protein was detected as a 37 kDa 
band, similar to the band detected in human HEK293T cells used as positive control (Figure 86). 
Wild-type flies (wiso), without any of the UAS-GAL4 components, were used as a negative control 
for the specificity of the antibody to see if the endogenous CG1847 expression is also detected. 
In addition, transgenic males from the stock carrying the UAS-hAIP constructs (without Gal4 
driver) were tested for leaky potential expression of the construct. 
 
Figure 86: Overexpression of pUAS-hAIP constructs driven by actin-Gal4. The proteins were extracted 
from adult male heads. Expression level appears equivalent for the different hAIP constructs ubiquitously 
expressed using the actin-Gal4 driver. In addition, the hAIP expression was not detected neither in wild- 
type flies (wiso) nor in the transgenic F0 males (as these only carry the UAS-hAIP construct and not the 
actin-Gal4 driver). Loading control is anti β-tubulin. The primary antibodies were Novus monoclonal 
AIP/ARA9 Antibody (35-2) and DSHB monoclonal β tubulin (E7). 
These results were consistently observed in four independent Western blots, with independent 
biological samples representing different protein extractions. All hAIP missense constructs 
which rescued the lethality resulted in a robust expression, similar to the hAIPwt construct. The 
37 kDa band of hAIP missense mutations was detected as having equal intensity when compared 
to wild-type hAIP.  
Based on the Western Blot results it is possible to conclude that the R16H, A299V and R304Q 
missense variants encode for proteins which not only have the same capacity of rescuing the 
lethality as the wt hAIP, but they also have the same stability.  
58kDa
Tubulin 55kDa
AIP 37kDa
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Regarding the pathogenic hAIP variants (truncated and C238Y) further experiments are required 
in order to investigate their levels of expression and protein stability. 
 
5.5 DISCUSSION 
In this project, I developed and optimised a new in vivo system to test the pathogenicity of AIP 
mutations using Gal4/UAS transgenes generated with the phiC31 integrase system275. The 
Gal4/UAS system brings significant advantages as it offers the possibility of expressing an 
exogenous gene in a transgenic animal while controlling the pattern of expression. The site-
specific phiC31 phage allows the integration of different constructs into the same landing site 
and, as the genetic background remains unchanged, the results of the different constructs are 
directly comparable464. This system has been previously successfully used to generate 
Drosophila transgenics for human genes, in order to understand their functional role or the 
importance of specific protein domains. In 2011, to unravel the underlying genetics, Grossman 
et al. selectively overexpressed mammalian candidate genes in the fly heart. The selected genes 
were thought to be involved in cardiac heart defects associated with Down syndrome. They 
investigated the effects of over-expressing the candidate genes by evaluating the basal heart 
rate and the frequency of heart failure following exposure to stress465. The evolutionary 
conservation of specific genes can also be investigated using a similar approach. In 2014, Ikmi et 
al. examine the Yap/Yorkie (yes-associated protein), which controls the organ size in both 
Drosophila and mammals by generating Drosophila transgenic stocks for Yap/Yorkie orthologues 
from mammalian lineages, including human, and their unicellular relatives. The results brought 
significant insights into the evolutionary history of Yap protein structure and function466. In yet 
another example, a group studied the implication of different pathological L1CAM mutations in 
a broad spectrum of neurological and non-neurological phenotypes. By overexpressing different 
missense mutations of the human gene L1CAM in Drosophila it was possible to significantly 
rescue the neuron guidance defects, showing that some of those variants were not 
pathogenic467. 
I exploited the power of Drosophila genetics approaches to evaluate the degree of functional 
conservation between fly and human AIP, by testing whether CG1847exon1_3 mutant flies can be 
rescued by human AIP. The last AIP α helix had previously been described as essential for AIP 
function and, as proof-of-principle, I also tested a truncated mutant AIP lacking this domain. 
Additionally, I tested whether the expression of 4 different missense variants identified in FIPA 
patients can compensate for the loss of CG1847. My data showed that the lethality of 
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CG1847exon1_3 mutants could be rescued by expression of human AIP, demonstrating that 
CG1847 is a true functional homologue of AIP and that human AIP is functionally conserved 
throughout evolution. Conversely, a C-terminus truncated human AIP mutant transgene failed 
to rescue the defects that cause lethality in CG1847 mutant flies. These results are the first to 
provide insights into the functional importance of the AIP α-7 helix in an in vivo system. The 
lethality of CG1847 mutants was also rescued by 3 of the 4 tested missense variants: p.R16H, 
p.A299V, and p.304Q. The p.C238Y missense variant, which is considered pathogenic, was 
unable to rescue the lethality of the CG1847 knockout. When compared with the truncated or 
C238Y variant, all the other hAIP missense constructs showed a strong ability in rescuing the 
lethality, reaching the same statistical significance as the wt hAIP. 
Moreover, the Western Blot results showed that the R16H, A299V and R304Q missense variants 
encode for proteins which have the same stability as the wt hAIP. As the hAIP truncated C238Y 
variants did not result in rescued males I was not able to extract proteins for Western Blot to 
evaluate their level of expression. However, this could be achieved via overexpressing these 
pathogenic variants in the wt background, as now the results in Figure 86 showed that the 
antibody used against hAIP protein does not detect the endogenous CG1847 protein. 
Some of the genes that encode for proteins involved in different cellular processes were proved 
to be essential (fundamental for organism viability). Many recent studies were interested in 
determining the gene essentiality and several comparative genomic analyses already confirmed 
that essential genes are conserved during evolution468-471. Even more, most of these genes 
remain essential in different organisms, as the orthologues of one gene tend to be essential in 
other organisms. However, some genes have become non-essential maybe due to 
environmental conditions, or have been lost from the genomes of other organisms469,471,472. 
My data support the evolutionary conservation of the AIP gene. As evidence for evolutionary 
conservation of the AIP gene, I have found that deletion of the endogenous Drosophila gene 
resulted in lethality, similarly to previously data from mice181,204. Furthermore, the human gene 
was able to functionally compensate for the deletion of the Drosophila orthologue, CG1847. 
Regarding the experiments with the truncated protein, no viable rescued progeny resulted, 
supporting the previous findings that the last α helix is essential for protein-protein interactions. 
It has been previously reported by that the TPR domain of AIP is required for the interaction 
with HSP90459. In 2012 Morgan et al. reported that the highly conserved C-terminus of AIP and 
the 7th α helix in particular, are involved in AIP interactions with different partners as AhR and 
PDE4A5. Consequently, loss of these domains leads to loss of interactions with these partners142. 
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AhR is best known for being involved in the defence mechanisms against halogenated dioxins 
and carcinogenic environmental chemicals473. In the view of the fact that AIP interacts with the 
chaperones at the level of the TPR motifs, it is possible that the loss of the last α helix could 
interfere with the normal folding of the TPR motifs. Under our experimental conditions, the 
results obtained with truncated AIP also predict that this final structure is essential for the 
normal function of the protein and binding to its partners. Consequently, the loss of the last α 
helix impaired the binding of AIP to different partners and results in lethality. Although this 
interferes with the translocation of the AhR into the nucleus, resulting in loss of activation of 
dioxin response elements, this might not be the mechanism leading to lethality as Ahr-null mice 
are viable205. Further investigations are required to determine the actual cause of lethality.  
In accordance with presented results my literature review regarding the p.R16H AIP variant 
revealed that most arguments favour a non-pathogenic role. 
The R16H variant was first reported in 2007 by Daly et al. in two cousins with acromegaly151. The 
initial hypothesis was that this variant is a disease causing one, but it was refuted only one year 
later by Georgitsi et al.460,461. Other groups also support the fact that it represents only a rare 
SNP179. A recent article reported a 3 generation Italian FIPA family with the R16H AIP change 
identified in 8 different individuals. However, only 2 individuals were diagnosed with pituitary 
adenomas and their conclusion was that this variant should be regarded as a rare 
polymorphism474. This variant does not segregate with the pituitary adenomas; however, there 
are no sufficient data to exclude a possible involvement of the p.R16H variant in these families, 
as part of an oligogenic model. The LOH status was investigated in pituitary tumorous tissues 
only in two patients and the wild-type allele was present456,461. 
This amino acid residue is moderately evolutionarily conserved151. The basic R amino acid is 
substituted by another basic amino acid. Consequently, the overall change in the protein 
structure is expected to be with no or minor deleterious effects. Furthermore, this variant seems 
to be relatively stable, it degrades at similar speed as the wild-type protein as shown in Figure 
86 and in an independent project (Hernandez-Ramirez et al., unpublished data). 
The impact of this amino acid change on AIP splicing has never been tested systematically. Two 
studies which performed a series of in silico prediction tests (as Berkeley Drosophila Genome 
Project, ESEfinder 2.0, Splice Scan, Alternative Splice Site Predictor, and NetGene2 programs) 
concluded that p.R16H is likely pathogenic208,475. At the same time, PolyPhen2453 reports this 
variant as possibly damaging. However, our investigation using 2 prediction softwares, Alamut 
and Pathogenic-or-Not Pipeline (PONP) concluded that this AIP variant is not pathogenic. The 
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frequency of rs145047094 (p.R16H) is low. The dbSNP476,477 reports an uncertain clinical 
significance and a frequency of 0.1% positive individuals 
(http://www.ncbi.nlm.nih.gov/snp/?term=rs145047094), while the EVS478 (Exome Variant 
Server) estimates frequencies up to 0.7% for the White American sample (n= 4295 individuals) 
and up to 0.14% for the African American sample (n=2200 individuals) 
(http://evs.gs.washington.edu/EVS). In the ExAC database there is one case reported 
homozygous for this AIP variant. Therefore, there are no convincing data in favour of a 
pathogenic role for AIP p.R16H variant which is supported by our in vivo model. 
The p.C238Y variant was first described by Leontiou et al. in 200889. This change was identified 
in a Mexican family with 3 members being diagnosed with acromegaly. All the arguments are in 
favour of a pathogenic role for this variant. The functional investigations have revealed that it 
has a reduced ability to block cellular proliferation89 and no interaction with PDE4A5 was 
detected89. The LOH status was investigated in pituitary tumour of the three Mexican patients 
and the wild-type allele could not be detected in any of the samples124. This is in agreement with 
the second hit hypothesis. 
This amino acid residue is moderately evolutionarily conserved. The amino acid substitution is 
conservative as a polar amino acid, cysteine, is exchanged with tyrosine, which is also a polar 
amino acid. However, there is a possible loss of a disulphide bound. The functional impact is 
significant, with serious disruption on the folding of the TPR domains, the packing of the 
hydrophobic core and severe steric clashes of the 3D protein structure142. Unpublished data 
from our lab reports that this protein is very unstable, with a very short half-life comparing with 
the wild-type AIP, and is rapidly degraded479. 
PolyPhen2 reports this variant as damaging with a very high score of 0.994. Prediction based on 
the Alamut software came to the same conclusion. This variant is not reported in dbSNP or EVS. 
The ExAC database480 reports 1 allele out of 118770 was found. 
In summary, all the available data, including our in vivo model, support the pathogenic role of 
p.C238Y. 
The p.A299V variant (rs148986773) was first identified in 2007 by Georgitsi et al.461 in a Dutch 
patient with a GH secreting pituitary adenoma. All the clinical and in vitro data are in favour of 
a non-pathogenic role for this variant and that A299V change may be just a rare 
polymorphism136,481. In a very interesting FIPA family five family members were identified with 
the A299V variant, two of them harbouring a truncating AIP mutation, (p.R304*), on different 
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alleles and without pituitary adenoma. The A299V missense mutation does not segregate with 
the disease and the LOH status of these patients was never investigated. 
A299V variant is localised at the border between the second and the third TPR domains, in a 
pocket essential for the interaction of AIP with HSP90. This AIP region is among the most 
conserved ones142 and it is very important for proper folding of the protein. Misfolded structures 
could be unstable and result in rapid degradation of the protein482. The amino acid substitution 
is conservative as a nonpolar amino acid (alanine) is exchanged with valine, also a nonpolar 
amino acid. 
Although PolyPhen2 reports this variant as possible damaging, PONP and Alamut consider it as 
not pathogenic. The frequency of rs148986773 is low. The dbSNP reports an uncertain clinical 
significance and global MAF of 0.001. In the EVS the frequencies of this variant are 0.14% for the 
White American samples (n=4293 individuals) and 0.023% for the African American samples 
(n=2195 individuals). 
In accordance with our results, a literature review regarding the p.A299V AIP variant revealed 
that most arguments favour a non-pathogenic role. 
The most controversial missense variant is the relatively frequent exon 6 genomic change 
c.911G>A, p.R304Q. The mutation is located in the C-terminal α-7 helix of the AIP protein, which 
is a CpG island hotspot. 
It`s pathogenicity is based mainly on clinical data. Multiple groups identified this change in 
patients with pituitary adenomas. A recently published article performed a literature review of 
these cases and revealed that p.R304Q seems to be much more common than the previous 
discussed missense mutations. So far 23 patients have been reported. The majority of these, 20 
patients, are familial cases, while the other are just sporadic cases117. However, none of the 
functional available data do not support the pathogenicity: neither the disruption of PDE4A5136 
or RET interaction162. Moreover, no LOH was detected in a patient's tumour tissue (unpublished 
data). 
On the other hand, the predicted changes in the protein structure bring arguments in favour of 
a pathogenic involvement. This amino acid residue is moderately evolutionarily conserved, 
especially in mammals. The arginine, a long side chain positively charged amino acid, is 
exchanged with glutamine, a polar and slightly shorter, uncharged, hydrophilic amino acid463. 
This mutation does not affect the HSP90 binding site directly; however, an abnormal C-terminal 
tail may disrupt the folding of the third TPR domain, and this may result in disruption of the 
  
214 
 
normal binding to the HSP90 MEEVD motif142. The half-life of the mutated protein was found to 
be slightly shorter than that of the wt protein (Hernandez et al., unpublished data). 
Additional information based on studies which used web prediction tools were contradictory. 
Occhi et al483 published that according to PolyPhen R304Q is a deleterious mutation. On the 
other hand, using a newer version of the same prediction pipeline, PolyPhen2, Tichomirowa et 
al208 reported that R304Q is a benign polymorphism. Our own investigation using 2 other in silico 
web tools (Alamut and PONP) showed that this variant is not suggested to be pathogenic. This 
is a rare variant as EVS reports a MAF of 0.0693 (the frequency for European American 
population is 0.1048, while for African American is 0). Interestingly, the ExAC database reports 
the presence of this variant in homozygosity in two out of 37894 Europeans and none of 20413 
non-Europeans, further increasing the uncertainty about its pathogenic role. 
The results of our project also not favour a pathogenic role for the R304Q mutation, even though 
the clinical suspicion is very high. As this AIP variant is able to rescue the Drosophila lethality and 
2 individuals were reported homozygous in the ExAC database, our conclusion is that p.R304Q 
alone is not the cause of pituitary adenomas. One possible hypothesis is that p.R304Q may 
change the AIP activity in addition to a different gene (oligogenic model), which would explain 
the retention of the wild-type allele and no LOH in the pituitary adenoma tissue. One other 
possibility is that p.R304Q might be just a surrogate marker, in reality another mutation with 
which it is associated by linkage of disequilibrium, is the cause of these pituitary adenomas. One 
last hypothesis is that maybe the AIP function is very complex, different amino acids being more 
or less important in different processes. As a consequence, a residue which is important for 
tumorigenesis may not interfere with normal fly development. 
Nondisjunction 
phiC31 recombination brings a series of significant advantages to Drosophila genetics. Maybe 
the most important feature of this system is the non-random integration. As the catalysed 
phiC31 integrase recombination process is site-specific, it allows a precise pre-selection of the 
insertion location. By eliminating the randomness of transgenesis while keeping the same 
genetic background, this system allows the integration of different constructs into the same 
landing site and the advantage of a direct comparison between results464. In this project I 
designed a vector-based system to facilitate in vivo AIP missense mutation analysis using phiC31 
recombination. 
Our system offers a number of advantages as well as some limitations. First, by design, using the 
same backbone to insert the different constructs at the same attP specific site in the Drosophila 
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genome allows equivalent transgene expression. We proved this by evaluating the level of 
expression of different variants capable of rescuing the fly lethality by immunoblotting (Figure 
80 and Figure 86). Homogenous expression for different constructs is essential for the 
comparison of wild-type and mutant transgenes484. Another important advantage of our 
constructs, a key feature for transgenic animal identification, is the use the mini-white gene, a 
common and easy to use phenotypic marker. 
Second, the pUAS-K10 vector used for generating Drosophila transgenics for different AIP 
constructs was selected based on results of previous studies which had shown a low basal and 
highly inducible expression of integrated transgenes485. This backbone has the significant 
advantage of avoiding non-specific ‘leaky’ transgene expression, as shown in Figure 86.  
Third, the majority of constructs used in this project were generated via site directed 
mutagenesis starting from the same vector. This system allows multiple parallel cloning of 
different missense mutations into the same vector, and simplifies the generation of transgenes. 
This strategy overcomes the disadvantages of other techniques such as the Gateway technology 
which may also be more expensive. Therefore this system has several advantages and we hope 
that the research community interested in the pathogenicity of AIP mutations will take 
advantage of it. 
Regardless of the presented results and the numerous advantages, our in vivo model faces some 
limitations among which is the issue of non-disjunction phenomenon which lead to a degree of 
false positive results. The first data regarding the discovery of non-disjunction phenomenon and 
its effect upon sex-linked inheritance was published in 1913 by Bridges C.B.486, and was 
explained in detail a few years later487,488. This first study of spontaneous X chromosome 
nondisjunction in Drosophila, although completed more than 100 years ago provided the 
insights regarding the mechanisms of non-disjunction of the chromosomes during meiosis. Over 
the last few years, studies on Drosophila genetics have produced significant advances regarding 
the molecular mechanisms of how meiotic chromosome pairing, synapsis and segregation take 
place489-491. 
Despite several controversies regarding which is the critical stage of the cell cycle when the 
normal separation of homologous chromosomes is impaired resulting in non-disjunction, there 
are a few aspects on which there is agreement. First of all, spontaneous recombination in 
Drosophila melanogaster males is an extremely rare event and the nondisjunction phenomenon 
takes place mainly in females. Second, the X chromosome nondisjunction is much more frequent 
in XXY females than it is in normal XX females. These XX-Y segregation events were called 
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‘‘secondary nondisjunction”487. Third, it has been revealed that abnormalities in genetic 
recombination will consequently perturb normal meiotic chromosome segregation. The 
different types of mutations which lower the possibility of recombination, including the ones in 
balancer chromosomes, will certainly increase the frequency of nondisjunction. It has been 
shown that the association of the two X and a Y chromosomes occurs and is maintained at a 
much higher rate in cases where the crossing over is suppressed. A study published in 2006 has 
proved that frequency of secondary nondisjunction in FM7/X/Y females is much higher as the 
inter-chromosomal genetic material exchange (recombination) is absent. A twenty-fold higher 
frequencies of X nondisjunction in FM7/X/Y females (70.8%) was reported when compared with 
the frequencies of X nondisjunction in XXY females (around 3%)492. 
In this project, as the deletion of CG1847 in not compatible with life, the mutant stock was 
balanced over the FM6 balancer chromosomes. Consequently, the rate of nondisjunction was 
increased. 
During gamete formation, the alleles for each gene segregate during meiosis and will later 
recombine following the Mendelian laws of inheritance. 
CG1847exon1_3/ FM6 
 
 CG1847exon1_3 FM6 
X
/Y
 
Y CG1847exon1_3/Y FM6 
X CG1847exon1_3/X FM6 
Figure 87 Overview of normal meiosis in the CG1847exon1_3 mutant stock. In bold: The segregation of 
maternal and paternal alleles during normal meiosis results in four haploid gametes, each containing one 
set of chromosomes. Normal segregation of a nonrecombinant chromosome pair results in normal 
disjunction.  
Out of the four possible chromosome combinations depicted in Figure 87, the nondisjunction 
phenotype occurs at highest rate in FM6 /X females. 
In the primary type of nondisjunction normal CG1847exon1_3 and FM6 female chromosomes fail 
to segregate during meiosis and consequently both will be found in the egg. 
The combination of such CG1847exon1_3/ FM6 and zero eggs with the X and the Y male 
chromosomes will result in four new types of zygotes, as shown in Figure 88. 
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CG1847exon1_3/ FM6 
 
 
CG1847exon1_3/ 
FM6  
0 
X
/Y
 
Y 
CG1847exon1_3/ 
FM6/ 
Y 
0 /Y 
Not viable 
X 
CG1847exon1_3/ 
FM6/ 
X 
0 /X 
Male phenotype  
Figure 88: Primary nondisjunction in CG1847exon1_3 mutant stock. A Punnett square for segregation and 
recombination of CG1847exon1_3 and Fm6 chromosomes through primary non-disjunction, and the possible 
resulting progeny. 
The CG1847exon1_3/FM6 females are the result of the primary nondisjunction. These females 
remain in the stock as they are not phenotypically different than CG1847exon1_3/FM6. 
In addition, Bridges noticed that almost all cases of X nondisjunction in XXY females is due to XX-
Y segregation. This particular type of nondisjunction was very well described in Drosophila; the 
result of such non-disjunctional events might result in females who inherit both X chromosomes 
from their mothers, while no sex chromosome comes from their fathers. Bridges observed that 
X chromosome nondisjunction is much more frequent in these types of females, an event called 
‘‘secondary nondisjunction.’’ The frequency of secondary nondisjunction is significantly 
increased in females with reduced X chromosomal exchange due to the presence balancer 
chromosomes493. 
CG1847exon1_3 /FM6 
  CG1847exon1_3 / FM6  Y 
X
/Y
 
Y CG1847
exon1_3 / FM6 / 
Y 
Y/Y 
Not viable 
X CG1847
exon1_3 / FM6 / 
X 
X/Y 
Male rescued-look like phenotype 
(but the X chr inherited from male 
parents) 
Figure 89: Secondary non-disjunction in the female. A Punnett square for segregation and recombination 
of CG1847exon1_3 and Fm6 chromosomes through secondary non-disjunction, and the possible resulting 
progeny. 
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In our in vivo assay the problem of non-disjunction was demonstrated by developing a PCR-
based genotyping system and by using statistical analysis to determine the significance of the 
results. 
Consequently, this system can be used to test human AIP missense variants, where 
pathogenicity cannot be easily determined based on clinical data. This is crucial for genetic 
counselling and management of the proband’s family102,136. The benefit of cascade genetic 
screening for these families would be immediate481,494, as clinical screening can identify the 
disease early and at a more manageable stage as it was shown already481,494 (screening and 
treatment are already available via NHS). 
 
5.6 CONCLUSIONS 
This chapter supports the evolutionary conservation of the AIP gene and helps to understand 
the pathogenesis of AIP mutations. As evidence for conservational evolution of the AIP gene we 
report that deletions of the endogenous Drosophila gene resulted in lethality of the flies while 
the human gene is able to functionally compensate for the deletion of the Drosophila 
orthologue, CG1847. 
Transgenically expressed AIP proteins with p.R16H, p.A299V, and p.R304Q variants had similar 
rescue capacities as the wild-type human protein and this allows us to conclude that these 
genetic changes do not have a significant impact on the AIP function at least in our model. Our 
data bring further support towards the hypothesis that these are just non-pathogenic SNPs. 
In view of the presented data, which conclusively demonstrated a benign role of the AIP p.R16H 
and p.A299V missense variants, it is not justifiable to offer AIP genetic screening to family 
members. Contrarily, for p.C238Y carriers, after appropriate counselling, all family members 
should be genetically and clinically tested, in order to avoid missing cases which developed or 
might develop pituitary adenomas. 
Regarding the pathogenic role of p.R304Q, it was demonstrated to have a benign role during 
organismal development, but the involvement in tumour development cannot conclusively be 
discarded. Until more detailed investigation will be available, it would be justifiable to offer AIP 
genetic screening to all family members of p.R304Q probands. 
In conclusion, p.R304Q remains an AIP variant with significant clinical suspicion and due to its 
very high frequency in pituitary adenoma patients, clarification of its effect is mandatory. 
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CHAPTER 6: GENERAL CONCLUSIONS AND FUTURE DIRECTIONS  
Three projects are presented in this thesis. They hopefully represent a step forward for a better 
understanding of AIP functions during development and tumorigenesis. The main results and 
conclusions identified during my studies are summarised in this chapter, specially highlighting 
the novel findings. Future directions for further studies are also presented here. 
Our main goals were: 
a.  To characterise the effect of Drosophila AIP orthologue CG1847 silencing via RNAi-
mediated gene knockdown and imprecise excision of a P-element.  
b. To test he possible mechanisms explaining the knockdown/knockout phenotype. 
c. To determine gene expression profiles using an established analysis pipeline and to 
identify key pathways that are significantly altered in the mutant, and that are related 
to embryonic development or survival. 
d. RNA sequencing and confirming its results.  
e. To functionally test the homology between hAIP and CG1847 and to test whether wild-
type hAIP, a truncated hAIP and four missense mutations can rescue the CG1847 
knockout phenotype.  
 
6.1 CG1847 is a Drosophila melanogaster AIP orthologue and is essential 
for normal development  
In order to analyse the role of AIP during development we generated Drosophila melanogaster 
model of CG1847 deficiency. The CG1847 loss of function results in lethality during larval stages, 
showing that in Drosophila, similar to human and murine data, this gene is an essential one. In 
addition, this is supported by the bioinformatics data, protein structure and rescue experiments 
with human protein. Furthermore, the lack of CG1847 is not compatible with normal 
development, as the larvae present an obvious delay in development by 72 h AEL. 
Nevertheless, the actual mechanism of lethality remains unknown. The answer to this question 
might be provided by future research involving GC1847 immunostaining during the very early 
stages of development. This might be possible by designing an antibody, since CG1847 is not a 
well investigated and no antibody is available at the moment. Designing an antibody for CG1847 
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will further help to identify the location of the protein in the cells during normal or abnormal 
development. 
 
6.2 RNA sequencing reveals possible new underlying CG1847 molecular 
mechanisms 
In order to gain further insight into the molecular mechanisms disturbed by loss of CG1847 
function a RNA sequencing was performed using the Illumina platform. The top differentially 
expressed genes were mapped to STRING database to construct the protein-protein interactions 
network and to reveal the underlying molecular mechanism of CG1847 deficiency. A very 
interesting cluster of proteins involved in body size, body regulation or cuticle formation was 
revealed by this study, implying that CG1847 may play an important role in body size and 
cuticular formation by interacting with different group of proteins such as Osiris, Twedl and 
cuticular proteins, interactions which were never described before. Meanwhile, heat shock 
proteins family was significantly downregulated transcripts in the mutant Drosophila larvae, and 
may be important for the underlying mechanisms of the lethality process. Results from this study 
might provide the groundwork for the understanding the role of AIP in organ development and 
tumorigenesis. 
Further experiments are needed in order to prove the role of the AIP in human or murine 
development, as the results from this thesis only describe the process in insects. The answer 
might be provided by a thorough search and validation of other expressed genes. The enormous 
advantage of our Drosophila model is that we can use the mutant CG1847-deficient flies to test 
whether transgenic flies that express different cDNAs of the validated downregulated transcripts 
(e.g. members of Hsp family) can rescue their lethality. In case of the upregulated transcripts an 
RNAi screen can be perform to identify components of affected signalling pathways. An in vivo 
validation of the RNAi screening will be possible by generating transgenic flies carrying mutated 
versions of the identified candidates and use them in our rescue experiments. 
The finding that numerous members of the heat shock protein family are significantly 
downregulated, suggest a possible further list of a new repertoire of interacting partners of AIP. 
Future studies could focus on determining the exact nature of Hsp-AIP interactions, bringing a 
possible new light in AIP roles. 
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6.3 The cytoskeletal disorganisation might be related to CG1847 loss of 
function, this being the mechanism for the tumour suppressor function 
of AIP  
Cytoskeletal network disorganisation and loss of normal cellular adhesion are signature for 
invasive tumours. The study of CG1847, the Drosophila orthologue for human AIP revealed an 
exciting novel involvement of this protein in the cell-to-ECM adhesion process. Furthermore, 
loss of CG1847 resulted in significant actin cytoskeleton deregulation and a possible involvement 
in regulation of integrins receptors. The interactions with actin indicates a possible strong 
influence of AIP in cell motility and migration, cellular functions which are essential for tumour 
growth, invasion and metastasis, hence providing encouraging insights into how the loss of AIP 
might promote adenoma formation and local invasion. This in vivo model supports the use of 
Drosophila melanogaster as a system to elucidate the molecular mechanisms of human 
tumorigenesis. 
The actual mechanisms by which AIP acts as a tumour suppressor gene remains still unknown. 
Cellular proliferation (pH3 staining, BrdU incorporation) or apoptosis (caspase staining, tunnel) 
assays are necessary to reveal if in Drosophila in vivo model AIP promotes tumorigenesis via 
increased proliferation or decreased cellular death. To further investigate the interactions 
between CG1847 and integrins-actin-cytoskeleton, if the design of a specific antibody is 
successful, the protein interactions could be tested by co-immunoprecipitation with or without 
cross-linking agents in Drosophila larvae. 
Does the human AIP interact with the same partners as CG1847 in vivo? To confirm that the 
human AIP does interacts with the same candidate genes as CG1847 in vivo (data obtained from 
the RNA sequencing) one possibility will be to use the human AIP rescued males and to perform 
Co-IP studies. The results could be further validated in the rat pituitary cell line (GH3) or human 
HEK293 cells. Other possible studies for data translation might involve investigation of integrin-
actin cytoskeleton expression in human pituitary adenomas from patients with AIP mutations 
and comparison to AIP-mutation negative adenomas. These tissues are available in the 
supervisor’s laboratory as part of her large cohort of FIPA families. RT-qPCR for actin and the 
most relevant integrin associated proteins might be performed in normal pituitary, sporadic 
adenomas and AIP-mutation positive adenomas (available as frozen tissues from 
transsphenoidal operations). 
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6.4 Human AIP variants have different capacities for compensating for 
CG1847 loss of function in an in vivo model 
To functionally test the homology between hAIP and CG1847, we used the Gal4/UAS system to 
perform rescue experiments using different UAS::hAIP constructs. We subsequently tested 
whether hAIP could rescue the lethality of CG1847exon1_3 mutants by expressing UAS::hAIP under 
the control of a ubiquitous promoter (i.e. actin) during fly development. Strikingly, hAIP 
expression is sufficient to rescue the lethality of CG1847 mutants, demonstrating that CG1847 
is the functional homologue of AIP. As a proof-of-principle, we have shown that, in contrast to 
wild-type hAIP, a truncated mutant AIP failed to rescue the lethality of the CG1847exon1_3 mutant. 
Additionally, CG1847 mutants failed to be rescued by a hAIP transgene carrying the p.C238Y 
variant, a pathogenic missense mutation identified in FIPA patients, known to disrupt a 
conserved, structurally important amino acid in the 2nd TPR domain. The rescue results for the 
other 3 missense variants (p.R16H, p.A299V, p.R304Q) support a rather non-pathogenic role 
than a disease-causing association. These results were in accordance with the literature data, 
except for p.R304Q missense variant for which the available information are highly 
contradictory. 
Given the fact that human AIP can functionally substitute for CG1847 in vivo, this Drosophila-
based in vivo assay might be used to discriminate between pathogenic and non-pathogenic AIP 
mutations on the basis of their ability to rescue phenotypes associated with loss-of-function of 
CG1847. The immediate benefit to patients and their families can be direct and immediate as to 
date 19 AIP missense variants have been described and the pathogenicity of 15 of these 
mutations remains questionable. Further rescue experiments could be performed in the future 
to test other hAIP missense variants. Whenever the lethality is rescued, it might be evaluated 
the development and lifespan of the flies for determining whether they acquire tumours. In 
addition, it can also be tested whether the rescued flies display changes in the RNA and/or 
protein level of known AIP interaction partners. For the pathogenic variants, which will not result 
in the rescue of mutant males, as the hAIP truncated of C238Y variants, their levels of expression 
could be further evaluated by overexpressing these pathogenic variants in the wt background 
(the antibody used against hAIP protein does not detect the endogenous CG1847 protein). 
Previous experiments in our lab showed that used antibody can detect both the truncated and 
C238Y proteins. 
These results demonstrate that Drosophila is a useful system in the study of human AIP missense 
variants pathogenicity. 
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APPENDICES 
Appendix 1 AIP sequence 
AIP cDNA sequence 
Transcript ID: ENST00000279146 
Length 1221 bp, 6 exons 
CCCTCAACCAAAATGGCGCTAGCTCGGAAGCTGCCGAGGTGCTAGGAGTTGCCGAAGCAAGTCCGGAAGC
TACCGAGCGAGTCCGGAAGTTGCCGAAAGGGAGCAGCGGGGAAGGAGGATGGCGGATATCATCGCAAGAC
TCCGGGAGGACGGGATCCAAAAACGTGTGATACAGGAAGGCCGAGGAGAGCTCCCGGACTTTCAAGATGG
GACCAAGGCCACGTTCCACTACCGGACGCTGCACAGTGACGACGAGGGCACCGTGCTGGACGACAGCCGG
GCTCGTGGCAAGCCCATGGAGCTCATCATTGGCAAGAAGTTCAAGCTGCCTGTGTGGGAGACCATCGTGT
GCACCATGCGAGAAGGGGAGATTGCCCAGTTCCTCTGTGACATCAAGCATGTGGTCCTGTACCCGCTGGT
GGCCAAGAGTCTCCGCAACATCGCGGTGGGCAAGGACCCCCTGGAGGGCCAGCGGCACTGCTGCGGTGTT
GCACAGATGCGTGAACACAGCTCCCTGGGCCATGCTGACCTGGACGCCCTGCAGCAGAACCCCCAGCCCC
TCATCTTCCACATGGAGATGCTGAAGGTGGAGAGCCCTGGCACGTACCAGCAGGACCCATGGGCCATGAC
AGACGAAGAGAAGGCAAAGGCAGTGCCACTTATCCACCAGGAGGGCAACCGGTTGTACCGCGAGGGGCAT
GTGAAGGAGGCTGCTGCCAAGTACTACGATGCCATTGCCTGCCTCAAGAACCTGCAGATGAAGGAACAGC
CTGGGTCCCCTGAATGGATCCAGCTGGACCAGCAGATCACGCCGCTGCTGCTCAACTACTGCCAGTGCAA
GCTGGTGGTCGAGGAGTACTACGAGGTGCTGGACCACTGCTCTTCCATCCTCAACAAGTACGACGACAAC
GTCAAGGCCTACTTCAAGCGGGGCAAGGCCCACGCGGCCGTGTGGAATGCCCAGGAGGCCCAGGCTGACT
TTGCCAAAGTGCTGGAGCTGGACCCAGCCCTGGCGCCTGTGGTGAGCCGAGAGCTGCAGGCCCTGGAGGC
ACGGATCCGGCAGAAGGACGAAGAGGACAAAGCCCGGTTCCGGGGGATCTTCTCCCATTGACAGGAGCAC
TTGGCCCTGCCTTACCTGCCAAGCCCACTGCTGCAGCTGCCAGCCCCCCTGCCCGTGCTGCGTCATGCTT
CTGTGTATATAAAGGCCTTTATTTATCTCTC 
AIP protein sequence 
Protein ID: ENSP00000279146 
Length: 330 aa 
MADIIARLREDGIQKRVIQEGRGELPDFQDGTKATFHYRTLHSDDEGTVLDDSRARGKPMELII
GKKFKLPVWETIVCTMREGEIAQFLCDIKHVVLYPLVAKSLRNIAVGKDPLEGQRHCCGVAQMR
EHSSLGHADLDALQQNPQPLIFHMEMLKVESPGTYQQDPWAMTDEEKAKAVPLIHQEGNRLYRE
GHVKEAAAKYYDAIACLKNLQMKEQPGSPEWIQLDQQITPLLLNYCQCKLVVEEYYEVLDHCSS
ILNKYDDNVKAYFKRGKAHAAVWNAQEAQADFAKVLELDPALAPVVSRELQALEARIRQKDEED
KARFRGIFSH 
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Appendix 2 CG1847 sequence 
CG1847 cDNA sequence 
Transcript ID: FBtr0073567 
Length: 1758 bp 
 
TAACGTCTGGTATCGAAAGGAAATTGTGTTGATTCCAAATAAATCCGATTCCAGCGGAGATGCAGTCGCG
CAGCAAGTCCGATATGAAGCCCATACGAAAGGAGATCCTCAATCCGGGAAACGCCTACATCGAGCTAACC
CCGGGCACCAGGGTGAAGTTCCACTTTCAAACGCGGAGGGCCGGCGACAGTCGCATCATCGATGATAGCC
GCAAGATGGAGAAGCCCATGGAGCTGGTCCTGGGGAAGAAGTTTAAGCTAGAGGTCTGGGAGCTGATTGT
GCAGCAGATGTCCCTTAACGAAGTGGCCAAGTTCACGGTACATAAGTCGCTCTGCGCTCAATATCCTTTT
ATATCCAAGACCCTGCGGGACATTGGCAAGAAACCGGAGGAGCGACGTCACTGCTGCGGAATGACATTGC
AGAACGAGGGCATTGGGTACACCGACCTGGATGAGCTGCTGCAAAATCCTTCCGATCTGGAGTTCATCAT
TGAACTGTTCTCCATTGAGCTGCCCGAGCAGTACGAAAAAGAGCGCTGGCAGATGTCCGACGACGAAAAG
ATGCTGGCCACCAGTACGCTGCGCGAACGGGGCAACAACTTCTATAAGGCCAGTCGGTTCACAGAGGCGG
AGACCTGCTACCGCGAGGCTGTCGGAATTGTGGAGCAGCTGATGCTAAAGGAGAAGCCGCACGACGAGGA
GTGGCAGGAGCTGGCGGCCATCAAGACACCGCTGTTGTTGAACTACGCGCAATGTCGGTTGATCGCCGGC
GACTTCTACGCTGTGATCGAGCACTGCAACGAGGTGCTCACCCTGGATCCGCGCAATGTCAAGGCACTTT
TTCGTCGGGCCAAGGCCCATGCGGGTGCCTGGAATCCAGCACAGGCACGTCGCGACTTCCTCGACGCCTT
GGCCTTGGACGCCAGCCTCAAGTCGACCGTGTCTAAGGAGCTCAAGTCCATCGAGGATCAGCAGCAGGCA
CGTAACGTCCAGGATCGCATTCACATGCAGAAGCTCTTCTAGAACATAAGTTGCGTCAACGTGCTGCTCA
TGCTGCTTGTCTATTGGAGCAGCTACCTGCAGCGCTAGCAGTACTTGTCACTACCTTCTTTTCTTTCGCT
GGCCGTCAGCTTCGCTCATGGTCTCGTGCTGCTCTGCTCGATGGCGAACCTATTCCTCTGCTGCTGGACC
CTCAAGAAGCTGCTGCGAGCAATGCAGGGGCTCAGCTGGTGATTTTGCGACAACATAACACAATCAACCA
ACTCGGTACCATACCACCTCATTTTGTGAGAGCTGCATTTTGGGGCACTATATGCCCATACTCATCCTCC
GCCTCGATTCACATTCAACGGTGTAGGCTAAAGGGTCTAAATATAATGTAAATGTACCATCCAGATGCTT
GTGTGGAATTGTAATCGTGTGTATATGGAATGAAAAATGTTGTTTGCGTAGCGTTACCAAAAATAGTAAT
CAAATGTTTCACATTTGTTGTCCATAGTCGTATATGTATGTTTGTATTGTATTGTATATCCCTATATGCG
ATATTTACTCGTAGCTAGAATCTACTCTAAATCTAGACAAATTGTGTAAGAAGTAATAAATGTGCTTTTG
ACCGCTGTCTAATTGTTAATTGTAGTTGAAGACTTTATTGTTTGTATACATATATGCGGCAAGCATACGT
AATAATATGCATTTGCATAAGAGAGAATACAGTGTATAAAATAAATATCCAAACCTTTAAATGGACAAAT
AAGGTCGT 
 
CG1847 protein sequence 
Protein ID: FBpp0073411 
Length: 320 
aaMQSRSKSDMKPIRKEILNPGNAYIELTPGTRVKFHFQTRRAGDSRIIDDSRKMEKPMELVLG
KKFKLEVWELIVQQMSLNEVAKFTVHKSLCAQYPFISKTLRDIGKKPEERRHCCGMTLQNEGIG
YTDLDELLQNPSDLEFIIELFSIELPEQYEKERWQMSDDEKMLATSTLRERGNNFYKASRFTEA
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ETCYREAVGIVEQLMLKEKPHDEEWQELAAIKTPLLLNYAQCRLIAGDFYAVIEHCNEVLTLDP
RNVKALFRRAKAHAGAWNPAQARRDFLDALALDASLKSTVSKELKSIEDQQQARNVQDRIHMQK
LF 
Appendix 3: Fly food recipe 
The fly food was prepared in Professor Ralf Stanewsky fly facility as follow: 
 Water 1 litre 
 Agar 10g 
 Sucrose 15g  
 Glucose 33g 
 Yeast 35g 
 Maize meal 15g 
 Wheat germ 10g 
 Treacle 30g 
 Soya our 1 table spoon 
 Nipagin 10 ml 
 Propionic Acid 5 ml 
 
 
Appendix 4: Structure of Inverted Repeats (IR) for RNAi constructs 
Using UAS-GAL4 system, the RNAi flies produce double stranded RNA in vivo, inducing post-
transcriptional gene silencing. This system is based on transcription of inverted repeats (IR), 
which are commonly used as they have high efficiency in making dsRNA. The IR are cloned in 
vectors backbones under a UAS sequence. Usually the final constructs are injected into 30-100 
eggs and the transformants adults are selected to establish IR fly lines. A phenotypical marker 
(usually white+) is used to select the transformants. Genotyping is usually performed by using 
traditional genetic methods (PCR).  
Although this technique is very efficient and IR sequences are choose to target very specific 
areas of gene of interest, there are possible some cross-reactions between IR fragments and off-
target genes. Consequently further investigation are necessary to proof that the effects are not 
due to an off-target effect.  
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SUPPORTING TABLE 1.The structure of IR constructs  
Stock ID IR fragment full Sequences 
1847R-1  TCCGATATGAAGCCCATACGAAAGGGAGATCCTCAATCCGGGAAACGCCTACATCGAGCTAACCCCGGGCACCAGGGTGAAGTTCCACTTTCAAACGCG
GAGGGCCGGCGACAGTCGCATCATCGATGATAGCCGCAAGATGGAGAAGCCCATGGAGCTGGTCCTGGGGAAGAAGTTTAAGCTAGAGGTCTGGGAGC
TGATTGTGCAGCAGATGTCCCTTAACGAAGTGGCCAAGTTCACGGTACATAAGTCGCTCTGCGCTCAATATCCTTTTATATCCANNGAccCTGCGGGACAT
TGGCAAGAAACCGGAGGAGCGACGTCACTGCTGCGGAATGACATTGCAGAACGAGGGCATTGGGTACACCGACCTGGATGAGCNGCTGCAAAATCCTTC
CGATCTGGAGTTCATCATTGAACTGTTCTCCATTGAGCtGCCCGAGCAGTACGAAAAAGAGCGCTGGCAGATGTCCGACGACGAAAAGATGCTGGCCACC
AGTAC 
1847R-2  TCCGATATGAAGCCCATACGAAAGGGAGATCCTCAATCCGGGAAACGCCTACATCGAGCTAACCCCGGGCACCAGGGTGAAGTTCCACTTTCAAACGCG
GAGGGCCGGCGACAGTCGCATCATCGATGATAGCCGCAAGATGGAGAAGCCCATGGAGCTGGTCCTGGGGAAGAAGTTTAAGCTAGAGGTCTGGGAGC
TGATTGTGCAGCAGATGTCCCTTAACGAAGTGGCCAAGTTCACGGTACATAAGTCGCTCTGCGCTCAATATCCTTTTATATCCANNGAccCTGCGGGACAT
TGGCAAGAAACCGGAGGAGCGACGTCACTGCTGCGGAATGACATTGCAGAACGAGGGCATTGGGTACACCGACCTGGATGAGCNGCTGCAAAATCCTTC
CGATCTGGAGTTCATCATTGAACTGTTCTCCATTGAGCtGCCCGAGCAGTACGAAAAAGAGCGCTGGCAGATGTCCGACGACGAAAAGATGCTGGCCACC
AGTAC 
43701 AGTCGGTTCACAGAGGCGGAGACCTGCTACCGCGAGGCTGTCGGAATTGTGGAGCAGCTGATGCTAAAGGAGAAGCCGCACGACGAGGAGTGGCAGGA
GCTGGCGGCCATCAAGACACCGCTGTTGTTGAACTACGCGCAATGTCGGTTGATCGCCGGCGACTTCTACGCTGTGATCGAGCACTGCAACGAGGTGCTC
ACCCTGGATCCGCGCAATGTCAAGGCACTTTTTCGTCGGGCCAAGGCCCATGCGGGTGCCTGGAATCCAGCACAGGCACGTCGCGACTTCCTCGACGCCT
TGGCCTT 
43702 AGTCGGTTCACAGAGGCGGAGACCTGCTACCGCGAGGCTGTCGGAATTGTGGAGCAGCTGATGCTAAAGGAGAAGCCGCACGACGAGGAGTGGCAGGA
GCTGGCGGCCATCAAGACACCGCTGTTGTTGAACTACGCGCAATGTCGGTTGATCGCCGGCGACTTCTACGCTGTGATCGAGCACTGCAACGAGGTGCTC
ACCCTGGATCCGCGCAATGTCAAGGCACTTTTTCGTCGGGCCAAGGCCCATGCGGGTGCCTGGAATCCAGCACAGGCACGTCGCGACTTCCTCGACGCCT
TGGCCTT 
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Appendix 5: Primers used in this study  
SUPPORTING TABLE 2: Primers used in this study.  
Primer name 5’-3’ Sequence - Forward 5’-3’ Sequence-Reverse Annealing °C 
Dm_CG1847_RT-PCR ataagtcgctctgcgctcaa tgaactccagatcggaagga 57.7 
Dm_RpL32_RT-PCR cgatatgctaagctgtcgcaca cgcttgttcgatccgtaacc 60 
Dm_EP ggacaaataacgtctggtatcg gaaaaggccaatatcatgagga 62.4 
Dm_EP_EL atccgtatcaactgggatcg tcagccaaccaaccacaata 60.9 
Ppr-Y ccaagctttgccttaattgc tcaattaaattatttccaaggctga 58 
Dm_NeoRgene atcaagagacaggatgaggatcgtttcg gcggcggtggaatcgaaatctcgtgatg 62 
FOR CLONING    
CG1847wt  ggatccgcaaacgcaaaggcaactat gcggccgcccaaagattttcctagctca 60 
hAIPwt acgagcggccgcatggcggatatcatcgcacgcctcc aatagcggccgctcaatgggagaagatcccccggaac 60 
MycAIP_trunc ggcaggtaccatggaacaaaagttga atattctagatcaccacaggcgccag 71.1 
FOR DIRECT SITE MUTAGENESIS    
ins_7nt_sense cagccctggcgcctgtggtgaaatcgaattcccgc gcgggaattcgatttcaccacaggcgccagggctg 60 
c.47G>A (p.R16H) ggacgggatccaaaaacatgtgatacaggaaggcc ggccttcctgtatcacatgtttttggatcccgtcc 60 
c.713G>A (p.C238Y) tgctgctcaactactgaccagtgcaagctggt accagcttgcactggtcagtagttgagcagca 60 
c.896C>T (p.A299V) acccagccctggtgcctgtggtgag ctcaccacaggcaccagggctgggt 60 
c.911G>A (p.R304Q) ctgtggtgagccaagagctgcgggc ggcccgcagctctcagctcaccacaggc 60 
FOR SEQUENCING CONSTRUNCTS    
M13 primers gttttcccagtcacgac caggaaacagctatgac  
AIP _Ex4B_F  gacccatgggccatgacagacgaaga   
AIP_Ex4A_R  gcatgtgaaggaggctgctgccaag  
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SUPPORTING TABLE 3. Genes included in validation set by the Multiplex-qPCR 
Gene symbol Full name RefSeq Function 
RpL32 Ribosomal protein L32 NM_170461. Housekeeping gene 
AlphaTub84b alpha-Tubulin at 84B NM_057424.4  Housekeeping gene 
CG1847 CG1847 NM_132530.4  Drosophila orthologue for human AIP 
Hsp70Bbb heat shock protein 70Bbb NM_176486.2  Mediating response to heat;response to hypoxia 
Hsp83 heat shock protein 83 NM_079175.4 ATP binding;ATPase activity, unfolded protein binding 
Osi18 Osiris 18 NM_141382.3 Protein of unknown function 
Osi19 Osiris 19 NM_001170058.2 Protein of unknown function 
TwdlG TweedleG NM_001275316.2 Chitin-based cuticle development; body morphogenesis 
cpr66Cb cuticular protein 66Cb NM_139952.3  Chitin-based cuticle development 
cpr97Eb cuticular protein 97Eb NM_143273.3 Chitin-based cuticle development; neurogenesis. 
Mhc myosin heavy chain NM_001259121.2 Epithelium migration; adult somatic muscle development; protein stabilization;  
Act57B actin 57B NM_079076.4 Cytoskeleton organization; heart development, skeletal muscle fiber. 
Pka-Cl 
Protein kinase cAMP-dependent, catalytic 
subunit 1 
NM_057629.4 Regulation of embryonic development; regulation of apoptotic process 
Gsalpha G protein alpha s subunit  NM_001299869.1 
regulation of cAMP biosynthetic process; tissue development; cell-cell signalling; 
regulation of cAMP metabolic process 
Octβ2R  octopamine beta2 receptor NM_001170125.3 
G-protein coupled receptor signalling pathway; positive regulation of adenylate 
cyclase activity involved in G-protein coupled receptor signalling pathway. 
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SUPPORTING TABLE 4. Primers used for Multiplex-qPCR  
Gene symbol Left Sequence w/o Universal Tags Right Sequence w/o Universal Tags 
RpL32 AGGTGACACTATAGAATAATGCTAAGCTGTCGCACAAA GTACGACTCACTATAGGGAGAACTTCTTGAATCCGGTGG 
AlphaTub84b AGGTGACACTATAGAATAAACCTGAACCGTCTGATTGG GTACGACTCACTATAGGGACGTAGGTCACCAGAGGGAAG 
CG1847 AGGTGACACTATAGAATAAGGTCTGGGAGCTGATTGTG GTACGACTCACTATAGGGACCGCAGGGTCTTGGATATAA 
Hsp70Bbb AGGTGACACTATAGAATACAAAATCGCAGAGGACATGA GTACGACTCACTATAGGGAATCTCCTCGGGAGCAAATCT 
Hsp83 AGGTGACACTATAGAATAGTCTACATGACCGAGCCCAT GTACGACTCACTATAGGGAGGACTTCATCAGCTTGCACA 
Osi18 AGGTGACACTATAGAATACAGTTCTGCCCTTCCTTCTG GTACGACTCACTATAGGGATGCACCACCTCGTAGTTGAC 
Osi19 AGGTGACACTATAGAATACACCTTTAGCTCCGTTCCTG GTACGACTCACTATAGGGAACTAGCTGGCTCCAAACTGC 
Twd1G AGGTGACACTATAGAATAGCAACAACGGAATTTCATCC GTACGACTCACTATAGGGAAATATGGCTGCAGAGTCGCT 
cpr66Cb AGGTGACACTATAGAATAGAGCTGCACGAACACCACTA GTACGACTCACTATAGGGAGTGGATATGCTTGTCCCTCC 
cpr97Eb AGGTGACACTATAGAATATCAACCTCTACACCGGTTCC GTACGACTCACTATAGGGAACTCTCTGGCCCAACTCAGA 
Mhc AGGTGACACTATAGAATAGAGGAGTCTCGCACTCTGCT GTACGACTCACTATAGGGATCTTGGCTTCGTTCAGGAGT 
Act57B AGGTGACACTATAGAATAAGGACCTGTACGCCAACATC GTACGACTCACTATAGGGACACCGATCCAGACGGAGTAT 
Pka-Cl AGGTGACACTATAGAATACGGCTATGCGGGTATTTTTA GTACGACTCACTATAGGGATTTGCTTTTCCATTTTCGCT 
Gsalpha AGGTGACACTATAGAATAGATATTCTTCGGTGCCGTGT GTACGACTCACTATAGGGACTTGAGCACGCAGTTACGAA 
Octβ2R  AGGTGACACTATAGAATAACACACGAACTGAATGCCAC GTACGACTCACTATAGGGAATGTTGTCCAGCCAATCCTC 
Kan(r) AGGTGACACTATAGAATAATCATCAGCATTGCATTCGATTCCTGTTTG GTACGACTCACTATAGGGAATTCCGACTCGTCCAACATC 
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Appendix 6: Immunostaining protocols  
Imaginal wing discs immunostaining 
Buffers and solutions 
1X PBS: Phosphate buffered saline (Oxoid - Product Code: 10209252). 1 tablet makes 100 ml of 
solution. Store at RT. 
Fixation buffer4%: 16% Formaldehyde vials (10 ml) and adjust with 1X PBS to a final volume of 
40 ml. Store at -20°C. 
Permeabilisation buffer (PBT 0.2%): 500 ml PBS+1000 µl Triton X-100. Store at RT. 
Blocking buffer (0.5%): 100 ml PBT+500mg BSA (Bovine Serum Albumin, SIGMA-ALDRICH, 
A2058). Store at 4°C. 
Method 
1. While in PBS, rip the larvae in half and turn the anterior half inside-out. Get rid of fat 
tissues and gut remaining. Keep for maximum 15-20min in PBS, in 1500 µl tubes. 
2. Remove the PBS with a Pasteur pipette, add 500 μl of fixation buffer and incubate for 
25 min at RT on rocker, protected from light (make sure that the samples are floating 
around). 
Can rinse out the fix with 2 PBS rinses and keep samples 2-3 days at 4˚C  
3. Remove the fixation solution with a Pasteur pipette carefully not to absorb the samples. 
Add 500 μl PBT 0.2%, 1 quick rinse to dilute the fix.  
4. Incubate the samples with 500 µl of permeabilisation buffer (PBT 0.2%), twice, for 15 
min each on the rocker. 
5. Remove the permeabilisation buffer with a Pasteur pipette and add 500 µl of blocking 
buffer for 1 h at RT. 
6. Remove the blocking buffer and add of the appropriate primary antibodies (adjust 
dilution in each case in 250 µl PAT). Rotate/rock overnight at 4˚C.  
7. Wash the samples twice with 500 µl of PAT for 15 min at RT, on the rocker. Remove PAT 
and do 2 more washes in 500 µl of PAT for 30 min each at RT, on the rocker. 
8. Add the appropriate secondary antibodies diluted in 250 μl of PAT and incubate for 2 h 
at RT or overnight at 4˚C, protected from light. 
9. Wash the samples with 400 µl of PBT for 5 min three times, at RT. 
10. Incubate in DAPI solution and wash the samples 3 times, for 15 min each, in PBT.  
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11. Dissect out the wing discs and add them on a glass slide in a drop mounting medium 
Vectashield (Vector Laboratories, ref H-1000). 
12. Add a few more drops of mounting medium, cover with a cover slip, ensuring no bubbles 
are left, seal the edges with nail polish and store overninght at 4°C, protected from light, 
until analysis. For longer term, keep at -20°C, protected from light. 
Pupal wing immunostaining 
Buffers and solutions 
1X PBS: Phosphate buffered saline (Oxoid - Product Code: 10209252). 1 tablet makes 100 ml of 
solution. Store at RT  
Fixation buffer4%: 16% Formaldehyde vials (10 ml) and adjust with 1X PBS to a final volume of 
40 ml. Store at -20°C 
Permeabilisation buffer (PBT 0.3%): For 500 ml use 498.5 ml PBS + 1.5 ml TritonX/Tween. Store 
at RT 
Blocking buffer (0.5%): For 500 ml use 483.5 ml PBS + 1.5 ml Triton X-100 + 15 ml BSA (Bovine 
Serum Albumin, SIGMA-ALDRICH, A2058). Store at 4°C 
Method  
1. Collect white pupae on double sticky tape. Keep them at 25°C for 24-28 h until they 
reach the appropriate stage. Dissect them while attached to the sticky tape. Grip tail 
and then remove operculum. In order to avoid fat going into the wings punch a hole in 
the pupae’ head while they are still in the pupae shield. Gently remove the hard cuticle. 
Put them very fast on PBS (no detergent). To protect the pupae each of them was put in 
one well of a 96wells plate. 
2. In each well add 300 μl of 4% formaldehyde in PBT and incubate overnight at 4°C 
protected from light (pre-fixation). 
3. NEXT DAY: Remove the fixing solution with a pipette, and wash the pupae in PBS. 
In this step pupae can be kept in PBS at 4°C for a few days, before moving to next step. 
4. Move the pupae into a dissecting dish. Grip the wing from the shoulder and remove the 
cuticle (starting from the shoulder – where the separation between wing and the cuticle 
is more obvious). Move each wing into a well of a Terasaki 60 Microwell Plate. 
5. Add 10 μl of fixation buffer and incubate for 10 min at RT, protected from light (fixation). 
From this step forward all the washes have to be done under the microscope. 
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6. Remove the fixation solution with a pipette and wash the cells thrice with 15 μl of PBS 
7. Wash in twice in PBT, for 10 min, at RT. 
8. Incubate the pupal wings in 15 µl of permeabilisation buffer for 20 min at RT. 
9. Remove the permeabilisation buffer and wash twice in PBT for 10min at RT. 
10. Add 15 µl of blocking buffer. Incubate 1 h at RT.  
If just phalloidin staining go to step 22. 
11. Remove the blocking buffer and add the appropriate primary antibodies (adjust dilution 
in each case) diluted in 15 µl of blocking buffer. Incubate overnight at 4°C, on a rocker. 
Pre - absorption of the primary antibody was done against third instar larvae to reduce 
the non - specific binding of the antibodies in the tissue of interest. 
Two mixes were prepared in order to perform double staining in the same time: 
MIX 1 primary antibodies MIX 2 primary antibodies 
anti talin – Mouse monoclonal  anti βPS2 – Mouse monoclonal  
anti-PINCH - Rabbit polyclonal anti-parvin - Rabbit polyclonal  
 
12. NEXT DAY: Remove the primary antibodies and rinse three times in 15 µl PAT. 
13. Wash twice for 20min in 15 µl PAT. 
14. Block as above, in 15 µl of blocking buffer for 1 h at RT. 
15. Add 15 µl the appropriate secondary antibodies dilutions in PAT and incubate for 1 h at 
RT protected from light. One mix was prepared for all the samples:  
MIX 
Fluorescein (FITC) Donkey Anti-Mouse  
Cy™5 Pure Donkey Anti-Rabbit  
phalloidin  
 
16. Rinse 3 times with 15 µl of PBT and then wash 10 min in PBT. 
17. Move the pupal wings with the tip of a syringe needle on a glass slide in drop of 24 µl 
mounting medium Vectashield (Vector Laboratories, ref H-1000). 
18. Cover with a cover slip, ensuring no bubbles are left, seal the edges with nail polish 
and store overnight at 4°C, protected from light, until analysis. For longer term keep at 
-20°C, protected from light.  
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Appendix 7: Antibodies used in this study 
SUPPORTING TABLE 5: Antibodies used in this study 
Primary antibodies Dilution Usage  Cat number Reference 
anti βPS2 – Mouse monoclonal (HB CF.6G11) 1: 15 Immunostaining Gift from N.Brown – Gurdon Institute  Brower et al., 1984 
anti talin – Mouse monoclonal 1:50 Immunostaining Gift from N.Brown – Gurdon Institute  Brown et al., 2002 
anti-parvin - Rabbit polyclonal 1:500 Immunostaining Gift from C.G. Zervas – Academy of Athens  Vakaloglou et al.,2012 
anti-PINCH - Rabbit polyclonal 1:500 Immunostaining Gift from M. Beckerle– University of Utah  Clark et al., 2003 
anti-AIP/ARA9 Mouse Monoclonal 1:20 Immunostaining Novus Biologicals  NB100-127 Kasuki et al 2011 
anti-AIP/ARA9 Mouse Monoclonal 1:1000 Western Blot Novus Biologicals  NB100-127 Kasuki et al 2011 
anti Tubulin, beta Mouse monoclonal 1:15000 Western Blot Developmental Studies Hybridoma Bank E7 Chu et al 1989 
Secondary antibodies  Dilution Usage  Cat number Reference 
Alexa Fluor® 488 Goat anti-Mouse 1:250 Immunostaining Invitrogen A11029  
Alexa Fluor® 488 Goat anti-Rabbit 1:250 Immunostaining Invitrogen A-11008  
Alexa Fluor 488® phalloidin 1:1000 Immunostaining Invitrogen A12379  
Fluorescein (FITC) Donkey anti-Mouse IgG H+L) 1:250 Immunostaining Jackson ImmunoResearch Laboratories  715-096-151  
Fluorescein (FITC) anti-Rabbit IgG (H+L) 1:250 Immunostaining Jackson ImmunoResearch Laboratories 711-096-152  
Cy™5 Pure Donkey anti-Rabbit IgG (H+L) 1:200 Immunostaining Jackson ImmunoResearch Laboratories 711-175-152  
Alexa Fluor® 647 Donkey anti-Mouse IgG (H+L), 1:200 Immunostaining Invitrogen A-31571  
IRDye® 680 RD Goat anti-Mouse IgM  1:1000 Western Blot LI-COR Biotechnology 926-68180  
Phalloidin-TRITC 1:250 Immunostaining Sigma-Aldrich P1951-1MG  
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Appendix 8: Preparing competent cells  
In order to prepare competent cells for plasmid DNA transformation we used the chemical 
method (Nicholas Renzette, Current Protocols in Molecular Biology, 2011) that has the 
advantages of being simple to complete, requires no special equipment and gives good 
transformation efficiencies. Disadvantages are that the efficiency is somewhat lower (vs. 
electroporation).  
Materials: 
 Single colony of JM109 or BL21 cells to be transformed 
 LB medium 
 LB amp plates (2 plates without any ampicillin + 4 with ampicillin)  
 M CaCl2, ice cold – autoclaved 
 M CaCl2+15% glycerol – autoclaved 
 42°C water bath for transformation 
Recipe:  
 For 1L of 0.1M CaCl2 solution, add 11.10g of CaCl2 
 For the CaCl2 +15% glycerol solution, make up 500 ml solution. 5.55 CaCl2 were added 
to 300 ml dH2O. Then 75 ml glycerol and the rest of the dH2O to a final volume of 500 
ml 
Procedure: 
Two ml LB medium were inoculated with one single colony from an LB agar plate (without 
antibiotics) of JM109 or BL21 bacteria and incubated overnight at 37°C and 225 RPM. 1-ml of 
the starter culture was used inoculate to a flask with 100 ml LB medium (in a 500 ml flask) and 
incubated with shaking at 37°C to OD600 ~ 0.25-0.3 (usually it took about 1.5-2 hours). The culture 
was then chilled on ice for 15 min. The 0.1M CaCl2 solution and 0.1M CaCl2 plus 15% glycerol 
were also placed on ice because all steps after harvesting the cell should be done on ice (or at 
4°C). The cells were harvested by centrifuging for 10 min at 4,000 rpm at 4°C. The medium was 
removed and the cells were resuspended in 40 ml of ice-cold 0.1M CaCl2 using the stripette. The 
cells were kept on ice for 30 min. After the centrifugation, the transformation medium was 
removed and the cell pellet was resuspended in 6 ml 0.1 M CaCl2 solution plus 15% glycerol. For 
storage 250 µl or 500 µl aliquots of competent cells were made in already labelled and chilled 
cryotubes. The aliquots were quickly frozen and kept at -80°C.  
In order to test the competent cells, the following tests were performed: 
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1) Viability of cells: 0.5 μl of untransformed cells were diluted in 30 μl water and were plated on 
LB plate without ampicillin.  
2) Antibiotic resistance of cells: 50 μl of untransformed culture were plated out onto an LB plate 
with ampicillin. 
3) Transformation efficiency of cells using vector of known concentration. In order to determine 
the transformation efficiency of the cells, 1 μg of vector DNA was used to transform the cells. 
During transformation, we used 500 LB media during the recovery period. From this, we plate 
out 5 μl, 10 μl, and 20 μl of the culture onto LB plates containing ampicillin. On the plates where 
the number of colonies could be determined, the transformation efficiency was calculated for 
the batch of competent cells using the formula:  
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Appendix 9: TruSeq Stranded mRNA Sample Preparation – Low Sample 
(LS) Protocol 
Introduction – Overview of the protocol (ILLUMINA PROPRIETARY, Catalog # RS-122-
9004DOC, Part # 15031047 Rev. E, October 2013). 
 
Figure 90: TruSeq Stranded mRNA Sample Preparation LS Workflow 
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Purify and Fragment mRNA 
This process purifies the polyA containing mRNA molecules using poly-T oligo attached magnetic 
beads using two rounds of purification. During the second elution of the polyA RNA, the RNA is 
also fragmented and primed for cDNA synthesis. It is important to follow this procedure exactly 
to be sure of reproducibility. 
NOTES: Allow the beads to fully pellet against the magnetic stand 5 minutes. Remove the 
supernatant from the beads immediately while the beads are still pelleted against the magnetic 
stand. 
Pre-program the thermal cycler with the following programs: Choose the pre-heat lid option and 
set to 100°C 
• 65°C for 5 minutes, 4°C hold—save as mRNA Denaturation 
• 80°C for 2 minutes, 25°C hold—save as mRNA Elution 1 
• 94°C for 8 minutes, 4°C hold—save as Elution 2 - Frag - Prime 
 
Make RBP 
1 Dilute the total RNA with nuclease-free ultrapure water to a final volume of 50 µl in the new 
96-well 0.3 ml PCR plate. 
2 Vortex the room temperature RNA Purification Beads tube vigorously to resuspend the oligo-
dT beads. 
3 Add 50 µl of RNA Purification Beads to each well of the RBP plate to bind the polyA RNA to the 
oligo dT magnetic beads. Gently pipette the entire volume up and down 6 times to mix 
thoroughly. 
4 Seal the RBP plate with a Microseal ‘B’ adhesive seal.  
 
Incubate 1 RBP 
1 Place the sealed RBP plate on the pre-programmed thermal cycler. Close the lid and select 
mRNA Denaturation (65°C for 5 minutes, 4°C hold) to denature the RNA and facilitate binding of 
the polyA RNA to the beads. 
2 Remove the RBP plate from the thermal cycler when it reaches 4°C. 
3 Place the RBP plate on the bench and incubate at room temperature for 5 minutes to allow 
the RNA to bind to the beads. 
 
Wash RBP 
1 Remove the adhesive seal from the RBP plate. 
2 Place the RBP plate on the magnetic stand at room temperature for 5 minutes to separate the 
polyA RNA bound beads from the solution. 
3 Remove and discard all of the supernatant from each well of the RBP plate. 
4 Remove the RBP plate from the magnetic stand. 
5 Wash the beads by adding 200 µl of Bead Washing Buffer in each well of the RBP plate to 
remove unbound RNA. Gently pipette the entire volume up and down 6 times to mix thoroughly. 
6 Place the RBP plate on the magnetic stand at room temperature for 5 minutes. 
7 Centrifuge the thawed Elution Buffer to 600 x g for 5 seconds. 
8 Remove and discard all of the supernatant from each well of the RBP plate. The supernatant 
contains most of the ribosomal and other non-messenger RNA. 
9 Remove the RBP plate from the magnetic stand. 
10 Add 50 µl of Elution Buffer in each well of the RBP plate. Gently pipette the entire volume up 
and down 6 times to mix thoroughly. 
11 Seal the RBP plate with a Microseal ‘B’ adhesive seal. 
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Incubate 2 RBP 
1 Place the sealed RBP plate on the pre-programmed thermal cycler. Close the lid and select 
mRNA Elution 1 (80°C for 2 minutes, 25°C hold) to elute the mRNA from the beads. 
2 Remove the RBP plate from the thermal cycler when it reaches 25°C. 
3 Place the RBP plate on the bench at room temperature. Remove the adhesive seal from the 
RBP plate. 
 
Make RFP 
1 Add 50 µl of Bead Binding Buffer to each well of the RBP plate. This allows mRNA to specifically 
rebind the beads, while reducing the amount of rRNA that non-specifically binds. Gently pipette 
the entire volume up and down 6 times to mix thoroughly. 
2 Incubate the RBP plate at room temperature for 5 minutes. 
3 Place the RBP plate on the magnetic stand at RT for 5 minutes. Discard all of the supernatant. 
4 Remove the RBP plate from the magnetic stand. 
5 Wash the beads by adding 200 µl of Bead Washing Buffer in each well of the RBP plate. Gently 
pipette the entire volume up and down 6 times to mix thoroughly. 
6 Place the RBP plate on the magnetic stand at room temperature for 5 minutes. 
7 Remove and discard all of the supernatant from each well of the RBP plate. The supernatant 
contains residual rRNA and other contaminants that were released in the first elution and did 
not rebind the beads. 
8 Remove the RBP plate from the magnetic stand. 
9 Add 19.5 µl of Fragment, Prime, Finish Mix to each well of the RBP plate. Gently pipette the 
entire volume up and down 6 times to mix thoroughly. Seal the RBP plate with a Microseal ‘B’ 
adhesive seal. 
 
Incubate RFP 
1 Place the sealed RBP plate on the pre-programmed thermal cycler. Close the lid and select 
Elution 2 - Frag - Prime (94°C for 8 minutes, 4°C hold) to elute, fragment, and prime the RNA. 
2 Remove the RBP plate from the thermal cycler when it reaches 4°C and centrifuge briefly. 
3 Proceed immediately to Synthesize First Strand cDNA on page 21. 
Synthesize First Strand cDNA 
This process reverse transcribes the cleaved RNA fragments that were primed with random 
hexamers into first strand cDNA using reverse transcriptase and random primers. The addition 
of Actinomycin D to the First Stand Synthesis Act D mix (FSA) prevents spurious DNA-dependent 
synthesis, while allowing RNA-dependent synthesis, improving strand specificity. 
Pre-program the thermal cycler with the following program and save as Synthesize 1st Strand: 
pre-heat lid option and set to 100°C, 25°C for 10 minutes, 42°C for 15 minutes, 70°C for 15 
minutes, Hold at 4°C 
 
Make CDP 
1 Place the RBP plate on the magnetic stand at RT for 5 minutes. 
2 Transfer 17 µl supernatant from each well of the RBP plate to the corresponding well of the 
new 0.3 ml PCR plate labelled with the CDP barcode. 
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3 Centrifuge the thawed First Strand Synthesis Act D Mix tube to 600g for 5 seconds. 
4 Add 50 µl SuperScript II to the First Strand Synthesis Act D Mix tube. 
5 Add 8 µl of First Strand Synthesis Act D Mix and SuperScript II mix to each well of the CDP plate. 
Gently pipette the entire volume up and down 6 times to mix thoroughly.  
6 Seal the CDP plate with a Microseal ‘B’ adhesive seal and centrifuge briefly. 
 
Incubate 1 CDP 
1 Place the sealed CDP plate on the pre-programmed thermal cycler. Close the lid, and then 
select and run the Synthesize 1st Strand program. a Choose the pre-heat lid option and set to 
100°C, 25°C for 10 minutes, 42°C for 15 minutes, 70°C for 15 minutes, Hold at 4°C 
2 When the thermal cycler reaches 4°C, remove the CDP plate from the thermal cycler and 
proceed immediately to Synthesize Second Strand cDNA. 
Synthesize Second Strand cDNA 
This process removes the RNA template and synthesizes a replacement strand, incorporating 
dUTP in place of dTTP to generate dscDNA. The incorporation of dUTP quenches the second 
strand during amplification, because the polymerase does not incorporate past this nucleotide. 
AMPure XP beads are used to separate the dscDNA from the second strand reaction mix. 
 
Add SMM 
1 Remove the adhesive seal from the CDP plate. 2 Do one of the following: 
2 Add 5 µl of Resuspension Buffer to each well of the CDP plate. 
3 Centrifuge the thawed Second Strand Marking Master Mix to 600g for 5 seconds. 
4 Add 20 µl of thawed Second Strand Marking Master Mix to each well of the CDP plate. Gently 
pipette the entire volume up and down 6 times to mix thoroughly. Seal the CDP plate. 
 
Incubate 2 CDP 
1 Place the sealed CDP plate on the pre-heated thermal cycler. Close the lid and incubate at 16°C 
for 1 hour. 
2 Remove the CDP plate from the thermal cycler, remove the adhesive seal and place it on the 
bench. 
3 Let the CDP plate stand to bring it to room temperature. 
 
Purify CDP 
1 Vortex the AMPure XP beads until they are well dispersed. 
2 Add 90 µl of well-mixed AMPure XP beads to each well of the CDP plate containing 50 µl of ds 
cDNA. Gently pipette the entire volume up and down 10 times to mix thoroughly. 
3 Incubate the CDP plate at room temperature for 15 minutes. 
4 Place the CDP plate on the magnetic stand at room temperature, for 5 minutes to make sure 
that all of the beads are bound to the side of the wells. 
5 Remove and discard 135 µl supernatant from each well of the CDP plate. Leave the CDP plate 
on the magnetic stand while performing the following 80% EtOH wash steps (6–8). 
6 With the CDP plate on the magnetic stand, add 200 µl freshly prepared 80%EtOH to each well 
without disturbing the beads. 
7 Incubate the CDP plate at room temperature for 30 seconds, and then remove and discard all 
of the supernatant from each well. 
8 Repeat steps 6 and 7 one time for a total of two 80% EtOH washes. 
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9 Let the CDP plate stand at room temperature for 15 minutes to dry, and then remove the plate 
from the magnetic stand. 
10 Centrifuge the thawed, room temperature Resuspension Buffer to 600g for 5 seconds. 
11 Add 17.5 µl Resuspension Buffer to each well of the CDP plate. Gently pipette the entire 
volume up and down 10 times to mix thoroughly. 
12 Incubate the CDP plate at room temperature for 2 minutes. 
13 Place the CDP plate on the magnetic stand at room temperature for 5 minutes. 
14 Transfer 15 µl supernatant (ds cDNA) from the CDP plate to the new 96-well 0.3 ml PCR plate. 
Adenylate 3' Ends 
A single ‘A’ nucleotide is added to the 3’ ends of the blunt fragments to prevent them from 
ligating to one another during the adapter ligation reaction. A corresponding single T’ nucleotide 
on the 3’ end of the adapter provides a complementary overhang for ligating the adapter to the 
fragment. This strategy ensures a low rate of chimera (concatenated template) formation. 
 
Add ATL 
1 Add 2.5 µl of Resuspension Buffer to each well of the ALP plate.  
2 Add 12.5 µl of thawed A-Tailing Mix to each well of the ALP plate. Gently pipette the entire 
volume up and down 10 times to mix thoroughly. Seal the ALP plate with a Microseal ‘B’ adhesive 
seal. 
 
Incubate 1 ALP 
1 Place the sealed ALP plate on the pre-programmed thermal cycler. Close the lid, then select 
and run the ATAIL70 program: pre-heat lid option and set to 100°C, 37°C for 30 minutes, 70°C 
for 5 minutes, Hold at 4°C 
2 When the thermal cycler temperature is 4°C, remove the ALP plate from the thermal cycler, 
then proceed immediately to Ligate Adapters. 
Ligate Adapters 
 
Add LIG 
1 Add 2.5 µl of Resuspension Buffer to each well of the ALP plate. 
2 Add 2.5 µl of Ligation Mix to each well of the ALP plate. 
3 Add 2.5 µl of the thawed RNA Adapter Index to each well of the ALP plate. Gently pipette the 
entire volume up and down 10 times to mix thoroughly. 
4 Use the bottom of a clean eight-tube strip, with caps attached, to pierce holes in the seals of 
the wells that will be used for ligation. Repeat with a new, clean eight-tube strip, with caps 
attached, for each row. 
5 Using an eight-tip multichannel pipette, transfer 2.5 µl of the thawed RNA Adapter to each 
well of the ALP plate. Gently pipette the entire volume up and down 10 times to mix thoroughly. 
6 Seal the ALP plate with a Microseal ‘B’ adhesive seal. Centrifuge the ALP plate to 280g for 1 
minute. 
 
Incubate 2 ALP 
1 Place the sealed ALP plate on the pre-heated thermal cycler. Incubate at 30°C for 10 minutes. 
2 Remove the ALP plate from the thermal cycler. 
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Add STL 
1 Remove the adhesive seal from the ALP plate. 
2 Add 5 µl of Stop Ligation Buffer to each well of the ALP plate to inactivate the ligation. Gently 
pipette the entire volume up and down 10 times to mix thoroughly. 
 
Clean Up ALP 
1 Vortex the AMPure XP Beads for at least 1 minute or until they are well dispersed. 
2 Add 42 µl of mixed AMPure XP Beads to each well of the ALP plate. Gently pipette the entire 
volume up and down 10 times to mix thoroughly and incubate the ALP plate at room 
temperature for 15 minutes. 
3 Place the ALP plate on the magnetic stand at room temperature for 5 minutes or until the 
liquid is clear. 
4 Remove and discard 79.5 µl supernatant from each well of the ALP plate. Take care not to 
disturb the beads. Leave the ALP plate on the magnetic stand while performing the following 
80% EtOH wash steps. 
5 With the ALP plate on the magnetic stand, add 200 µl freshly prepared 80% EtOH to each well 
without disturbing the beads. Incubate the ALP plate at RT for 30 seconds, and then remove and 
discard all of the supernatant from each well. Take care not to disturb the beads. 
6 Repeat step5 one time for a total of two 80% EtOH washes. 
7 With the ALP plate on the magnetic stand, let the samples air-dry at room temperature for 15 
minutes. 
8 Remove the ALP plate from the magnetic stand and add 52.5 µl Resuspension Buffer to each 
well of the ALP plate. Gently pipette the entire volume up and down 10 times to mix thoroughly 
or until the beads are fully resuspended. 
9 Incubate the ALP plate at room temperature for 2 minutes. 
10 Place the ALP plate on the magnetic stand at RT for 5 minutes or until the liquid is clear. 
11 Transfer 50 µl supernatant from each well of the ALP plate to the corresponding well of the 
new 0.3 ml PCR plate labelled with the CAP barcode. Take care not to disturb the beads. 
12 Vortex the AMPure XP Beads until they are well dispersed. 
13 Add 50 µl of mixed AMPure XP Beads to each well of the CAP plate for a second cleanup. 
Gently pipette the entire volume up and down 10 times to mix thoroughly. 
14 Incubate the CAP plate at RT for 15 minutes and place the CAP plate on the magnetic stand 
at room temperature for 5 minutes or until the liquid is clear. 
15 Remove and discard 95 µl supernatant from each well of the CAP plate. With the CAP plate 
on the magnetic stand, add 200 µl freshly prepared 80% EtOH to each well. Take care not to 
disturb the beads. 
16 Incubate the CAP plate at RT for 30 seconds, and then discard all of the supernatant from 
each well. 
17 Repeat the 80% EtOH washes. With the CAP plate on the magnetic stand, let the samples air-
dry at room temperature for 15 minutes, and then remove the plate from the magnetic stand. 
18 Add 22.5 µl Resuspension Buffer to each well of the CAP plate. Gently pipette the entire 
volume up and down 10 times to mix thoroughly or until the beads are fully resuspended. 
19 Incubate the CAP plate at room temperature for 2 minutes, then place the CAP plate on the 
magnetic stand at room temperature for 5 minutes or until the liquid is clear. 
20 Transfer 20 µl supernatant from each well of the CAP plate to the corresponding well of the 
new 0.3 ml PCR plate labelled with the PCR barcode. Take care not to disturb the beads. 
Enrich DNA Fragments 
This process uses PCR to selectively enrich those DNA fragments that have adapter molecules 
on both ends and to amplify the amount of DNA in the library. The PCR is performed with a PCR 
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Primer Cocktail that anneals to the ends of the adapters. Minimize the number of PCR cycles to 
avoid skewing the representation of the library. PCR enriches for fragments that have adapters 
ligated on both ends. Fragments with only one or no adapters on their ends are by-products of 
inefficiencies in the ligation reaction. Neither species can be used to make clusters. Fragments 
without any adapters cannot hybridize to surface-bound primers in the flow cell. Fragments with 
an adapter on only one end can hybridize to surface bound primers, but cannot form clusters. 
 
Make PCR 
1 Add 5 µl of thawed PCR Primer Cocktail to each well of the PCR plate. 
2 Add 25 µl of thawed PCR Master Mix to each well of the PCR plate. Gently pipette the entire 
volume up and down 10 times to mix thoroughly. 
3 Seal the PCR plate with a Microseal ‘B’ adhesive seal. 
 
Amp PCR 
1 Place the sealed PCR plate on the pre-programmed thermal cycler. Close the lid, then select 
and run PCR to amplify the plate. Choose the pre-heat lid option and set to 100°C, 98°C for 30 
seconds, 15 cycles of: 98°C for 10 seconds/ 60°C for 30 seconds/ 72°C for 30 seconds. Final step 
72°C for 5 min. Hold at 4°C 
 
Clean Up PCR 
1 Remove the adhesive seal from the PCR plate. 
2 Vortex the AMPure XP Beads until they are well dispersed. 
3 Add 50 µl of the mixed AMPure XP Beads to each well of the PCR plate containing 50 µl of the 
PCR amplified library. Gently pipette the entire volume up and down 10times to mix thoroughly. 
4 Incubate the PCR plate at room temperature for 15 minutes. 
5 Place the PCR plate on the magnetic stand at room temperature for 5 minutes or until the 
liquid is clear. 
6 Remove and discard 95 µl supernatant from each well of the PCR plate. 
7 With the PCR plate on the magnetic stand, add 200 µl freshly prepared 80% EtOH to each well 
without disturbing the beads. 
8 Incubate the PCR plate at RT for 30 seconds, then discard all of the supernatant. Repeat 80% 
EtOH wash. 
9 With the PCR plate on the magnetic stand, let the samples air-dry at room temperature for 15 
minutes, and then remove the plate from the magnetic stand. 
10 Add 32.5 µl Resuspension Buffer to each well of the PCR plate. Gently pipette the entire 
volume up and down 10 times to mix thoroughly. 
11 Incubate the PCR plate at room temperature for 2 minutes. 
12 Place the PCR plate on the magnetic stand at RT for 5 minutes or until the liquid is clear. 
13 Transfer 30 µl supernatant from each well of the PCR plate to the corresponding well of the 
new 0.3 ml PCR plate labelled with the TSP1 barcode. 
Validate Library 
Illumina recommends performing the following procedures for quality control analysis on your 
sample library and quantification of the DNA library templates. 
 
Quantify Libraries 
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To achieve the highest quality data on Illumina sequencing platforms, it is important to create 
optimum cluster densities across every lane of the flow cell. Optimizing cluster densities requires 
accurate quantitation of DNA library templates. Quantify your libraries using qPCR according to 
the Illumina Sequencing Library qPCR Quantification Guide (part # 11322363). 
 
Quality Control 
1 Load 1 µl of the resuspended construct on an Agilent Technologies 2100 Bioanalyzer using a 
DNA-specific chip such as the Agilent DNA 1000. 
2 Check the size and purity of the sample. The final product should be a band at approximately 
260 bp. 
Normalize and Pool Libraries 
This process describes how to prepare DNA templates for cluster generation. Indexed DNA 
libraries are normalized to 10 nM in the DCT plate and then pooled in equal volumes in the PDP 
plate. DNA libraries not intended for pooling are normalized to 10 nM in the DCT plate. 
 
Make DCT 
1 Transfer 10 µl of sample library from each well of the TSP1 plate to the corresponding well of 
the new MIDI plate labelled with the DCT barcode. 
2 Normalize the concentration of sample library in each well of the DCT plate to 10 nM using a 
mix of Tris-HCl 10 mM, pH 8.5 with 0.1% Tween 20. 
3 Gently pipette the entire normalized sample library volume up and down 10 times to mix 
thoroughly. 
 
Make PDP (for pooling only) 
1 Determine the number of samples to be combined together for each pool. 
2 Transfer 10 µl of each normalized sample library to be pooled from the DCT plate to one well 
of the new 0.3 ml PCR plate labelled with the PDP barcode. 
The total volume in each well of the PDP plate is 10 X the number of combined sample libraries 
and 20–240 µl (2–24 libraries). For example, in our case, the volume for 8 samples was 80 µl. 
3 Gently pipette the entire volume up and down 10 times to mix thoroughly. 
4 Proceed to cluster generation. 
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Appendix 10: RNA-seq – Table 
SUPPORTING TABLE 5: Differentially expressed genes (the most downregulated transcripts are on top of the table) 
  gene_id gene locus sample_1 sample_2 value_1 value_2 log2(fold_change) p_value q_value oID_genes 
1 XLOC_000064 Lsp1beta 2L:898643-901316 Ctr Mut 21.732 0.20409 -6.734 5.00E-05 0.00245 FBgn0002563 
2 XLOC_009430 Hsp70Bbb 3R:8328231-8330822 Ctr Mut 6.53143 0.121707 -5.746 5.00E-05 0.00245 FBgn0051354 
3 XLOC_011176 CR32865 3R:8295701-8304065 Ctr Mut 172.408 7.62157 -4.5 5.00E-05 0.00245 FBgn0052865 
4 XLOC_011881 Hsp68 3R:19880139-19883029 Ctr Mut 188.604 12.7823 -3.883 5.00E-05 0.00245 FBgn0001230 
5 XLOC_003924 CG10073 2R:15268047-15272470 Ctr Mut 82.6779 7.96064 -3.377 5.00E-05 0.00245 FBgn0034440 
6 XLOC_005673 CG3264 2R:18096411-18098247 Ctr Mut 107.861 12.5462 -3.104 5.00E-05 0.00245 FBgn0034712 
7 XLOC_014779 CG34330 X:18962305-18962925 Ctr Mut 155.109 18.4714 -3.07 5.00E-05 0.00245 FBgn0085359 
8 XLOC_005304 IM23 2R:14270208-14270737 Ctr Mut 15.8438 1.92163 -3.044 5.00E-05 0.00245 FBgn0034328 
9 XLOC_003925 CG10081 2R:15273427-15276823 Ctr Mut 50.9421 6.51389 -2.967 5.00E-05 0.00245 FBgn0034441 
10 XLOC_009432 Hsp70Bc 3R:8334797-8337183 Ctr Mut 15.074 1.95085 -2.95 5.00E-05 0.00245 FBgn0013279 
11 XLOC_009431 Hsp70Bb 3R:8331514-8334105 Ctr Mut 52.1496 6.92209 -2.913 5.00E-05 0.00245 FBgn0013278 
12 XLOC_011175 Hsp70Ba 3R:8291025-8293500 Ctr Mut 9.58651 1.40245 -2.773 5.00E-05 0.00245 FBgn0013277 
13 XLOC_001566 CG15353 2L:2006762-2007193 Ctr Mut 300.451 44.8723 -2.743 5.00E-05 0.00245 FBgn0040718 
14 XLOC_001134 ninaD 2L:18081629-18083608 Ctr Mut 2.57373 0.385647 -2.739 5.00E-05 0.00245 FBgn0002939 
15 XLOC_008002 Hsp26 3L:9369517-9370475 Ctr Mut 513.165 77.0631 -2.735 5.00E-05 0.00245 FBgn0001225 
16 XLOC_014469 CG11071 X:13744880-13884528 Ctr Mut 0.763823 0.118598 -2.687 5.00E-05 0.00245 FBgn0263115 
17 XLOC_014469 mamo X:13744880-13884528 Ctr Mut 0.763823 0.118598 -2.687 5.00E-05 0.00245 FBgn0030532 
18 XLOC_013279 CG1847 X:11763220-11765201 Ctr Mut 7.23844 1.18461 -2.611 5.00E-05 0.00245 FBgn0030345 
19 XLOC_001238 CG16772 2L:19962678-19963844 Ctr Mut 3.05377 0.511087 -2.579 5.00E-05 0.00245 FBgn0032835 
20 XLOC_006566 Hsp27 3L:9377162-9378382 Ctr Mut 193.978 35.6058 -2.446 5.00E-05 0.00245 FBgn0001226 
21 XLOC_007314 CG32444 3L:21630046-21632160 Ctr Mut 60.1528 11.0785 -2.441 5.00E-05 0.00245 FBgn0043783 
22 XLOC_003070 Lcp3 2R:4322814-4323600 Ctr Mut 54.0499 10.0496 -2.427 5.00E-05 0.00245 FBgn0002534 
23 XLOC_006292 CG11350 3L:4482808-4484370 Ctr Mut 1220.35 226.958 -2.427 5.00E-05 0.00245 FBgn0035552 
24 XLOC_013810 CG13360 X:678823-684312 Ctr Mut 124.579 23.3674 -2.414 5.00E-05 0.00245 FBgn0025620 
25 XLOC_002297 CG9928 2L:13142493-13142902 Ctr Mut 11.9928 2.46779 -2.281 5.00E-05 0.00245 FBgn0032472 
26 XLOC_006565 Hsp23 3L:9374981-9375865 Ctr Mut 385.882 80.4126 -2.263 5.00E-05 0.00245 FBgn0001224 
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  gene_id gene locus sample_1 sample_2 value_1 value_2 log2(fold_change) p_value q_value oID_genes 
27 XLOC_000883 CG5867 2L:13236492-13239296 Ctr Mut 5.45954 1.16017 -2.234 5.00E-05 0.00245 FBgn0027586 
28 XLOC_008415 CG42718 3L:16313929-16314372 Ctr Mut 112.352 25.0911 -2.163 5.00E-05 0.00245 FBgn0261635 
29 XLOC_007885 CG32376 3L:7534681-7535557 Ctr Mut 1.78108 0.401468 -2.149 0.0006 0.01944 FBgn0052376 
30 XLOC_005555 CG43710 2R:16664231-16665254 Ctr Mut 3.18182 0.737946 -2.108 0.0001 0.00448 FBgn0263849 
31 XLOC_000339 Cyp28d2 2L:5207266-5209345 Ctr Mut 58.9185 13.8134 -2.093 5.00E-05 0.00245 FBgn0031688 
32 XLOC_006562 Hsp22 3L:9365821-9368064 Ctr Mut 186.688 44.4412 -2.071 0.0001 0.00448 FBgn0001223 
33 XLOC_006562 Hsp67Bb 3L:9365821-9368064 Ctr Mut 186.688 44.4412 -2.071 0.0001 0.00448 FBgn0001228 
34 XLOC_002448 TepI 2L:15888638-15893811 Ctr Mut 0.745169 0.178166 -2.064 0.0011 0.03093 FBgn0041183 
35 XLOC_004016 IM14 2R:16757896-16758183 Ctr Mut 29.3402 7.11787 -2.043 0.0007 0.02195 FBgn0067905 
36 XLOC_001953 CG7214 2L:7743676-7744841 Ctr Mut 21.0819 5.15237 -2.033 5.00E-05 0.00245 FBgn0031940 
37 XLOC_003728 snoRNA:U3:54Ab 2R:13033134-13034026 Ctr Mut 5.7294 1.41325 -2.019 0.00125 0.03415 FBgn0065047 
38 XLOC_005615 CG30288 2R:17406747-17409482 Ctr Mut 3.01157 0.753787 -1.998 0.00025 0.00942 FBgn0050288 
39 XLOC_005615 CG30289 2R:17406747-17409482 Ctr Mut 3.01157 0.753787 -1.998 0.00025 0.00942 FBgn0050289 
40 XLOC_011090 CR43283 3R:7073349-7081916 Ctr Mut 43.613 10.9697 -1.991 5.00E-05 0.00245 FBgn0262972 
41 XLOC_008403 CG34248 3L:16263468-16264002 Ctr Mut 35.2717 8.87464 -1.991 5.00E-05 0.00245 FBgn0085277 
42 XLOC_008782 CG14565 3L:21736347-21737369 Ctr Mut 122.528 30.9103 -1.987 5.00E-05 0.00245 FBgn0037129 
43 XLOC_013276 CR43908 X:11731575-11732059 Ctr Mut 494.77 126.457 -1.968 5.00E-05 0.00245 FBgn0264509 
44 XLOC_001438 CG17018 2L:22311930-22368796 Ctr Mut 0.589344 0.152225 -1.953 0.0001 0.00448 FBgn0039972 
45 XLOC_000517 CG7224 2L:7998933-8004313 Ctr Mut 205.125 53.7754 -1.931 0.0002 0.00793 FBgn0031971 
46 XLOC_014033 CG34434 X:5508586-5510403 Ctr Mut 2.27512 0.607058 -1.906 0.0001 0.00448 FBgn0250904 
47 XLOC_007806 Cpr65Ax2 3L:6143157-6143957 Ctr Mut 69.2301 18.5246 -1.902 5.00E-05 0.00245 FBgn0042118 
48 XLOC_012090 Cpr97Eb 3R:22915425-22916964 Ctr Mut 13.7466 3.71012 -1.89 5.00E-05 0.00245 FBgn0039481 
49 XLOC_008781 CG14566 3L:21732578-21733409 Ctr Mut 208.541 58.0778 -1.844 5.00E-05 0.00245 FBgn0037127 
50 XLOC_007326 CG14572 3L:21734633-21735541 Ctr Mut 125.315 35.5982 -1.816 5.00E-05 0.00245 FBgn0037128 
51 XLOC_003741 CG10764 2R:13340923-13343234 Ctr Mut 0.589858 0.168019 -1.812 0.00165 0.04288 FBgn0034221 
52 XLOC_010668 CG14661 3R:779227-780975 Ctr Mut 7.74517 2.21541 -1.806 5.00E-05 0.00245 FBgn0037288 
53 XLOC_014489 CG13403 X:14085247-14086019 Ctr Mut 13.0043 3.78246 -1.782 5.00E-05 0.00245 FBgn0030544 
54 XLOC_013400 CG11585 X:14083548-14084788 Ctr Mut 77.8925 23.0131 -1.759 5.00E-05 0.00245 FBgn0030543 
55 XLOC_007752 blanks 3L:5490622-5492058 Ctr Mut 5.76446 1.7253 -1.74 5.00E-05 0.00245 FBgn0035608 
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56 XLOC_007797 l(3)mbn 3L:6117033-6121907 Ctr Mut 42.175 12.7285 -1.728 5.00E-05 0.00245 FBgn0002440 
57 XLOC_010531 CG15530 3R:26003598-26005903 Ctr Mut 1.22738 0.3786 -1.697 0.00015 0.00635 FBgn0039752 
58 XLOC_010488 Obp99d 3R:25540260-25540674 Ctr Mut 19.4452 6.02601 -1.69 0.0003 0.01084 FBgn0039684 
59 XLOC_008952 Hph 3R:1082762-1095297 Ctr Mut 85.8225 26.9312 -1.672 0.0002 0.00793 FBgn0264652 
60 XLOC_012147 CG43124 3R:24088456-24090504 Ctr Mut 10.8337 3.40539 -1.67 0.0004 0.01385 FBgn0262587 
61 XLOC_012147 CG43125 3R:24088456-24090504 Ctr Mut 10.8337 3.40539 -1.67 0.0004 0.01385 FBgn0262588 
62 XLOC_001224 CG13077 2L:19563903-19567359 Ctr Mut 40.0333 12.6016 -1.668 5.00E-05 0.00245 FBgn0032810 
63 XLOC_001224 CG13078 2L:19563903-19567359 Ctr Mut 40.0333 12.6016 -1.668 5.00E-05 0.00245 FBgn0032809 
64 XLOC_007393 CG11131 3L:22891843-22893362 Ctr Mut 471.945 149.262 -1.661 5.00E-05 0.00245 FBgn0037204 
65 XLOC_014285 CG15308 X:10112038-10113172 Ctr Mut 586.355 186.877 -1.65 5.00E-05 0.00245 FBgn0040941 
66 XLOC_007766 DnaJ-1 3L:5743128-5745289 Ctr Mut 182.369 59.2321 -1.622 5.00E-05 0.00245 FBgn0263106 
67 XLOC_012056 TwdlO 3R:22451729-22452419 Ctr Mut 334.705 110.297 -1.601 5.00E-05 0.00245 FBgn0039438 
68 XLOC_012952 Cpr5C X:5698709-5699377 Ctr Mut 11.4301 3.77434 -1.599 0.00025 0.00942 FBgn0029811 
69 XLOC_001490 CG11835 2L:560567-563347 Ctr Mut 3.37205 1.1194 -1.591 5.00E-05 0.00245 FBgn0031264 
70 XLOC_001954 CG7203 2L:7752167-7753156 Ctr Mut 324.836 107.943 -1.589 5.00E-05 0.00245 FBgn0031942 
71 XLOC_006368 Lcp65Aa 3L:6144403-6144903 Ctr Mut 261.484 87.5947 -1.578 5.00E-05 0.00245 FBgn0020645 
72 XLOC_007802 Lcp65Ae 3L:6130682-6131218 Ctr Mut 155.104 51.9618 -1.578 5.00E-05 0.00245 FBgn0020640 
73 XLOC_000968 Adh 2L:14599768-14689326 Ctr Mut 5266.79 1768.03 -1.575 5.00E-05 0.00245 FBgn0000055 
74 XLOC_000968 Adhr 2L:14599768-14689326 Ctr Mut 5266.79 1768.03 -1.575 5.00E-05 0.00245 FBgn0000056 
75 XLOC_006973 CG13067 3L:16264381-16265018 Ctr Mut 1927.84 654.105 -1.559 5.00E-05 0.00245 FBgn0036589 
76 XLOC_007072 CG7497 3L:17626548-17630975 Ctr Mut 8.54687 2.90929 -1.555 5.00E-05 0.00245 FBgn0036742 
77 XLOC_000123 Nplp4 2L:2008459-2008966 Ctr Mut 1339.23 456.409 -1.553 5.00E-05 0.00245 FBgn0040717 
78 XLOC_003116 CG13748 2R:4827919-4828641 Ctr Mut 126.142 42.9972 -1.553 0.00095 0.02805 FBgn0033355 
79 XLOC_009157 Atg13 3R:4175523-4178539 Ctr Mut 42.4394 14.5206 -1.547 0.0009 0.02717 FBgn0261108 
80 XLOC_009326 Ugt86Dc 3R:6980376-6982235 Ctr Mut 7.19726 2.48006 -1.537 5.00E-05 0.00245 FBgn0040257 
81 XLOC_005277 proPO-A1 2R:13761451-13814148 Ctr Mut 34.6074 12.0992 -1.516 5.00E-05 0.00245 FBgn0261362 
82 XLOC_008797 CG7130 3L:22068155-22068856 Ctr Mut 10.4691 3.68428 -1.507 0.0001 0.00448 FBgn0037151 
83 XLOC_000678 CG33301 2L:10049481-10050956 Ctr Mut 7.0418 2.48883 -1.5 5.00E-05 0.00245 FBgn0053301 
84 XLOC_011873 CG12268 3R:19769349-19774141 Ctr Mut 38.7036 13.9172 -1.476 5.00E-05 0.00245 FBgn0039131 
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85 XLOC_008658 CG7365 3L:20117397-20120481 Ctr Mut 19.9037 7.168 -1.473 5.00E-05 0.00245 FBgn0036939 
86 XLOC_008411 CG13044 3L:16295589-16296278 Ctr Mut 846.606 305.344 -1.471 5.00E-05 0.00245 FBgn0036599 
87 XLOC_010227 CG31103 3R:21045007-21047163 Ctr Mut 10.4994 3.80111 -1.466 5.00E-05 0.00245 FBgn0051103 
88 XLOC_005773 chrw 2R:19407361-19411096 Ctr Mut 31.4098 11.3926 -1.463 0.0008 0.02472 FBgn0015372 
89 XLOC_011984 CG10560 3R:21144271-21145801 Ctr Mut 37.3235 13.6398 -1.452 5.00E-05 0.00245 FBgn0039325 
90 XLOC_007003 CG4229 3L:16549922-16551058 Ctr Mut 289.674 105.89 -1.452 0.00015 0.00635 FBgn0036639 
91 XLOC_008003 Hsp67Ba 3L:9370901-9372634 Ctr Mut 4.58809 1.68227 -1.447 0.0002 0.00793 FBgn0001227 
92 XLOC_004604 Lcp2 2R:4321301-4322080 Ctr Mut 29.8738 11.0082 -1.44 0.0003 0.01084 FBgn0002533 
93 XLOC_008579 CG34256 3L:18981835-18982915 Ctr Mut 5.97674 2.21397 -1.433 0.00125 0.03415 FBgn0085285 
94 XLOC_006820 stv 3L:13470640-13476615 Ctr Mut 98.0141 36.408 -1.429 0.00055 0.0181 FBgn0086708 
95 XLOC_014566 CG15599 X:15578717-15582995 Ctr Mut 5.82233 2.16531 -1.427 5.00E-05 0.00245 FBgn0030667 
96 XLOC_013446 CG6324 X:15370021-15375755 Ctr Mut 3.28488 1.22934 -1.418 5.00E-05 0.00245 FBgn0030647 
97 XLOC_006983 CG13060 3L:16312955-16313554 Ctr Mut 176.651 66.1886 -1.416 0.00015 0.00635 FBgn0036606 
98 XLOC_004781 CG13218 2R:7120768-7121209 Ctr Mut 179.559 67.4227 -1.413 0.0001 0.00448 FBgn0033587 
99 XLOC_008412 CG13043 3L:16298324-16298970 Ctr Mut 597.248 224.922 -1.409 0.0002 0.00793 FBgn0036600 
100 XLOC_008778 CG14569 3L:21723824-21724650 Ctr Mut 358.927 135.194 -1.409 0.0002 0.00793 FBgn0037123 
101 XLOC_010766 CG15597 3R:2110180-2110922 Ctr Mut 154.353 58.4937 -1.4 5.00E-05 0.00245 FBgn0037420 
102 XLOC_012255 CG31029 3R:25955010-25958117 Ctr Mut 0.845408 0.326161 -1.374 0.00135 0.03642 FBgn0051029 
103 XLOC_005156 CR43730 2R:12176829-12178927 Ctr Mut 67.0347 26.0723 -1.362 5.00E-05 0.00245 FBgn0263981 
104 XLOC_008779 CG14568 3L:21725905-21726587 Ctr Mut 229.553 89.5976 -1.357 0.0003 0.01084 FBgn0037124 
105 XLOC_007831 ple 3L:6707137-6712625 Ctr Mut 109.25 42.9276 -1.348 5.00E-05 0.00245 FBgn0005626 
106 XLOC_006972 CG13068 3L:16262491-16263011 Ctr Mut 536.478 210.899 -1.347 0.00045 0.01528 FBgn0036588 
107 XLOC_004792 Cpr47Eg 2R:7165460-7165946 Ctr Mut 5681.34 2237.57 -1.344 5.00E-05 0.00245 FBgn0086519 
108 XLOC_005740 CG13545 2R:19041400-19049553 Ctr Mut 455.401 180.392 -1.336 0.0001 0.00448 FBgn0034828 
109 XLOC_010005 CG7069 3R:18198556-18201301 Ctr Mut 0.838872 0.334754 -1.325 0.00115 0.03208 FBgn0038952 
110 XLOC_003261 CG13228 2R:7121507-7121915 Ctr Mut 119.517 47.8564 -1.32 5.00E-05 0.00245 FBgn0033588 
111 XLOC_009280 CG31477 3R:5947494-5948042 Ctr Mut 12.8956 5.16838 -1.319 0.00105 0.02992 FBgn0051477 
112 XLOC_008563 CG12477 3L:18714992-18716372 Ctr Mut 8.68613 3.50669 -1.309 5.00E-05 0.00245 FBgn0036809 
113 XLOC_007664 CG12766 3L:3938623-3940125 Ctr Mut 6.95344 2.80943 -1.307 0.0006 0.01944 FBgn0035476 
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114 XLOC_010229 CG11852 3R:21063346-21064617 Ctr Mut 176.98 71.8569 -1.3 5.00E-05 0.00245 FBgn0039297 
115 XLOC_014288 CG12643 X:10158265-10159296 Ctr Mut 39.5161 16.2466 -1.282 5.00E-05 0.00245 FBgn0040942 
116 XLOC_011190 CG5999 3R:8567679-8569402 Ctr Mut 11.5723 4.76525 -1.28 5.00E-05 0.00245 FBgn0038083 
117 XLOC_013568 CG5162 X:17109334-17111409 Ctr Mut 10.0183 4.15535 -1.27 0.00025 0.00942 FBgn0030828 
118 XLOC_006289 CG32248 3L:4471748-4472438 Ctr Mut 192.03 79.92 -1.265 5.00E-05 0.00245 FBgn0052248 
119 XLOC_011481 Edg91 3R:13436577-13437233 Ctr Mut 95.3078 39.9 -1.256 0.0002 0.00793 FBgn0004554 
120 XLOC_008416 CG13039 3L:16318182-16319862 Ctr Mut 722.418 303.544 -1.251 0.00035 0.01228 FBgn0036609 
121 XLOC_008416 CG13040 3L:16318182-16319862 Ctr Mut 722.418 303.544 -1.251 0.00035 0.01228 FBgn0036608 
122 XLOC_004644 PO45 2R:4929765-4932213 Ctr Mut 60.5837 25.6193 -1.242 5.00E-05 0.00245 FBgn0033367 
123 XLOC_008414 CG13041 3L:16312053-16312626 Ctr Mut 333.969 141.834 -1.236 0.00025 0.00942 FBgn0036605 
124 XLOC_006984 CG13059 3L:16316771-16317408 Ctr Mut 696.059 296.916 -1.229 0.00035 0.01228 FBgn0036607 
125 XLOC_004251 CG13560 2R:19635095-19635741 Ctr Mut 876.361 374.119 -1.228 0.00015 0.00635 FBgn0034899 
126 XLOC_010128 CG13606 3R:19997934-20009752 Ctr Mut 71.9911 30.7475 -1.227 0.0011 0.03093 FBgn0039161 
127 XLOC_002677 CG17570 2L:20263379-20264703 Ctr Mut 10.007 4.27965 -1.225 0.0002 0.00793 FBgn0260000 
128 XLOC_002475 CG5953 2L:16508075-16532877 Ctr Mut 31.7608 13.6132 -1.222 0.0015 0.03966 FBgn0263555 
129 XLOC_005193 Ugt37c1 2R:12730800-12732543 Ctr Mut 23.5817 10.1546 -1.216 0.00015 0.00635 FBgn0026754 
130 XLOC_009674 CG17560 3R:12443671-12445600 Ctr Mut 10.9523 4.73 -1.211 0.0002 0.00793 FBgn0038450 
131 XLOC_003262 CG13227 2R:7122758-7123260 Ctr Mut 105.254 45.4569 -1.211 0.00025 0.00942 FBgn0033589 
132 XLOC_011983 CG10553 3R:21142182-21143833 Ctr Mut 3.58872 1.56124 -1.201 0.0017 0.04354 FBgn0039324 
133 XLOC_011483 CG14324 3R:13444002-13444513 Ctr Mut 138.158 60.753 -1.185 0.002 0.0492 FBgn0038527 
134 XLOC_007730 CG32237 3L:4847182-4852708 Ctr Mut 318.934 140.658 -1.181 0.0018 0.04544 FBgn0052237 
135 XLOC_004080 CG33225 2R:17477890-17479089 Ctr Mut 7.64226 3.38216 -1.176 0.00185 0.04626 FBgn0053225 
136 XLOC_007800 Lcp65Ag1 3L:6127796-6128374 Ctr Mut 2092.22 930.964 -1.168 5.00E-05 0.00245 FBgn0020638 
137 XLOC_002404 mol 2L:14975746-14997559 Ctr Mut 20.8796 9.30152 -1.167 0.00015 0.00635 FBgn0086711 
138 XLOC_009718 CG42821 3R:13238733-13239263 Ctr Mut 70.1204 31.4534 -1.157 0.00025 0.00942 FBgn0262003 
139 XLOC_008690 CG11796 3L:20429349-20432972 Ctr Mut 183.973 82.7544 -1.153 0.0003 0.01084 FBgn0036992 
140 XLOC_006860 shd 3L:14607557-14615305 Ctr Mut 16.1022 7.2448 -1.152 5.00E-05 0.00245 FBgn0003388 
141 XLOC_010568 CG15544 3R:26653498-26667756 Ctr Mut 3.87806 1.76018 -1.14 0.0007 0.02195 FBgn0039804 
142 XLOC_011430 Scp2 3R:12400264-12409382 Ctr Mut 33.28 15.138 -1.136 0.00015 0.00635 FBgn0020907 
  
249 
 
  gene_id gene locus sample_1 sample_2 value_1 value_2 log2(fold_change) p_value q_value oID_genes 
143 XLOC_003374 Cpr49Af 2R:8293509-8293948 Ctr Mut 106.149 48.4462 -1.132 0.0002 0.00793 FBgn0033729 
144 XLOC_011008 CG42857 3R:5646235-5646913 Ctr Mut 9.68486 4.42239 -1.131 0.00105 0.02992 FBgn0262104 
145 XLOC_007756 CG10625 3L:5531507-5544280 Ctr Mut 408.193 189.606 -1.106 0.0003 0.01084 FBgn0035612 
146 XLOC_005521 CG13868 2R:16196281-16204422 Ctr Mut 280.598 130.78 -1.101 0.00105 0.02992 FBgn0034501 
147 XLOC_006473 CG13678 3L:8215240-8216053 Ctr Mut 954.63 446.702 -1.096 0.00115 0.03208 FBgn0035859 
148 XLOC_006192 Hsp83 3L:3192968-3197631 Ctr Mut 749.786 387.733 -1.095 0.0002 0.00793 FBgn0001233 
149 XLOC_001646 CG17224 2L:3016590-3018308 Ctr Mut 12.7966 6.03424 -1.085 0.00095 0.02805 FBgn0031489 
150 XLOC_013564 CG5070 X:17097146-17097965 Ctr Mut 123.881 58.6552 -1.079 0.0002 0.00793 FBgn0030824 
151 XLOC_004271 Tal 2R:19827935-19829637 Ctr Mut 501.871 238.365 -1.074 0.00035 0.01228 FBgn0023477 
152 XLOC_007157 Cpr76Bb 3L:19512748-19513519 Ctr Mut 51.5536 24.5953 -1.068 0.0008 0.02472 FBgn0036879 
153 XLOC_011978 CG31097 3R:21119179-21128039 Ctr Mut 73.7198 35.2114 -1.066 0.00175 0.0445 FBgn0051288 
154 XLOC_011978 CG31102 3R:21119179-21128039 Ctr Mut 73.7198 35.2114 -1.066 0.00175 0.0445 FBgn0051097 
155 XLOC_011978 CG31288 3R:21119179-21128039 Ctr Mut 73.7198 35.2114 -1.066 0.00175 0.0445 FBgn0051102 
156 XLOC_011697 CG3301 3R:17099964-17101973 Ctr Mut 40.183 19.3845 -1.052 0.00025 0.00942 FBgn0038878 
157 XLOC_010570 Cpr100A 3R:26693244-26694908 Ctr Mut 194.102 93.7259 -1.05 0.00175 0.0445 FBgn0039805 
158 XLOC_011678 Mvl 3R:16877104-16886523 Ctr Mut 76.7857 37.1095 -1.049 0.0005 0.01666 FBgn0011672 
159 XLOC_003750 CG4847 2R:13399027-13401364 Ctr Mut 112.724 54.5119 -1.048 0.00095 0.02805 FBgn0034229 
160 XLOC_009412 GstD7 3R:8204115-8204977 Ctr Mut 149.782 72.5543 -1.046 0.00065 0.02068 FBgn0010043 
161 XLOC_013222 CG15201 X:11038152-11038842 Ctr Mut 24.7431 12.01 -1.043 0.00155 0.04068 FBgn0030272 
162 XLOC_000625 Aldh 2L:9370308-9415156 Ctr Mut 670.262 325.788 -1.041 0.0003 0.01084 FBgn0012036 
163 XLOC_007798 Lcp65Ag2 3L:6123485-6126693 Ctr Mut 5409.42 2637.64 -1.036 5.00E-05 0.00245 FBgn002063 
164 XLOC_007798 Lcp65Ag3 3L:6123485-6126693 Ctr Mut 5409.42 2637.64 -1.036 5.00E-05 0.00245 FBgn0086611 
165 XLOC_013750 CG34120 X:20994753-21012062 Ctr Mut 6.2822 3.08376 -1.027 0.0015 0.03966 FBgn0083956 
166 XLOC_007708 CG32241 3L:4465103-4466932 Ctr Mut 492.191 242.305 -1.022 0.00105 0.02992 FBgn0052241 
167 XLOC_002166 CG7296 2L:10686390-10686988 Ctr Mut 1079.97 534.024 -1.016 0.0017 0.04354 FBgn0032283 
168 XLOC_002581 CG42502 2L:18810035-18810986 Ctr Mut 106.086 52.5898 -1.012 0.00145 0.03872 FBgn0040992 
169 XLOC_004536 CG12826 2R:3557831-3558614 Ctr Mut 42.4752 21.2215 -1.001 0.00045 0.01528 FBgn0033207 
170 XLOC_009843 CG17752 3R:15435765-15438166 Ctr Mut 93.3581 187.682 1.0074 0.00065 0.02068 FBgn0038718 
171 XLOC_009803 CG14302 3R:14558422-14558756 Ctr Mut 1528.84 3103.22 1.0213 0.0006 0.01944 FBgn0038647 
  
250 
 
  gene_id gene locus sample_1 sample_2 value_1 value_2 log2(fold_change) p_value q_value oID_genes 
172 XLOC_011562 CG14291 3R:14736772-14738641 Ctr Mut 6.73496 13.6718 1.0215 0.00035 0.01228 FBgn0038660 
173 XLOC_000050 CG13947 2L:779172-779655 Ctr Mut 80.96 164.841 1.0258 0.00035 0.01228 FBgn0031277 
174 XLOC_006714 CG7252 3L:11940774-11942348 Ctr Mut 60.8624 123.922 1.0258 0.00025 0.00942 FBgn0036226 
175 XLOC_005078 CG8093 2R:11101785-11103191 Ctr Mut 7.84335 16.1261 1.0399 0.0012 0.03321 FBgn0033999 
176 XLOC_000098 CG33128 2L:1494089-1495456 Ctr Mut 343.173 707.19 1.0432 0.00015 0.00635 FBgn0053128 
177 XLOC_006553 PGRP-LA 3L:9327431-9331436 Ctr Mut 10.738 22.1476 1.0444 0.0018 0.04544 FBgn0035975 
178 XLOC_011976 CG10514 3R:21104145-21105541 Ctr Mut 54.4335 112.348 1.0454 0.0007 0.02195 FBgn0039312 
179 XLOC_010214 CG11836 3R:20896852-20898434 Ctr Mut 9.96505 20.6502 1.0512 0.00085 0.02603 FBgn0039272 
180 XLOC_007561 CG5687 3L:1933632-1938740 Ctr Mut 9.50584 19.7321 1.0537 0.0001 0.00448 FBgn0035293 
181 XLOC_004931 CG13323 2R:8934237-8937132 Ctr Mut 981.74 2042.16 1.0567 0.00115 0.03208 FBgn0033788 
182 XLOC_008666 CG7017 3L:20203391-20205262 Ctr Mut 290.07 604.283 1.0588 0.00035 0.01228 FBgn0036951 
183 XLOC_003180 CG1698 2R:5653866-5694370 Ctr Mut 14.1789 29.6999 1.0667 0.00055 0.0181 FBgn0033443 
184 XLOC_006353 Jon65Aii 3L:6045420-6046315 Ctr Mut 188.37 396.193 1.0726 0.0004 0.01385 FBgn0035666 
185 XLOC_006202 CG12009 3L:3291458-3299000 Ctr Mut 16.8805 35.5859 1.0759 0.00015 0.00635 FBgn0035430 
186 XLOC_004187 CG9826 2R:18728357-18729988 Ctr Mut 11.8752 25.0608 1.0775 0.0002 0.00793 FBgn0034784 
187 XLOC_013817 CG3706 X:824963-826704 Ctr Mut 2.0898 4.43946 1.087 0.00105 0.02992 FBgn0040342 
188 XLOC_014720 CG32557 X:17746990-17750156 Ctr Mut 8.90336 18.9303 1.0883 0.00025 0.00942 FBgn0052557 
189 XLOC_006330 Blimp-1 3L:5623959-5643812 Ctr Mut 3.10495 6.62457 1.0933 0.0003 0.01084 FBgn0035625 
190 XLOC_006816 CG10725 3L:13431053-13432109 Ctr Mut 520.684 1111.87 1.0945 0.0001 0.00448 FBgn0036362 
191 XLOC_008667 CG6933 3L:20211599-20213520 Ctr Mut 670.713 1436.17 1.0985 5.00E-05 0.00245 FBgn0036952 
192 XLOC_003427 CG13325 2R:9003809-9013517 Ctr Mut 4.007 8.58533 1.0994 0.0002 0.00793 FBgn0033792 
193 XLOC_005579 Cht9 2R:16955486-16956813 Ctr Mut 254.781 547.998 1.1049 5.00E-05 0.00245 FBgn0034582 
194 XLOC_000887 CG31728 2L:13251508-13257426 Ctr Mut 13.7833 29.7011 1.1076 0.00015 0.00635 FBgn0051728 
195 XLOC_009511 tal-AA 3R:9638830-9640370 Ctr Mut 40.0736 86.386 1.1081 0.0001 0.00448 FBgn0259731 
196 XLOC_002035 CG9289 2L:8681313-8684350 Ctr Mut 37.6492 81.2407 1.1096 0.00085 0.02603 FBgn0032058 
197 XLOC_003363 CG30043 2R:8246940-8250730 Ctr Mut 17.1834 37.2144 1.1149 0.00015 0.00635 FBgn0050043 
198 XLOC_012234 Jon99Ci 3R:25750947-25751911 Ctr Mut 250.699 543.716 1.1169 0.0001 0.00448 FBgn0003358 
199 XLOC_000654 CG4017 2L:9767058-9768727 Ctr Mut 2.65353 5.76484 1.1194 0.0012 0.03321 FBgn0032143 
200 XLOC_012290 PH4alphaSG1 3R:26329386-26331383 Ctr Mut 3.33517 7.29475 1.1291 0.0002 0.00793 FBgn0051014 
  
251 
 
  gene_id gene locus sample_1 sample_2 value_1 value_2 log2(fold_change) p_value q_value oID_genes 
201 XLOC_012203 CG11470 3R:25414757-25416761 Ctr Mut 131.788 291.218 1.1439 0.00065 0.02068 FBgn0039671 
202 XLOC_012203 CG31041 3R:25414757-25416761 Ctr Mut 131.788 291.218 1.1439 0.00065 0.02068 FBgn0051041 
203 XLOC_002557 CG10283 2L:18472963-18484573 Ctr Mut 3.92372 8.69094 1.1473 0.0003 0.01084 FBgn0032681 
204 XLOC_005213 Amy-p 2R:13006210-13013887 Ctr Mut 134.272 298.336 1.1518 0.00165 0.04288 FBgn0000079 
205 XLOC_012951 CG12239 X:5686179-5688576 Ctr Mut 7.9618 17.7984 1.1606 5.00E-05 0.00245 FBgn0029810 
206 XLOC_000504 CG7191 2L:7767623-7775040 Ctr Mut 7.66408 17.3393 1.1779 5.00E-05 0.00245 FBgn0031945 
207 XLOC_005287 CG10912 2R:13943567-13944564 Ctr Mut 420.073 950.946 1.1787 5.00E-05 0.00245 FBgn0034296 
208 XLOC_000049 CG12506 2L:773546-776918 Ctr Mut 13.5498 30.6975 1.1799 0.0015 0.03966 FBgn0031276 
209 XLOC_000049 CG13946 2L:773546-776918 Ctr Mut 13.5498 30.6975 1.1799 0.0015 0.03966 FBgn0040725 
210 XLOC_004724 CG12912 2R:6091595-6124853 Ctr Mut 6.83549 15.5198 1.183 0.00075 0.02331 FBgn0000448 
211 XLOC_004724 Hr46 2R:6091595-6124853 Ctr Mut 6.83549 15.5198 1.183 0.00075 0.02331 FBgn0033497 
212 XLOC_009442 CG14395 3R:8488552-8499686 Ctr Mut 2.64887 6.01455 1.1831 5.00E-05 0.00245 FBgn0038073 
213 XLOC_000973 CG34166 2L:14743252-14743859 Ctr Mut 790.567 1799.38 1.1865 0.00015 0.00635 FBgn0085195 
214 XLOC_006427 CG18417 3L:7393169-7394771 Ctr Mut 23.2746 53.1451 1.1912 0.0001 0.00448 FBgn0035780 
215 XLOC_008498 Jon74E 3L:17523180-17542227 Ctr Mut 158.571 365.792 1.2059 0.00075 0.02331 FBgn0023197 
216 XLOC_009183 CG8369 3R:4647729-4648560 Ctr Mut 74.2016 171.812 1.2113 5.00E-05 0.00245 FBgn0040532 
217 XLOC_002040 CG9463 2L:8765360-8772344 Ctr Mut 7.25103 16.8242 1.2143 5.00E-05 0.00245 FBgn0032066 
218 XLOC_002040 CG9465 2L:8765360-8772344 Ctr Mut 7.25103 16.8242 1.2143 5.00E-05 0.00245 FBgn0032067 
219 XLOC_009690 CG5225 3R:12854427-12856423 Ctr Mut 24.1347 56.0932 1.2167 5.00E-05 0.00245 FBgn0038468 
220 XLOC_003280 sha 2R:7211818-7223968 Ctr Mut 0.887007 2.07106 1.2234 5.00E-05 0.00245 FBgn0003382 
221 XLOC_011372 CG14872 3R:11333780-11335676 Ctr Mut 128.748 301.003 1.2252 5.00E-05 0.00245 FBgn0038346 
222 XLOC_000606 CG9568 2L:9010585-9011358 Ctr Mut 202.832 477.651 1.2357 0.0001 0.00448 FBgn0032087 
223 XLOC_011462 Mur89F 3R:12977587-13027935 Ctr Mut 12.793 30.1621 1.2374 0.0011 0.03093 FBgn0038492 
224 XLOC_007793 Jon65Ai 3L:6046683-6047543 Ctr Mut 775.503 1833.99 1.2418 5.00E-05 0.00245 FBgn0035667 
225 XLOC_012425 yellow-h 4:248549-251054 Ctr Mut 13.8626 33.1027 1.2558 5.00E-05 0.00245 FBgn0039896 
226 XLOC_004578 Obp44a 2R:4018937-4022588 Ctr Mut 263.126 630.886 1.2616 0.00025 0.00942 FBgn0033268 
227 XLOC_008527 CG5506 3L:17872195-17877476 Ctr Mut 179.893 432.693 1.2662 0.00015 0.00635 FBgn0036766 
228 XLOC_008253 CG10154 3L:13428779-13430236 Ctr Mut 81.5316 196.683 1.2704 5.00E-05 0.00245 FBgn0036361 
229 XLOC_010241 CG11892 3R:21107269-21108964 Ctr Mut 34.8713 84.6199 1.279 5.00E-05 0.00245 FBgn0039313 
  
252 
 
  gene_id gene locus sample_1 sample_2 value_1 value_2 log2(fold_change) p_value q_value oID_genes 
230 XLOC_000757 CG17134 2L:10804268-10842603 Ctr Mut 70.5108 171.507 1.2824 0.00125 0.03415 FBgn0032304 
231 XLOC_012748 CG11382 X:1104002-1105886 Ctr Mut 20.6205 50.7274 1.2987 5.00E-05 0.00245 FBgn0040367 
232 XLOC_011968 Cad96Cb 3R:21049877-21058043 Ctr Mut 0.623151 1.536 1.3015 0.00125 0.03415 FBgn0039294 
233 XLOC_000547 CG14275 2L:8327455-8332911 Ctr Mut 12.3333 30.5993 1.3109 5.00E-05 0.00245 FBgn0032022 
234 XLOC_001570 CG42296 2L:2032634-2035936 Ctr Mut 3.04095 7.54833 1.3116 0.00185 0.04626 FBgn0259192 
235 XLOC_011913 CG5768 3R:20211824-20216089 Ctr Mut 3.49094 8.66815 1.3121 0.0003 0.01084 FBgn0039198 
236 XLOC_006133 CG13806 3L:2266393-2267640 Ctr Mut 21.5374 53.6067 1.3156 5.00E-05 0.00245 FBgn0035325 
237 XLOC_010696 CG2663 3R:1226315-1229851 Ctr Mut 31.0395 77.9 1.3275 5.00E-05 0.00245 FBgn0037323 
238 XLOC_008164 obst-G 3L:11945400-11946417 Ctr Mut 15.2566 38.4208 1.3325 5.00E-05 0.00245 FBgn0036228 
239 XLOC_010597 mey 3R:27324960-27332716 Ctr Mut 6.69616 16.9632 1.341 5.00E-05 0.00245 FBgn0039851 
240 XLOC_002682 CG16798 2L:20376982-20382355 Ctr Mut 2.30975 5.87391 1.3466 5.00E-05 0.00245 FBgn0032856 
241 XLOC_007681 mas 3L:4161665-4167464 Ctr Mut 9.87177 25.175 1.3506 5.00E-05 0.00245 FBgn0011653 
242 XLOC_009023 CG31560 3R:2135717-2136612 Ctr Mut 9.67755 24.7251 1.3533 5.00E-05 0.00245 FBgn0051560 
243 XLOC_010182 CG13631 3R:20594690-20596687 Ctr Mut 10.1682 26.0224 1.3557 5.00E-05 0.00245 FBgn0040600 
244 XLOC_000833 CG17211 2L:12114359-12129896 Ctr Mut 1.59323 4.09729 1.3627 5.00E-05 0.00245 FBgn0032414 
245 XLOC_008599 CG14089 3L:19273219-19273900 Ctr Mut 74.8296 193.375 1.3697 5.00E-05 0.00245 FBgn0036861 
246 XLOC_010503 neo 3R:25644833-25651522 Ctr Mut 34.9169 90.2799 1.3705 5.00E-05 0.00245 FBgn0039704 
247 XLOC_006406 CG15829 3L:7122002-7122480 Ctr Mut 172.854 447.837 1.3734 5.00E-05 0.00245 FBgn0035743 
248 XLOC_010935 CG11966 3R:4775923-4788760 Ctr Mut 4.00914 10.4212 1.3782 5.00E-05 0.00245 FBgn0037645 
249 XLOC_011220 Lip3 3R:9195390-9197626 Ctr Mut 2.11262 5.50742 1.3823 0.0001 0.00448 FBgn0023495 
250 XLOC_014660 wus X:16832529-16834903 Ctr Mut 8.82736 23.1449 1.3906 5.00E-05 0.00245 FBgn0030805 
251 XLOC_010767 CG31556 3R:2132706-2135106 Ctr Mut 12.0779 32.1914 1.4143 0.0002 0.00793 FBgn0051556 
252 XLOC_004806 epsilonTry 2R:7232741-7233571 Ctr Mut 934.289 2495.49 1.4174 5.00E-05 0.00245 FBgn0010425 
253 XLOC_010550 Jon99Fi 3R:26314684-26315617 Ctr Mut 1462.32 3910.72 1.4192 5.00E-05 0.00245 FBgn0039778 
254 XLOC_008406 CG13048 3L:16275901-16277061 Ctr Mut 35.901 96.1071 1.4206 0.0018 0.04544 FBgn0036593 
255 XLOC_003886 CG15080 2R:14670805-14682105 Ctr Mut 10.0405 27.0252 1.4285 0.0017 0.04354 FBgn0034391 
256 XLOC_007712 NT1 3L:4501651-4508433 Ctr Mut 6.52158 17.6027 1.4325 5.00E-05 0.00245 FBgn0261526 
257 XLOC_014066 CG4666 X:5970105-5971587 Ctr Mut 17.3974 47.1084 1.4371 5.00E-05 0.00245 FBgn0029838 
258 XLOC_004605 Cyp4ad1 2R:4326899-4330311 Ctr Mut 18.4917 50.2592 1.4425 5.00E-05 0.00245 FBgn0033292 
  
253 
 
  gene_id gene locus sample_1 sample_2 value_1 value_2 log2(fold_change) p_value q_value oID_genes 
259 XLOC_004978 CG42807 2R:9459028-9460045 Ctr Mut 59.2631 162.158 1.4522 5.00E-05 0.00245 FBgn0261989 
260 XLOC_010325 TwdlS 3R:22462435-22463182 Ctr Mut 11.4598 31.454 1.4567 0.00195 0.04831 FBgn0039443 
261 XLOC_010825 Gld 3R:3075520-3091423 Ctr Mut 9.77219 26.8999 1.4609 5.00E-05 0.00245 FBgn0001112 
262 XLOC_010825 Pbprp4 3R:3075520-3091423 Ctr Mut 9.77219 26.8999 1.4609 5.00E-05 0.00245 FBgn0011282 
263 XLOC_009312 CG4089 3R:6641012-6643214 Ctr Mut 4.62652 12.8226 1.4707 5.00E-05 0.00245 FBgn0037838 
264 XLOC_006509 Cpr66D 3L:8633538-8636684 Ctr Mut 42.8269 119.543 1.4809 0.001 0.02928 FBgn0052029 
265 XLOC_014919 lcs X:21267753-21268326 Ctr Mut 94.4453 263.702 1.4814 5.00E-05 0.00245 FBgn0028583 
266 XLOC_010465 CG14515 3R:25023304-25024933 Ctr Mut 5.27957 14.8611 1.4931 0.00185 0.04626 FBgn0039648 
267 XLOC_002251 CG6785 2L:12041048-12045200 Ctr Mut 4.38303 12.3881 1.499 0.00055 0.0181 FBgn0032399 
268 XLOC_006189 CG32284 3L:3186663-3187245 Ctr Mut 180.857 516.018 1.5126 5.00E-05 0.00245 FBgn0052284 
269 XLOC_014737 upd2 X:18134688-18139206 Ctr Mut 0.733816 2.09396 1.5127 0.0012 0.03321 FBgn0030904 
270 XLOC_002367 CG43333 2L:14163504-14180681 Ctr Mut 12.7529 36.4789 1.5162 0.001 0.02928 FBgn0263038 
271 XLOC_005286 CG10911 2R:13940051-13941569 Ctr Mut 290.371 833.345 1.521 5.00E-05 0.00245 FBgn0034295 
272 XLOC_012686 tyn X:39387-97296 Ctr Mut 21.4836 61.6564 1.521 5.00E-05 0.00245 FBgn0029128 
273 XLOC_003343 CG43315 2R:8128722-8129264 Ctr Mut 7.8951 22.726 1.5253 0.00035 0.01228 FBgn0263020 
274 XLOC_007202 CG6996 3L:20200633-20202700 Ctr Mut 18.1567 52.392 1.5288 5.00E-05 0.00245 FBgn0036950 
275 XLOC_008902 TwdlU 3R:69327-71262 Ctr Mut 1.08298 3.15648 1.5433 0.00155 0.04068 FBgn0037223 
276 XLOC_011369 CG6118 3R:11246825-11259906 Ctr Mut 9.69039 28.4101 1.5518 0.00025 0.00942 FBgn0038339 
277 XLOC_005640 CG4386 2R:17686834-17688405 Ctr Mut 21.1043 62.2835 1.5613 5.00E-05 0.00245 FBgn0034661 
278 XLOC_014536 CG9095 X:15033961-15057255 Ctr Mut 15.0702 44.5009 1.5621 5.00E-05 0.00245 FBgn0030617 
279 XLOC_004639 CG34350 2R:4880448-4894092 Ctr Mut 8.70067 25.6983 1.5625 5.00E-05 0.00245 FBgn0085379 
280 XLOC_006200 CG14960 3L:3271035-3276255 Ctr Mut 11.8606 35.1304 1.5665 5.00E-05 0.00245 FBgn0035428 
281 XLOC_008755 CG5656 3L:21435326-21437919 Ctr Mut 2.55847 7.57973 1.5669 5.00E-05 0.00245 FBgn0037083 
282 XLOC_007938 CG7201 3L:8283385-8288427 Ctr Mut 3.81519 11.3153 1.5684 0.0005 0.01666 FBgn0035865 
283 XLOC_008903 TwdlF 3R:72743-74040 Ctr Mut 174.186 519.08 1.5753 0.00065 0.02068 FBgn0037224 
284 XLOC_010630 TwdlG 3R:74433-77467 Ctr Mut 55.912 168.186 1.5888 0.00105 0.02992 FBgn0037225 
285 XLOC_006812 ImpL1 3L:13375864-13377099 Ctr Mut 74.6957 225.777 1.5958 5.00E-05 0.00245 FBgn0001256 
286 XLOC_002908 CG43366 2R:1781323-1818996 Ctr Mut 5.53372 16.7677 1.5994 5.00E-05 0.00245 FBgn0263109 
287 XLOC_009203 CG8420 3R:5072370-5077153 Ctr Mut 33.3051 102.882 1.6272 5.00E-05 0.00245 FBgn0037664 
  
254 
 
  gene_id gene locus sample_1 sample_2 value_1 value_2 log2(fold_change) p_value q_value oID_genes 
288 XLOC_004358 spz6 2R:20644902-20647989 Ctr Mut 16.3428 50.6848 1.6329 5.00E-05 0.00245 FBgn0035056 
289 XLOC_009911 CG15695 3R:16667863-16670709 Ctr Mut 2.88911 8.98311 1.6366 5.00E-05 0.00245 FBgn0038832 
290 XLOC_003095 PGRP-SC1a 2R:4597267-4597825 Ctr Mut 30.8452 95.9132 1.6367 5.00E-05 0.00245 FBgn0043576 
291 XLOC_005557 CG43666 2R:16675821-16678640 Ctr Mut 81.5211 253.514 1.6368 5.00E-05 0.00245 FBgn0263741 
292 XLOC_005557 CG43667 2R:16675821-16678640 Ctr Mut 81.5211 253.514 1.6368 5.00E-05 0.00245 FBgn0263760 
293 XLOC_005557 CG43677 2R:16675821-16678640 Ctr Mut 81.5211 253.514 1.6368 5.00E-05 0.00245 FBgn0263742 
294 XLOC_010562 Spn100A 3R:26516365-26518490 Ctr Mut 30.611 95.2712 1.638 5.00E-05 0.00245 FBgn0039795 
295 XLOC_011426 Cad89D 3R:12310287-12321141 Ctr Mut 0.578649 1.80098 1.638 0.0006 0.01944 FBgn0038439 
296 XLOC_009817 CG6026 3R:14859255-14870350 Ctr Mut 8.28078 26.0506 1.6535 5.00E-05 0.00245 FBgn0038676 
297 XLOC_006201 CG12017 3L:3280238-3290896 Ctr Mut 8.21501 26.1564 1.6708 5.00E-05 0.00245 FBgn0035429 
298 XLOC_014753 CG15043 X:18337059-18399457 Ctr Mut 243.575 780.028 1.6792 0.0003 0.01084 FBgn0030929 
299 XLOC_014746 CG32548 X:18329747-18334614 Ctr Mut 27.994 90.2723 1.6892 0.00035 0.01228 FBgn0052548 
300 XLOC_009967 burs 3R:17584301-17596047 Ctr Mut 4.28532 13.8578 1.6932 5.00E-05 0.00245 FBgn0038901 
301 XLOC_009967 CG42335 3R:17584301-17596047 Ctr Mut 4.28532 13.8578 1.6932 5.00E-05 0.00245 FBgn0259237 
302 XLOC_007850 Cpr65Eb 3L:7080812-7081887 Ctr Mut 29.6654 96.0684 1.6953 0.0005 0.01666 FBgn0035736 
303 XLOC_006483 Cpr66Cb 3L:8329771-8331695 Ctr Mut 4.82177 15.6745 1.7008 0.0002 0.00793 FBgn0035875 
304 XLOC_005830 CG4324 2R:19902432-19904753 Ctr Mut 3.14831 10.2921 1.7089 5.00E-05 0.00245 FBgn0034956 
305 XLOC_009998 CG7080 3R:18155022-18156268 Ctr Mut 13.0949 42.8661 1.7108 0.0003 0.01084 FBgn0038941 
306 XLOC_007952 CG32354 3L:8404950-8415305 Ctr Mut 2.07254 6.79244 1.7125 0.0005 0.01666 FBgn0052354 
307 XLOC_006271 CG1273 3L:4263718-4277778 Ctr Mut 3.48678 11.5591 1.7291 5.00E-05 0.00245 FBgn0035522 
308 XLOC_010669 CG2016 3R:782720-787072 Ctr Mut 19.9646 66.5106 1.7361 5.00E-05 0.00245 FBgn0250839 
309 XLOC_013272 m X:11648305-11663541 Ctr Mut 2.85741 9.52379 1.7368 5.00E-05 0.00245 FBgn0002577 
310 XLOC_004242 St1 2R:19569146-19570475 Ctr Mut 6.45377 21.656 1.7466 0.0001 0.00448 FBgn0034887 
311 XLOC_005554 CG43709 2R:16663398-16663907 Ctr Mut 2.78933 9.38669 1.7507 0.0004 0.01385 FBgn0263848 
312 XLOC_004014 CG15225 2R:16680471-16681191 Ctr Mut 165.374 556.67 1.7511 5.00E-05 0.00245 FBgn0034551 
313 XLOC_002027 Bace 2L:8491867-8506845 Ctr Mut 28.6797 96.5775 1.7517 5.00E-05 0.00245 FBgn0032049 
314 XLOC_000301 CG3355 2L:4651402-4652892 Ctr Mut 135.625 456.924 1.7523 5.00E-05 0.00245 FBgn0031619 
315 XLOC_014367 dy X:11663801-11672800 Ctr Mut 2.12608 7.20186 1.7602 5.00E-05 0.00245 FBgn0004511 
316 XLOC_006481 CG34461 3L:8318958-8321407 Ctr Mut 4.80596 16.3028 1.7622 5.00E-05 0.00245 FBgn0250833 
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317 XLOC_007855 CG14829 3L:7229899-7231358 Ctr Mut 0.459196 1.56882 1.7725 0.00035 0.01228 FBgn0035751 
318 XLOC_012060 TwdlQ 3R:22518355-22519245 Ctr Mut 18.8223 64.5411 1.7778 0.0001 0.00448 FBgn0039448 
319 XLOC_003380 CG13157 2R:8303959-8305647 Ctr Mut 4.22345 14.7132 1.8006 5.00E-05 0.00245 FBgn0033732 
320 XLOC_009009 Osi24 3R:2022993-2033403 Ctr Mut 3.85093 13.5343 1.8133 5.00E-05 0.00245 FBgn0037409 
321 XLOC_004009 CG13438 2R:16580374-16581114 Ctr Mut 33.6896 118.484 1.8143 5.00E-05 0.00245 FBgn0034545 
322 XLOC_014327 C901 X:10858151-10861167 Ctr Mut 1.42079 5.00172 1.8157 5.00E-05 0.00245 FBgn0021742 
323 XLOC_002170 Lip1 2L:10699407-10701458 Ctr Mut 6.32754 22.2789 1.816 0.00025 0.00942 FBgn0023496 
324 XLOC_003282 betaTry 2R:7233839-7234641 Ctr Mut 1365.42 4828.03 1.8221 5.00E-05 0.00245 FBgn0010357 
325 XLOC_009024 Osi17 3R:2137491-2153129 Ctr Mut 3.12688 11.1302 1.8317 5.00E-05 0.00245 FBgn0037427 
326 XLOC_010598 nyo 3R:27368753-27391887 Ctr Mut 6.87153 24.5262 1.8356 5.00E-05 0.00245 FBgn0039852 
327 XLOC_004012 CG34202 2R:16640109-16641244 Ctr Mut 135.503 484.403 1.8379 5.00E-05 0.00245 FBgn0085231 
328 XLOC_007387 CG13239 3L:22853886-22854590 Ctr Mut 2.48204 8.95219 1.8507 0.0002 0.00793 FBgn0037197 
329 XLOC_003484 CG6347 2R:9723925-9726869 Ctr Mut 9.53212 34.4286 1.8527 5.00E-05 0.00245 FBgn0033874 
330 XLOC_009264 Spn85F 3R:5822884-5827137 Ctr Mut 0.889567 3.22888 1.8599 0.0011 0.03093 FBgn0037772 
331 XLOC_000505 Uro 2L:7780084-7781415 Ctr Mut 23.7836 86.5583 1.8637 5.00E-05 0.00245 FBgn0003961 
332 XLOC_008664 CG7298 3L:20195169-20196787 Ctr Mut 430.129 1565.75 1.864 5.00E-05 0.00245 FBgn0036948 
333 XLOC_011909 CG42811 3R:20192248-20192942 Ctr Mut 2.16645 7.88943 1.8646 5.00E-05 0.00245 FBgn0261993 
334 XLOC_008060 ect 3L:10183374-10194937 Ctr Mut 70.8772 261.366 1.8827 5.00E-05 0.00245 FBgn0000451 
335 XLOC_014922 CG10918 X:21293169-21328761 Ctr Mut 60.1141 221.707 1.8829 5.00E-05 0.00245 FBgn0031178 
336 XLOC_004638 CG8213 2R:4856714-4873429 Ctr Mut 8.39915 31.2643 1.8962 5.00E-05 0.00245 FBgn0033359 
337 XLOC_011911 CG17782 3R:20196471-20198484 Ctr Mut 1.92462 7.16462 1.8963 5.00E-05 0.00245 FBgn0039195 
338 XLOC_010753 CG10280 3R:1836280-1838934 Ctr Mut 3.03928 11.3184 1.8969 5.00E-05 0.00245 FBgn0037395 
339 XLOC_013414 CG12540 X:14390169-14391275 Ctr Mut 6.95944 26.0222 1.9027 0.0009 0.02717 FBgn0030570 
340 XLOC_011144 CG4702 3R:7947299-7953919 Ctr Mut 33.957 127.047 1.9036 5.00E-05 0.00245 FBgn0037992 
341 XLOC_003809 CG10910 2R:13907753-13909911 Ctr Mut 302.593 1137.01 1.9098 5.00E-05 0.00245 FBgn0034289 
342 XLOC_009013 Osi6 3R:2057257-2062816 Ctr Mut 406.454 1530.01 1.9124 5.00E-05 0.00245 FBgn0027527 
343 XLOC_008765 CG7173 3L:21548472-21551326 Ctr Mut 3.30272 12.4929 1.9194 5.00E-05 0.00245 FBgn0037099 
344 XLOC_009021 Osi15 3R:2127340-2130291 Ctr Mut 181.462 693.751 1.9348 5.00E-05 0.00245 FBgn0037424 
345 XLOC_011216 CG15887 3R:9113370-9114532 Ctr Mut 24.7212 94.5457 1.9353 5.00E-05 0.00245 FBgn0038132 
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346 XLOC_006853 CG43120 3L:14375012-14376399 Ctr Mut 0.847401 3.24286 1.9362 5.00E-05 0.00245 FBgn0262580 
347 XLOC_011653 CG17267 3R:16561341-16564567 Ctr Mut 16.2011 62.2299 1.9415 5.00E-05 0.00245 FBgn0038821 
348 XLOC_003687 CG5550 2R:12704095-12706745 Ctr Mut 44.0338 169.153 1.9416 5.00E-05 0.00245 FBgn0034160 
349 XLOC_001191 amd 2L:19110158-19114110 Ctr Mut 8.38565 32.2991 1.9455 5.00E-05 0.00245 FBgn0000075 
350 XLOC_014701 CG8568 X:17343017-17346576 Ctr Mut 2.46059 9.49891 1.9488 0.0001 0.00448 FBgn0030841 
351 XLOC_007808 CG13297 3L:6149691-6150477 Ctr Mut 16.8005 65.3755 1.9602 5.00E-05 0.00245 FBgn0035685 
352 XLOC_008529 CG16775 3L:17879047-17879745 Ctr Mut 17.4425 68.5032 1.9736 5.00E-05 0.00245 FBgn0036767 
353 XLOC_009463 Hsc70-2 3R:8870480-8873112 Ctr Mut 0.467092 1.83548 1.9744 5.00E-05 0.00245 FBgn0001217 
354 XLOC_003445 CG17047 2R:9187106-9189045 Ctr Mut 7.41122 29.2453 1.9804 5.00E-05 0.00245 FBgn0033827 
355 XLOC_009027 Osi20 3R:2165818-2167146 Ctr Mut 121.812 481.068 1.9816 5.00E-05 0.00245 FBgn0037430 
356 XLOC_012877 CG15239 X:3778204-3784520 Ctr Mut 24.8507 98.1453 1.9816 5.00E-05 0.00245 FBgn0029681 
357 XLOC_009018 Osi12 3R:2104252-2108217 Ctr Mut 1.18754 4.70062 1.9849 5.00E-05 0.00245 FBgn0037419 
358 XLOC_011628 CG4362 3R:16131937-16133258 Ctr Mut 198.709 789.311 1.9899 5.00E-05 0.00245 FBgn0038784 
359 XLOC_014437 CG12723 X:13083675-13085915 Ctr Mut 15.6144 62.1549 1.993 0.0001 0.00448 FBgn0030459 
360 XLOC_009017 Osi10 3R:2089437-2093262 Ctr Mut 0.639865 2.55673 1.9985 0.0007 0.02195 FBgn0037417 
361 XLOC_006784 CG17672 3L:13022061-13029604 Ctr Mut 19.9941 80.3402 2.0066 5.00E-05 0.00245 FBgn0083978 
362 XLOC_006205 dro2 3L:3314348-3314681 Ctr Mut 48.5817 196.783 2.0181 5.00E-05 0.00245 FBgn0052279 
363 XLOC_010208 CG11786 3R:20872046-20873131 Ctr Mut 25.1621 102.008 2.0194 5.00E-05 0.00245 FBgn0039264 
364 XLOC_009016 Osi9 3R:2085934-2087832 Ctr Mut 89.1747 365.955 2.037 5.00E-05 0.00245 FBgn0037416 
365 XLOC_004013 CG13443 2R:16661193-16662869 Ctr Mut 8.61873 35.3796 2.0374 5.00E-05 0.00245 FBgn0034548 
366 XLOC_009014 Osi7 3R:2074713-2077405 Ctr Mut 121.334 498.155 2.0376 5.00E-05 0.00245 FBgn0037414 
367 XLOC_003516 CG34444 2R:10256684-10258621 Ctr Mut 0.985987 4.07991 2.0489 0.0009 0.02717 FBgn0085473 
368 XLOC_004011 CG34201 2R:16638451-16639628 Ctr Mut 30.3836 126.565 2.0585 5.00E-05 0.00245 FBgn0085230 
369 XLOC_009026 Osi19 3R:2160998-2162919 Ctr Mut 90.6602 385.629 2.0887 5.00E-05 0.00245 FBgn0037429 
370 XLOC_006486 ImpE1 3L:8365504-8384271 Ctr Mut 7.67726 32.9869 2.1032 5.00E-05 0.00245 FBgn0001253 
371 XLOC_009025 Osi18 3R:2155971-2157536 Ctr Mut 63.4048 273.256 2.1076 5.00E-05 0.00245 FBgn0037428 
372 XLOC_013138 CG15370 X:9119488-9120601 Ctr Mut 3.2796 14.2283 2.1172 5.00E-05 0.00245 FBgn0030107 
373 XLOC_011840 CG33337 3R:19415666-19418502 Ctr Mut 1.21027 5.41907 2.1627 5.00E-05 0.00245 FBgn0053337 
374 XLOC_003096 PGRP-SC1b 2R:4600948-4601587 Ctr Mut 19.3875 86.8636 2.1636 5.00E-05 0.00245 FBgn0033327 
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375 XLOC_004842 Damm 2R:7751665-7753908 Ctr Mut 4.37792 20.3545 2.217 5.00E-05 0.00245 FBgn0033659 
376 XLOC_010088 CG31148 3R:19526359-19528324 Ctr Mut 7.76002 36.6681 2.2404 5.00E-05 0.00245 FBgn0051148 
377 XLOC_004988 CG6337 2R:9713879-9722593 Ctr Mut 23.6537 113.218 2.259 0.00025 0.00942 FBgn0033873 
378 XLOC_010280 MCO3 3R:21723197-21725466 Ctr Mut 1.44111 7.14989 2.3107 5.00E-05 0.00245 FBgn0039387 
379 XLOC_011912 CG17780 3R:20199175-20210770 Ctr Mut 5.11759 25.3919 2.3108 5.00E-05 0.00245 FBgn0039197 
380 XLOC_011912 CG17781 3R:20199175-20210770 Ctr Mut 5.11759 25.3919 2.3108 5.00E-05 0.00245 FBgn0039196 
381 XLOC_010154 CG13616 3R:20218631-20219502 Ctr Mut 5.22073 26.6516 2.3519 5.00E-05 0.00245 FBgn0039200 
382 XLOC_009373 CG14720 3R:7537500-7538076 Ctr Mut 1.24108 6.47883 2.3841 0.0017 0.04354 FBgn0037940 
383 XLOC_009022 Osi16 3R:2130867-2132036 Ctr Mut 1.09495 5.74398 2.3912 5.00E-05 0.00245 FBgn0051561 
384 XLOC_007762 CG10591 3L:5591656-5592792 Ctr Mut 0.232809 1.23748 2.4102 0.0007 0.02195 FBgn0035621 
385 XLOC_010183 CG42331 3R:20597902-20610284 Ctr Mut 3.8151 20.7072 2.4403 5.00E-05 0.00245 FBgn0259233 
386 XLOC_005578 Cht4 2R:16952884-16954592 Ctr Mut 27.0575 147.77 2.4493 5.00E-05 0.00245 FBgn0022700 
387 XLOC_009915 TotC 3R:16698709-16699310 Ctr Mut 1.93065 10.5465 2.4496 5.00E-05 0.00245 FBgn0044812 
388 XLOC_000087 CG42329 2L:1219317-1229802 Ctr Mut 0.959453 5.37126 2.485 5.00E-05 0.00245 FBgn0259229 
389 XLOC_009691 CG31268 3R:12857538-12859237 Ctr Mut 11.5768 67.3905 2.5413 5.00E-05 0.00245 FBgn0051268 
390 XLOC_011752 CG13857 3R:18215501-18219826 Ctr Mut 2.15513 13.4446 2.6412 0.0006 0.01944 FBgn0038958 
391 XLOC_008168 CG42397 3L:11966184-11966890 Ctr Mut 3.15012 19.9335 2.6617 5.00E-05 0.00245 FBgn0259748 
392 XLOC_000287 CG33003 2L:4400952-4403142 Ctr Mut 3.38111 21.4192 2.6633 5.00E-05 0.00245 FBgn0053003 
393 XLOC_009842 CG17751 3R:15432975-15435044 Ctr Mut 5.46427 36.7634 2.7502 5.00E-05 0.00245 FBgn0038717 
394 XLOC_006653 CG12522 3L:11101334-11101832 Ctr Mut 70.7546 477.189 2.7537 5.00E-05 0.00245 FBgn0036131 
395 XLOC_008037 CG6749 3L:9724337-9726907 Ctr Mut 0.637892 4.33214 2.7637 0.0001 0.00448 FBgn0263541 
396 XLOC_009223 CG8147 3R:5320033-5322675 Ctr Mut 0.810923 5.54246 2.7729 5.00E-05 0.00245 FBgn0043791 
397 XLOC_003686 CG15919 2R:12680161-12680585 Ctr Mut 5.59236 42.4773 2.9252 5.00E-05 0.00245 FBgn0040743 
398 XLOC_008095 CG32071 3L:11096520-11096973 Ctr Mut 18.5365 144.989 2.9675 5.00E-05 0.00245 FBgn0052071 
399 XLOC_001815 CG9021 2L:5903358-5904674 Ctr Mut 0.262034 2.14408 3.0325 5.00E-05 0.00245 FBgn0031747 
400 XLOC_010837 snRNA:7SK 3R:3300274-3300718 Ctr Mut 1.69003 28.9889 4.1004 5.00E-05 0.00245 FBgn0065099 
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